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Human  herpesvirus  6  (HHV-6)  was  discovered  in  1986  in  patients  with 
lymphoproliferative diseases and it has a predominant tropism for CD4+  T cells 
in vitro and in vivo.  The virus can be divided into two variants: HHV-6A and 6B, 
based on the differences in biological properties and DNA sequences.  HHV-6B 
has been shown to be the causative agent of exanthem subitum while HHV-6A 
has  no clear association with any disease yet.  The genome for both variants 
has  been  defined  and  each  encodes  just  over  100  open  readings  frames 
(ORFs).  However,  there  is  limited  knowledge  regarding  the  functions  and 
transcription kinetics of most ORFs.
This thesis discusses the development of DNA microarrays for HHV-6 and the 
application of the arrays to characterise HHV-6B gene expression in the SupT1 
cell  line.  The  expression  pattern  of  individual  viral  genes  over  a  60h  time 
course  (<1  replication  cycle) was  profiled.  Viral  genes were further classified 
into  three  kinetic  groups:  immediately-early  (IE),  early  (E),  and  late  (L), 
according  to  their  transcriptional  activity  in  the  absence  of  de  novo  protein 
synthesis or DNA replication.
In  addition,  HHV-6  presents  an  atypical  stage  in  the  herpesvirus  life  cycle  in 
which the viral genome is integrated into host chromosomes.  The prevalence of 
HHV-6  integration  was  estimated  to  be  between  0.21%  to  3%.  An  individual 
harbouring  integrated  HHV-6 was previously identified.  The molecular biology 
and  gene  expression  of  this  integrated  HHV-6  DNA  were  characterised. 
Expression  of viral  genes  belonging to  all  three  kinetic classes  (IE,  E,  and  L) 
was  detected  in  vitro  and  ex  vivo.  The  data  strongly  suggest  that  the 
chromosomal HHV-6 sequence is transcriptionally active and the implications of 
this are discussed.
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19TBE Tris/borate EDTA buffer
TBS Tris buffered solution
TBST TBS + Tween20
TE Tris & EDTA
TERT protein component of TR
TK thymidine kinase
TPA 12-o-tetradecanoyl phorbol-13-acetate
TR telomerase RNA
Tris tris(hydroxymethyl)aminomethane
tRNA transfer RNA
TRS telomeric repeat sequence
UBC ubiquitin conjugating enzyme
UCL University College London
UV ultra-violet
vTR telomerase RNA
VZV varicella-zoster virus
wt wild type
X-gal 5-bromo-4-chloro-3-indolyl-beta-D-galactoside
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1.1  Herpesviridae
1.1.1  Overview
There  are  over  130  members  identified  to  date  in  the  Herpesviridae  family 
(Roizman  and  Pellett,  2001).  They are widely distributed  in  nature and  infect 
both vertebrate and invertebrate species.  Some herpesviruses exhibit tropism 
for more than one host species.  The properties of different herpesviruses are 
very  diverse  but  they  all  share  the  same  virion  architecture  (figure  1.1);  the 
double stranded  DNA (dsDNA) is packed inside a capsid, which is made up of 
162 capsomeres arranged as an icosahedron.  The icosahedron is surrounded 
by  a  tegument  and  all  these  components  are  enclosed  within  a  lipid  bilayer 
envelope.
Figure 1.1  A schematic representation of a typical herpesvirus virion
Envelope
Capsid
DNA genome
Tegument 
Glycoproteins
Figure kindly provided by Dr S Wilson (Centre for Virology,  University College 
London (UCL)).
1.1.2  Lifecycle
The life cycle of herpesviruses is illustrated in figure 1.2.  Typically, it is divided 
into  seven  main  stages:  (1)  virus  attachment  and  entry,  (2)  uncoating  and 
translocation  into  the  nucleus,  (3)  viral  DNA  circularization,  (4)  viral  gene 
transcription,  (5) viral  DNA replication,  (6) viral  assembly and  morphogenesis, 
and (7) virus egress.
22Figure 1.2 The life cycle of herpesviruses
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See  text for description  (section  1.1.2).  a,  p  and y  =  immediate-early,  early  and  late,  respectively  (refer to 
section 1.2.7 for details).  Figure adapted and modified from Roizman and Knipe, (2001).General Introduction
Furthermore,  herpesviruses  are  characterised  by  their  ability  to  establish 
latency  in  the  host  lifelong.  The  latent  viral  genomes  generally  exist  as 
episomes  with  minimal  expression  of  viral  genes,  thereby  minimizing  the 
chance  of  activating  the  host’s  immune  defence  (DiMaio  and  Coen,  2001). 
However, these genomes retain the capacity to undergo lytic replication (section 
1.2.7.1), or reactivation, leading to the production of infectious progeny viruses. 
The reactivation of virus can cause disease or be asymptomatic.
1.1.3  Human herpesviruses and their classification
To date, eight herpesviruses infecting humans have been identified (see figure
1.3 for the timeline of identification): herpes simplex virus types 1   and 2 (HSV-1 
and  HSV-2),  varicella  zoster  virus  (VZV),  Epstein-Barr  virus  (EBV),  human 
cytomegalovirus (HCMV), human herpesvirus 6 (HHV-6),  human herpesvirus 7 
(HHV-7)  and  human  herpesvirus  8  (HHV-8);  also  referred  to  as  Kaposi’s 
sarcoma-associated herpesvirus (KSHV).
Figure 1.3 Timeline of the identification of human herpesviruses
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CMV  EBV  HHV-6  HHV-8
r  1 -------- 1 --------1 -------- 1 --------r"
1900  1910  1920  1930  1940  1950
“ I--------- 1 --------- 1 ---------1
1970  1980  1990  2000 1960
Adapted  from  the  monograph  published  on  the  International  Herpes 
Management Forum website at: 
http://www.ihmf.org/Library/monograph/m_03.pdf
All  human  herpesviruses  are  classified  into  three  subfamilies  based  on  the 
differences in their biological properties (see Table 1.1).
24Table 1.1 The human herpesviruses
Subfamilies  Properties  Common names  Systematic  Major diseases
nomenclature
Alphaherpesviruses 1.  Short replicative cycle,
2.  rapid spread in cell culture,
3.  highly cytotoxic,
4.  broader host range,
5.  establish  latent  infection  primarily  in  sensory 
ganglia.
Herpes  simplex  virus  type  1  Human herpesvirus 1  (HHV 1)  Cold sores, encephalitis 
(HSV-1)
Herpes  simplex  virus  type  2  HHV 2  Genital  infection,  erythema 
(HSV-2)  multiforme
Varicella zoster virus (VZV)  HHV 3  Chickenpox, zoster
Beta herpes vi ru ses 1.  Long replicative cycle,
2.  slow progression in cell culture,
3.  infected cells become enlarged,
4.  restricted host range,
5.  establish  latent  infection  in  secretory  gland  and 
lymphoreticular cells.
Human  cytomegalovirus  HHV 5  Hearing loss, retinitis 
(HCMV)
Human herpesvirus 6 (HHV-6)  HHV 6  Exanthem subitum, febrile fits 
Human herpesvirus 7 (HHV-7)  HHV 7  Exanthem subitum, febrile fits
Gammaherpesvirus 1.  All members replicate in lymphoblastoid cells,
2.  exhibit tropism for either T or B lymphocytes,
3.  most restricted host range
4.  establish latent infection in lymphoid tissue.
Epstein-Barr virus (EBV)  HHV 4  Infectious  mononucleosis,
Burkitt’s lymphoma
Kaposi's  sarcoma  associated  HHV 8  Kaposi's sarcoma 
virus (KSHV)
Adapted and modified from Griffiths, (2001).General Introduction
1.2  The biology of HHV-6
1.2.1  Overview
HHV-6  was first  isolated  in  1986  (Salahuddin  et al.,  1986)  and  exists  as  two 
variants: 6A and 6B, each with distinct genetic and biological properties (Clark,
2000).  Both  variants  have  been  fully  sequenced  (Dominguez  et  al.,  1999; 
Gompels  et  al.,  1995;  Isegawa  et  al.,  1999)  and  the  size  of the  genomes  is 
approximately 160kb, each encoding at least 100 open reading frames (ORFs). 
HHV-6A is  not associated with disease but HHV-6B is the cause of exanthem 
subitum  (ES)  (Yamanishi,  2001).  Primary  infection  occurs  in  early  childhood 
(Hall  et  al.,  1994;  Zerr  et  al.,  2005)  and  often  produces  symptoms  including 
fever and fussiness (Zerr et al., 2005). Thereafter, the virus establishes lifelong 
latency  in  the  host.  HHV-6  reactivation  in  immunocompromised  hosts  is 
increasingly  recognised  as  pathogenic,  particularly  in  the  transplant  setting 
(Clark and Griffiths, 2003).
HHV-6  is  among  the  least  studied  human  herpesviruses  due  to  its  apparent 
benign clinical properties.  Research data on certain aspects of HHV-6 biology, 
such as capsid trafficking and virus assembly, are thus lacking.  In such cases, 
data  obtained  for  HSV-1  (the  prototype  human  herpesvirus)  or  HCMV  (the 
prototype  p-herpesvirus)  are  discussed  to  implicate  possible  mechanisms 
employed by HHV-6.
1.2.2  History
HHV-6  is  one of the  more  recent entries to the  human  herpesvirus family.  It 
was  first  isolated  in  1986  from  cultured  peripheral  blood  mononuclear  cells 
(PBMCs) of individuals with acquired immune deficiency syndrome (AIDS) and 
lymphoproliferative  disorders  (Salahuddin  et al.,  1986).  The  PBMCs  showed 
classical  signs  of cytopathic effects  (CPE)  during  culture  (section  1.2.10) and 
these  cells  harboured  virions  with  human  herpesvirus-like  morphology,  as 
shown by electron microscopy (EM).  Despite this, the virus was initially named 
human  B-lymphotropic virus due to  its  apparent tropism to  B-lymphocytes,  as 
revealed  by  surface  marker  analysis.  Moreover,  the  serology  and  genomic 
sequence  of  the  virus  differed  from  the  known  members  of  the  human
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herpesviruses  at  the  time  (Josephs  et  al.,  1988;  Salahuddin  et  al.,  1986). 
However, further analyses  have clearly demonstrated that the virus exhibits  a 
predominant in vivo & in vitro tropism for CD4+  T lymphocytes (Downing et al., 
1987; Lopez et al., 1988; Lusso et al., 1987), hence it was renamed HHV-6.
1.2.3  HHV-6 variant A and variant B
Many HHV-6 isolates have been identified in patients with a variety of diseases: 
HHV-6(GS) -  the original HHV-6 isolate (Salahuddin et al., 1986), 
HHV-6(U1102) -  isolated from an  Ugandan patient with AIDS (Downing et al., 
1987),
HHV-6(Z29)  -   isolated  from  a  Zairian  patient  who  is  seropositive  for  human 
immunodeficiency virus-1  (HIV-1) (Lopez et al., 1988),
HHV-6(OK)  and  (HST)  -   isolated  from  Japanese  patients  with  exanthem 
subitum (ES) (Kikuta et al.,  1989; Yamanishi et al., 1988), respectively, 
HHV-6(AJ)  -   isolated  from  a  Gambian  patient  with  HIV2-associated  AIDS 
(Tedder et al., 1987).
It  later  emerged  that  all  the  HHV-6  isolates  can  be  divided  into  two  groups, 
variant A (6A) and variant B (6B), based on their differential properties (Ablashi 
et al., 1993; Campadelli-Fiume et al., 1993; Foa-Tomasi et al., 1995; Pellett and 
Black, 1996; Schirmeret al., 1991) as summarised in table 1.2.
Table 1.2  The differential properties between HHV-6A and HHV-6B
Properties HHV-6A HHV-6B
T cell lines which support productive replication Immature T cells Mature T cells
e.g.  HSB-2 e.g.  Molt-3
Disease association Undefined Exanthem subitum
Monoclonal antibody (mAb) 2D9 Reactive Non-reactive
mAb 6E2 Non-reactive Reactive
In  addition,  it  has  been  shown  that  each  variant  has  its  distinct  restriction 
endonuclease profile (Schirmer et al.,  1991).  The implied differences between 
the  genomes  of HHV-6A and  6B  were  later verified  by the  publication  of the 
genomic sequence of both variants (section 1.2.4).
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1.2.4  HHV-6 genomes
The  genomes  of  three  different  prototype  strains  of  HHV-6  have  been 
sequenced,  which  include  HHV-6A(U1102)  (Gompels  et  al.,  1995),  HHV- 
6B(Z29)  (Dominguez  et al.,  1999),  and  HHV-6B(HST)  (Isegawa  et al.,  1999). 
All three genomes are 160-162 kb in size and each encodes -100 ORFs (figure 
1.4).  Sequence analyses demonstrated that the genomes of HHV-6A and  6B 
are colinear and confirmed the close-relatedness of the two variants reviewed in 
Clark,  (2000).  However, the significant sequence variations observed in a few 
ORFs  plus  the  presence  of  variant-specific  ORFs,  may  well  account  for  the 
differential properties between HHV-6A and 6B (section 1.2.3).
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Figure 1.4  A schematic representation of HHV-6A genome
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HHV-6A genome  arranged  colinear  to  the  unique  long  region  of  HCMV.  UL, 
unique  long;  U,  unique;  DR,  direct  repeat.  HHV-6  ORFs  of  known  function 
including inference from HCMV homologues are shown according to the colour 
code.  Full size segment represents  HHV-6 ORF with  positional and  sequence 
homology to HCMV gene. Half size segment within main circle represents HHV- 
6  ORF  with  positional  homology  to  HCMV  only.  Half-size  pointed  segment 
inside  main  circle  represents  position  of  HHV-6  ORFs  with  no  positional  or 
sequence homology to HCMV.  Adapted from Clark, (2000).
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In comparison with other herpesviral genomes, HHV-6 is most closely related to 
HHV-7 (another member of the roseolovirus genus) followed  by HCMV (Clark, 
2000;  Pellett and  Dominguez, 2001a).  They all contain the seven herpesvirus 
core gene  blocks which  are conserved  among all  human  herpesviruses.  The 
existence of a gene block (HHV-6 U2-U19) which is specific to HHV-6,  HHV-7 
and  HCMV,  plus  the  fact  that  they  share  significant  homology  over  the 
conserved regions, supports the p-herpesvirus subfamily classification.
The HHV-6 genome has a class A arrangement (see figure 1.5) - a long unique 
region flanked  by two direct repeats: direct repeat left (DR|_) and direct repeat 
right (DRr), without reiterations (Lindquester and Pellett, 1991).
Figure 1.5  A schematic representation of the class A arrangement of 
the HHV-6 genome
.  —160 kbp  .
DRl  DRr
  ►    ►
10 kbp
The  ORFs  were  named  according  to  their  locations  and  relative  positions  to 
each other.  ORFs located  in the direct repeats are prefixed  DR,  and those in 
the  unique  region  are  termed  U1-100  from  the  left  to  the  right  hand  of  the 
genome  (reviewed  in  Clark,  2000).  The  genome  of  HHV-7  is  essentially 
colinear  with  that  of  HHV-6,  and  they  share  roseolovirus  specific  genes 
including  U20,  U21,  U23,  U24,  U24A,  U26,  and  U100.  However,  ORFs  DR3, 
U6,  U22,  U83,  and  U94  are  not  present in  HHV-7;  hence  they are  unique to 
HHV-6.
Recent  studies  have  demonstrated  that  members  of  the  herpesvirus  family 
encode microRNAs (miRNAs).  These include HSV-1  (Gupta et al., 2006), EBV 
(Cai  et al.,  2006;  Pfeffer et al.,  2004),  HCMV (Dunn  et al.,  2005;  Grey et al.,
29General Introduction
2005; Pfeffer et al., 2005), KSHV (Cai et al., 2005; Pfeffer et al., 2005) and MDV 
(Burnside  et  al.,  2006).  MicroRNAs  are  a  class  of ~22-nucleotide-long  non­
coding  RNAs,  which  function  as  sequence-dependent  negative  regulators  of 
gene  expression  at  the  post-transcriptional  level  (reviewed  in  Ambros,  2004; 
Cullen,  2006;  He  and  Hannon,  2004).  These  miRNAs  are  evolutionarily 
conserved  and  have  been  identified  in  human  and  all  other  metazoan 
eukaryotes  analysed  to  date.  Many  characterised  eukaryotic  miRNAs  are 
involved  in  a  wide  range  of  cellular  activities,  including  apoptosis,  cell 
differentiation,  growth  control  and  tissue  development.  In  the  context  of 
herpesviral  miRNAs,  HSV-1  miR-LAT  is  the  only  miRNA  that  has  been 
functionally characterised thus far (Gupta et al., 2006).  This miRNA has been 
shown to suppress apoptosis in infected cells by regulating TGF-p1 and SMAD3 
expression.  No  data  are  available  on  the  function(s)  of  the  remaining 
herpesviral miRNAs that have been identified.
The  genomes  of  other  human  herpesviruses  have  been  analysed  using  an 
algorithm for predicting the miRNA encoding capacity (Pfeffer et al.,  2005).  It 
was predicted that VZV, HHV-6A and HHV-7 encode no miRNA but this has yet 
to  be  confirmed  experimentally.  It  is  important to  note  that the  prediction for 
HHV-6A  does  not  necessary  apply  to  HHV-6B,  as  most  of  the  currently 
identified herpesviral miRNAs are located within regions of the genome that are 
specific to each human  herpesvirus.  Future experiments involving the cloning 
of small  RNAs  in  HHV-6A-  and  6B-infected  cells would  be  useful  to  clarify  if 
miRNAs play any role in HHV-6 infection.
1.2.5  HHV-6 virions
EM  studies  revealed  that  HHV-6  has  a  typical  herpesvirus  virion  structure 
(Lopez et al.,  1988;  Pellett and  Black,  1996).  The  nucleocapsids of the virus 
are  about  106nm  in  diameter  (range:  90-125nm)  containing  the  dsDNA 
genome.  The additions of the tegument and the lipid  bilayer envelope lead to 
an increase in the overall size, so that the mature virions average about 163nm 
in diameter (range:  143-173nm).  Recent proteomic analyses detailed the viral 
components that are found in the virions of EBV, HCMV and KSHV (Johannsen 
et al.,  2004; Varnum et al., 2004; Zhu et al., 2005),  and without exception, the
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incorporation  of virion-associated  host  proteins.  Most of these  host  proteins, 
such  as  actins  and  heat  shock  proteins,  are  abundantly  expressed  in  cells. 
Further studies are required to define the functional significance of these virion- 
associated  host  proteins,  and  the  mechanism  for their  incorporation.  Similar 
analysis has not been performed for HHV-6 virions, however, individual studies 
have identified several virion-associated proteins for HHV-6.  These include gH 
(U48),  gL(U82),  gO(U47)  (Mori  et  al.,  2004),  gQ(U100)  (Akkapaiboon  et  al., 
2004),  U14  and  human  p53  protein  (Takemoto  et  al.,  2005).  Additionally, 
cholesterol  was  shown  to  be  a  component  of the  viral  envelope,  and  it  was 
required for membrane fusion but not virus binding (Huang et al., 2006).
1.2.6  Virus entry
The initial attachment of many herpesviruses to host cells involves the binding 
of  heparan  sulphate,  which  allows  the  anchoring  of  the  viruses  on  the  cell 
surface  to  facilitate  the  interaction  between  entry  ligands  and  receptors 
(reviewed in Shukla and Spear, 2001).  Entry ligands generally exist in the form 
of viral glycoproteins that are expressed on the viral envelope.  The binding of 
viral glycoproteins to their cognate entry receptors and/or co-receptors on the 
host cells results in virus entry through two possible pathways depending on the 
cell types:  1) direct fusion of the viral envelope with the plasma membrane, and
2)  endocytosis  of  the  virus  followed  by  acidification  which  triggers  fusion 
between the viral envelope and the endosomal membrane (Milne et al.,  2005; 
Nicola  et al.,  2005).  After fusion,  the viral  DNA is  eventually trafficked to the 
nucleus for lytic replication.
In the context of HHV-6, viral entry to T cells appears to be less dependent on 
the binding of heparan sulphate, as the treatment of cells with either heparinase 
or heparitinase (for cleaving heparan sulphate) had minimal inhibitory effect on 
infectivity (Conti et al., 2000).  Although  HHV-6 exhibits a selective tropism for 
CD4+   T-lymphocytes  in  vitro  (section  1.2.12),  CD4  membrane  receptor is  not 
required for virus entry (Lusso et al.,  1989).  As the addition of the soluble form 
of CD4  protein,  OKT4a,  or Leu3a  (both  are  anti-CD4  monoclonal  antibodies) 
completely abrogated  HIV-1  but not HHV-6 infection.  A study by Santoro and 
colleagues  (1999)  investigated  the  expression  of  a  panel  of  cell  surface
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antigens during HHV-6A infection in vitro, and demonstrated that CD46 was the 
only  marker  which  was  progressively  downregulated  during  the  course  of 
infection.  This selective downregulation of CD46 was observed at 4-day post­
infection (4dpi) and its expression was completely abolished by 6dpi.  The pre­
treatment  of  cells  with  anti-CD46  mAb  significantly  reduced  both  HHV-6 
infection  and  virus-induced  fusion.  Furthermore,  the  introduction  of 
recombinant  human  CD46  into  a  mouse  cell  line,  which  was  otherwise 
refractory  to  HHV-6  infection,  allowed  the  entry  of the  virus.  Similar  results 
were  obtained  with  HHV-6B(Z29)  and  a  clinical  isolate  (Santoro  et  al.,  1999) 
and these data strongly suggested that CD46 is the cellular receptor for HHV-6. 
Of interest,  CD46 is also the entry receptor for the vaccine strains of measles 
virus (Dorig et al.,  1994),  bovine viral diarrhea virus (Maurer et al., 2004), and 
different  serotypes  of  adenoviruses  (Gaggar  et  al.,  2003;  Segerman  et  al., 
2003).
In  terms  of  the  viral  ligands,  the  mAbs  against  HHV-6  gB  and  the  gH-gL 
complex  have  been  demonstrated  to  neutralise  infection  in  vitro  (Liu  et  al., 
1993;  Pfeiffer  et  al.,  1993;  Takeda  et  al.,  1997;  Takeda  et  al.,  1996b), 
suggesting  that  they  are  involved  in  virus  entry.  Subsequent 
immunoprecipitation studies have identified two additional glycoproteins, termed 
gO (U47) and gQ (U100), which are individually associated with gH-gL to form 
two different tripartite complexes: gH-gL-gO and gH-gL-gQ (Mori et al., 2003a; 
Mori et al., 2004).  The function of the former is yet to be determined, whereas 
the HHV-6A encoded gH-gL-gQ complexes have been shown to bind to soluble 
CD46 (Mori et al., 2003b).  Further characterisation of the HHV-6A gQ revealed 
that there are two versions of the glycoprotein: gQ1-80K and gQ2-37K (Mori et 
al., 2004), and that the gH-gL-gQ complex in fact exists as a heterotetrameric 
complex (gH-gL-gQ1-gQ2).  In addition, the expression of the gH-gL-gQ1-gQ2 
complex  on  the  viral  envelope  was  also  demonstrated.  Taken  together,  the 
data  suggest  that  this  complex  is  involved  in  cell  entry.  In  contrast,  no 
association  was  observed  between  soluble  CD46  and  the  HHV-6B  gH-gL-gQ 
complex (Mori  et al.,  2003b).  Moreover,  it was observed that the presence of 
recombinant CD46  in  culture failed to inhibit  HHV-6B  infection.  These  results 
contradict  with  a  previous  report  which  suggested  that  CD46  is  the  cellular
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receptor for HHV-6B (Santoro et al.,  1999).  Further work is required to clarify 
the conflicting data.
The binding of entry ligands to receptors triggers virus entry, which appears to 
proceed via the endocytic pathway for both  HHV-6A and 6B infection of two T 
cell-lines (HSB-2 and JJhan) and PHA-stimulated PBMCs (Cirone et al.,  1992). 
It  was  demonstrated  that  no  viral  proteins  were  detected  on  the  plasma 
membrane at all times of virus entry i.e.  no fusion between the virus envelope 
and  the  plasma  membrane.  HHV-6  infection  in  the  presence  of drug  which 
inhibits  endocytosis  almost completely abrogates viral  infectivity.  However,  it 
was observed that both HHV-6A and HHV-6B infection of other cell-lines, such 
as  SupT1  and  Molt3,  induced  cell-cell  fusion  from without  (Mori  et al.,  2002; 
Pedersen  et  al.,  2006).  The  resulting  syncytium  formation  between  infected 
cells  required  no  prior  protein  synthesis,  suggesting  that  the  fusion-inducing 
components were incorporated in the virions, and that they were present on the 
plasma  membrane  of  the  infected  cells  immediately  after  virus  entry.  This 
suggests  that  direct  fusion  between  viral  envelope  and  plasma  membrane 
occurs  in  some  cell  lines.  Hence,  the  pathway  utilised  for  HHV-6  entry  may 
vary according to cell types.
Following the entry of virus, viral DNA has to be translocated into the nucleus to 
utilize  the  host’s  transcription  and  replication  machinery  for  virus  replication. 
Nothing is known about the uncoating of the HHV-6 DNA and its transport to the 
cell nucleus (Braun et al.,  1997),  but these processes are better characterised 
for  HSV-1.  As depicted  in  figure  1.6a  and  1.6b,  HSV-1  capsids  appeared  to 
dissociate from  the tegument  (electron-dense  mass  left  behind  at the  plasma 
membrane) post-entry.  Immunofluorescence microscopy images demonstrated 
that  viral  capsids  were  transported  along  the  microtubules  (MT)  to  the 
microtubule  organisation  centre  (MTOC)  (Sodeik  et al.,  1997),  which  is  often 
located  near the  nucleus  (Greber and Way,  2006).  It was  later demonstrated 
that the binding of HSV-1  capsid to dynein was responsible for the minus-end- 
directed  (going toward  MTOC) MT transport,  as overexpression of dynactin  (a 
cofactor  of  dynein)  inhibited  the  translocation  of  viral  capsids  to  nucleus 
(Dohner et al.,  2002).  The subsequent transfer of HSV-1  capsids from  MTOC
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to the nuclear pore complexes (NPCs) remains to be defined.  Nevertheless, it 
was demonstrated that a few HSV-1  capsids reached the NPCs as soon as 1h 
post-infection  (hpi), and  by 4hpi the majority were present at NPCs (Sodeik et 
al.,  1997).  EM  images  revealed  that  68%  and  87%  of  the  capsids  on  the 
nuclear  membrane  lacked  the  electron-dense  central  mass  at 2hpi  and  4hpi, 
respectively (figure 1.6c and  1.6d).  These “empty’ capsids are most likely the 
remnant  of  virions  after  the  delivery  of  viral  DNA  into  nucleus.
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Figure 1.6  EM images depicting the uncoating of HSV-1 DNA
(a  and  b)  Release  of the  capsid  (arrow).  The  tegument  (arrowheads)  stays 
behind at the plasma  membrane (PM),  (c and d)  Binding to the nuclear pore. 
At  later  times  after  entry,  the  capsids  (arrows)  have  arrived  at  the  nuclear 
envelope  (NE),  where  they  are  exclusively  located  in  close  apposition  to  the 
nuclear pore complexes.  Almost all of the capsids at the nuclear pores appear 
empty and have lost the electron-dense DNA core.  Bar,  100 nm.
Adapted and modified from Sodeik et al., (1997).
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No  experimental  data  are  available  on  the  state  of  HHV-6  DNA  once  it  has 
entered the nucleus.  However,  by analogy with other human herpesviruses,  it 
is believed that viral genomes become circularized shortly after infection - prior 
to viral protein synthesis and DNA replication (Alfieri et al.,  1991; Garber et al., 
1993;  McVoy  and  Adler,  1994).  Viral  episomes  serve  as  template  for  DNA 
replication, which proceeds via a rolling circle mechanism to generate head-to- 
tail  concatemers,  and  therefore  no  specialized  mechanism  is  required  to 
replicate  the  genomic  termini.  However,  this  model  was  challenged  by  the 
revelation  that  HSV-1  episomes were absent in  productively-infected  cells,  as 
determined  by Gardella gel analysis (Jackson and  DeLuca, 2003;  please refer 
to section 5.1  for the principle of Gardella gel analysis).  In addition, this study 
suggested  that  the  configuration  of  the  viral  DNA  was  determined  by  the 
expression  activity  of  the  HSV-1  immediate-early  gene  encoding  ICPO. 
Decreased  levels  of  ICPO  favoured  the  circularization  of  viral  genomes, 
whereas high levels of ICPO prevented episome formation.  Thus, ICPO appears 
to act as a switch  between  latent and  lytic infection.  However, these findings 
were questioned  in  a  recent  report  by Strang  and  colleagues  (2005).  It was 
demonstrated  that,  in  the  presence  of  ICPO,  the  ‘end-joining’  between  two 
reconstructed  HSV-1  genomes  occurred  shortly  after  infection  (Strang  and 
Stow, 2005).  However, this study failed to produce concrete evidence showing 
the  presence  of  circular  DNA  in  infected  cells.  Therefore,  the  exact 
configuration  of  herpesviral  DNA  after  nuclear  entry  and  the  mode  of  DNA 
replication are still subject to debate.
1.2.7  Viral gene expression
All viruses rely on the transcriptional and translational  machineries of the  host 
for the expression of their genes.  Thus, the interaction between viral genomes 
and host factors would determine the outcome of viral gene expression.  In the 
context  of  herpesvirus,  it  is  generally  accepted  that  there  are  three  possible 
outcomes: lytic replication, abortive replication and latent infection (please refer 
to section 1.2.17.1 for a detailed discussion on latency).
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1.2.7.1  Lytic replication
The aim of lytic replication is to produce infectious progeny.  This involves the 
transcription of the lytic genes encoding a wide array of functions including:
1)  priming  the  host environment to facilitate  the  replication  of viral  instead  of 
host DNA,
2) modulating the synthesis of viral and host protein/DNA,
3) supporting viral DNA replication and the formation of viruses,
4) blocking host defence system.
The  co-ordination  between  these  processes  is  essential  (at  least  in  vivo)  for 
facilitating viral DNA replication and to ensure the completion of virion formation 
and release.
It  is well  recognised  that  expression  of herpesviral  lytic genes  proceeds  in  a 
tightly regulated cascade fashion (reviewed in Roizman and Knipe, 2001).  In a 
seminal study on the expression of HSV-1  lytic genes, it was demonstrated that 
viral  RNAs  and  proteins  could  be  divided  into  three  different  kinetic  classes: 
immediate-early  (IE),  early  (E)  and  late  (L)  (Honess and  Roizman,  1973).  IE 
genes, or a-genes, are the first set of genes to be expressed immediately post­
entry.  It was shown  that transcription  of I E-genes was  permitted  even  in  the 
presence  of  protein  synthesis  inhibitors  such  as  cycloheximide  (CHX)  or 
puromycin.  The  presence  of functional  IE  proteins  initiates expression  of the 
second  set of genes  termed  the  E  genes,  or  p-genes.  Many  E  proteins  are 
involved  in  DNA metabolism  and  viral  replication,  hence they are synthesised 
before  the  onset  of viral  DNA  replication.  The  third  set  of  genes  termed  L 
genes,  or  y-genes,  encodes  structural  proteins  that  are  required  for  viral 
assembly  and  packaging.  It  was  found  that  transcription  of  L  genes  was 
suppressed  in the presence of DNA synthesis inhibitors such as hydroxyurea, 
or  more  commonly  phosphonoacetic  acid  (PAA)  (Crumpacker,  2001).  As  a 
result, the attainment of maximal expression of the L genes is dependent on the 
onset of DNA replication.
Although  kinetic  classification  for  almost  all  HHV-6A  (Yao  et  al.,  2006)  and 
<50%  of  HHV-6B  genes  (Oster and  Hollsberg,  2002)  is  available  at  present, 
transcription kinetics of only about twenty HHV-6 genes were described before
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the start of this project (Mirandola et al., 1998).  Kinetic classification of HHV-6B 
genes  is discussed  in  Chapter 4 in detail  in the context of the findings of this 
thesis.  Regarding  the  function  of  HHV-6  lytic  genes,  the  well  documented 
difficulties  in  generating  high-titre  virus  stock  hampered  in-depth 
characterisation  of the viral  genes  (Pellett and  Black,  1996).  As a  result,  the 
function  of many HHV-6 ORFs was  predicted  based on  homology (sequence, 
structural and positional) with HSV-1  and HCMV genes (Pellett and Dominguez, 
2001b;  as  summarised  in table  1.3).  Although  several  studies  have  reported 
the characterisation of individual  HHV-6 genes, which are reviewed below, the 
function of many viral genes remains unclear.
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Table 1.3  Putative function of HHV-6 ORFs
ORF  Properties or putative functions*
U2  HCMV US22 gene  family
U3  HCMV US22 gene  family
U7EX  HCMV US22 gene  family
U11  Antigenic tegument protein
U12  G-protein-coupled receptor
U14  Antigenic tegument protein
U15  HCMV UL25/UL35 gene family
U17  HCMV US22 gene  family, IE-B
U18  IE-B
U19  IE-B
U20  Glycoprotein
U21  Glycoprotein
U22  Glycoprotein
U23  Glycoprotein
U24  Glycoprotein (VIDA)
U25  HCMV US22 gene family
U27  Polymerase processivity factor
U28  Ribonucleotide reductase large subunit
U29  Capsid assembly and DNA maturation
U30  Tegument protein
U31  Large tegument protein
U32  Capsid protein
U33  Virion protein
U34  Membrane-associated phosphoprotein
U35  DNA packaging
U36  DNA packaging
U37  Putative phosphoprotein
U38  DNA polymerase
U39  Glycoprotein B
U40  Transport/capsid assembly
U41  single-stranded DNA (ssDNA) binding protein
U42  Conserved transactivator
U43  Helicase-primase complex
U45  dUTPase (VIDA)
U46  Membrane protein
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Table 1.3 (cont’)
ORF Properties or putative functions*
U47 Glycoprotein O
U48 Glycoprotein H
U49 Putative fusion protein
U50 DNA packaging; Virion tegument protein
U51 G-protein-coupled receptor
U53 Protease; proteinase
U54 Virion transactivator
U56 Capsid protein
U57 Major capsid protein
U64 DNA packaging; tegument protein
U65 Tegument protein
U66 Putative terminase; DNA packaging protein (VIDA)
U69 Phosphotransferase; ganciclovir kinase
U70 Alkaline exonuclease
U71 Myristylated virion protein
U72 Glycoprotein M
U73 Origin binding protein
U74 Helicase-primase complex
U76 DNA packaging, virion protein
U77 Helicase-primase complex
U79 DNA replication
U81 Uracil-DNA glycosylase
U82 Glycoprotein L
U83 Intercrine cytokine
U85 Viral CD200 homologue (Shiratori et al., 2005)
U86 IE-A
U89 IE-A
U90 IE-A, transactivator
U91 IE-A
U94 Parvovirus rep homolog
U95 HCMV TRS1  homolog (Davison Reno Abstract)
U97 Envelope glycoprotein (VIDA)
U98 Part of gp85/105 glycoprotein (VIDA)
U99 Part of gp85/105 glycoprotein (VIDA)
U100 Spliced envelope glycoprotein gp82/105
*  Implied  functions  of homologous  genes  as  described  in  Pellett  and  Dominguez,  (2001b),  or 
VIDA (Alba et al., 2001), unless otherwise stated.
40General Introduction
1.2.7.1.1  U3
U3 is a member of the HCMV US22 gene family and a homolog of HCMV UL24 
(Gompels et al.,  1995).  It encodes two transcripts: 2- and 3.5-kb and both are 
unspliced  (Mori  et  al.,  1998).  The  latter was  the  more  abundant of the  two, 
however, they appeared to encode the same polypeptide.  The U3 protein was 
47kDa  in  size  which  is  higher  than  expected  (43kDa)  from  sequence 
calculation, and the presence of two N-linked glycosylation sites suggested that 
it  was  post-translationally  modified  (Mori  et  al.,  1998).  The  function  of  U3 
remains  unclear.  However,  the  analysis  of its  predicted  secondary  structure 
revealed  the  presence  of  motifs  belonging  to  the  PD-(D/E)XK  endonuclease 
structure  groups  (Knizewski  et al.,  2006).  The  majority of the  proteins  in this 
group  are  involved  in  DNA  cleaving  and  repairing.  A viral  mutant  of  HSV-1 
UL24 (a homolog of HHV-6 U3) exhibited small-plaque phenotype and impaired 
replication  in  eye  and  ganglia,  which  suggests  that  the  viral  protein  is  non- 
essential  but  is  required  for optimal  replication.  The  non-essential  nature  of 
HHV-6  U3  for  viral  replication  has  been  reported  previously  (Kondo  et  al., 
2003a).  Protein expression of U3 was inhibited  by PAA, thus indicating that it 
may be a late protein (Mori et al., 1998).
1.2.7.1.2  DR7
DR7 may be essential for virus replication as no replicating virus was observed 
for  a  DR2-DR7  deletion  mutant  (Kondo  et  al.,  2003a).  In  addition,  it  was 
reported  that  mouse  fibroblasts  transfected  with  DR7-expressing  plasmids 
developed  transforming  foci  (Kashanchi  et  al.,  1997).  The  subsequent 
introduction of these transfected cells into nude mice induced tumour formation. 
The  mechanism  underlying  the  transforming  activities  is  unclear  but  it  may 
involve  the  binding  of  DR7  to  p53.  Transcription  kinetics  of  DR7  were  not 
defined in the study by Kashanchi and colleagues (1997), but RT-PCR analysis 
revealed that DR7 transcripts appeared only after 18hpi.
1.2.7.1.3  U12
U12 was predicted to encode a homolog of cellular G-protein-coupled receptor 
(GCR;  (Gompels  et al.,  1995).  The  cDNA of HHV-6B  U12  was  amplified  by 
PCR and generated two products of 1165- and  1088-bp long  representing the
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unspliced  and  spliced  transcripts  respectively  (Isegawa  et  al.,  1998).  The 
spliced transcript was generated by the joining of two exons after splicing out of 
a 77nt intron.  The resulting product is a 353aa long polypeptide which exists as 
a seven transmembrane protein.  The binding of a range of chemokines to U12 
was  investigated  by  measuring  intracellular  Ca2+   levels  of  a  U12-transfected 
K562  cell-line  (otherwise with  no surface chemokine  receptor).  It was shown 
that  U12-transfected  K562  cells  responded  to  all  the  p-chemokines  tested 
(RANTES,  MIP-1a,  MIP-1b,  and  MCP-1)  but  not  to  IL-8  (an  a-chemokine). 
Thus,  the  profile of U12  receptor was very similar to that of CCR1.  Although 
1112 transcription was found to be suppressed by PAA treatment in the study by 
Isegawa and  colleagues  (1998)  i.e.  it was assigned as a  L gene,  its apparent 
insensitivity  to  CHX  and  PAA  treatment  has  also  been  documented  in  other 
studies (see chapter 4 for details).  Hence, transcription kinetics of U12 appear 
to be variable.
1.2.7.1.4  U14
U14  encodes  a  75kDa  protein  which  was  shown  to  be  associated  with  p53 
(possibly via other host factors) in HHV-6-infected-cells (Takemoto et al., 2005). 
The  exact function  of U14  and  the  mechanism  of its  interaction with  p53  are 
unclear.  Northern  blot analysis of the  U12-U13-U14  region  revealed  that this 
gene cluster encodes a series of co-terminal transcripts and their expressions at 
72hpi  were  inhibited  by  PAA  treatment  i.e.  they  were  assigned  as  L  genes. 
However,  Western  blot  analysis  revealed  the  presence  of  U14  protein  in 
infected-cells immediately after virus entry.  U14 protein was later found to be 
abundantly incorporated in HHV-6 virions i.e. it was delivered into the cells upon 
infection (Takemoto et al., 2005).
1.2.7.1.5  U16-U17
Northern  analysis  revealed  that  the  locus  of  U16-U17  encodes  at  least  five 
differentially spliced  variants  (Flebbe-Rehwaldt  et  al.,  2000).  The function  of 
these transcripts remains unknown but gene products of two spliced transcripts 
(U17/U16  and  U16+)  were  shown  to  transactivate  HIV-long  terminal  repeat 
(LTR).  Transcription of the different spliced variants appeared to be regulated
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independently.  While the shorter version of U17/U16 was transcribed with  IE- 
gene kinetics, transcription of U16+  exhibited L-gene kinetics.
1.21.1.6  U27
U27  encodes  a  41kDa  nuclear  phosphoprotein  (Chang  and  Balachandran, 
1991) which was found to be associated with the HHV-6 viral DNA polymerase 
(pol)  in  infected-cells  (Lin  and  Ricciardi,  1998).  By  using  an  in  vitro  DNA 
synthesis  assay,  it  was  demonstrated  that  the  U27  protein  (or  p41)  did  not 
exhibit any catalytic  activity on  its  own,  whereas the  use  of HHV-6  pol  alone 
resulted in the synthesis of DNA products that were <100nt in length.  However, 
the  addition  of p41  to  HHV-6  pol was found  to  enhance  the  synthesis of full- 
length DNA products.  Transcription of U27 was suppressed by CHX treatment, 
and to a lesser extent,  by PAA treatment (Zhou et al.,  1997).  This incomplete 
inhibition by PAA suggests that some transcripts were synthesised prior to viral 
DNA  synthesis.  Regarding  the  kinetics  of  U27  protein  synthesis,  the  protein 
was  first  detected  between  8  to  24hpi,  and  its  maximal  expression  was 
observed between 24 to 48hpi (Chang and  Balachandran,  1991).  U27 protein 
expression  was  found  to  be  inhibited  but  not  completely  abolished  in  the 
presence of PAA.  Hence, U27 was considered as an E-L protein.
1.2.7.1.7  U31
U31  encodes a  putative tegument protein which  is a  homolog of HCMV UL48 
(Pellett  and  Dominguez,  2001a).  U31  was  assigned  as  an  E  gene  as  its
expression was not inhibited by PAA treatment (Mirandola et al., 1998).
1.2.7.1.8  U38
U38 encodes a 110kDa protein corresponding to the viral DNA pol (Gompels et 
al.,  1995;  Lin and  Ricciardi,  1998).  It was shown that HHV-6 pol  had a much 
lower  Km  for  deoxynucleotide  triphosphates  (dNTPs)  compared  to  the  host 
DNA polymerase i.e. it is more efficient in competing for the dNTPs required for 
DNA synthesis than that of the host (Bapat et al.,  1989).  Like DNA pol of other 
herpesviruses,  HHV-6  pol  exhibited  a  broader  substrate  specificity  than  host 
polymerases  which  allowed  the  development  of antiviral  compounds  such  as 
nucleoside  analogues  (see  section  1.2.20  for  further  details).  Transcription
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kinetics of U38 were analysed  but the results varied  between different studies 
(see chapter 4 for details).  Regarding the synthesis of U38 protein, its maximal 
expression was observed between 48 to 72 hpi (Lin and Ricciardi, 1998).
1.2.7.1.9  U39
U39 encodes gB, a glycoprotein that is expressed on the viral envelope and is 
conserved  among  herpesviruses  (Pellett  and  Dominguez,  2001a).  It  was 
demonstrated that gB was essential for virus entry (Takeda et al.,  1996b).  U39 
was assigned as an E gene (Mirandola et al., 1998).
1.2.7.1.10  U41
U41 encodes a putative ssDNA binding protein (Pellett and Dominguez, 2001a). 
U41 transcription was shown to be inhibited by CHX- but not PM-treatment i.e. 
it was assigned as an  E gene (Mirandola et al., 1998).
1.2.7.1.11  U42
U42 encodes a putative transactivator which is a homolog of HSV-1  ICP27 and 
HCMV  UL69  (Pellett  and  Dominguez,  2001a).  Since  U42  transcripts  were 
detected  by RT-PCR in  HHV-6-infected-cells treated with  CHX, this gene was 
therefore designated in the IE class (Mirandola et al., 1998).
1.2.7.1.12  U47 and  U48
U47  and  U48  encode  glycoproteins that are  homologs  of HCMV gO  and  gH, 
respectively (Mori JVI04).  It was shown that gO and gH were incorporated into 
the HHV-6 virions and existed as a complex with gL.  The function of gO or the 
gH-gL-gO complex is unclear, whereas gH was implicated in the entry of HHV-6 
(section  1.2.6).  Transcription kinetics of U47 are discussed in chapter 4, while 
U48 was assigned as an E gene (Isegawa et al., 1998).
1.2.7.1.13  U51
U51  encodes a 28kDa, seven-transmembrane protein which is a viral homolog 
of  GCR  (Milne  et  al.,  2000).  This  gene  is  essential  for  lytic  replication,  as 
demonstrated by the lack of viral DNA replication in the presence of U51-siRNA 
(Zhen  et  al.,  2005).  It  was  found  that  the  expression  of  U51  enhanced
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fusogenic  activity  between  cells,  thereby  facilitating  the  cell-to-cell  spread  of 
HHV-6.  Furthermore,  U51  protein showed specific binding to CC chemokines 
including RANTES, and this binding led to a 10-fold downregulation of RANTES 
production  at  both  transcript  and  protein  level  (Milne  et  al.,  2000).  U51
expression was reported to be low in U51 -transfected cells and HHV-6 infected 
cells  (Bradel-Tretheway et al.,  2003;  Menotti  et al.,  1999;  Milne  et al.,  2000). 
However,  it  was  shown  that  enhanced  U51  expression  (>10-fold)  could  be 
achieved  using  a  codon-optimised  U51-expressing  plasmid  (Bradel-Tretheway 
et al., 2003).  Transcription of U51 was sensitive to CHX- but not PAA-inhibition 
i.e. it was assigned as an E gene (Menotti et al., 1999).
1.2.7.1.14  U53
U53 encodes a viral proteinase which is required for the formation of infectious 
virions (reviewed in Pellett and Dominguez, 2001a).  U53 was assigned as an E 
gene (Mirandola et al., 1998).
1.2.7.1.15  U69
It  was  demonstrated  that  the  viral-encoded  protein  kinase  (pU69)  conferred 
ganciclovir  (GCV)  susceptibility  on  baculovirus  (Ansari  and  Emery,  1999), 
suggesting that U69 protein is responsible for the first phosphorylation of GCV. 
U69 transcription is discussed in detail in chapter 4.
1.2.7.1.16  U73
U73 encodes a  homolog of alphaherpesvirus origin  binding  protein which was 
required  for  lytic  DNA  replication  (Dykes  et  al.,  1997),  see  section  1.2.8  for 
further  details).  U73  has  been  classified  as  either  an  IE-  (Mirandola  et  al., 
1998) or E-gene (Rapp et al., 2000) in two different studies.
1.2.7.1.17  U79-U80
The locus of U79-U80 encodes four differentially spliced transcripts and they all 
consist of four exons  (Taniguchi  et al.,  2000).  The first two exons  located  in 
ORF U79 are shared between all transcripts.  They differ in the use of different 
splicing  junctions  for  joining  exon  2  to  3  and  3  to  4.  Products  of  these 
transcripts  are  nuclear  proteins  that  were  shown  to  colocalise  with
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U27(polymerase  processivity  factor)  and  U41  (ssDNA  binding  protein), 
suggesting  that  they  are  associated  with  the  viral  DNA  replication  complex. 
Transcription from this locus was detected, albeit at a low level, in the presence 
of  CHX  but  these  transcripts  were  not  translated  under  IE  conditions. 
Furthermore,  it was found  that the  36-,  41-,  and 44-kDa  proteins,  but not the 
59kDa  protein,  were expressed  in  the  presence of a  DNA synthesis  inhibitor. 
As  a  result,  the  transcripts  corresponding  to  the  former  three  proteins  were 
assigned as E transcripts, while the remaining one as an L transcript.
1.2.7.1.18  U82
U82 encodes gL,  a viral glycoprotein that was found to exist as complexes of 
gH-gL-gQ and gH-gL-gO in infected cells or virions (Akkapaiboon et al., 2004; 
Mori et al., 2004).  The former was implicated in virus entry but the function of 
the latter remains unclear.
1.2.7.1.19  U83
The function and transcription kinetics of U83 are discussed in chapter 4.
1.2.7.1.20  IE1 (U90IU89)  and IE2 (U90/U86)
The  HHV-6  IE-A  locus  contains  five  full  ORFs:  three  are  transcribed  in  the 
antisense  direction  (U86,  U89  and  U90)  and  two  in  the  sense direction  (U88 
and  U91).  The  function  of  U88  and  U91  is  unknown.  Regarding  the  three 
remaining  ORFs  spanning  U86-U90,  this  region  was  shown  to  support  the 
transcription  of  two  major  spliced  transcripts  of  3.5kb  (U90/U89)  and  4.7kb 
(U90/U86)  encoding  IE1  and  IE2,  respectively  (Papanikolaou  et  al.,  2002; 
Takeda  et  al.,  1996a).  It  was  postulated  that  the  both  IE1  and  IE2  shared 
common  exons derived from  ORF  U90  (Schiewe et al.,  1994) and which was 
later confirmed experimentally (Gravel et al., 2003; Papanikolaou et al., 2002).
IE1  protein of HHV-6A and 6B is 941- and  1078-a.a. long, respectively (Gravel 
et  al.,  2002).  It was  shown  by  Western  blot  analysis  that  HHV-6B  IE1  was 
between 155-170kDa in size (Gravel et al., 2004; Gravel et al., 2002; Takeda et 
al.,  1996a).  Peptide  sequence  analysis  identified  a  number  of  putative
phosphorylation  sites  in  IE1.  Indeed,  the  phosphorylation  of IE1  in  HHV-6B-
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infected cells was observed at serine and threonine residues, as demonstrated 
by Western  blot analysis  using  anti-phosphoserine  and  anti-phosphothreonine 
antibodies  (Gravel  et  al.,  2002).  In  addition,  IE1  protein  was  found  to  be 
modified  by small  ubiquitin-like  modifier (SUMO-1),  a  protein  moiety of 11kDa 
which is covalently attached to target lysine (K) residues through four enzymatic 
reactions  (reviewed  in  Boggio  and  Chiocca,  2006).  It was  reported  that  the 
efficiency of IE1  SUMOylation with the two other SUMO proteins (SUMO-2 and 
SUMO-3) was similar to that of SUMO-1  (Gravel et al., 2004).  Putative sites for 
SUMOylation  were  identified,  based  on  the  presence  of consensus  motifs,  at 
K665 for 6A- and  K802 for 6B-IE1  (Gravel  et al.,  2002;  Stanton  et al.,  2002). 
The SUMOylation site of the latter was confirmed by mutation analysis of K802 
(Gravel et al., 2004).  SUMOylation of host cell proteins is associated with the 
regulation of protein stability, protein trafficking, and gene expression (reviewed 
in Seeler and Dejean, 2003).  For example, the assembly of PML-nuclear body 
(PML-NB,  also  known  as  ND10  or  PODS)  was  shown  to  be  dependent  on 
SUMOylation  of  its  constituent  proteins  (reviewed  in  Regad  and  Chelbi-Alix,
2001).  PML-NB is a dynamic nuclear structure that was reportedly involved in a 
wide  range  of  cellular  process  including  transcription,  apoptosis,  DNA 
replication and repair (reviewed in Bernardi and Pandolfi, 2003).  Interestingly, it 
was found  that infection with  herpesviruses such  as  HSV-1  and  HCMV led  to 
the  disruption  of  PML-NB  (Kelly  et  al.,  1995;  Maul  et  al.,  1993).  The  exact 
function  of PML-NB and  its disruption  in the context of herpesviral  infection  is 
controversial  (reviewed  in  Everett and  Zafiropoulos,  2004).  PML-NB  is either 
considered as a negative regulator, or a depot harnessing the required nuclear 
factors for the facilitation of viral DNA replication.
In  the  context  of  HHV-6  infection,  unlike  HSV-1  and  HCMV,  no  dispersal  of 
PML-NB  was  observed  in  productively-infected  cells  (Gravel  et  al.,  2002; 
Stanton et al., 2002).  Instead, PML-NB was found to aggregate into a few large 
nuclear entities containing both IE1  and SUMO-1, and the association between 
IE1  and PML-NB was observed throughout the course of infection (Gravel et al.,
2002).  Mutation  of the  K802  SUMOylation  site,  and  PAA  treatment,  had  no 
effect  on  the  colocalisation  of  IE1  and  PML-NB,  hence  the  HHV-6  mediated 
PML-NB condensation was independent of SUMOylation and the expression of
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L genes (Gravel et al., 2004).  Apart from its association with PML-NB, IE1 was 
shown to be a transactivator of HIV-LTR, albeit a less efficient one compared to 
IE2  (Gravel  et  al.,  2004).  Interestingly,  it  was  demonstrated  that  the  co­
expression of IE1  and  IE2 greatly enhanced the transactivation of HIV-LTR (a 
30-fold increase compared to IE1  alone; (Gravel et al., 2004).  Mutation analysis 
of the K802 site revealed that the SUMOylation status of IE1  had  no effect on 
HIV-LTR  transactivation.  Taken  together,  the  functional  significance  of  IE1 
SUMOylation remains undetermined.
IE2 is a nuclear protein that was found to persist in the nucleus throughout the 
course of HHV-6 infection (Gravel et al., 2003; Papanikolaou et al., 2002).  IE2 
of HHV-6A is 1466 a.a. in length (Tomoiu et al., 2006), which is 167 a.a. shorter 
than its HHV-6B counterpart (Gravel et al., 2003).  HHV-6A IE2 was estimated 
to be 165kDa in size based on its peptide sequence.  However, the size of IE2 
in  infected  cells  was  found  to  be  220-  and  225kDa  for  HHV-6A  and  6B 
respectively, as determined by Western blot analysis (Gravel et al., 2003).  The 
data  suggest  that  IE2  of  both  variants  is  subjected  to  post-translational 
modification.  Peptide  sequence  analysis  revealed  the  presence  of  several 
putative  casein  kinase  II  and  protein  kinase  C  phosphorylation  sites  in  IE2, 
suggesting that it may be a phosphoprotein (Gravel et al., 2003).  Additionally, 
the protein contains at least 40 reiterated tetrapeptide motifs of SSRA,  SSRD, 
SSKA  and  SRKA,  but  the  functional  significance  of  these  repeated  motifs 
remains elusive.  Cotransfection experiments (using an IE2-expressing plasmid 
plus individual promoter attached upstream of a report gene) demonstrated that 
HHV-6A  IE2  was  a  potent  transactivator  of  promoters  including  that  of  CD4 
(Flamand  et al.,  1998),  COX2  (Janelle  et al.,  2002),  HIV-LTR,  HHV-6  IE  and 
other promoter elements such as NFAT, TATA box, CRE, NF-KB (Gravel et al.,
2003).  It was  suggested that  IE2  may play a  role  in  cellular processes other 
than  transcription  regulation,  as  demonstrated  by  its  association  with  other 
cellular proteins such as heterogeneous nuclear riboprotein  K (involved in pre- 
mRNA processing; (Shimada et al., 2004)), the beta subunit of casein kinase 2 
(a  pleiotropic  protein  kinase  with  >100  known  cellular  substrates;  (Pinna, 
1994)),  and  ubiquitin-conjugating  enzyme  9  (UBC-9;  (Tomoiu  et  al.,  2006)). 
The functional significance of the former two protein  partners remains unclear.
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In  contrast,  it  was  shown  that  the  association  of  UBC-9  to  IE2  led  to  the 
suppression  of  IE2  transactivation  of  HIV-LTR  and  COX2  promoters. 
Overexpression of UBC-9 reduced HHV-6A IE but not HIV-1  Tat transactivation 
of both promoters, suggesting that the inhibition was specific to IE2.  Although 
the  interaction  with  UBC-9  is  typically  linked  to  SUMO-conjugation,  both 
confocal  microscopy  and  immunoprecipitation  failed  to  demonstrate  the 
association  of IE2 and  SUMO-1  (Tomoiu  et al.,  2006),  hence the  inhibition  of 
IE2 activity was independent of SUMOylation.
Both  IE1  and  IE2  have  been  consistently  classified  as  IE  genes  in  several 
independent studies  (Gravel  et al.,  2002;  Gravel  et al.,  2003;  Isegawa  et  al., 
1998;  Mirandola  et  al.,  1998;  Papanikolaou  et  al.,  2002;  Rapp  et  al.,  2000; 
Schiewe et al., 1994).
1.2.7.1.21  U91
U91  encodes two mRNA species: the ~570bp unspliced- and ~460bp spliced- 
form (Dominguez et al.,  1999).  The function of U91  protein is unclear.  Kinetic 
analysis of transcription by RT-PCR revealed that the two mRNA species were 
differentially regulated (Mirandola et al., 1998).  For HHV-6A, the unspliced U91 
was  characterised  as  an  IE-  but  the  spliced  one  as  E-gene,  whereas  the 
reverse was reported for HHV-6B.  However, Northern blot analysis of the same 
gene revealed that no U91  transcript was detected under IE condition (Schiewe 
et al., 1994).
1.2.7.1.22  U94
The function and transcription kinetics of U94 are discussed in detail in section
5.1  and section 4.3.7, respectively.
1.2.7.1.23  U95
U95 encodes a spliced gene of about 1.8kb in  length (Takemoto et al., 2001). 
Its cDNA consisted of two exons: exon  1   was 47bp  long and was joined to a 
1.8kb exon 2 by splicing out a  1.6kb intron containing ORF U94 in an inverted 
orientation.  The  function  of  U95  is  unknown.  However,  its  HCMV  homolog 
TRS1  was  shown  to  encode  a  dsRNA  binding  protein  which  prevented  the
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phosphorylation of elF-2alpha, the activation of RNase L, and the shutoff of viral 
and cellular protein synthesis (Child et al., 2004).  In addition, it was shown that 
a  mutant  virus  lacking  U95  failed  to  replicate  in  cell  culture  (Kondo  et  al., 
2003a).
1.2.7.1.24  U100
The  ORF  U100  consists  of  11  exons  and  it  encodes  a  number  of  related 
polypeptides, as a result of differential splicing, that form the gp82-105 complex 
(Pfeiffer et al., 1995).  Two of U100-encoded polypeptides were designated gQ- 
80k  and  gQ-37k  (Akkapaiboon  et al.,  2004).  Both  gQ-80k  and  gQ-37k were 
reported to form virion-associated complexes with gH and gL.  In addition, these 
complexes were shown  to  be targets for virus-neutralising  antibodies i.e.  they 
are implicated in virus entry (Pfeiffer et al., 1993; section 1.2.5).  It was reported 
that transcription of the U100 region followed L gene kinetics (Mirandola et al., 
1998).
1.2.7.2  Abortive replication
Abortive replication designates the incomplete expression of lytic genes leading 
to non-productive infection  i.e.  no production of infectious progeny.  Several in 
vitro  studies  have  described  the  detection  of  a  subset  of viral  transcripts  in 
infected  cells,  but  not  expression  of  late  viral  antigens  nor  production  of 
infectious  virions  (Ahlqvist  et  al.,  2005;  Donati  et  al.,  2005;  Yoshikawa  et al.,
2002).  In addition, all three studies have demonstrated the gradual decrease in 
the  copy number of viral  genome over time during  long term  culture of these 
abortively-infected  cells.  However,  the  biological  significance  of  abortive 
replication in vivo is unclear.
1.2.8  Viral DNA replication
The mechanism for DNA replication of herpesviruses  is best characterised for 
HSV-1  (reviewed in Boehmerand Lehman, 1997; Lehman and Boehmer,  1999; 
Roizman  and  Knipe,  2001).  Soon  after the synthesis of early  proteins  in  the 
cytoplasm, they are translocated  into the nucleus and aggregate at the HSV-1 
origins (the cis-elements required for DNA replication) to form the prereplicative 
sites,  which  mark  the  start  of  DNA  replication.  There  are  three  origins  of
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replication  (orl)  in  the  HSV-1  genome:  or/L  and  two  copies  of  oriS.  The 
sequence  of  oriS  and  or/L  differ  in  size  but  has  similar  core  structure;  a 
sequence containing imperfect palindrome with an AT-rich stretch at its centre, 
which  is  flanked  by the  binding  sites of origin-binding  protein  (OBP;  Lehman 
and  Boehmer,  1999).  The  use  of temperature-sensitive  viral  mutants  and  in 
vitro DNA replication assays helped to identify the other trans-elements required 
for  HSV-1  replication.  It  was  shown  that  the  expression  of  seven  HSV-1 
proteins  were  sufficient  to  reconstitute  the  in  vitro  replication  of  HSV-1  ori- 
containing plasmids.  These included the viral DNA pol (UL30), ssDNA-binding 
protein  (SBP;  UL29),  DNA  pol  processivity  factor  (UL42),  components  of 
helicase-primase  protein  complex  (UL5,  UL8  and  UL52),  and  OBP  (UL9)  as 
described  previously.  Apart  from  the  OBP,  six  of  the  seven  proteins  were 
conserved  among  all  human  herpesviruses  (Davison  et al.,  2002),  suggesting 
that their DNA  replication  shares  a  common  mechanism.  In  addition,  HSV-1 
encodes  a  number  of  proteins  involved  in  nucleotide  metabolism  including 
thymidine kinase  (TK),  deoxyuridine triphosphatase (dUTPase),  ribonucleotide 
reductase, uracil N-glycosylase, and alkaline nuclease.  Although these proteins 
were shown to be non-essential for DNA replication in vitro, most likely they had 
an important role in facilitating HSV-1  replication in terminally-differentiated cells 
such as neurons.
Based  on  the  available  information,  a  model  for  HSV  DNA  replication  was 
proposed (Boehmer and Lehman,  1997; see figure 1.7 for an illustration).  This 
involved the (1) circularisation of viral DNA, (2) the binding of OBP and SBP to 
the  origin  leading  to  the  localised  distortion  of  DNA,  which  facilitates  (3)  the 
recruitment  of  helicase-primase  complex  for  the  unwinding  of  DNA  and 
synthesis  of  primers,  thereby  allowing  the  extension  by  pol  and  UL42.  It  is 
believed  that  (4)  initial  HSV-1  replication  proceeds  in  the  theta  mode,  but 
subsequently  switched  to  (5)  the  rolling  circle  mode  by  an  undefined 
mechanism, leading to (6) the formation of head-to-tail concatamers.
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Figure 1.7  A model for HSV-1 replication
ICP8 (SSDNA BINDING PROTEIN)
UL9 (ORIGIN BINDING PROTEIN)
INITIATION
HELICASE-PRIMASE
POLYMERASE/
POL. ACCESSORY FACTOR
THETA REPLICATION
UL9 (ORIGIN BINDING 
PROTEIN)
ROLLING CIRCLE REPLICATION
See text for description (section 1.2.8). 
Adapted from Roizman and Knipe, (2001).
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HHV-6  replication  is  believed  to  adopt  a  similar  mechanism  as  the  one 
proposed  for  HSV-1  (reviewed  in  Pellett  and  Dominguez,  2001a;  Pellett  and 
Black,  1996).  The virus is  believed to replicate via a rolling circle mechanism 
based on the identification of head-to-tail concatamers in infected cells (Martin 
et al., 1991).  In addition, HHV-6 encodes homologs of all seven HSV-1  proteins 
required  for  DNA  replication,  including:  viral  DNA  pol  (U38),  SBP  (U41),  pol 
processivity factor (U27), components of helicase-primase complex (U43,  U74 
and  U77),  and  OBP (U73).  U73 protein  is conserved  among  a-herpesviruses 
and HHV-7, but not in other human herpesviruses including HCMV, suggesting 
that  the  initiation  of  HHV-6  replication  is  more  similar  to  that  of  a-  than  p- 
herpesvirus (Inoue et al.,  1994;  Krug et al., 2001).  The predicted size of U73 
protein was 90kDa which is similar to the one observed for the in vitro translated 
protein  (~95kDa)  (Inoue  et  al.,  1994).  Sequence  analysis  of  U73  protein 
revealed  the  presence  of  a  helicase  motif  which  is  well  conserved  among 
OBPs.  However, the region corresponding to the DNA-binding domain differs to 
that  of  other  OBPs  (Inoue  et  al.,  1994),  which  may  explain  its  failure  to 
recognise binding sites of HSV-1  OBP.  Similar to HSV-1,  HHV-6 replication is 
thought to  be  initiated  by the  binding  of U73  and  U41  to  HHV-6  origin.  The 
origin  of lytic replication  (or/Lyt) was first  identified  in  HHV-6B  genome  at the 
intergenic region between SBP (U41) and U42 (a homolog of HSV-1  ICP27), a 
positional  homolog of origin of other herpesviruses including  HSV-1, VZV, and 
HCMV (Dewhurst et al.,  1993a;  Inoue et al.,  1994).  A similar genetic element 
was also reported for HHV-6A (Dewhurst et al.,  1993a) but only the 6B-version 
has  been  functionally  characterised.  It was  suggested  that the  minimal  core 
domain  of  HHV-6B  or/Lyt  contained  two  binding  sites  for  U73  protein,  as 
mapped  by gel  mobility shift assays,  which  are  separated  by  a  short AT-rich 
spacer  (Inoue  et  al.,  1994;  Inoue  and  Pellett,  1995).  Further  experiments 
demonstrated  that  plasmids  containing  the  putative  HHV-6  or/Lyt  were 
replicated in the presence of helper virus (Borenstein et al., 2004;  Dewhurst et 
al.,  1993a;  Turner  et  al.,  2002).  Interestingly,  it  was  reported  that  some 
laboratory-passaged  HHV-6B  genomes  contained  amplified  copies  of  or/Lyt, 
and  this  conferred  growth  advantage  in  vitro  (Stamey  et  al.,  1995).  Other 
essential components of HHV-6 replication that were functionally characterised 
include  U27  and  U38  (see  sections  1.2.7.1.6  and  1.2.7.1.8),  however,  no
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experimental data is available for U41, U43, U74 and U77.  By analogy to other 
herpesviruses,  HHV-6  encodes  a  number of non-essential  early  proteins  that 
are  involved  in  nucleic  acid  metabolism,  including:  dUTPase  (U45), 
phosphotransferase  (U69),  alkaline  exonuclease  (U70)  and  uracil-DNA 
glycosylase (U81) (Clark, 2000; Pellett and Dominguez, 2001a).
1.2.9  Virus assembly and release
The formation and  release of herpesviruses can  be  broadly divided  into three 
main steps: (1) capsid assembly, (2) DNA encapsidation, and (3) virus egress. 
All of these steps are dependent on the expression of L genes, which typically 
encode  structural  proteins  (Roizman  and  Knipe,  2001).  L  proteins  generally 
contain cellular sorting signals for trafficking to the subcellular locations to fulfill 
their  specific  functions  (Hunter,  2001).  Little  data  is  available  regarding  the 
formation and release of HHV-6 virions, but these events are better delineated 
for HSV-1 and HCMV.
1.2.9.1  Capsid assembly
In HSV-1, the capsid proteins are transported into the nucleus where the capsid 
assembly  occurs  (reviewed  in  Roizman  and  Knipe,  2001).  These  proteins 
include the major capsid  protein (VP5 or UL19), the outer tip of hexons (VP26 
or UL35),  two different capsid  triplex proteins (VP23 and VP19C or UL18 and 
UL38,  respectively), and a scaffold protein (VP22a or UL26).  Studies tracking 
the  movement of capsid  proteins  by  immunofluorescence  suggested  that the 
initial assembly of some proteins took place in cytoplasm,  possibly to facilitate 
the  nuclear  transportation  of  capsid  components  which  lack  the  nuclear 
localisation  signal  (NLS) e.g.  VP5.  Much  of the current knowledge about the 
process of capsid formation derived from in  vitro assembly experiments  using 
HSV-1  proteins  expressed  by  baculoviruses.  The  assembly  of  functional 
capsids  was  initiated  by  the  complexes  containing  the  HSV-1  portal  protein 
(UL6; further details later), VP5 and VP22a (Newcomb et al., 2005; Newcomb et 
al.,  1999).  The subsequent capsid  polymerisation involved the cross-linking of 
further VP5-VP22a complexes (excluding  UL6) with the capsid triplex proteins 
(VP23 and VP19C) to form a partial capsid, and further additions of capsomers 
comprising  either VP5-hexamers  or VP5-pentamers  to  turn  the  partial  capsid
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into a procapsid (Roizman and Knipe, 2001; Zhou et al., 2000).  Following DNA 
encapsidation  (further  details  later),  the  procapsids  are  processed  by  viral 
protease  to  become  mature  capsids  (the  structural  changes  are  reviewed  in 
Heymann et al., 2003), which are classified into three types: A capsids - contain 
the outer shell only without scaffolding protein or DNA,  B capsids - contain the 
outer shell and scaffolding protein, C capsids - contain the outer shell and DNA 
but not scaffolding protein.  Only the C capsids have the potential of becoming 
infectious  virions  (Roizman  and  Knipe,  2001).  There  is  no  data  on  HHV-6 
capsid assembly except for the characterisation of U53 (proteinase; Tigue and 
Kay,  1998;  Tigue et al.,  1996),  but homologs of all  HSV-1  capsid  proteins are 
present  in  the  HHV-6  genome  (see  Table  1.3).  These  include  U29  (capsid 
triplex protein),  U32 (the outer tip of hexons),  U56 (capsid triplex protein), and 
U57 (major capsid protein).
1.2.9.2  DNA encapsidation
The aim of DNA encapsidation is to process the head-to-tail DNA concatamers 
into  unit-length  viral  genomes  for  packaging  into  procapsids,  leading  to  the 
formation of C capsids (reviewed in Roizman and Knipe, 2001).  Encapsidation 
of HSV-1  DNA  required  the  pad  and  pac2  packaging  signals within  the viral 
genome  (Deiss  et  al.,  1986),  and  the  expression  of  seven  viral  proteins 
including UL6, UL15, UL17, UL25, UL28, UL32 and UL33 (Salmon and Baines, 
1998).  Neither the  processing  of unit-length  viral  genome  from  concatamers 
nor  formation  of  C  capsids  were  observed  in  the  absence  of  any  of  these 
proteins (Salmon and Baines,  1998).  Regarding the function of these proteins, 
the properties of UL6 proteins were found to be similar to the portal proteins of 
DNA bacteriophages (Newcomb et al., 2001).  These include the observations 
that UL6 proteins were labeled at one vertex site per capsid, and they formed a 
ring-like structure on the capsid which possibly act as a channel through which 
viral  DNA  can  pass.  Consistent  with  this  assessment,  further  EM  study 
demonstrated  that  the  architecture  of  UL6  proteins  was  similar  to  that  of 
bacteriophage  portal  proteins  (Trus  et al.,  2004).  In  addition,  the  interaction 
between UL6 and a putative terminase was reported (White et al., 2003).  This 
terminase  consisted  of UL15  and  UL28,  which  are  homologs  of HCMV  UL89 
and UL56, respectively (Roizman and Knipe, 2001).  The HCMV terminase was
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better characterised  than  its  HSV-1  counterparts  (reviewed  in  Bogner,  2002). 
Briefly, gel mobility shift assays revealed the binding of UL56 to DNA containing 
both  pad  and  pac2  signals  (Bogner et al.,  1998).  It was  reported  that  both 
UL56 and UL89 possessed nuclease activity, as demonstrated by the nicking of 
plasmids  in  the  presence  of  purified,  baculovirus-expressed  UL56  and  UL89 
(Bogner et  al.,  1998;  Scheffczik  et  al.,  2002).  It was  also  shown  that  UL56 
protein  contained  ATPase  activity which  may  play  a  role  in  driving  the  DNA 
translocation into the capsid (Hwang and  Bogner, 2002).  The function of four 
remaining proteins is not very well-characterised: UL17 was reportedly involved 
in the efficient binding of UL25 (a putative portal-capping protein; (Newcomb et 
al.,  2006) to the capsid  (Thurlow et al., 2006),  UL32 was implicated  in nuclear 
localisation  of capsids  (Lamberti  and  Weller,  1998),  and  UL33  was  shown  to 
associate with the terminase (Beard et al., 2002).  In the context of HHV-6, pad 
and  pac2  were  identified  at  the  left  and  right  genomic  termini  of  HHV-6, 
respectively (Deng and Dewhurst, 1998).  It was found that plasmids containing 
the pac2-pac1  element were cleaved in HHV-6B infected cells.  Furthermore, it 
was  reported  that  both  green  fluorescent  protein  (GFP)-  and  gD-expressing 
amplicons containing pad  and pac2 were packaged into virions in the presence 
of  helper  virus,  as  demonstrated  by  the  apparent  transduction  of  uninfected 
cells by the culture supernatants containing virions incorporating the GFP- and 
gD-expressing plasmids (Borenstein et al., 2004).  Although there is no data on 
the  HHV-6  proteins that are  implicated  in  DNA encapsidation  including  portal 
protein  (U76),  terminase  (U66 and  U40),  and  homologs of UL17,  UL25,  UL32 
and  UL33  (U64,  U50,  U36  and  U35,  respectively),  by  analogy to  HSV-1  and 
HCMV, they should function in similar ways (Pellett and Dominguez, 2001a).
1.2.9.3  Virus egress
Virus egress represents the final step in the release of infectious virions.  This 
requires the development of C capsids into virus particles after the acquisition of 
tegument proteins (reviewed in Mettenleiter, 2002) and viral envelope, together 
with  their  translocation  from  the  nucleus  to  the  plasma  membrane  of  the 
infected  cells for their release  into the  extracellular space.  The  route for the 
intracellular  movement  of virus  particles  is  controversial  (reviewed  in  Hunter, 
2001; Mettenleiter, 2002; Roizman and Knipe, 2001) but two models have been
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proposed:  the  (1)  reenvelopment  or  (2)  lumenal  pathways  (see  figure  1.8). 
Much of the experimental data supporting these two models were derived from 
EM examinations of the localisation and morphology of intracellular virions of a- 
herpesviruses.  Briefly, the first model suggests that nucleocapsid buds through 
the inner nuclear membrane to reach the perinuclear space.  This is followed by 
the  de-envelopment  at  the  outer  nuclear  membrane  to  release  the  naked 
nucleocapsid into the cytoplasm where the tegument proteins may be acquired. 
Eventually  the  reenvelopment  of  nucleocapsid  occurs  at  cytoplasmic 
membranes,  possibly  at the  frans-Golgi  network,  to  form  an  infectious  virion. 
The  second  model  proposes  that  the  nucleocapsid  buds  through  the  inner 
nuclear membrane to form  a  primary virion.  Subsequently,  the  primary virion 
transverses through the endoplasmic reticulum (ER) and the Golgi apparatus to 
the cell surface.  To complicate the matter further, a recent report observed that 
HSV-1  infection led to the disruption of nuclear pores in the infected cells, and 
proposed  that  nucleocapsids  can  be  released  directly  into  the  cytoplasm 
through  these  disrupted  pores  (see  reply to  Campadelli-Fiume  and  Roizman, 
2006).  However,  this finding  was  not reproduced  in two  independent studies 
(Mettenleiter, 2002;  Remillard-Labrosse et al., 2006), thus casting doubt on the 
validity of this  model.  The  relative  merits  of the  different  models  have  been 
extensively  reviewed  (Campadelli-Fiume  and  Roizman,  2006;  Hunter,  2001; 
Mettenleiter,  2002;  Mettenleiter and  Minson,  2006;  Roizman and  Knipe,  2001) 
and therefore will not be discussed here.
In the context of HHV-6, the pathway for virus egress appears to be closer to 
the  reenvelopment  model  based  on  the  limited  amount  of  experiment  data 
(reviewed  in  Hunter,  2001;  Pellett  and  Dominguez,  2001a).  The  supporting 
evidence includes: (1) primary virions in the perinuclear space displayed no sign 
of  tegument,  (2)  the  large  number  of  naked  nucleocapsids  observed  in  the 
cytoplasm,  (3)  the  associations  between  nucleocapsids  and  tegument  in  the 
cytoplasm,  (4)  the  absence  of  virion  glycoproteins  in  both  the  nuclear  and 
plasma  membranes  but  they  are  abundantly  expressed  in  cytoplasmic 
structures  known  as  annulate  lamellae  i.e.  possible  cytoplasmic  site  for 
reenvelopment.
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A schematic diagram illustrating the two different models of viral morphogenesis and egress
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(1) Reenvelopment pathway, (2) lumenal pathway.  See text for description (section 1.2.9.3). 
Adapted and modified from Roizman and Knipe, (2001).General Introduction
1.2.10  Effect on host cell
The  effects of HHV-6  infection on  host cells have  been  reviewed  (Pellett and 
Dominguez,  2001a;  Pellett and  Black,  1996).  Briefly,  the  virus-induced  CPE 
include  ballooning  of  cells,  increased  cell  refractility,  syncytia  formation  and 
ultimately  cell  lysis  (see  figure  1.9).  Furthermore,  it was  shown  that  HHV-6 
infection  (1) inhibited host DNA synthesis (Di Luca et al.,  1990), (2) stimulated 
host  cell  protein  synthesis  (Black  et  al.,  1992),  (3)  enhanced  expression  of 
specific host proteins such as interferon-a (Kikuta et al.,  1990), tumor necrosis 
factor-a  (Flamand  et  al.,  1991)  and  EB1  (Hasegawa  et  al.,  1994),  (4) 
suppressed CXCR4 expression (Secchiero et al., 1998; Yasukawa et al., 1999), 
and  (5)  induced  apoptosis  in T lymphocytes (Inoue et al.,  1997;  Yasukawa et 
al.,  1998).  However,  some effects were variant-specific and only observed  in 
cells  infected with  HHV-6A, which  included the upregulation of CD4  (Lusso et 
al.,  1995), the downregulation of CD3 (Lusso et al.,  1991b) and  interleukin-1 (3  
(Flamand et al.,  1991).  This section covers recent findings that have not been 
reviewed previously.
1.2.10.1  Cell cycle
Recent  studies  have  provided  insight  into  the  interaction  between  HHV-6 
infection  and  cell  cycle  progression.  It  was  demonstrated  that  productive 
infection with HHV-6 led to arrest in the cell cycle (De Bolle et al., 2004b; Oster 
et al., 2005).  Fluorescent-activated cell sorting (FACS) analyses revealed that 
both HHV-6A- and HHV-6B-infected cells accumulated at G2/M phase of the cell 
cycle, but also at G1/S phase for the latter.  It was suggested that the cell cycle 
arrest was mediated through the p53 pathway for HHV-6B (Oster et al., 2005) 
but not for HHV-6A (De Bolle et al., 2004b).
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Figure 1.9  The cytopathic effects of HHV-6 in vitro 
(a) uninfected SupT1  cells
(b)  HHV-6B(Z29)-infected SupT1  cells showing typical CPE including, 
(i) ballooning of cells, (ii) increased cell refractility, and (iii) cell lysis.
(c)  HHV-6B-induced syncytia formation of SupT1  cells
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1.2.10.2  p53
The  upregulation of p53 as a  result of infection with  HHV-6A or 6B  has been 
demonstrated  in  cord  blood  mononuclear  cells  (CBMCs)  and  a  range  of 
continuous  cell-lines  such  as  Molt-3  (T cells),  U937  (monocytes)  and  HepG2 
(hepatocytes) (De Bolle et al., 2004b; Oster et al., 2005; Takemoto et al., 2004). 
However, the levels of downstream effectors of p53 such as p21,  14-3-3sigma, 
and  PUMA  in  HHV6-infected  cells  were  unaffected  (De  Bolle  et  al.,  2004b; 
Oster et al., 2005).  The function of this p53 enhancement is unclear, but it was 
observed only in virus-infected cells but not in bystander cells, as shown by the 
co-staining of p53 and HHV-6 IE1  (Takemoto et al., 2004).  The increase in p53 
level was detected as early as 2hpi  (De  Bolle et al.,  2004b),  peaked  at 48hpi 
and  remained high until 72hpi (De Bolle et al.,  2004b; Takemoto et al., 2004). 
In  contrast,  the  alteration  of p53  was  not detected  in  cells  infected  with  UV- 
irradiated virus suggesting that the synthesis of viral products was required (De 
Bolle et al., 2004b; Oster et al., 2005; Takemoto et al.,  2004).  Transfection of 
vectors  expressing  HHV-6  IE1  and  U95  failed  to  induce  p53  indicating  that 
these two genes alone were insufficient for upregulating p53 (Takemoto et al.,
2004).  Pulse chase experiments showed that HHV-6 infection enhanced  both 
the  stability  and  synthesis  of  p53  protein.  In  mock-infected  cells,  the  p53 
protein  was  mainly found  in  the  nucleus where  it  is functional,  and  thus  they 
were susceptible to p53-dependent apoptosis when exposed to lethal doses of 
UV.  However,  as shown  by immunofluorescence assay (IFA),  the  majority of 
p53 in  HHV-6-infected cell localised in the ER and Golgi apparatus (Takemoto 
et al., 2004).  The increased levels of cytoplasmic p53 in  HHV-6-infected cells 
were observed in two independent studies (De Bolle et al., 2004b; Oster et al.,
2005).  The  absence  of  p53  in  the  nucleus  at  any  stage  of  HHV-6  infection 
suggested that the localisation of p53 was affected by viral products (Takemoto 
et  al.,  2004),  and  the  cells  would  be  resistant  to  p53-dependent  apoptosis. 
Indeed, UV exposure of cells infected with HHV-6 at 24hpi showed little sign of 
apoptosis.  However,  the  infected  cells  at  6hpi  became  apoptotic  after  UV 
exposure.  The time lag between the increase of p53 (4hpi) and the resistance 
to UV-induced apoptosis (24hpi) suggested that the two effects were mediated 
by different viral products.  Recently, HHV-6 U14 was found to interact with p53 
and  they  were  both  packaged  in  the  virions  (Takemoto  et  al.,  2004).  The
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association  between  the  two  proteins was  confirmed  by  immunoprecipitation. 
HHV-6 U14 was found to localize to both nucleus and cytoplasm, hence it was 
not  responsible  for  inhibiting  the  nuclear  localization  of  p53.  The  functional 
significance  of the  association  between  HHV-6  U14  and  p53  remains  to  be 
defined.
1.2.10.3  RANTES
The expression of RANTES was shown to be upregulated  in  endothelial  cells 
and  marcophages  infected  with  HHV-6A  (Caruso  et  al.,  2003;  Csoma  et  al.,
2006).  The increased  levels of RANTES mRNA were detected  after 6hpi and 
peaked  at 24hpi  (Caruso  et al.,  2003).  However,  this study failed  to  provide 
sufficient  data  to  determine  whether  HHV-6A  infection  exerted  a  direct  or 
indirect effect on RANTES expression.
1.2.10.4  Interleukin 8
It was reported that transcription of interleukin-8 (IL-8) was markedly increased 
in HHV-6B-infected HepG2 cells (hepatocytes;  Inagi et al.,  1996) and  HHV-6A- 
infected  macrophages  (Csoma  et  al.,  2006).  No  changes  in  IL-8  expression 
was  observed  in  cells  inoculated  with  either  heat-inactivated  or  UV-irradiated 
HHV-6  i.e.  the  upregulation  was  dependent  on  viral  replication  (Inagi  et  al.,
1996).
1.2.10.5  Interleukin 12
Interleukin-12 (IL-12) is  a cytokine mainly produced by antigen-presenting cells
such as mononuclear phagocytic cells and dendritic cells  (DCs).  Two reports 
demonstrated  that  IL-12  production,  as  measured  by  Enzyme-Linked 
ImmunoSorbent  Assay  (ELISA),  was  significantly  reduced  (by  >90%)  in 
macrophages and stimulated DCs infected with either HHV-6A or 6B (Smith et 
al.,  2003;  Smith  et al.,  2005).  Interestingly,  similar levels of IL-12  production 
were observed  in cells infected with  UV-inactivated virus,  suggesting that viral 
replication was not required for the suppression.  IL-12 (p70) is a heterodimer 
comprises alpha- (p35) and beta-chain (p40).  The two chains are encoded by 
different genes and their expression is independently regulated.  No change in 
expression  level  of  both  transcripts  was  observed  in  HHV-6-infected
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macrophages,  suggesting  that  the  IL-12  was  repressed  at  the 
posttranscriptional  level  (Smith  et al.,  2003).  It was suggested  that the  IL-12 
suppression was mediated by binding of HHV-6 to CD46 but this has yet to be 
confirmed experimentally (Smith et al., 2003).
1.2.10.6  Interleukin-15
It  was  reported  that  HHV-6A  infection  stimulated  interleukin-15  (IL-15) 
expression in PBMCs and monocytes (Flamand et al.,  1996).  The increase in 
expression of IL15 mRNA was first detected at 2hpi and  peaked at 10hpi at a 
level that is three-fold higher than mocked-infected cells.  This induction of IL-15 
was also observed at the protein level with a slightly delayed kinetics.  Further 
analysis  revealed  that the  IL-15  expression was  not  detected  in  T  and  B-cell 
fractions  of  PBMCs.  However,  it  was  shown  that  UV-  and  heat-inactivated 
HHV-6A was still capable of upregulating IL-15 expression, hence the induction 
was independent of viral gene expression and the presence of thermolabile viral 
components.
1.2.10.7  Major histocompatibility complex  class I
DCs  are  permissive  to  both  HHV-6A  and  6B  (section  1.2.12),  however,  only 
HHV-6A-infected  DCs  exhibited  a  reduced  expression  level  of  major 
histocompatibility  complex  (MHC)  class  I  (Hirata  et  al.,  2001).  MHC  class  I 
expression was downregulated as early as 2hpi and almost completely inhibited 
by 12hpi.  No reduction of MHC class I was reported in cells infected with UV- 
inactivated virus i.e. the effect is dependent on viral replication.  Other cell types 
such  as  macrophages,  T-  and  B-cells  infected  with  HHV-6A  were  also 
examined but no suppression of MHC class I was detected.  Thus, the effect in 
this in vitro model appears to be specific to DCs.
1.2.10.8  DC-SIGN
It was demonstrated that the cell surface expression of DC-SIGN (Dendritic Cell 
-   Specific  Intercellular  Adhesion  Molecule-grabbing  Nonintegrin),  or  CD209, 
was downregulated in immature DCs infected with HHV-6B (Niiya et al., 2004). 
The  downregulation  was  first  detected  at  3dpi  and  the  analyses  by  reverse- 
transcriptase-polymerase  chain  reaction  (RT-PCR)  and  Northern  blot showed
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that the  expression  was  regulated  at the transcriptional  level.  Similar  results 
were  obtained  in  immature  DCs  infected  with  HHV-6A.  The  effect was virus 
specific since  no  suppression  of DC-SIGN  was  observed  with  UV-inactivated 
HHV-6  inoculum.  DC-SIGN  is a  surface  marker on  DCs which  interacts with 
ICAM-3  and  ICAM-2  to  mediate  the  T  lymphocyte  activation  and  peripheral 
roaming of the DCs respectively.  Hence, its downregulation may play a role in 
modulating host response against HHV-6 infection.  In addition,  DC-SIGN was 
also identified as a receptor for HIV-1.  However, it was shown that HHV-6 was 
able  to  infect  DCs  in  the  presence  of  mAbs  against  DC-SIGN  (Niiya  et  al.,
2004).  Hence, DC-SIGN is not involved in the binding and entry of HHV-6.
1.2.10.9  Cyclooxygenase-2
Expression  of  cyclooxygenase-2  (Cox-2)  was  reported  to  be  upregulated  in 
monocytes  infected with  HHV-6B  (Janelle et al.,  2002).  The enhancement of 
Cox-2  protein  was  detected  at  4-8hpi,  whereas  none  was  expressed  in  the 
mock-infected  monocytes.  By  analysing  the  activity  of  a  reporter  plasmid 
containing the Cox-2 promoter, it was demonstrated that the activation of Cox-2 
was dependent on viral gene expression, as no promoter activity was observed 
in  monocytes  infected  with  UV-  or  heat-inactivated  virus.  Further  analysis 
revealed  that  HHV-6  IE2  was  highly  efficient  in  transactivating  the  Cox-2 
promoter, possibly via the binding to the cyclic AMP-responsive element.  COX-
2  is  one  of  the  two  types  of  cyclooxygenease  enzymes  which  regulate  the 
biosynthesis of prostaglandin  E2  (PGE2).  The  upregulation  of COX-2  in  turn 
enhances the expression of PGE2.  It was suggested that HHV-6 infection may 
benefit from higher levels of PGE2 in two ways.  Firstly, the efficiency of HHV-6 
replication in PBMCs was improved in the presence of PGE2.  Secondly, PGE2 
was  shown  to  inhibit  the  synthesis  of  a  wide  range  of  proinflammatory 
cytokines,  thus  facilitating  the  negative  modulation  of  the  immune  response 
against HHV-6.
1.2.11  Physiochemical properties
The  virus  particles,  either  enveloped  or  naked,  are  released  into  the  culture 
supernatant by HHV-6-infected cells and the number ranged between 4 x 108  to
3 x  109   particles  per ml  (Shiraki  et al.,  1991).  The virus  particle to  infectivity
64General Introduction
ratio  of  HHV-6  was  estimated  to  be  approximately  103:1,  and  those  of VZV, 
HSV, & HCMV were approximately 106:1, 10-80:1  and 160-1050:1, respectively 
(Shiraki et al., 1991).  To arrange them in ascending order in terms of particle to 
infectivity ratio:  VZV «   HHV-6 <  HCMV <  HSV.  The virus was stable below 
37°C  during  virus  inoculation.  The  infectivity  was  halved  or  abolished  if 
inoculating at 42°C and 50°C, respectively.  The infectivity of HHV-6 was found 
to  be  affected  by  pH.  HHV-6  was  stable  at  pH  values  above  6.5,  but  the 
infectivity was shown to be significantly reduced below this critical point.
1.2.12  Cell tropism and host range
HHV-6  is  potentially  tropic  for  all  types  of  human  cells  (except  erythrocytes) 
according to the surface expression of CD46 (section 1.2.6).  This is reflected in 
the detection of HHV-6 DNA in a broad range of tissue samples (see table 1.4). 
However,  many  cell  types  were  non-permissive  to  HHV-6  infection  in  vitro, 
suggesting that virus entry may require the presence of co-receptors (table 1.5; 
Pellett and  Dominguez,  2001a).  Successful  HHV-6  entry  in  certain  cell-lines 
has  been  demonstrated  by the  detection  of viral  transcripts/proteins,  but viral 
replication was often abortive  (particularly in cell-lines that are originated from 
the  central  nervous  system  (CNS;  see  table  1.5),  suggesting  the  possible 
requirement  of  cell-specific  host  factors  for  productive  infection.  There  are 
conflicting data in the literature regarding the permissiveness of individual cell- 
types  to  HHV-6  infection,  e.g.  dendritic  cells  (table  1.5).  Reasons  for  the 
discrepancies between studies are not apparent, but may be attributable to the 
use of different virus strains or culturing conditions.  Efficient viral replication is 
achieved  only  in  cells  of T-lymphocyte  lineage.  Interestingly,  the two  HHV-6 
variants  showed  differential  tropism  for  T  cells:  HHV-6A  predominately 
replicated  in immature T cell-lines such as JJHAN  and  HSB-2, whereas  HHV- 
6B replication was more efficient in mature T cell-lines such as Molt-3 and MT-4 
(Di Luca et al., 1996).
Betaherpesviruses  are  characterised  by  their  restricted  host  range  (Roizman 
and Pellett, 2001).  Only cell-types of human- and chimpanzee-origin have been 
shown  to  be  permissive  to  HCMV  and  HHV-6  infection,  whereas  cells  from 
other  simian  species  were  non-permissive  (Lusso  et  al.,  1990;  Perot  et  al.,
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1992).  Incidentally,  a  recent report described  the  identification  of PanHV6,  a 
simian homologue of HHV-6 (Lacoste et al., 2005).  This discovery was based 
on the detection of HHV-6-like sequences in blood samples from chimpanzees 
(21/77  positive,  3/4 species) by PCR.  However,  the  isolation  of PanHV6  has 
yet to be demonstrated.
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Table 1.4  Distribution of HHV-6 in ex vivo tissues and cell types
Tissue____________________
Aortic endothelium 
Astrocytes 
Astrocytes 
Bone marrow 
Brain tissue 
Brain tissue 
Brain tissue 
CD34+  cells 
Cerebrospinal fluid 
Cervical cells 
Cervix 
Cord blood 
Cord blood
Early bone marrow progenitors
Fibroblast
Granulocytes
Human PBMCs
Intestines
Labial
Large intestine
Liver
Lung
Lung tissue
Lymph nodes
Lymph nodes
Macrophages
Microglia
Microglia
Monocytes
Monocytes/Macrophages 
Natural Killer cells 
Neurons
Oligodendrocytes 
Oligodendrocytes 
Pancreas 
Plasma 
Prostate 
Salivary glands 
Salivary glands 
Skin
Stomach
Thyroid
Tonsil
Urinary Tract
* denotes variants not specified
Comment
HHV-6B
Co-infection with HIV-1* 
*
*
*
HHV-6  A and 6B
HHV-6B
*
HHV-6A and 6B 
*
HHV-6B 
HHV-6  A and 6B
HHV-6  A 
*
HHV-6A and 6B 
*
HHV-6B
HHV-6B
★
HHV-6B 
HHV-6A and 6B 
HHV-6A and 6B 
HHV-6A and 6B 
Co-infection with HIV-1* 
Co-infection with HIV-1*
HHV-6B
HHV-6A
Co-infection with HIV-1*
Co-infection with HIV-1*
*
*
HHV-6A and 6B
HHV-6B,  low  prevalence;  1/9
HHV-6B
*
HHV-6A and 6B 
★
★
it
HHV-6B
Reference________________
(Rotola et al., 2000)
(Saito et al.,  1995)
(Goodman et al., 2003) 
(Yoshikawa etal.,  1991)
(Luppi et al.,  1995)
(Chan et al., 2001b)
(Donati et al., 2003) 
(Andre-Garnier et al., 2004) 
(Hall et al.,  1998)
(Chan et al., 2001a)
(Di Luca et al., 1996)
(Hall et al., 2004)
(Adams et al., 1998)
(Luppi et al.,  1999)
(Di Luca et al.,  1996)
(Luppi et al.,  1999)
(Di Luca et al.,  1996)
(Chen and Hudnall, 2006)
(Di Luca et al.,  1996)
(Amo et al., 2003)
(Chen and Hudnall, 2006)
(Di Luca et al.,  1996)
(Cone et al.,  1996)
(Di Luca et al.,  1996)
(Levine et al.,  1992)
(Saito et al.,  1995)
(Saito et al.,  1995)
(Goodman et al., 2003)
(Kondo et al., 2002a)
(Kondo et al.,  1991)
(Lusso et al.,  1993)
(Saito et al.,  1995)
(Saito et al.,  1995)
(Goodman et al., 2003)
(Chen and Hudnall, 2006) 
(Reddy  and  Manna,  2005) 
(Di Luca et al., 1996)
(Di Luca et al.,  1996)
(Chen and Hudnall, 2006)
(Di Luca et al.,  1996)
(Chen and Hudnall, 2006) 
(Chen and Hudnall, 2006) 
(Chen and Hudnall, 2006)
(Di Luca et al.,  1996)
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Table 1.5  HHV-6 cell tropism
In vitrolex vivo infection HHV-6A HHV-6B Productive
replication
Reference
324K (SV40 human Non-permissive (Lopez et al.,  1988)
kidney)
8166 (T cell) Permissive (Tedder et al., 1987)
A431  (epidermoid Permissive No (Yoshikawa et al.,
carcinoma) 2003b)
Astrocytes Permissive (Meeuwsen et al., 2005)
Bone marrow (Knox and Carrigan,
mononuclear cells 1992)
CD34+  cells Permissive (Isomura et al., 2003)
CEM (T cell) Permissive (Downing et al.,  1987)
Cord blood mononuclear Permissive Permissive (Yamanishi, 2001)
cells (CMBC)
Daudi (B lymphoblastoma) Permissive Inconclusive (De Bolle et al., 2005b)
Dendritic cells Permissive Permissive Yes (Kakimoto et al., 2002)
Dendritic cells Permissive Permissive Yes (Asada et al.,  1999)
Dendritic cells Non-permissive Non-permissive (Smith et al., 2005)
Endothelial cells Permissive (Caruso et al., 2003)
Epithelial cells (Simmons et al.,  1992)
FM3A (Mouse breast Non-permissive Non-permissive (De Bolle et al., 2005b)
carcinoma)
H9 (T cell) Permissive (Downing et al.,  1987)
Haematopoietic progenitor Permissive Permissive (Isomura et al., 2000)
cells
HEB (embryonic glia) Permissive (Tedder et al.,  1987)
HEL (embryonic lung) Non-permissive (Tedder et al.,  1987)
HEL (embryonic lung) Non-permissive (Lopez et al.,  1988)
HEL (embryonic lung) Inconclusive Inconclusive (De Bolle et al., 2005b)
HEL (megakaryocyte) Permissive Yes (Ablashi et al.,  1987)
HepG2 Permissive Yes (Inagi et al.,  1996)
HFB-1  (myeloma) Permissive (Tedder et al.,  1987)
HL60 Permissive (Downing et al., 1987)
HL60 (promyelocyte) Non-permissive (Tedder et al.,  1987)
HSB-2 (T cell) Permissive Permissive (De Bolle et al., 2005b)
HSB-2 (T cell) Permissive Yes (Ablashi et al., 1987)
HT (T cell) Permissive (Lopez et al.,  1988)
HTB-14 (glioblastoma) Low infectivity No (Ablashi et al.,  1987)
HTLV-1  positive MT-4 (Cao and Sullivan,  1992)
Human astrocytes Permissive (Yao et al., 2006)
Human fetal astrocytes Permissive Permissive Yes (He et al.,  1996)
human PBMC Permissive Yes (Lusso et al.,  1991a)
Human progenitor-derived Permissive Non-permissive  Yes (Donati et al., 2005)
astrocytes
human tonsil Permissive Permissive (Grivel et al., 2003)
HuT78 (T cell) Permissive (Lopez et al.,  1988)
IM-9 (EBV-infected B- Low infectivity Yes (Ablashi et al.,  1987)
lymphoblastoid cell line)
JJHAN Permissive Yes (Tedder et al.,  1987)
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Table 1.5 (cont’)
In vitrolex vivo infection HHV-6A HHV-6B Productive
replication
Reference
JURKAT Permissive (Flamand et al.,  1995)
JURKAT Permissive (Lusso et al.,  1991b)
Jurkat (T cell) Permissive (Downing et al.,  1987)
K1034 (retinal pigment Permissive No (Arao et al., 1997)
epithelial)
K562 (erythroleukaemia) Non-permissive (Tedder et al.,  1987)
K562 (erythroleukaemia) Inconclusive Inconclusive (De Bolle et al., 2005b)
KG-1  (lymphomyeloid (Furlini et al., 1996)
progenitor cell lines)
L4 (Pre B cell) Permissive (Tedder et al., 1987)
M03.13 Permissive Permissive (De Bolle et al., 2005b)
(oligodendroglioma)
Macrophages Permissive No (Csoma et al., 2006)
MOLT-3 Non-permissive  Permissive (Ablashi et al.,  1987)
MOLT-3 Permissive (Lopez et al., 1988)
MOLT-3 ATCC Permissive Permissive (De Bolle et al., 2005b)
MOLT-3 NCI Permissive Permissive (De Bolle et al., 2005b)
MOLT-4 Permissive (Lopez et al.,  1988)
Monocytes (Janelle and Flamand, 
2006)
Monocytes/Macrophages Permissive (Kondo et al.,  1991)
MRC-5 (fibroblast) Permissive Yes (Robert et al.,  1996)
MRL-13 (B cell) Permissive (Lopez et al.,  1988)
MT4 Permissive Permissive (De Bolle et al., 2005b)
Natural Killer cells Permissive (Lusso et al.,  1993)
Oligodendrocytes Permissive Non-permissive (De Bolle et al., 2005b)
Placental Permissive No (Csoma et al., 2002)
syncytiotrophoblast
Raji Permissive (Downing et al.,  1987)
Ramos Permissive (Downing etal.,  1987)
SK-N-SH (neuroblastoma) Inconclusive Inconclusive (De Bolle et al., 2005b)
SUPT1 Permissive Permissive (De Bolle etal., 2005b)
TF-1  (erythromyeloid (Furlini et al.,  1996)
progenitor cell lines)
THP-1  (monocytoma) Inconclusive Inconclusive (De Bolle et al., 2005b)
Transformed cervical Permissive (Chen et al.,  1994)
epithelial cells
U373 MG (astrocytoma) Inconclusive Inconclusive (De Bolle et al., 2005b)
U937 Permissive (Downing et al.,  1987)
U937 Non-permissive (Tedder et al.,  1987)
U937 Non-permissive (Lopez et al.,  1988)
U937 Permissive Inconclusive (De Bolle et al., 2005b)
Vero B (African green Non-permissive Non-permissive (De Bolle et al., 2005b)
monkey kidney)
WIL-2 (EBV-infected B- Low infectivity Yes (Ablashi et al.,  1987)
lymphoblastoid cell line)
WMPT (EBV B cell) Permissive (Tedder et al.,  1987)
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1.2.13  Epidemiology
HHV-6  is  commonly  acquired  within  the  first  two  years  of  life  and  peaks 
between six to eight months of age (Asano et al.,  1994;  Hall et al.,  1994), at a 
stage  when  the  maternal  antibodies  to  HHV-6  have  declined  (Enders  et  al., 
1990;  Hall et al.,  1994; Takahashi  et al.,  1988; Yoshikawa et al.,  1989).  The 
seroprevalence  of  HHV-6  in  the  adult  population  worldwide  is  >90%  (Clark,
2000).  The  lack  of a  serological  test to  distinguish  between  the  two  HHV-6 
variants  means  there  is  no  serological  data  on  the  variant  distribution  within 
different populations.
1.2.14  Transmission
The route of transmission for HHV-6 has yet to be clearly defined (reviewed in 
Yamanishi,  2001).  Several  mechanisms  have  been  suggested,  including 
intrauterine transmission (Adams et al., 1998; Aubin et al., 1992), organ or bone 
marrow transplantation (Lau  et al.,  1998; Yoshikawa et al.,  1998) and salivary 
contact (reviewed  in  Clark,  2000).  The  latter represents the  most convincing 
route of all,  based on the frequent detection of HHV-6  DNA in saliva (Cone et 
al.,  1993; Jarrett et al.,  1990; Saito et al.,  1991) and salivary glands (Fox et al., 
1990).  This is further support by the findings that infants (<1-year of age) who 
received  parental  saliva  via  kissing  and  having  older  siblings  were 
independently associated with  increased  risk of HHV-6 acquisition  (Rhoads et 
al., 2006).  The isolation of HHV-6 from saliva has been  reported (Levy et al.,
1990)  but it has yet to be reproduced elsewhere (Hidaka et al., 1993; Wyatt and 
Frenkel,  1992; Yamanishi, 2001).  It was later revealed that only HHV-6B,  but 
not HHV-6A DNA,  could  be detected  in  saliva  (Aberle et al.,  1996;  Rhoads et 
al., 2006).  Hence, the mode of HHV-6A transmission remains elusive.
1.2.15  Primary infection and clinical presentations
Primary infection with HHV-6 commonly occurs in children under 2 years of age 
(Hall  et  al.,  1994;  Zerr  et  al.,  2005)  and  is  usually  symptomatic  (Zerr  et  al.,
2005), with fever and fussiness being the main manifestations.  It accounts for 
10-21%  of hospital visits among  children with febrile  illness  (Hall  et al.,  1994; 
Zerr,  2006),  including  exanthem  subitum  (ES) - a  common  childhood  disease
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characterised  by a high fever,  and the appearance of a rash on the trunk and 
face  coinciding  with  the  subsidence  of fever  (reviewed  in  Yamanishi,  2001). 
HHV-6  infection  was  identified  as  the  causative  agent  of ES  on  the  basis  of 
virus  isolation  from  PBMCs  of  ES  patients,  and  the  seroconversion  of  ES 
patients  against  HHV-6  after the  acute  phase  of disease  (Ueda  et  al.,  1989; 
Yamanishi et al.,  1988).  It was later demonstrated that almost all cases of ES 
were associated with HHV-6B (Dewhurst et al.,  1993b).  Symptoms associated 
with  HHV-6  infection  are  generally  self-limiting,  however,  complications  were 
documented  in individuals presenting in the acute care setting.  These include 
febrile seizures and suspected encephalitis (Ward et al., 2005a), both are more 
common than other associated complications such as meningitis, diarrhoea and 
hepatitis (Clark, 2000).  However, no febrile seizures were observed in patients 
with primary HHV-6 infection outside the acute care setting (Zerr et al.,  2005). 
Primary  infection  with  HHV-6  in  adults  is  less  common  but  is  reportedly 
associated with more acute symptoms such as fuminant hepatitis (Sobue et al.,
1991)  and infectious mononucleosis-like syndrome (Akashi et al., 1993).
1.2.16  Immune response to HHV-6
Like  most viral  infections,  HHV-6  is  controlled  by  humoral  and  cell-mediated 
immunity of the host.  The fact that primary infection with HHV-6 usually occurs 
after the decline of maternal antibodies in infants (section 1.2.13) demonstrates 
their  protective  effect.  However,  primary  HHV-6  infection  in  the  presence  of 
maternal antibodies has been reported (Sugimoto et al., 2002), suggesting that 
the  protection  offered  by  anti-HHV-6  antibodies  alone  is  incomplete.  The 
serologic response in ES patients has been reviewed (Pellett and Black,  1996; 
Yamanishi,  2001).  Briefly,  IgM  antibodies are  generally detectable  on  day 5, 
and  persist  for  2-3  weeks,  but  disappear  in  most  sera  1-2  months  after  the 
onset of disease.  As for the anti-HHV-6 IgG, it usually develops 7-10 days after 
the febrile  phase of ES,  peaks after 3 weeks and  remains at detectable  level 
thereafter.
Similar to other herpesviruses, HHV-6 causes opportunistic infections when the 
host’s  immune  system  is  impaired,  particularly  in the transplant setting  (Clark 
and  Griffiths,  2003).  The  fact  that  HHV-6  infection  occurs  in  seropositive,
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immunocompromised individuals suggested that the cell-mediated immunity has 
an integral role in restricting viral replication.  T-cell immunity against HHV-6 is 
poorly characterised  except for the  isolation  of T  cell  clones with  anti-HHV-6 
activity (Yakushijin et al., 1992; Yasukawa et al., 1993).  HHV-6 infection is also 
considered  as  immunosuppressive  due  to  its  tropism  for  both  naive  and 
memory CD4+  and CD8+  T lymphocytes, which would consequently lead to their 
cytolysis (Grivel et al., 2003).
It is believed that natural  killer (NK) cells are involved  in  controlling the acute 
phase of HHV-6 infection (Kumagai et al., 2006; Takahashi et al., 1992).  This is 
supported  by  the  demonstration  of  NK-mediated  cell  lysis  of  HHV-6  infected 
cells in vitro (Lusso et al., 1993).  HHV-6 infection was also found to upregulate 
IL-15  production  resulting  in  enhanced  NK cytotoxicity  (Flamand  et al.,  1996), 
however, the benefit of this modulation to HHV-6 infection is not apparent.
As discussed in section 1.2.10, HHV-6 infection has been shown to modulate a 
wide  range  of cytokines  and  cell  surface  expression  markers  (e.g.  CD3).  In 
addition,  HHV-6 encodes two viral chemokine receptors (U12 and  U51) and  a 
viral chemokine  (U83),  all of which  may play a  role in  modifying  host immune 
response  (sections  1.2.7.4,  1.2.7.14,  and  4.3.4).  The  possible  outcomes  of 
these  HHV-6-mediated  changes  include  1)  T  lymphocytes  depletion  (e.g. 
downregulation  of  IL-2  and  cell  apoptosis),  2)  the  facilitation  of virus  spread 
(e.g.  expression  of U51  and  U83),  and  3)  immunoevasion  by downregulating 
the expression of MHC class I (Dewin et al., 2006;  Flamand et al.,  1995; Hirata 
et al., 2001; Yasukawa et al., 1998; Zhen et al., 2005).
1.2.17  Viral Persistence
All herpesviruses examined to date establish lifelong persistence in their hosts 
(Roizman  and  Pellett,  2001)  which  is  commonly  manifested  in  two  forms  - 
latency  and  chronic  infection.  However,  unlike  most  human  herpesviruses, 
there  is  increasing  evidence  in  the  literature  demonstrating  a  third  form  of 
persistence  for  HHV-6,  in  which  the  viral  genome  integrates  into  the  host 
chromosomes (reviewed in section 5.1).  An individual harbouring chromosomal 
integration of HHV-6 has previously been identified (Clark et al.,  1996).  B cells
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obtained  from  this  individual  have  been  immortalised  by  EBV-transformation 
(Clark  et  al.,  2006),  and  two  samples  of  PBMCs  were  also  collected  at  two 
separate occasions (20 months apart).  These materials were used as a model 
to study the molecular biology and  gene expression of HHV-6 integration and 
the results are presented in Chapter 5.
1.2.17.1  Latency
The discovery of herpesviral latency has been reviewed (Roizman and Whitley,
2001).  Briefly,  a  report by Andrew and  Carmichael  provided  the first clue to 
herpesviral  latency.  It was observed that recurrent infections  (HSV) occurred 
only  in  adults  who  carried  neutralising  antibodies  (Andrew  and  Carmichael, 
1930).  This  finding  prompted  much  debate  on  this  unusual  feature  of  HSV 
biology,  and  subsequently  led  to  the  hypothesis  proposed  by  Burnet  and 
Williams,  which  stated  that  'Herpes  simplex  infections,  however,  once 
contracted,  seem to persist for life.  The virus remains for the most part latent; 
but under the stimulus of trauma, fever, and so forth it may at any time be called 
into activity and provoke a visible herpetic lesion’ (Burnet and Williams,  1939). 
This  statement  still  holds  true  for  HSV  latency,  except  that  reactivation  may 
remain asymptomatic i.e. no induction of herpetic lesion (Whitley, 2001).  But for 
a  more general  definition  of herpesviral  latency,  it denotes the  persistence  of 
viral genome in host cells with minimal viral gene expression i.e. no production 
of infectious virions, and that the viral genome can reactivate upon stimulation 
leading to lytic replication (DiMaio and Coen, 2001;  Kieff and  Rickinson, 2001; 
Mocarski and Courcelle, 2001; Roizman and Knipe, 2001).
Latency  is  studied  in  greater  depth  for the  prototype  of the  three  classes  of 
human  herpesviruses:  a  -  HSV-1  (reviewed  in  Efstathiou  and  Preston,  2005; 
Roizman  and  Knipe,  2001),  p  -  HCMV  (reviewed  in  Mocarski  and  Courcelle, 
2001;  Sinclair  and  Sissons,  2006),  and  J 3   -  EBV  (reviewed  in  Kieff  and 
Rickinson,  2001;  Rickinson  and  Kieff,  2001).  Based  on  the  available  data,  a 
consensus on the key characteristics of latency has emerged.  Firstly, although 
the exact mechanism leading to the establishment of latency remains elusive, it 
is clearly dependent on the host cell environment.  This is supported by the fact 
that,  even though  both  HSV-1  and  HCMV can  infect a wide range of host cell
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types in vivo (Pass, 2001;  Whitley,  2001),  reactivation of their latent genomes 
ex  vivo  was  demonstrated  only  in  trigeminal  ganglions  (Stevens  and  Cook, 
1971)  and  the  myeloid  lineage  of haematopoietic  cells  (Reeves  et  al.,  2005; 
Soderberg-Naucler  et  al.,  1997),  respectively.  At  the  molecular  level,  it  is 
believed that the interplay between viral and host factors regulates the state of 
IE  gene  expression  (reviewed  in  Everett,  2000;  Wysocka  and  Herr,  2003), 
which  in  turn  determines  the  switch  between  lytic  and  latent  infection.  The 
former is favoured under conditions which promote  IE gene transcription, such 
as  the  availability  of  cell-specific  host  transcription  factors  in  infected  cells 
(Kristie et al., 1999).  In contrast, latent infection ensues under conditions which 
repress  IE  gene  transcription  e.g.  methylation  of  histone  H3  leading  to  the 
association of heterochromatin with the viral genome  (reviewed  in  Lieberman,
2006).  The fact that expression of only a single IE gene, such as HSV-1  ICP0, 
EBV  ZEBRA,  and  KSHV  RTA,  is  sufficient  for  inducing  reactivation  of  their 
respective latent genomes in cell culture or animal model (reviewed in  Everett, 
2000;  Miller,  1990;  West  and  Wood,  2003)  supports  the  notion  that  IE  gene 
transcription  (or  rather  the  lack  of  it)  plays  an  integral  role  in  establishing 
latency.
The  second  key  feature  of  latency  is  the  limited  expression  of  viral  genes. 
During  latency,  the  viral  genome  exists  as  an  episome  and  there  is  no 
expression  of the  lytic  genes.  Instead,  transcription  is  limited  to  a  few  viral 
genes  that  are  thought  to  be  essential  for  maintaining  the  latent  state. 
Transcription  of these  latent  genes  is  best  characterised  for  EBV  among  all 
human herpesviruses.  There are three recognised transcription programmes fi­
ll I) associated with latent EBV infection, and each latency state is defined by the 
transcription  of  different  combinations  of  up  to  nine  latent  transcripts  (see 
Thorley-Lawson,  (2001) for an  extensive  review).  Some of the  key functions 
encoded  by  these  latent  transcripts  include  the  maintenance  of  the  latent 
genomes in dividing cells (EBNA-1; reviewed in Leight and Sugden, 2000), the 
transcriptional  regulation  of the  latent genes  (EBNA-2;  Ling  et al.,  1994),  and 
the  prevention  of  apoptosis  in  latently-infected  B  cells  (LMP1;  Gires  et  al.,
1997).  HSV-1  also  encodes  a  latency-associated  transcript  (LAT)  which 
functions differently to the EBV latent transcripts.  HSV-1  LAT is transcribed  in
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the  antisense  direction  to  the  IE  gene  ICPO  (the  putative  switch  between 
lytic/latent  infection;  (Stevens  et  al.,  1987).  It was  suggested  that  the  ICPO 
antisense  RNA may  negatively regulate  ICPO  expression  in  order to  maintain 
HSV-1  latency.  Further  analysis  revealed  that  expression  of  HSV-1  LAT 
promoted the formation  of heterochromatin  near the viral  lytic-gene  promoter, 
thereby repressing lytic replication of the viral genome (Wang et al., 2005).  In 
addition,  as  discussed  in  section  1.2.4,  HSV-1  LAT  encodes  a  miRNA which 
confers anti-apoptotic activity to the infected cells (Gupta et al., 2006).
The third  key feature, which  distinguishes  latency from  abortive  replication,  is 
the  capacity  to  reactivate.  A  range  of  possible  stimuli  for  herpesviral 
reactivation in vivo have been documented including trauma at or close to the 
latent  site,  physical  or  emotional  stress,  hyperthermia,  exposure  to  UV, 
immunosuppression,  and  cell  differentiation  (reviewed  in  Kieff and  Rickinson, 
2001; Roizman and Knipe, 2001; Sinclair and Sissons, 2006).  In addition, there 
are various strategies to induce reactivation of herpesviruses in vitro,  including 
intracellular  calcium  mobilisation,  histone  acetylation,  and  IgG  cross-linking 
(reviewed  in  Kieff and  Rickinson,  2001).  However,  the  use of phorbol  esters, 
such  as  12-0-tetradecanoylphorbol-13-acetate  (TPA),  is  most common  due to 
their reliability and  effectiveness  in  reactivating  most herpesviruses  (Kieff and 
Rickinson,  2001).  It is  believed  that most induction  strategies  induce  cellular 
changes which  invariably trigger the activation  of IE genes, for example,  EBV 
ZEBRA (Kieff and  Rickinson,  2001) and  KSHV  RTA (West and  Wood,  2003), 
leading to the reactivation of the respective herpesviruses.
Regarding  HHV-6  latency,  latent  HHV-6  DNA  can  be  detected  in  PBMCs  of 
healthy individuals.  However, this requires a large amount of input DNA (105- 
106  cells) and the use of highly sensitive nested PCR (Cone et al., 1993; Jarrett 
et al.,  1990).  The apparently low viral load in PBMCs suggests that only a few 
cells  harbour  the  latent  genomes.  Further  studies  identified  monocytes  and 
bone  marrow  progenitors  (CD34+   cells)  as  the sub-fractions  of PMBCs which 
harboured  latent  HHV-6  DNA  (Kondo  et  al.,  1991;  Luppi  et  al.,  1999).  The 
study  by  Kondo  and  colleagues  (1991)  demonstrated  the  detection  of  viral 
antigen  in  latently-infected  monocytes following  TPA-stimulation.  In  contrast,
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although no viral antigen was detected in CD34+  cells per se, it was suggested 
that the differentiation of latently-infected  CD34+  into granulocytes may trigger 
HHV-6 reactivation,  leading to the detection of viral antigen in the latter (Luppi 
et al.,  1999).  Taken together, both monocytes and CD34+  cells are considered 
as  putative  sites  of HHV-6  latency,  but the  isolation  of reactivated  virus from 
these cells has yet to be demonstrated.  A HHV-6 gene, U94, was implicated in 
the  maintenance  of viral  latency  (Rotola  et  al.,  1998).  This  is  based  on  the 
observation that, of the seven  HHV-6 genes examined,  low levels of only U94 
mRNA were detected in peripheral blood of healthy individuals harbouring latent 
HHV-6  genomes.  Furthermore,  it  was  reported  that  cells  containing  U94- 
expressing  plasmids restricted the replication of HHV-6A (Caselli  et al.,  2006; 
Rotola  et al.,  1998;  Turner et al.,  2002),  HHV-6B,  HCMV and  HHV-7  but not 
HSV-1  (Caselli et al., 2006).  However, the detection of U94 mRNA in PBMCs 
has yet to be reproduced independently, and the mechanism of U94-restriction 
on the replication of p-herpesviruses remains undefined.  Apart from U94, a set 
of HHV-6 LATs was described and it appears that these genes were transcribed 
antisense to the genes encoding IE1/IE2 (Kondo et al., 2002).  Further analysis 
revealed  the  apparent  upregulation  of  the  LATs  in  latently-infected 
macrophages after TPA-treatment, suggesting that these transcripts play a role 
in  reactivation  (Kondo  et  al.,  2003).  Other  reported  stimuli  for  HHV-6 
reactivation ex vivo included HHV-7 infection (Katsafanas et al.,  1996; Tanaka- 
Taya  et  al.,  2000)  and  cytokine-induced  differentiation  of  CD34+   cells  into 
monocytes  and  granulocytes  (Andre-Gamier et al.,  2004).  Regarding  HHV-6 
reactivation  in  vivo,  possible  stimuli  include  immunosuppression,  severe 
illnesses and viral infection, as demonstrated by the frequent detection of high 
HHV-6  viral  load  in  immunocompromised  patients  (reviewed  in  Clark,  2000; 
Yamanishi, 2001) and critically-ill patients (Desachy et al., 2001;  Razonable et 
al., 2002), plus the frequent isolation of HHV-6 in children with measles (Suga 
et al., 1992a) and dengue hemorrhagic fever (Balachandra et al., 1994).
1.2.17.2  Chronic infection
Chronic infection denotes the continuous production of infectious virions in the 
infected hosts.  This is best represented by the persistence of HHV-7 in salivary 
gland tissues (Black et al., 1997).  HHV-7 can be frequently isolated from saliva
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of healthy,  HHV-7  seropositive  individuals  (reviewed  in  Yamanishi,  2001)  but 
nothing  is known  about the mechanism of chronic infection.  In the context of 
HHV-6, its viral DNA can be frequently detected in saliva and salivary glands of 
healthy individuals (reviewed in Miller et al., 2005; Yamanishi, 2001).  However, 
the  isolation of HHV-6 from saliva was  inconsistent and  less  readily achieved 
than for HHV-7.  Nevertheless, the salivary glands were tentatively considered 
as the site of chronic HHV-6 infection.
1.2.18  Disease associations
The ubiquitous nature of HHV-6, and the fact that HHV-6 DNA is present in a 
wide range of tissues (table 1.4), may explain its apparent association with over 
ten  disease conditions  (reviewed  in  Dockrell,  2003).  The  link to a  number of 
diseases  has  been  investigated  in  greater  depth  including  multiple  sclerosis 
(MS),  CNS  disease,  AIDS,  neoplasm  and  post-transplant  disease  in  the 
immunocompromised.  The  role  of HHV-6  in  MS  remains  controversial;  there 
are  just  as  many  reports  in  the  literature  supporting  this  link  as  there  are 
disputing it (extensively reviewed in Clark, 2004; De Bolle et al., 2005a).  HHV-6 
has  been  implicated  in  seizures,  meningitis  and  encephalitis  in  both 
immunocompetent and immunocompromised individuals based on the frequent 
detection of HHV-6 DNA in cerebrospinal fluid (CSF) and brain tissue (reviewed 
in  Clark,  2000;  De  Bolle et al.,  2005a;  Dewhurst,  2004).  It was hypothesised 
that  HHV-6  acts  as  a  cofactor  to  facilitate  the  progress  of  AIDS  disease 
(Griffiths, 1998) and indeed higher proviral load of HIV was observed in autopsy 
containing  HHV-6  DNA  (Emery  et  al.,  1999).  However,  in  vitro  data 
contradicting  with  the  HHV-6  cofactor  hypothesis  have  also  been  reported 
(Clark,  2000).  The  link  between  HHV-6  and  several  neoplasms  has  been 
extensively  reviewed  (Braun  et  al.,  1997;  Clark,  2000).  Existing  evidence 
suggests that HHV-6 may play a role in the pathogenesis of oral carcinoma and 
S100-positive  T  cell  chronic  lymphoproliferative  disease  (Braun  et  al.,  1997). 
Regarding post-transplant disease, it is clear that HHV-6 infection (as a result of 
reactivation  or re-infection)  is  common  in the  immunocompromised.  There  is 
mounting evidence, particularly in bone marrow and solid organ transplantation, 
linking  HHV-6  to  severe  disease  including  encephalitis,  marrow  suppression,
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pneumonitis and hepatitis (reviewed in Clark and Griffiths, 2003; De Bolle et al., 
2005a).
1.2.19  Laboratory diagnosis of HHV-6
The  methods  that  have  been  developed  over the  years  for the  diagnosis  of 
HHV-6 have been reviewed (Ward, 2005; Yamanishi, 2001).  These diagnostic 
tests  aim to  differentiate  between  primary infection  or reactivation from  latent 
infection  to  aid  the  clinical  management  of  HHV-6  infection.  All  the  HHV-6 
diagnostic  methods  can  be  classified  into  three  main  types:  virus  isolation, 
serological assays, and nucleic acid analyses.
1.2.19.1  Virus isolation
HHV-6 can  be isolated  by the cultivation of PBMCs of ES  patients in  medium 
containing  interleukin-2  (IL-2) and  phytohemagglutinin  (PHA; Yamanishi  et al., 
1988).  The timing of the sample collection is critical to the success of isolation; 
it ranges from 100% for samples collected during the febrile phase to 0% on >= 
day 8 post-onset of fever (Yamanishi, 2001).  Cells typically show sign of CPE 
at  about  day  9  after  cultivation  (Yamanishi  et  al.,  1988)  and  the  virus 
propagation  can  be  readily  achieved  by  the  co-cultivation  of  HHV-6-infected 
cells with mitogen-stimulated cord  blood lymphocytes (CBL; Yamanishi, 2001). 
This method is not only time-consuming, but its main disadvantage is that CPE 
alone provides no information on the identity of the virus.  Thus, HHV-6 infection 
has to be confirmed  using other methods with defined  specificity,  such as the 
use of HHV-6 specific mAbs in IFA and HHV-6 PCR.
1.2.19.2  Serological assay
The demonstration of the presence of antibodies against HHV-6 in paired serum 
(a specimen collected during the acute phase and one during the convalescent 
phase) is the gold standard for confirming primary infection (reviewed in Ward, 
2005; Yamanishi, 2001).  The serological assays for HHV-6 mainly involve the 
detection of serum IgM/IgG to HHV-6.  These assays come in several different 
formats  including  immunofluorescence  (indirect  or  anticomplement), 
neutralisation,  competitive  radioimmunoassay,  and  enzyme  immunoassay 
(EIA).  However,  there  are  several  disadvantages  associated with the  use of
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HHV-6 serological assays (Braun et al.,  1997; Ward, 2005) including  (1) these 
assays  are  generally  labour  intensive,  (2)  IgM  to  HHV-6  is  not  always 
detectable during primary infection (Chiu et al.,  1998; Suga et al.,  1992b), and 
(3)  they  cannot  differentiate  between  HHV-6A  infection  and  that  of  HHV-6B. 
Variant-typing can only be achieved by virus isolation and subsequent analysis 
using variant-specific mAbs (reviewed in Arsenault et al., 2003) or PCR (Kidd et 
al.,  1998; Yamamoto et al., 1994).  There are also concerns with the specificity 
of the patient's serum due to the genetic similarity between HHV-6, HHV-7 and 
HCMV,  and  indeed  low  levels  of cross-reactivity  between  HHV-6  and  HHV-7 
antibodies have been reported (Black et al.,  1996; Ward et al., 2002; Wyatt et 
al.,  1991; Yoshikawa et al., 2001).  Furthermore, it was reported that the titre of 
HHV-6 IgG declines with increasing age or as a result of clinical treatment, and 
the low antibody-titre may be misinterpreted as seronegative for HHV-6 (Brown 
et al.,  1988).  This problem can be resolved by examining the avidity of HHV-6 
IgG, which allows the differentiation between primary and recurrent/latent HHV- 
6 infection (Ward et al.,  1993).  The principle is that the HHV-6  IgG generated 
immediately  after  primary  infection  exhibits  a  lower  affinity  (avidity)  to  the 
antigen, however, the avidity improves as the immune response develops over 
time and HHV-6 specific B cell clones undergo somatic mutation.  The strength 
of the antigen-IgG interaction can  be estimated  by exposing the complexes to 
varying  concentration  of  protein  denaturant.  IgG  with  high  avidity  would 
suggest past infection with HHV-6 regardless of the antibody-titre.
1.2.19.3  Nucleic acid detection
Different molecular biological  techniques  have  been  used  for the  detection  of 
HHV-6  nucleic  acids  in  clinical  specimens  including  Southern  blotting,  in  situ 
hybridisation,  and  a  range  of  PCR-based  methods.  The  latter  is  particularly 
popular due to its speed, ease of use and sensitivity.  On the other hand, the 
high  sensitivity  of PCR  also  makes  it  prone  to  yielding  false-positive  results. 
Hence, all the necessary precautions to reduce cross-contamination should be 
undertaken when handling the samples.  Initially, the detection of HHV-6 DNA, 
and  indeed  that  of  other  herpesviruses,  by  qualitative  PCR  offers  limited 
diagnostic  value,  as  a  positive  result  indicates  past  infection  of the  host  but 
provides  no  information  on  the  current  status  of  infection.  This  problem  is
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resolved  following  the  development of quantitative  PCR,  which  allows  one  to 
estimate the copy number of the sequence of interest in  a  particular sample. 
One of the differences between latent and active viral infection is that the latter 
results  in  the  production of large amount of virus  progenies.  Several  studies 
have demonstrated the usefulness of this technique to measure the difference 
in viral loads between latently- and actively-infected samples (Chiu et al., 1998; 
Clark  et  al.,  1996;  Gautheret-Dejean  et  al.,  2002;  Sashihara  et  al.,  2002). 
Alternatively,  latent and active infection can be differentiated by using RT-PCR 
to  detect the  presence of HHV-6 transcripts in  the test sample.  Several  RT- 
PCR assays  have  been developed  and validated  (Andre-Garnier et al.,  2003; 
Norton  et  al.,  1999;  Pradeau  et  al.,  2006;  Van  den  Bosch  et  al.,  2001; 
Yoshikawa  et al.,  2003a),  and  the  primers  employed  in  three  studies  (Andre- 
Garnier et al.,  2003;  Norton  et al.,  1999;  Van  den  Bosch  et al.,  2001) target 
intron-spanning regions of HHV-6 spliced genes, thus allowing easy distinction 
between the detection of viral transcripts and possible viral DNA contamination. 
In  addition,  better  understanding  of  the  HHV-6  genomes  allows  the 
development  of variant-typing  of  PCR.  It  works  by  exploiting  the  sequence 
differences  between the genomes of the two variants.  One  approach  utilises 
primers that can bind to the same region of both variants but amplify amplicons 
of  different  sizes  (Yamamoto  et  al.,  1994).  Some  typing  methods  amplify 
regions spanning a restriction site that exists in one variant but not in the other 
(Kidd et al.,  1998;  Rajcani  et al.,  1995).  Alternatively,  it is  possible to design 
PCR primers targeting  regions in the genome that are variant-specific,  so that 
these primers can amplify DNA of HHV-6 variant A but not that of variant B, or 
vice versa (section 2.3.3).
1.2.20  Antiviral agents against HHV-6
The lack of a well-controlled trial for evaluating the efficacy of currently licenced 
antivirals against HHV-6 means there is no clear guideline for the administration 
of antiviral therapy for HHV-6 infection (De Bolle et al., 2005a).  The pattern of 
susceptibility of HHV-6 replication to antiviral agents in vitro has been shown to 
resemble that of HCMV -  it is effectively inhibited by ganciclovir, foscarnet and 
cidofovir but not by aciclovir (which is effective for inhibiting alphaherpesviruses) 
(reviewed in Clark, 2000).  A number of case reports have described the use of
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these  four  compounds  for  treating  HHV-6  infection  with  varying  outcomes. 
Additionally, the recent discovery of gene silencing by RNA interference (RNAi) 
(Fire  et  al.,  1998)  has  provided  a  novel  method  for  inhibiting  viral 
replication/infection (Novina et al., 2002; Palliser et al., 2006).
1.2.20.1  Ganciclovir and aciclovir
Gancicloivir (GCV or 9-[1,3-dihydrooxy-propoxymethyl] guanine) is licenced and 
marketed  as  Cytovene  for  the  treatment  of  HCMV  disease  in 
immunocompromised patients (Gilbert and Boivin, 2005).  It belongs to a class 
of  antiviral  drugs  termed  nucleoside  analogues,  which  also  include  Aciclovir 
(ACV  or  9-[2-hydroxyethoxymethyl]  guanine)  (Crumpacker,  2001).  They  are 
both acyclic analogues of deoxyguanosine in which the ribose sugar moiety of 
the guanosine is replaced by an acyclic side chain (figure 1.10).  GCV differs to 
ACV  in  that the former contains  a  hydroxyl  methyl  group  at  position  3  of the 
sugar  ring  and  this  structural  difference  confers  a  superior  antiviral  activity 
against  HCMV  (Crumpacker,  1996).  The  oral  bioavailability  of  nucleoside 
analogues is poor but it can be improved by the esterification of the compounds 
with  valine  (Jung  and  Dorr,  1999).  The  prodrug  form  of  the  nucleoside 
analogues are thus prefixed with “val”,  such as valaciclovir and valganciclovir. 
The  prodrugs that entered  the  gut are  rapidly converted  back  into the  parent 
compounds  and  valine  by  intestinal  and  hepatic  esterases.  Once  the 
nucleoside  analogues  have  been  absorbed  into  the  cells,  they  have  to  be 
phosphorylated three times to reach the active form for inhibiting the viral DNA 
polymerase (figure 1.10).  In fact, it is the first step of the phosphorylation which 
offers  the  specificity  of  the  antivirals  against  the  infected  cells.  The  virus- 
encoded thymidine kinase or protein kinase are more efficient in converting the 
nucleoside  analogues  into  the  monophosphate  forms.  In  the  case  of  HHV-6 
infection, the gene product of U69 was implicated in the first phosphorylation of 
GCV (section  1.2.7.17).  Subsequently, cellular kinases (GMP kinase and NDP 
kinase) convert GCV monophosphate into the di- and tri-phosphate form.  And it 
is the  GCV triphosphate which competes with the  normal  nucleotides for viral 
DNA polymerase.  For ACV, once the ACV triphosphate is incorporated during 
DNA  elongation,  it  acts  as  chain  terminator  which  prevents  further  chain 
elongation.  However, the presence of the 3' hydroxyl group in GCV means that
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the GCV molecule can be incorporated into the interior of the DNA chain.  This 
may partly explain the enhanced toxicity observed for GCV -  it is  mutagenic, 
carcinogenic, teratogenic and associated with severe neutropenia (Crumpacker, 
2001; Goodrich et al., 1991), whereas ACV exhibits little toxicity.
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Figure 1.10  Structures of antiherpetic drugs and their mechanisms of 
action
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Adapted  from  the  monograph  published  on  the  International  Herpes 
Management Forum website at: 
http://www.ihmf.org/Library/monograph/m_02.pdf
1.2.20.2  Foscarnet
Foscarnet (phosphonoformic acid  or trisodium  phosphonoformate or marketed 
as Foscavir) belongs to a class of antivirals termed non-nucleoside analogue, or 
pyrophophate analogue (reviewed in De Bolle et al., 2005a), see figure 1.10 for 
its structure).  The drug  is already in  its active form,  and  has antiviral activity 
against  a  broad  range  of  viruses  including  most  herpesviruses,  HIV  and 
hepatitis B virus.  It works by interfering with the pyrophosphate release of the 
viral DNA polymerase and thereby inhibiting the DNA elongation,  hence it is a 
product  inhibitor.  The  drug  must  be  administered  intravenously  since  oral 
bioavailability is poor.  The main side effect is nephrotoxicity and  may lead to 
renal failure.
1.2.20.3  Cidofovir
Cidofovir  (also  known  as  [(S)-1-(3-hydroxy-3-
phosphonylmethoxypropyl)cytosine]  or  HPMPC)  is  licenced  and  marketed  as
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Vistide  for  treating  CMV  retinitis  in  AIDS  patients  (see  figure  1.10  for  its 
structure;  reviewed  in  De  Clercq,  2003).  It  belongs  to  a  class  of  antivirals 
termed  the  nucleoside  phosphonates.  Unlike  the  nucleoside  analogues,  this 
group  of compounds  already  contains  a  phosphate-mimetic  group,  and  thus 
prior activation  by viral  kinases  (essential  for the  antiviral  effect  of ACV  and 
GCV)  is  not  required.  For  this  reason,  the  nucleoside  phosphonates  have 
antiviral activities against a board spectrum of DNA viruses.  The presence of 
the  negatively  charge  phosphonate  group  hinders  the  absorption  of  the 
compounds,  but the bioavailability can be improved by the esterification of the 
phosphonate groups.  Once absorbed into the cells, cidofovir is phosphorylated 
twice to become cidofovir diphosphate by cellular kinases.  The phosphorylation 
occurs in both uninfected and virus-infected cells.  The antiviral specificity relies 
on  the  preferential affinity of cidofovir diphosphate for viral  over cellular  DNA 
polymerases.  The diphosphate form  is the active  metabolite which competes 
with the natural substrate deoxycytidine triphosphate (dCTP) for the viral DNA 
polymerase.  The incorporation of two consecutive cidofovir molecules into the 
DNA  chain  completely  leads  to  termination  of  DNA  elongation.  The  oral 
bioavailability of the drug is poor and therefore it is administered intravenously. 
The  long  intracellular  half-life  (approximately  48h)  allows  infrequent  dosing 
(once  a  week  or  every  other week)  to  sustain  antiviral  activity,  whereas  the 
nucleoside analogues have to be administered several times daily.  The use of 
cidofovir  to  treat  HHV-6  infection,  or  HCMV  infection  for  that  matter,  is 
uncommon due to the considerable risk of developing nephrotoxcity.  It is often 
reserved  as  a  second-line  therapy  for  the  ganciclovir-  or  foscarnet-resistant 
HCMV  strains.  The  case  reports  or  studies  on  antiviral  treatments  against 
HHV-6 infection are summarised in table 1.6.
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Reference Clinical details
Number of 
subjects ACV GCV FJ
(Birnbaum et al., 2005) Patient with meningoencephalitis 1 V
(Capouya et al., 2006) HHV-6 Mollaret meningitis 1 V
(Carvajal et al., 2001) Cord blood transplant recipient 1 V V
(Chik et al., 2002) Cord blood transplant recipient 3 V V
(Denes et al., 2004) HHV-6 encephalomyelitis 1 V
(Johnston et al.,  1999) Bone marrow recipient 1 V V
(Lau et al.,  1998) Bone marrow recipient 1 V V
(Mookerjee and Vogelsang, 
1997) Bone marrow recipient 1 V V
(Nash et al., 2004) Cardiac transplant recipient 1 V
(Paterson et al.,  1999) Liver transplant patient 1 V
(Rieux et al.,  1998) Bone marrow recipient 1 V V
(Rossi et al., 2001) Kidney transplant recipient 1 V V
(Tiacci et al., 2000) Stem cell transplant recipients 1 V V
(Tokimasa et al., 2002) Stem cell transplant recipients 49 V
(Zerr et al., 2002) Stem cell transplant recipients 11 V V
Reduced viral load in CSF and serum 
Viral load clearance 
Symptoms resolved
Mixed outcome - two deceased, one was asymptomatic for 
>1 year
Symptoms resolved 
Viral load clearance 
Symptoms resolved
Symptoms resolved
Improved clinical status 
Symptoms resolved 
Symptoms resolved
HHV-6 infection worsen leading to the death of the patient 
HHV-6 infection worsen leading to the death of the patient 
HHV-6 infection observed in 1/13 with prophalytic 
treatment, compared to 5/36 without treatment.
Median viral load in CSF decreased over time but this is 
not universally observed  ___   ______
ACV - aciclovir, GCV - ganciclovir, FSN - foscarnet, CDF - cidofovir.General Introduction
1.2.20.4  Resistance to antiviral agents
There is little data on the detection of drug-resistant HHV-6 strains.  However, 
many reports have documented the emergence of drug-resistant HCMV strains 
in immunocompromised patients (reviewed in Gilbert and Boivin, 2005).  It is of 
little surprise that these  mutants contained  mutations that are  associated with 
the UL97 (HCMV protein kinase) and the UL54 gene (HCMV pol), of which the 
former  is  required for the  initial  phosphorylation  of GCV  and  the  latter is the 
target  of  most  antiviral  agents  (Crumpacker,  2001).  Risk  factors  that  are 
associated  with  the  development  of  resistant  strains  include  prolonged 
administration  of antiviral  agents,  treatment failure,  a  high  pre-therapy  HCMV 
load,  frequent discontinuation  of treatment,  and  profound  immunosuppression 
status  (Gilbert  and  Boivin,  2005;  Pass,  2001).  One  report  described  the 
emergence  of a  drug-resistant  HHV-6  isolate  after  long-term  passage  in  the 
presence of GCV.  The mutations were identified in the HHV-6 encoded protein 
kinase  (pU69)  and  DNA  polymerase,  leading  to  the  M318V  amino  acid 
substitution  and  A961V  substitution,  respectively  (Manichanh  et  al.,  2001). 
Interestingly, the M318V mutation was also identified in HHV-6-infected PBMCs 
from an AIDS patient who had received long-term GCV treatment, representing 
a  possible  case  of  the  emergence  of  drug-resistant  HHV-6  in  vivo. 
Subsequently,  two  in  vitro  studies  have  demonstrated  that  the  M318V 
substitution  of  pU69  led  to  inefficient  GCV  phosphorylation  (De  Bolle  et  al., 
2004c; Safronetz et al., 2003).  These data suggest that M318V substitution of 
pU69  confers  drug  resistance  to  HHV-6,  but  the  significance  of  the  A961V 
substitution of HHV-6 pol remains to be clarified.
1.2.20.5  HHV-6 siRNA
It was demonstrated that the use of siRNA sequences targeting HHV-6 U38 and 
U51  inhibited viral infection (Yoon et al., 2004; Zhen et al., 2005).  Other human 
herpesviruses  which  have  been  shown  to  be  susceptible  to  siRNA  inhibition 
include  HSV-1  (Bhuyan  et  al.,  2004),  HSV-2  (Palliser  et  al.,  2006),  HCMV 
(Wiebusch et al., 2004), and KSHV (Guasparri et al., 2004).
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1.3  DNA Microarrays
1.3.1  Functional genomics
The term ‘functional genomics’ evolved from ‘genomics’, which is derived from 
the  term  ‘genome’  (Hieter  and  Boguski,  1997).  Genome  is  defined  as  “an 
organism’s complete set of genes and chromosomes”  Genomics refers to “the 
scientific  discipline  of  mapping,  sequencing,  and  analysing  genomes” 
However, the emphasis of the current research has shifted from the physical to 
functional  characterisation  of  genomes,  which  is  reflected  by  the  division  of 
genomics  into  ‘structural  genomics’  and  ‘functional  genomics’.  Structural 
genomics is designated as “an initial phase of genome analysis and has a clear 
end point - the construction of high-resolution genetic, physical,  and transcript 
maps  of an  organism”  While  the  term  functional  genomics  represents  “the 
development  and  application  of  global  (genome-wide  or  system-wide) 
experimental  approaches  to  assess  gene  function  by  making  use  of  the 
information and reagents provided by structural genomics”
The  need  to  characterise  gene  function  at  a  global  level  has  led  to  the 
development  of  high-throughput  technologies  and  methodologies  for  the  so 
called  “omic”  research,  which  designates  “the  study  of entities(biological)  in 
aggregates,  in this case the DNA,  RNA, protein...of a cell,  tissue or organism” 
(Weinstein,  1998).  Examples of the “omic”  research  are summarised  in table 
1.7.  For  the  scope  of  this  thesis,  the  discussion  is  limited  to  the  use  of 
microarrays for transcriptomic research.
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“Omic” Research Definition Technologies Reference
Genome Complete set of genes of an organism or its organelles DNA sequencing (Sanger etal.,  1977)
Differential display (Liang and Pardee,  1992)
Transcriptome Complete set of mRNA molecules present in a cell, tissue or organ
Subtractive hybridisation
Serial analysis of gene expression
Microarrays
(Bonaldo etal., 1996) 
(Velculescu et al.,  1995) 
(Schena et al.,  1995)
Proteome Complete set of protein molecules present in a cell, tissue or organ
Two-dimension gel electrophoresis + 
peptide mass fingerprinting
Yeast two hybrid analysis 
Mass spectrometry 
Protein arrays
(Norbeck and Blomberg, 
1997)
(Uetz et al., 2000)
(Ho et al., 2002)
(Zhu etal., 2001)
Metabolome Complete set of metabolites in a cell, tissue or organ
Nuclear magnetic resonance 
spectrometry
Mass spectrometry 
Infra-red spectroscopy
(Raamsdonk et al., 2001)
Glycome Complete set of glycan molecules in a cell, tissue or organ
Mass spectrometry 
Carbohydrate microarrays
(Morelle et al., 2006) 
(Fukui et al., 2002)
Lipidome Complete set of lipid molecules in a cell, tissue or organ Mass spectrometry (Brugger et al., 2006)
Interactome Complete set of protein-protein interactions in a cell, tissue or organ Yeast two hybrid analysis (Uetz et al., 2000)
Phenome Complete phenotypic representation of the species Transposon insertional mutagenesis (Kuromori et al., 2006)
Spliceome Complete set of all possible alternative splices in a cell, tissue or organ
Fiber-optic arrays 
Microarrays
(Yeakley et al., 2002) 
(Johnson et al., 2003)General Introduction
1.3.2  Microarrays
The term 'microarrays' was first described in  1995, which  denotes a  research 
tool  capable  of  measuring  expression  levels  of  thousands  of  known  genes 
simultaneously (Schena et al.,  1995).  Figure 1.11  outlines the main steps in a 
typical  microarray  experiment:  1)  microarrays  were  prepared  by  high-speed 
robotic spotting of known cDNA sequences, or DNA probes, on a solid support 
(microscope slide in this case).  The size of each spot, or feature, ranges from 
about 10 to 400pm depending on the production technology (see section  1.3.3 
for  details).  Hence,  one  slide  can  accommodate  many  thousands  of  DNA 
probes, which are arranged in pre-defined patterns so that the identity of each 
spot is known.  Microarrays share the same principle as Northern blot analysis; 
ssDNAs  naturally  hybridise to their complementary counterparts to form  DNA 
duplexes.  2) RNA sample(s) that is/are under investigation can then be labeled 
(and converted into cDNA in the process) and hybridised to the arrays.  Each 
DNA  probe  hybridises  to  labeled  cDNA  targets  in  a  sequence-dependent 
manner.  Following  3)  hybridisation,  the  arrays  are  washed  to  remove 
unhybridised targets and 4) scanned to produce the array image.  The intensity 
of label  reflects the number of duplexes formed  between  the  probes and  the 
targets, thereby allowing the measurement of relative mRNA abundance for the 
corresponding gene.
Figure 1.11  Microarray experiment
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Figure adapted and modified from www.genome.gov.
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It  should  be  noted  that  the  nomenclature  in  this  thesis  conforms  to  the 
consensus  (Phimister,  1999),  in  which  the  immobilised  nucleic  acid  is 
designated  as  'probes'  and  the  labeled  cDNAs  (originating  from  mRNAs)  as 
'targets'.
Although  the  microarray  platform  was  initially  described  as  a  tool  for  gene 
expression studies, the same format has been adapted and modified for other 
purposes such as single nucleotide polymorphisms(SNP)-genotyping (Pastinen 
et  al.,  2000),  ChlP-CHIP  analysis  (chromatin  immunoprecipitation-microarray; 
Ren et al., 2000), analysis of alternative splicing (Johnson et al., 2003; Yeakley 
et al., 2002), array CGH (comparative genomic hybridization; Pinkel et al., 1998; 
SolinasToldo  et al.,  1997),  'living'  arrays  (Ziauddin  and  Sabatini,  2001),  RNA 
interference (Silva et al., 2004) and microRNA arrays (Krichevsky et al., 2003; 
Liu  et  al.,  2004).  Microarrays  for  the  assay  of  immobilised  biological 
molecules/entities other than  nucleic acids have also been developed.  These 
include  protein-  (Emili  and  Cagney,  2000;  MacBeath  and  Schreiber,  2000), 
glycan-  (Wang  et  al.,  2002),  and  tissue-arrays  (Kononen  et  al.,  1998).  For 
clarity, this thesis  uses the terms ‘microarrays’  and  ‘arrays’ for the purpose of 
gene expression analysis only.
The capacity to study thousands of genes simultaneously is the main attraction 
of  microarrays  and  its  high-throughput  allows  one  to  adopt  an  explorative 
approach in research (reviewed in Brown and Botstein, 1999).  A well-designed 
microarray experiment generally provides many leads for further research.  Any 
interesting  idea  can  then  be  followed  up  by  the  traditional  hypothesis-driven 
approach.  In  addition,  microarray  experiment  excels  in  identifying  common 
gene  expression  patterns  across  different  samples.  Genes  with  similar 
functions  are  often  transcriptionally co-regulated  and  therefore  have  common 
expression  profiles (Chu  et al.,  1998).  Importantly,  It has  been  demonstrated 
that the function  of previously uncharacterised  genes can  be assigned  on the 
basis of sharing similar expression pattern with known genes (Chu et al.,  1998; 
Hughes et al., 2000).
90General Introduction
1.3.3  Different types of DNA arrays
The  type  of DNA arrays  as  described  by  Schena  et al.,  (1995)  is  commonly 
known as spotted cDNA microarrays.  However, there are other methodologies 
for the production of DNA arrays including photolithography, ink-jet printing, and 
fiber-optics  arrays.  Table  1.8  compares  and  summarises  the  properties  and 
relative merits of the different methodologies.
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Technology Photolithography Ink-jet printing Fiber-optic arrays Robotic arraying
Array probes Sensitivity Specificity
cDNA V V High Low
synthetic 50-90mer V V Moderate High
synthetic 50mer on beads V High High
in situ 25mer V V Low High
in situ 60mer V Moderate High
Solid support Glass Glass Fiber-optic bundle Glass
Label Fluorescein
Cyanine (Cy) or 
Alexa dyes
Cy-dyes Cy- or Alexa dyes
Signal detection Affymetrix scanner
Fluorescent
scanner
BeadArray Reader
Fluorescent
scanner
Cost High High High Low
Production time Off the shelf Off the shelf Off the shelf Long Long
Room for customisation Low High but expensive High but expensive High
Intra- and inter-arrays 
variations
Low Low Low High
It should be noted that prior knowledge of the gene sequences is required for all types of oligonucleotide arrays. 
Table adapted and modified from Stears et al., (2003) and Jenner, (2002).General Introduction
It should be noted that the protocols for different types of array platforms differ 
substantially  from  one  another.  As  a  result,  the  equipment  suitable  for 
hybridisation  or  signal  detection  of  a  particular  array  platform  is  often 
incompatible for a different type of DNA array; this goes some way to explain 
that most academic labs adopt only one array platform rather than utilise all the 
different array platforms.  In addition, the manner in which array hybridisation is 
carried out is dependent on the array platform used.  It is well recognised that 
the  intra-  and  inter-array  variations  for  cDNA  microarrays  are  high.  For 
example, the amount of DNA in one spot on one array is different to the same 
spot on another array.  These systematic variations can be effectively controlled 
by the  use of competitive  hybridisation  in which two samples are differentially 
labeled  (typically  ‘test’  sample  in  red  and  ‘reference’  sample  in  green)  and 
hybridised to the same array i.e. the two-colour system as described in Schena 
et  al.,  1995.  Any  discrepancy  should  have  the  same  effect  on  the  label 
intensities for both the test and reference sample so that the expression ratios 
remain  constant.  In  contrast,  the  array  platforms  that  are  produced 
commercially have a much  lower intra- and inter-array variations (Patterson et 
al., 2006), therefore no reference RNA is required for array hybridisation i.e. one 
sample per hybridisation.
1.3.3.1  Affymetrix chip
The  use  of photolithography  for  DNA  array  production  was  first  described  in 
1991  (Fodor  et  al.,  1991).  The  resulting  in  situ  synthesised  oligonucleotide 
arrays  are  commercially  marketed  by  Affymetrix  and  commonly  known  as 
Affymetrix-  or  DNA-chip.  As  illustrated  in  figure  1.12a,  the  DNA  probes  are 
made  of  oligonucleotide  chains  that  are  25nt  long  (25mer).  These 
oligonucleotides are synthesised by attaching polynucleotides, one by one, onto 
the synthetic linkers that are already immobilised on a glass substrate.  There is 
a  photochemically  removable  'cap'  at  the  end  of  each  synthetic  linker. 
Precision-directed  illumination  on each  linker leads to the  removal of the cap, 
thus, the linker becomes 'de-protected'.  The deprotection of individual linkers is 
governed  by  a  set  of  photolithography  masks.  One  mask  is  used  for  the 
addition  of  a  single  base  to  the  chain.  After  illumination,  the  surface  is 
incubated  with  a  single  species  of  hydroxyl-protected  deoxynucleosides  e.g.
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deoxyguanosine triphosphate  (dGTP),  to  allow base  attachment so that all  of 
the deprotected  sites become elongated  by one  G  base.  A new mask and  a 
different deoxynucleoside are used for the next elongation,  hence, four masks 
are required to complete the addition of the first base (A, T, G, C) on the entire 
chip, and the cycle is repeated until all the probes are synthesised to full length 
(100  masks for 25mer).  Affymetrix chips typically contain  multiple  probes for 
each  gene.  The  use  of  perfect  match  probes  and  mismatch  control  probes 
(containing  a  single  base  mutation) facilitates the  distinction  between  specific 
and non-specific hybridisation.
1.3.3.2  Agilent arrays
The  use  of  ink-jet  printing  for  array  fabrication  was  first  described  in  1997 
(Blanchard  et  al.,  1996),  and  it  has  been  successfully  transferred  for  the 
commercial  production  of Agilent  oligonucleotide-arrays  of 25mer  (Hughes  et 
al.,  2001)  or  60mer  (Shoemaker  et  al.,  2001).  These  oligonucleotides  are 
synthesised in situ base by base, as shown in figure 1.12c.  A printer equipped 
with four high-precision  nozzles  (one for each  base - A,  T,  G,  C) delivers the 
first layer of bases onto the activated glass surface.  The process is repeated, 
so that the oligonucleotides are built layer-by-layer,  until the 25mer- or 60mer- 
arrays  are  synthesised.  The  ink-jet  printer  can  also  print  pre-synthesised 
oligonucleotides  or  PCR  products,  however,  the  60mer-arrays  are  the 
mainstream product marketed by Agilent.
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a) RNA is labeled with fluorescein (shown in blue) and hybridised to an array of oligonucleotides synthesised in situ (see 1.3.3.1 for 
description).  The hybridised array is scanned using an Affymetrix fluorescent scanner.
b) RNA is labeled with a fluorescent dye and hybridised to a randomly assembled BeadArray (see section 1.3.3.3 for description). 
The hybridised array is scanned using BeadArray Reader.
c) One RNA sample is labeled with green fluorescent dye (e.g. Cy3) and the other with red fluorescent dye (e.g. Cy5).  These  are
mixed and  hybridised to an array of PCR products or oligonucleotides printed  (or synthesised in situ) on a glass slide (only the 
Agilent inkjet printing  is shown  in the figure).  Please refer to figure  1.11  for robotic arraying of cDNA.  The hybridised  array is 
scanned with a fluorescent scanner at two wavelengths and a composite image generated.
Figure  adapted  and  modified  from  Jenner,  (2002).  Source  of the  images:  Affymetrix  chip  -  www.affymetrix.com,  BeadArray  -
www.illumina.com, and Agilent arrays - www.agilent.com/chem/DNA.General Introduction
1.3.3.3  BeadArray
The  use  of  fiber-optics  in  DNA  arrays  was  pioneered  by  Ferguson  and 
colleagues  (1996) and  the technology  is  currently  marketed  as  BeadArray  by 
Illumina.  Each array is assembled on a fiber-optic bundle consisting of about 
50 000 individual fibers fused together into a hexagonally packed matrix.  Each 
fiber has a light-conducting strand core that is surrounded by a strand cladding 
of different refractive index (see figure 1.12b).  As the chemical properties of the 
strand core are different to that of its surrounding cladding, the end of each fiber 
can  be  chemically  treated  and  polished  to  generate  a  microwell  i.e.  50  000 
microwells for a bundle.  This is followed by the random assembly of a master 
bead  pool  comprising  1536  to  250  000  different  microscopic  beads 
(approximately  3pm  in  size)  into  the  patterned  microwells,  with  each  well 
accommodating only one bead.  Each bead contains several hundred thousand 
copies of a particular DNA probe (pre-synthesised, 50mer oligonucleotide).  For 
the signal detection, an excitation beam is transmitted to the beads through the 
fiber  bundle,  and  fluorescent  signals  emitted  from  the  hybridised,  labeled 
targets are channeled back up the fiber.
1.3.3.4  cDNA microarray
The  use  of  cDNA  microarrays  remains  a  popular  choice  among  academic 
researchers due to its comparatively low costs and flexibility.  However, the cost 
for oligonucleotides  and  commercial  arrays has  reduced  significantly over the 
years and they are an increasingly attractive option.  Nevertheless, the cDNA- 
based  approach  was the chosen  option  at the  beginning  of this  PhD  project. 
Please refer to chapter 3 for a detailed description of the construction of cDNA 
microarrays  in  the  context  of  HHV-6  research.  The  rest  of  the  discussion 
focuses on the applications of cDNA microarrays for herpesviral research.
1.3.4  Microarray analysis
Microarray  analyses  in  virological  research  fall  into  two  main  categories:  the 
direct comparison of samples under different experimental conditions,  and the
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profiling of viral and/or host gene expression over time (typically the  length of 
one replication cycle).
1.3.4.1  Direct comparison
The simplest analysis is the direct comparison of two different samples e.g. a 
mutant- versus wide type (wt)-virus on the same array.  Total or poly(A)+  RNA 
samples  from  cells  infected  with  either  the  mutant-  or  wt-virus  are  reverse- 
transcribed  into  cDNA  with  the  incorporation  of  fluorescently-labeled 
nucleotides.  The two most popular series of fluorescent labels are the Alexa 
and  Cy dyes.  Each series comprises compounds which emit fluorescence at 
different  wavelengths  i.e.  a  range  of  dyes  with  different  fluorescent  colours. 
Often the mutant cDNA sample is labeled in red (Alexa647 or Cy5) and the wt 
sample in green  (Alexa555 and  Cy3).  The two labeled  samples are then  co­
hybridised onto the same array to allow bindings between targets and  probes, 
and any unbound targets are subsequently washed off.  The array is scanned 
using a confocal laser scanner.  The laser excites the dye molecules leading to 
the  release  of  photons  (fluorescence).  The  intensity  of fluorescence  at  this 
stage  is  still  very  low.  Therefore,  the  photons  have  to  be  amplified  by 
photomultiplier  tube  (PMT)  and  converted  into  electrical  energy  to  facilitate 
detection  (Timlin,  2006).  The  final  output  is  proportional  to  the  number  of 
photons emitted from the original source.  The electrical output for the red and 
green fluorescence is detected and captured to generate two images.  The red 
and  green  fluorescence  intensities  of each  feature  reflect the  relative  mRNA 
abundance  of  the  corresponding  genes  in  the  mutant-  and  wt-samples, 
respectively.  A qualitative description of the two samples can  be obtained  by 
overlaying the red and green images: red and green features represent highly- 
expressed genes in the mutant- and wt- sample, respectively.  Genes which are 
unaffected  by  the  mutation  would  have  similar  expression  levels  in  both  the 
mutant- and wt-sample i.e. they appear as yellow spots on the overlay image.
Regarding  the  quantitative  analysis  of  the  overlay  image,  there  are  several 
commercial or freeware packages for image analysis which aim to convert the 
fluorescence intensities of each spot into numerical values to generate the raw 
data  for  analysis.  The  two  main  functions  of  these  software  packages
98General Introduction
(reviewed in Leung and Cavalieri, 2003) include 1) spot recognition, or gridding, 
which provides identification of a gene based on the co-ordinates of the spot on 
the arrays; and 2) signal quantification which provides the foreground intensities 
(fluorescence  emitted  from  the  bound  labeled  targets)  and  background 
intensities (non-specific signal e.g. autofluorescence of the glass slide) of all the 
spots on the arrays.
Before  analysing  the  raw  data  to  determine  the  relationship  between  all  the 
genes,  it  is  crucial  to filter the  data  of poor quality,  or pre-processing,  which 
would  otherwise  affect  the  accuracy  and  reliability  of  array  analysis.  For 
instance,  the  automated  gridding  process  is  not faultless,  and  it  is  crucial  to 
inspect the images and the grids visually to flag the spots with poor morphology 
due to scratches or sub-optimal printing.  Another important factor to consider is 
the  signal  to  noise  ratio  (SNR)  of  individual  features,  which  is  calculated  by 
dividing the foreground  by background intensities.  It has been shown that the 
removal of the features with low SNR enhanced the quality and  reproducibility 
of the array analysis (Jenner, 2002; Yang et al., 2001).  In addition, the detector 
of most scanners can only register a 16-bit image (Timlin, 2006), which means 
the maximum signal for each pixel is 65 535 (21 6 -1).  Scanning at a PMT level at 
which  the  brightest  spots  are  just  below  the  detection  limit  is  therefore 
recommended.  Features with a  signal  intensity above this level appear white 
on  the  array  image  and  are  said  to  be  ‘saturated'.  Expression  ratios  of the 
saturated  features  would  therefore  be  underestimated.  Hence,  any  feature 
which is flagged, saturated, or failed to pass the SNR filter is excluded from the 
subsequent analysis.
It is common to log2-transform the filtered  data  before  proceeding with further 
analysis  because  it  makes the  data  follow a  normal  distribution,  which  is the 
basic requirement of many statistical analyses (Bland and Altman, 1996a; Bland 
and Altman,  1996b).  In addition, the log-transformation converts multiplicative 
errors  into  additive  errors  which  are  easier  to  model  (Cui  et  al.,  2003). 
Intuitively,  the  representation  of expression  ratios in  a  log2  scale  is also  more 
perceptive (Quackenbush,  2001).  For example, the expression ratio of genes 
that are equally expressed in both samples would be 1, which is equal to zero
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after  log2  transformation.  For a  gene  that  is  downregulated  by  8-fold  in  the 
mutant  sample,  the  expression  ratio  is  0.125,  which  would  be  readily 
appreciated  if  it  is  presented  as  a  log2  ratio  of  -3.  Therefore,  after  log2 
transformation,  genes that are  above zero  are  more abundant in  the  mutant- 
than wt-sample, while the reverse is true for genes below zero.
1.3.4.2  Multiple comparisons
Most  viral-host  microarray  studies,  however,  involve  a  more  complex 
comparison  between  multiple samples on  different arrays.  For example,  the 
profiling  of  viral  gene  expression  over  time,  or  a  time-course  experiment, 
requires the comparison of samples collected at different time points.  This type 
of  analysis  demands  a  different  experimental  design  and  approach  for  data 
processing.  A  direct  comparison  can  only  be  made  if  two  samples  are 
hybridised on the same array, but not for samples on different arrays due to the 
high systematic variations  between cDNA arrays.  A common solution for this 
type of analysis is the use of a universal reference.  A sample from each time 
point (red) is co-hybridised with the universal  reference (green) to allow direct 
comparison between the two samples (T1 vs R, T2 vs R...Tn vs R).  In turn, the 
reference  acts  as  a  base-line  so  that  indirect  comparisons  can  be  made 
between different time points (T1/R vs T2/R... vs Tn/R).  Ideally, transcripts in 
the common reference should hybridise to the majority of the probes on a given 
array so that most features emit detectable fluorescence, since the expression 
ratio of a gene is derived from the intensity of red divided by that of the green 
fluorescence.  Any probe that is  not bound  by the  reference  has  a  low or no 
green fluorescence signal.  Hence, no base-line can be drawn for that particular 
gene and therefore it is no longer suitable for inter-array analysis.  A common 
reference is typically prepared by pooling mRNA samples extracted from a wide 
range of cell types, including cells infected with viruses if viral array probes are 
used,  so  that  the  reference  contains  cDNA  sequences  covering  most  of the 
probes.
The  analysis of individual  arrays follows the  same  procedure  as  described  in 
section  1.3.4.1.  Namely,  the  extraction  of  data  from  the  scanned  image 
followed  by  the  pre-processing  and  log-transformation  of  the  raw  data.
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However, the use of a universal reference allows data normalisation across all 
arrays  in  the  same  experiment,  which  aims  to  remove  the  systematic 
differences  such  as  unequal  RNA quantities,  differential  labeling  efficiency or 
scanner  introduced  bias  (reviewed  in  Quackenbush,  2002).  Many  different 
normalisation strategies and  algorithms  have been developed  and there  is no 
consensus on the best normalisation method for microarray analysis.  However, 
most methods assume the average or median expression ratio of each array is 
equal to 1, as differential expressions are observed for only a small percentage 
of  genes.  Figure  1.13  illustrates  the  distribution  of data  after  normalisation, 
individual log2  expression ratios of each array are adjusted so that the average 
or median  expression  ratio equals to 0  (as  log2(1) = 0).  Some  normalisation 
algorithms  allow further adjustment of the  data  depending  on  signal  intensity 
e.g.  LOWESS  (locally weighted  scatterplot smoothing;  Yang et al.,  2002) and 
spatial bias e.g. SNOMAD (Colantuoni et al., 2002).
Figure 1.13  Data normalisation
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Boxplots showing the re-distribution of the expression ratios of different arrays 
after normalisation.
Figure adapted from Armstrong and van de Wiel, (2004).
At this stage, the relationship between genes in the dataset is not apparent.  To 
make sense of the microarray dataset, the data can be analysed using a large
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group of statistical methods collectively known as ‘cluster analysis’.  In general, 
the  cluster  algorithms  can  be  divided  into  ‘supervised’  and  ‘unsupervised’ 
approaches (reviewed in Quackenbush, 2001).  The key difference between the 
two approaches is that supervised methods require the user input on the prior 
knowledge about the dataset e.g. to define a set of cancer-associated genes for 
tumour classification.  In contrast,  unsupervised methods organise data based 
on the inherent properties of the data without reference to any prior knowledge 
about the  question  being  addressed.  The  nature  of expression  profiling  and 
kinetic  classification  of  herpesviral  genes  is  explorative  research  i.e.  it  is  not 
hypothesis-driven  to  address  a  particular question.  Hence,  the  unsupervised 
approaches are more suitable for this type of analysis.  Indeed,  unsupervised 
clustering methods were employed for data analysis in all of the transcriptomic 
studies of human  herpesviruses thus far (see section  1.3.5) and  they are the 
subject for further discussion.
The aim of clustering is to divide the whole dataset, typically contains thousands 
of gene expression data, into smaller groups based on pattern similarity.  Genes 
with  similar patterns fall  into the same cluster, whereas dissimilar ones fall  in 
different clusters.  Gene expression clusters tend to consist of genes required in 
similar  biological  functions  i.e.  this  allows  one  to  infer  possible  function  for 
unknown  genes  in  the  same  cluster  (D'Haeseleer,  2005).  In  the  context  of 
mathematics,  cluster analysis  addresses  similarity  by  defining  the  location  of 
each  ‘expression vector’  (derived from all the expression  ratios of a  particular 
gene)  in  ‘expression  space’  (Quackenbush,  2001).  For  example,  in  an 
experiment consisting of data generated from three array hybridisations, there 
are  three  expression  ratios  for each  gene.  Imagine  plotting  a  3-dimensional 
diagram (x-y-z) to depict the whole dataset in the expression space, and for a 
given gene, the expression ratio from 1st, 2nd, and 3rd  hybridisation represent the 
co-ordinate on x-, y-, and z-axis.  Hence, every single gene (expression vector) 
occupies  a  place  in  the  expression  space.  For  a  second  gene  with  similar 
expression  ratios,  it would  be located close to the first gene in the expression 
space.  In contrast, a gene with dissimilar expression ratios is placed far away 
from  those  two  genes  in  the  expression  space.  This  principle  applies  to 
experiments  containing  more  than  three  arrays,  the  only  difference  is  the
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increase in dimensionality of expression space corresponding to the number of 
arrays.  The similarity between expression vectors is typically calculated using 
Pearson  correlation  or  Euclidean  distance.  The  former  measures  the 
correlation of the trends between expression vectors e.g. a gene with increasing 
expression  over time clusters closer to a gene with  constant expression  level 
than  another  gene  with  decreasing  expression.  In  the  case  of  Euclidean 
distance, it measures the absolute distance between expression vectors in the 
/7-dimensional  space.  The  way  in  which  Pearson  correlation  is  calculated 
means  it  is  insensitive  to  the  difference  in  magnitude  between  expression 
vectors e.g. two upregulated genes cluster together even though there is a ten­
fold  difference  between  the  levels  of  upregulation.  In  contrast,  Euclidean 
distance takes the difference between expression vectors directly and may be 
overly sensitive to the magnitude of changes (Cai et al., 2004).  A variation on 
the  Pearson  correlation  referred  to  as  the  uncentered  Pearson  correlation 
provides  a  compromise  as  it  retains  information  about  the  similarity  and 
magnitude between expression vectors (Gollub and Sherlock, 2006).
There are many different published clustering algorithms and it is impossible to 
do a fair evaluation of to determine whether a given  method  is better than the 
other (D'Haeseleer, 2005).  As “There is no single best criterion for obtaining a 
partition because no precise and workable definition of ‘cluster’ exists”, the best 
way  to  verify  the  suitability  of a  clustering  algorithm  is  to  scrutinise  the  data 
output  and  see  whether  the  clusters  match  up  with  existing  biological 
knowledge.  The software CLUSTER  (Eisen  et al.,  1998) is the  most popular 
algorithm  for  microarray analysis  (D'Haeseleer,  2005).  More  importantly,  the 
use  of  hierarchical  clustering  in  the  CLUSTER  program  for  analysing 
herpesviral gene expression has been extensively validated (Jenner, 2002) and 
successfully applied to study the transcriptomes of KSHV (Jenner et al., 2001) 
and murine gammaherpesvirus 68 (Ahn et al., 2002).  Hierarchical clustering is 
“an  agglomerative  approach  (iterative  assembling)  in  which single  expression 
vector is joined to form groups (according to pattern similarity), which are further 
joined  until  the  process  has  been  carried  to  completion,  forming  a  single 
hierarchical tree” (Quackenbush, 2001).  This hierarchical tree can be visualised 
using TreeView (Eisen et al.,  1998), which displays the data in the format of a
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gene expression map and dendrograms (see figure 4.3 for an example).  The 
gene expression map is a graphical representation of all the numerical data for 
individual arrays (columns) and genes (rows).  The gene expression ratios are 
colour-coded.  Black represents genes with log2  ratios of zero, expression ratios 
above zero are in red and below in green.  The intensity of the colour indicates 
the degree of deviation from zero i.e. increasing expression ratios are shown in 
progressively  brighter  shade.  Dendrogram  is  a  tree  structure  showing  the 
distance  between  items  which  represents  the  degree  of  similarity  between 
genes (rows) or arrays (columns).
1.3.4.3  Data validation
It should be noted that the results obtained in a microarray experiment are not 
definitive.  Any  conclusion  drawn  from  a  microarray  experiment  should  be 
validated  by an  independent  method  such  as  Northern  blotting,  RT-PCR and 
quantitative RT-PCR.
1.3.5  Herpesviral microarray analyses
A  PubMed  search  performed  on  31/12/06  with  the  terms  ‘herpesviridae’  and 
‘microarray’  returned  97  hits.  These studies  ranged from  viral  gene  mutation 
analysis (Sun et al., 2004), viral gene characterisation (An et al., 2005; Pages et 
al., 2005) and the effect of viral infection on host gene expression (Carter et al., 
2002;  Mossman  et al.,  2001;  Wang et al.,  2004).  This thesis focuses on the 
expression  profiling  and  kinetic  classification  of human  herpesviruses.  Table 
1.9 lists the published microarray studies of the different human herpesviruses.
104Table 1.9 Microarray analysis of herpesviral transcriptomes
Virus Viral probes (no.)  Host probes (no.)  Type of study Comment Array type Reference
HSV-1
HSV-2
VZV
VZV
EBV
HCMV
KSHV
KSHV
99
92
152
71
206
96
88
57
0
2
10
0
197
10
88
8-hour time course
8-hour time course 
4-day time course 
72-hour time course
72-hour time course
72-hour time course
72-hour time course 
96-hour time course
Expression profiling and kinetic 
classification 
Expression profiling and kinetic 
classification 
Expression profiling 
Expression profiling in two 
different cell-lines 
Expression profiling and kinetic 
classification 
Expression profiling and kinetic 
classification (this is the first 
human herpesvirus-specific 
array study) 
Expression profiling and lytic 
versus latent replication 
Expression profiling and kinetic 
classification
75mer oligo-arrays
75mer oligo-arrays 
cDNA arrays 
75mer oligo-arrays
75mer oligo-arrays
(Stingley et al., 2000)
(Aguilar et al., 2005) 
(Cohrs et al., 2003) 
(Kennedy et al., 2005)
(Yuan et al., 2006)
75mer oligo-arrays  (Chambers et al., 1999)
cDNA arrays 
cDNA arrays
(Jenner et al., 2001)
(Paulose-Murphy et al., 
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1.4  Scope of this thesis
Functional  genomics  of  HHV-6  is  largely  uncharacterised.  A  better 
understanding  of  expression  profile  and  kinetic  classification  of  HHV-6  lytic 
genes would facilitate the characterisation of gene function, which is essential to 
improve  our  understanding  of  HHV-6  pathogenesis.  In  addition,  it  has  been 
recently estimated that about 0.2 to 3% of the population harbour chromosomal 
HHV-6 integration (section 5.1).  Nothing is known about viral gene expression 
of integrated  HHV-6 DNA in vivo.  This thesis describes the characterisation of 
viral gene expression during lytic cycle and chromosomal integration of HHV-6.
Although  two  different  microarrays  for  HHV-6  are  available  at  present 
(Ohyashiki et al., 2005; Yao et al., 2006), none was available when this project 
commenced.  Chapter 3 of this thesis describes the construction and validation 
of the HHV-6 array containing DNA probes to almost all HHV-6 genes and 914 
human  genes.  The  HHV-6  arrays  created  in  chapter  3  were  then  used  for 
profiling  HHV-6B  gene  expression  during  lytic  replication.  Chapter 4  of this 
thesis describes transcription kinetics of 93 out of 97 HHV-6B genes during lytic 
replication.  Chapter 5 of this thesis describes the  investigation  on  viral  gene 
transcription,  in  vitro  and ex  vivo,  in  cells  harbouring  integrated  HHV-6  DNA. 
Finally,  in  Chapter  6,  the  expression  data  resulting  from  these  analyses  are 
summarised  and  future  experiments  derived  from  the  work  of this  thesis  are 
discussed.
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Materials and MethodsMaterials and Methods
2.1  Reagents, buffers and solutions
Please refer to appendix I for details.
2.2  Cell culture
2.2.1  Cell-lines
All cell culture procedures were carried out in class II biosafety cabinets.  All cell 
lines were grown in complete medium, which consists of Roswell Park Memorial 
Institute (RPMI)-1640 medium (Invitrogen,  Paisley,  UK),  10% foetal calf serum 
(FCS;  Invitrogen),  100  units/ml  penicillin  and  100  pg/ml  streptomycin  (Sigma, 
Poole, UK), at 37°C, with 5% C02, in a humidified incubator.
Table 2.1 CD4+  cell-lines
Cell-line Description Reference
JJhan A clone of Jurkat T-lymphocyte (Gompels et al.,  1993)
Molt-3 A mature T cell-line originated from PBMCs of an 
individual with acute lymphoblastic leukemia
(Minowada et al.,  1978)
SupT1 An immature T cell-line originated from a non 
Hodgkins T cell lymphoma
(Ablashi et al., 1991)
JJhan  and  Molt-3 were  split  1:5 twice a week.  SupT1  were  split  1:5 once  a 
week.  The mycoplasma status of all cell-lines was regularly checked using an 
in-house mycoplasma PCR assay (section 2.2.2) or by the research services at 
Cancer Research UK.  Mycoplasma was never detected in any of the cell-lines 
used in this study.
2.2.2  Mycoplasma testing
This  is  a  PCR-based  assay.  The  following  primers  (MWG,  Ebersberg, 
Germany) amplify the 16s RNA of all species of mycoplasma and give rise to a 
288bp product:
MGS-O:  TGC ACC ATC TGT CAC TCT GTT AAC CTC
GPO-3:  GGG AGC AAA CAG GAT TAG ATA CCC T
PCR reactions were prepared  using  HotStarTaq  DNA polymerase kit (Qiagen, 
Crawley, UK).  Each reaction comprised 1X PCR Buffer, 10 mmol of each dNTP 
(Promega,  Southampton,  UK),  10  pmol of each  primer,  2.5  U  of HotStar Taq
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DNA Polymerase (5 u/|jl), and 100 ng of template DNA in a total volume of 50 pi 
per reaction.  Each reaction was placed in a thermal cycle (Hybaid  Multiblock 
System;  Hybaid,  Middlesex,  UK) and subjected to the cycling conditions listed 
below:
95°C 1   minute (min)
ii. 94°C 1   min
iii. 66°C 1   min
iv. 72°C 2 min
V. Cycle for 40 times from step ii to iv
vi. 72°C 10 min
Both positive control (DNA from mycoplasma positive culture) and water control 
were  used  for each  PCR  reaction.  The  PCR  products were  analysed  by gel 
electrophoresis.
2.2.3  Gel preparation
The percentage of agarose gel determines the range of size separation e.g. a 2- 
3% gel is suitable for analysing PCR products of 200-500 bp.  The appropriate 
amount  of  agarose  (Bioline,  London,  UK)  was  dissolved  in  50  ml  of  TBE 
(Appendix I) buffer (National Diagnostics, Atlanta, GA) e.g. for a 3% gel, 1.5 g of 
agarose  was  required.  The  molten  agarose  was  cooled  to  ~40-50°C  under 
running  water.  Two  microlitres  of ethidium  bromide  (10  pg/pl;  Sigma)  were 
added to the agarose which was then poured onto a gel tray with a comb and 
allowed to set. The comb was removed and the gel tray was then  placed  in a 
gel tank filled with 1x TBE buffer ready for the loading of samples.
2.2.4  Sample preparation and gel electrophoresis
Samples were prepared by mixing 10 pi of PCR product with 5 pi of loading dye 
(Bioline).  The samples were then  loaded  into the wells of the gel.  Two  lots of 
size  markers  (Bioline) were  loaded  to flank the  PCR  products.  The  gel  was 
electrophoresed at 5 V/cm and  left to run for 50 min.  The resolved  products 
were  visualised  on  a  UV  transilluminator  and  the  photographic  images  were 
taken if required.
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2.2.5  Freezing cells
Cells were pelleted at 325 g for 5 min and  resuspended at 5 x  106  cells/ml  in 
freeze-down  medium  (FDM,  containing  90%FCS  +  10%  tissue  culture  grade 
dimethyl  sulphoxide  (DMSO;  Sigma)).  Cells  were  aliquoted  into  cryovials 
(Alpha  Laboratories,  Eastleigh,  UK)  and  gradually  cooled  to  -80°C  in  an 
isopropanol-containing  cryo-container  (Nalgene,  Rochester,  NY)  before  being 
transferred to liquid Nitrogen (N2).
2.2.6  Thawing cells
Cells were taken out from liquid N2 and allowed to thaw rapidly in a 37°C water 
bath.  The contents in the cryotube were layered onto 2 ml of culture medium 
and left to stand for 2-3 min (to dilute the DMSO in the FDM).  Cells were then 
spun at 325 g for 5 min.  The cell pellet was washed with 5 ml of medium.  Cells 
were then centrifuged again at 325 g for 5 min.  The supernatant was discarded 
and the pellet was resuspended in  1   ml of medium.  The suspension was then 
transferred  into  a  tissue  culture  flask  (Corning  Lifescience,  Corning,  NY) 
containing 9 ml of medium and the cells were cultured at 37°C in 5% C02.
2.2.7  Cell cloning
The number of cells was counted using a haemocytometer.  Cells were diluted 
to 20,  2  and  0.2  cells/ml  and  cultured  in  96-well  plates  (Corning  Lifescience) 
containing  150  pl/well  of cell  suspension.  The  plate  derived  from  the  lowest 
concentration of cells that yielded viable cultures was selected as the source of 
clonal cell cultures.
2.3  Preparing HHV-6 virus inocula
2.3.1  Passaging HHV-6-infected cells
Strain  U1102  (a  kind  gift from  Fox  J,  Cardiff,  UK)  and  Z29  (a  kind  gift from 
Pellett  PE,  CDC,  Atlanta,  GA)  of  HHV-6  were  grown  and  analysed  in 
JJhan/SupT1  and  Molt-3/SupT1  cell  lines,  respectively.  Cells  were  grown  in 
suspension  at 37°C  in  complete medium  (section  2.2.1)  in  5%  CO2.  Infected
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cells were passaged by mixing uninfected and infected cells at 1:1  or 1:2 ratios, 
depending on cell density, twice a week.
2.3.2  Cell-free virus inocula
HHV-6-infected cells (showing >50% CPE) were centrifuged at 325 g for 5 min 
to pellet the cells.  The supernatant was discarded and the pellet resuspended 
in 1   ml of filtered FCS.  The cell suspension was then subjected to three cycles 
of  freezing  (in  liquid  N2)  and  thawing  (in  37°C  waterbath)  to  release  the 
intracellular  virus  particles.  Five  millilitres  of  serum-free  medium  containing 
RNase A (50 pg/ml; Sigma) were added to the lysate, vortexed, and incubated 
at  37°C  for  30  min.  The  suspension  was  spun  at  325  g  for  5  min,  the 
supernatant transferred into a fresh 15 ml Falcon tube and spun again at 2,300 
g for 5 min.  The supernatant was stored  at -80°C in  1   ml  aliquots as  HHV-6 
virus stocks.
2.3.3  Variant-typing PCR
The  HHV-6A(U1102)  and  HHV-6B(Z29)  stocks  were  used  to  infect  SupT1. 
DNA was extracted (as described in section 2.4.2) from the infected cells 3-day 
post-infection  (3dpi)  and  used  as templates for variant-typing  PCR to confirm 
the homogeneity of each stock.  PCR reactions were carried out as described in 
section  2.2.2  with  modifications.  Variant-typing  PCR  was  performed  using 
primers for HHV-6A DR8 and  HHV-6B B5 (appendix  II).  Both sets of primers 
target  variant-specific  regions  of  the  virus  genome,  thus  allowing  the 
differentiation between the two variants.  In addition, the cycling conditions were 
adjusted to:
i.  95°C for 15 min
ii.  94°C for 30 seconds (s)
iii.  50°C for 30  s
iv.  72°C for 30 s
v.  Repeat step ii to iv for 35 times
vi  72°C for 7 min
PCR products were analysed as described in sections 2.2.3 and 2.2.4.
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2.3.4  Slide preparation for IFA
Cells  to  be  assayed  by  IFA were  pelleted.  The  cell  density was  adjusted  to 
approximately 2 x  106 cells/ml.  Twelve well  poly-tetra-fluoro-ethylene- (PTFE) 
coated slides (Hendley Essex,  Essex,  UK) were used for cell fixation.  Fifteen 
microlitres of the cell suspensions were spotted onto each well and allowed to 
air dry for 45 min in a class II  microbiological safety cabinet.  Once dried,  the 
slides were fixed in ice-cold 100% acetone (BDH, Lutterworth, UK) at -20°C for 
10 min.  The slides were then transferred into a slide box and kept at -20°C until 
use.
2.3.5  HHV-6 IFA
The IFA was performed using the following mAbs: 
Table 2.2  HHV-6 specific mAbs
Antigen Comment Source Reference
p41/38 Recognises early nuclear 
protein of HHV-6A
Chemicon, Chandlers Ford, 
UK
(Iyengar et al.,  1994)
p101 Recognises a HHV-6B late 
protein
Chemicon (Iyengar et al., 1994)
gpi 16 Recognises both HHV-6A 
and 6B.
Not suitable for Western 
blotting
Advanced Biotechnologies, 
Columbia, MD
(Balachandran et al., 
1989)
The  primary  mAbs  were  typically  used  at  a  1:50  -   1:100  dilution.  Fifteen 
microlitres  of  the  diluted  mAbs  were  spotted  onto  each  well.  Slides  were 
incubated  at  37°C  for  40  min  in  a  humidified  chamber  and  washed  with 
phosphate buffered saline (PBS, appendix I) 3 times, each wash lasting 5 min. 
The  secondary antibody (fluorescein  isothiocyanate  (FITC) -conjugated  rabbit 
anti-mouse IgG; Sigma) was used at 1:100 dilution and  10 pi was spotted onto 
all wells.  Slides were  incubated for 40  min  at 37°C  in a  humidified  chamber, 
washed as described above.  The excess liquid on the slides was removed by 
tapping  them  against  tissue  paper.  The  slides  were  mounted  with  Citifluor 
mounting fluid (UKC, Canterbury, UK) and overlaid with a coverslip to preserve 
the fluorescence.  Slides were inspected with an Olympus immunofluorescence 
microscope and the photographic images taken if required.
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2.3.6  HHV-6 infectivity
Three  independent  infections were  carried  out whereby  5  x  106   SupT1  cells 
were  exposed  to  1   ml  of  virus  inoculum  for  60  min  at  37°C,  washed,  and 
incubated  at 37°C for another 59  hours  (59h)  i.e.  60h  in total.  Infected  cells 
were  examined  by  IFA  using  anti-gp116  mAb  as  described  in  section  2.3.5. 
The  number  of  infected/uninfected  cells  per  field  was  recorded,  and  the 
infectivity index calculated as the average percentage of gp116-positive cells at 
60h post-infection (60hpi).
2.4  Cloning of HHV-6 array probes
2.4.1  HHV-6 primer design
Forward and reverse primers were designed using the online Primer3 program 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi).  The sequence of the 
gene  of  interest  was  copied  and  pasted  onto  the  online  interface  and  the 
program returned a list of primer pairs based on the default parameters.  For the 
design of primers to HHV-6 ORFs, the published sequence of HHV-6A(U1102) 
and  HHV-6B(Z29)  were  used  and  the  accession  numbers  are  X83413  and 
AF157706  respectively.  All  primer  sequences  were  analysed  with  BLAST 
(http://www.ncbi.nlm.nih.gov/BLAST/) (Altschul et al.,  1990) to ensure that they 
were unique to HHV-6.  The sequence of each amplicon was also analysed to 
check  for  cross-hybridisation  between  HHV-6A,  HHV-6B  and  other  human 
herpesviruses.  The oligonucleotides were ordered from  Eurogentec (formerly 
Oswel,  Southampton,  UK) and their details were listed in appendix II.  Primers 
for other PCR were ordered from MWG-Biotech (Ebersberg, Germany), Operon 
(Cologne, Germany), or Thermo Hybaid (Waltham, MA).
2.4.2  HHV-6 DNA extraction
The  Wizard  DNA  purification  kit  (Promega)  was  used  for  DNA  extraction. 
Approximately  2  x  106   of  HHV-6A(U1102)-infected  JJhan  and  HHV-6B(Z29)- 
Molt-3 cells were washed with PBS.  The cells were pelleted and lysed with 600 
pi of nuclei  lysis buffer.  Three  microlitres of RNase were added to the lysate 
and the sample was incubated at 37°C for 15 min.  The sample was cooled to
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room temperature  before adding 200  pi  of protein  precipitation  buffer.  It was 
vortexed and then incubated on ice for 5 min.  The protein and cell debris were 
precipitated  by  centrifugation  at  16,000  g  for  4  min.  The  supernatant 
(containing the DNA) was transferred into a fresh tube.  Five hundred microlitres 
of  isopropanol  were  added  to  precipitate  the  DNA.  The  DNA  sample  was 
pelleted and washed with 1   ml of 70% ethanol.  It was then resuspended in 100 
pi of nuclease-free water,  incubated  at 65°C for an  hour to dissolve the  DNA. 
The  sample  was  quantified  by  measuring  the  O.D.  260nm  using  UV- 
spectrometry (O.D. 1   = 50 pg/ml dsDNA; GeneQuant, Pfizer, Sandwich, UK).
2.4.3  HHV-6 PCR
Fragment(s)  of  individual  ORFs  for  HHV-6A(U1102)  and  HHV-6B(Z29)  were 
PCR  amplified  as  described  in  section  2.3.3,  using  the  primers  listed  in 
appendix  II.  PCR products were analysed  as described  in sections 2.2.3 and 
2.2.4.
2.4.4  PCR purification
PCR products were purified  using the QIAquick  PCR purification  kit (Qiagen). 
Two hundred microlitres of buffer PB were added to 40 pi of the PCR products. 
The mixture was transferred  into a binding column and spun at 16,000 g for 1  
min.  The flow-through was discarded.  Seven  hundred  and fifty microlitres of 
buffer PE were added to wash the column and was spun for 1   min.  The column 
was centrifuged at 16,000g for another 2 min to remove residual ethanol from 
the buffer PE.  The column was transferred into a fresh  1.5 ml microfuge tube 
and 30 pi of nuclease-free water were added to the membrane to resuspend the 
DNA.  The column was spun at 16,000g for 1   min to collect the DNA.
2.4.5  Ligation
The  pGEM-T  Easy  vector  system  (Promega)  was  used  for  cloning  HHV-6 
ORFs.  Since the majority of the amplicons was 300 bp in size, the optimised 
ligation  ratio  was  50  ng  vector  DNA:  15  ng  insert  DNA  per  reaction.  The 
reaction was prepared by adding 5 pi of ligation buffer,  1   pi of T4 ligase, 50 ng
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of vector  and  15  ng  of  insert  DNA  and  adjusted  to  10  pi  total  volume  with 
nuclease-free water.  The ligation was carried out at 4°C overnight.
2.4.6  Preparing competent cells (Inoue et al., 1990)
Escherichia coli (E.  coli) strain JM109 was used for this procedure.  Bacteria, 
stored  in the form of a  glycerol stock, were streaked  on  a  1.5%  Luria-Bertani 
(LB)  agar  plate  (appendix  I)  without  antibiotic  selection.  The  plate  was 
incubated overnight at 37°C.  A single colony was picked to inoculate a starter 
culture  of  3  ml  of  LB-broth  without  selection  (appendix  I).  The  culture  was 
incubated at 18°C for 8h with shaking.  Two and a half millilitres of this starter 
culture were then added to  125 ml of SOB (appendix I) in a  1   L conical flask. 
The  culture  was  incubated  at  18°C  overnight  with  shaking.  It  was  then 
incubated on ice for 10 min.  The culture was split into 3 x 40 ml and the cells 
were pelleted by centrifuging at 3,000 g for 10 min at 4°C.  The supernatant was 
discarded.  The same volume  of 80  ml  ice-cold  TB  (appendix  I) was  used  to 
resuspend all the pellets.  The suspension was spun at 3,000 g for 10 min at 
4°C.  The supernatant was discarded.  The pellet was resuspended in 20 ml of 
TB  with  the  addition  of  1.4  ml  of  DMSO  (7%  final  concentration).  The 
suspension was  incubated  on  ice for  10 min.  It was then  divided  into 450  pi 
aliquots.  The competent cells were immediately frozen in liquid  N2  and stored 
at -80°C until required.
2.4.7  Transformation
Aliquots of competent cells were thawed on  ice.  Ten to twenty nanograms of 
DNA were transferred  into a  microfuge tube and  incubated  on  ice for 10  min. 
Fifty microlitres of competent cells were added to the DNA and incubated on ice 
for another 30 min.  The cells were then subjected to a heat shock at 42°C for 
40 s.  The tube was then put back on ice.  Eight hundred microlitres of LB-broth 
were added into the tube and transferred into a 37°C waterbath to incubate for 
an  hour.  Forty  microlitres  of cell  suspension  was  plated  on  agar containing 
ampicillin  (100  pg/ml,  Sigma).  The  plate  was  turned  upside  down  and 
incubated at 37°C overnight.
115Materials and Methods
2.4.8  PCR screening
PCR was used to screen for colonies which carry plasmid with the correct insert 
size.  The  universal  primers  (appendix  II)  bind  to the vector sequence which 
flank the  cloning  site,  hence  the  detection  of amplicons  at the  expected  size 
indicates successful cloning of HHV-6 ORFs.  PCR reactions were prepared as 
described in section 2.2.2 but the cycling conditions were modified to:
i.  95°Cfor15min
ii.  94°C for 30  s
iii.  50°C for 30  s
iv.  72°C for 30  s
v.  Repeat step ii to iv for 25 times
vi  72°C for 7 min
PCR products were analysed (sections 2.2.3 and 2.2.4) and the clones carrying 
the correct insert, as determined by the amplicon’s size, were cultured in 3 ml of 
ampicillin-containing LB-broth at 37°C overnight.
2.4.9  Plasmid DNA extraction
The  QIAprep  Spin  Miniprep  kit  (Qiagen)  was  utilised  for  the  plasmid  DNA 
extraction.  One millilitre of overnight culture was pelleted at 3,000 g for 3 min 
and resuspended in  100 pi of sterile 20% glycerol for archiving.  Two millilitres 
of overnight culture were transferred into a microfuge tube and spun at 3,000 g 
for 3 min. The pellet was resuspended in 250 pi of buffer P1.  Two hundred and 
fifty microlitres of buffer P2 were added and the tubes were inverted 5 times to 
lyse the bacterial cells.  Three  hundred  and fifty microlitres of buffer N3 were 
added, the inversions were repeated and the mixture was spun at 16,000 g for 
10 min.  The supernatant,  containing the plasmid  DNA, was transferred into a 
spin column, spun for 1   min and the flow-through was discarded.  Five hundred 
microlitres  of buffer PB were  added,  the  column  was spun  for  1   min  and  the 
flow-through was discarded.  Seven  hundreds and fifty microlitres of buffer PE 
were added,  the  column was spun for  1   min,  the flow-through was discarded 
and then spun for another 2 min to remove the residual ethanol.  The column 
was  placed  in  a fresh  microfuge tube,  and  50  pi of nuclease-free water were 
added to the tube. The column was left at room temperature for 1   min and spun
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for  1   min to  collect the  plasmid  DNA.  The purified  sample was quantified  by 
UV-spectrometry and stored at -20°C.
2.4.10  EcoRI restriction analysis
Three hundred nanograms of plasmid DNA were mixed with 2 pi of EcoRI buffer 
and  adjusted  to  19  pi  with  nuclease-free  water.  This  was  followed  by  the 
addition  of  1   pi  of EcoRI enzyme.  The tube was vortexed,  spun  briefly,  and 
then incubated at 37°C for 3h.  Digested plasmid DNA was mixed with loading 
buffer and analysed by gel electrophoresis.  The size of the vector backbone is 
~3kb, the smaller band represents the fragment of individual HHV-6 ORFs that 
was cloned.
2.4.11  DNA sequencing
One and a half microlitres of plasmid DNA were mixed with 3.5 pi of nuclease- 
free water and  heated  at 95°C  for 5  min.  Four microlitres  of QuickStart  mix 
(Beckman  Coulter,  High  Wycombe,  UK)  and  5  pmoles  of  the  relevant 
sequencing primer (appendix II) were added.  The reaction mix was placed in a 
thermal cycler and subjected to the following conditions:
94°C 3 min
ii. 96°C 20 s
iii. 50°C 20 s
iv. Step i to iii cycle for 30 times
V. 60°C 4 min
DNA was  precipitated  from  the  sequencing  reaction  by  adding  2  pi  of  1.5M 
sodium acetate (Sigma), 2 pi of 50 mM EDTA (ethylenediaminetetraacetic acid; 
Sigma) and 1   pi of 20 mg/ml glycogen (Beckman Coulter) in a final volume of 20 
pi.  Sixty  microlitres  of  ice-cold  95%  (v/v)  ethanol/water  were  added  to  the 
mixture, vortexed and left on ice for 10 min.  DNA was pelleted by centrifugation 
at 14,000 g for 15 min at room temperature.  The supernatant was discarded, 
the pellet washed with 200 pi of ice-cold 70% ethanol and centrifuged at 14,000 
g at 5°C for 5 min.  The supernatant was discarded and the tube left open at 
room  temperature  until  the  ethanol  was  completely  evaporated.  DNA  was 
dissolved in 40 pi of deionised formamide (Mallinckrodt Baker, Phillipsburg, NJ)
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and  transferred  to a  96-well  plate.  The sequences were  determined  using  an 
automated  capillary  DNA  sequencer  (Beckman  Coulter)  according  to  the 
manufacturer’s instructions.
2.4.12  BLAST2 analysis
BLAST2  is  an  online  sequence  alignment  program 
(http://www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html).  This  program was  used  to 
confirm  the  sequence  identity  of  individual  cloned  elements  by  comparing 
experimental results to the published sequencing data.
2.5  Array fabrication
2.5.1  Amplification of viral array probes
All  131  HHV-6 clones were arranged  into two 96-well  plates and  used for the 
amplification  of HHV-6  array probes.  PCR was  performed  using  the  Hotstart 
Immolase kit (Bioline).  Each reaction comprises 1x Immolase buffer, 20 mmol 
dNTPs,  40  pmol  of both forward  and  reverse  universal  primers  (Appendix  II),
1.5 mM MgCb, and 2.5 U of Immolase.  The cycling conditions were:
95°C for 7 min
ii. 94°C for 30 s
iii. 50°C for 30 s
iv. 72°C for 30 s
V. Repeat step ii to iv for 40 times
vi 72°C for 7 min
Two  microlitres  of each  PCR  products  were  analysed  by  gel  electrophoresis 
(sections 2.2.3 and 2.2.4).  Any failed PCR (no or multiple bands) was repeated 
until a single band was yielded for each reaction.
2.5.2  Amplification of host gene array probes
Host  array  probes  were  PCR  amplified  from  the  IMAGE  lymphochip  set  of 
-2100 cDNA clones (MRC geneservice, Cambridge,  UK).  The clone set was 
stored  as  bacterial glycerol  stocks  (LB-broth,  8%  glycerol,  50  pg/pl  ampicillin) 
arrayed  in  96-well  formats.  Five  microlitres  of  culture  of  individual  IMAGE 
clones  were  inoculated  in  145  ^l  of  LB-broth  with  50  jug/jal  ampicillin  and
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incubated at 37°C for 8 hours with gentle shaking.  Five microlitres of this starter 
culture were then added into 995 pi of LB-broth (containing ampicillin plus 8% 
glycerol) and the mixture was incubated at 37°C overnight.  Two lots of 200 pi of 
overnight  culture  was  kept  at  -80°C  for  archiving.  Twenty  microlitres  of 
overnight culture was added into 80 pi of nuclease-free water.  The suspension 
was heated at 98°C for 10 min to lyse the bacterial cells.  It was placed on ice 
immediately after the heat treatment and incubated for 10 min.  It was then spun 
at 3,000 g for 3 min to pellet the cell debris.  Ten  microlitres of the supernatant
were used as templates to set up the PCR (as described  in section 2.5.1) using
M13 forward  and T7/T3  reverse  primers  (both  primers designed  by Cheryl  Li, 
UCL; appendix II).
2.5.3  Purification of array probes
PCR products for both human and viral genes were purified using the Montage 
PCR384 purification plates (Millipore, Consett, UK).  The membrane filter has a 
cut-off of  138  bp  DNA  in  size  and  thus  the  dNTPs  or  excess  primers  were 
removed by filtration under 254 mm Hg vacuum for 15 minutes.  Purified  DNA 
was resuspended  in 20  ml spotting  buffer,  containing 3x  saline sodium citrate 
buffer (SSC;  Sigma) and  1.5  M  Betaine (Sigma) and transferred  into 384-well 
arraying plates (Genetix,  New Milton,  UK).  The process was automated  using 
Biomek  2000  Liquid  Handler (Beckman  Coulter).  The  probes were  kept  at - 
20°C until use.
2.5.4  Spotting buffers test
The  evaporation  rate  of four different  buffers was  assessed:  DMSO,  Genetix 
spotting buffer (Genetix), betaine, and 3x SSC.  All buffers were diluted 1:2 with 
dH20  to  achieve  working  concentration.  Three  lots  of  10  pi  of each  diluted 
buffer  were  transferred  onto  a  384-well  plate.  The  plate  was  left  at  room 
temperature overnight (>16 hours) and the remaining volume of the buffers was 
recorded.
The spot morphology of DMSO  and  betaine  buffer was also assessed.  Cy3- 
dCTP  (25nmol;  GE  Healthcare,  Amersham,  UK)  was  mixed  1:1  with  either
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DMSO  or  betaine  buffer.  Each  of  the  dye-buffer  mix  was  deposited  onto 
microscopic glass slides into a  11  x  11  grid.  The slide was then scanned and 
the spot morphology between the DMSO and betaine buffer was analysed using 
the GenePix Pro 4 software (section 2.6.12).
2.5.5  Optimisation of the washing/drying protocol
The  2x  spotting  buffer  (SB  -   Genetix)  and  12nmol  of Cy-dyes  (Cy3  or  Cy5) 
were arranged in the following order:
1-4: SB(1) -  Cy3(2) -  SB(3) -  SB(4)
5-8: SB(5) -  Cy5(6) -  SB(7) -  SB(8)
Each hyphen represents a washing/drying cycle.
These samples were arrayed onto glass slides using the QArray2 arrayer (both 
from  Genetix).  The  levels  of  non-specific  signals  were  established  from  the 
fluorescent  intensities  emitted  by the  first  set  of SB  features.  The  split  pins 
were washed  and  dried,  then  picked  up the Cy3 dye for the second  round  of 
spotting, and the cleaning of the pins was repeated.  Any carryover of the Cy3 
dye into the spotting of SB(3) and  SB(4) suggests sub-optimal washing/drying 
conditions,  the  washing/drying  conditions  were  adjusted  until  no  above­
background signal was detected in these features.  The same principle applies 
to samples 5-8 and the only difference was the dye (Cy5) used.
2.5.6  Array substrate test
Six different makes of microarray slides were acquired  and  assessed for their 
suitability for array construction, they were:
(1)  UltraGAPS  (Corning  Lifescience),  (2)  Nexterion  slide  A  (Schott,  Stafford, 
UK),  (3)7star (GE  Healthcare),  (4) Quantifoil aminosilane (Schott),  (5) ArrayXL 
cDNA (Genetix), and (6) Amine (Genetix).  All the slides were scanned  before 
printing to check for the quality of coating and background fluorescence.  HHV-6 
array probes were printed onto all the slides using the QArray2  arrayer (Genetix) 
at 55%  relative  humidity.  Array probes were  immobilised  by baking  in  a dry- 
oven  (80°C)  for  4h.  All  array  slides  were  post-processed  by  incubating  in 
succinic anhydride solution (see appendix I) for 15 min.  This treatment converts 
the active amine into carboxylic moieties and therefore reduces the non-specific
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binding of nucleic acids to the surface (Schena et al.,  1995).  The slides were 
then  rinsed  twice  in  dH20,  followed  by  a  2-min  incubation  at  95°C  for  the 
denaturation  of the  array probes.  They were then  rinsed  in  isopropanol,  and 
dried by centrifugation at 1,000g for 2 min.  All slides were hybridised with the 
same  Cy5-  and  Cy3-labeled  target  mix,  which  was  prepared  from  the  same 
mRNA  sample  purified  from  HHV-6B-infected  SupT1.  Slides  were  scanned 
using the same settings and the signal-to-noise (SNR) were compared between 
the different makes of slides.
2.5.7  Optimisation of post-processing methods
HHV-6 array probes were printed onto Schott Nexterion Slide A as described in 
section 2.5.6.  The array slides were  post-processed using either the succinic 
anhydride solution or the in-house blocking solution (appendix I).  For the latter 
treatment,  after baking the arrays for 4h,  they were  immersed  in the in-house 
blocking solution for 30  min  at 50°C.  This was followed  by rinsing with dH20 
twice,  heat-denatured  at 95°C for two min,  and  re-incubated  in fresh  in-house 
blocking  solution  for another 30  min.  The  slides  were  again  rinsed  in  dH20 
twice and spun dried at 200 g for 2 min.  The processed slides were hybridised 
with the same Cy5- and  Cy3-labeled target mix, which was prepared from the 
same  mRNA  sample  purified  from  HHV-6B-infected  SupT1.  The  two  post­
processing methods were assessed on the basis of SNR and spot morphology.
2.5.8  Array printing and processing
This  section  describes  the  optimised  protocol  for  HHV-6  arrays.  The  array 
probes  were  thawed  at  room  temperature  at  least  an  hour  before  spotting. 
Overall,  131  HHV-6- and 914 host-genes were arrayed onto Nexterion Slide A 
(Schott) using the QArray2  arrayer (12-pin head configuration, Genetix) at 55% 
relative  humidity.  All  array probes were printed  in triplicate,  in  a format of 36 
sub-grids, with 196 spots (14 columns by 14 rows) per grid.  Printed arrays were 
air-dried  overnight (>12h),  followed  by baking  at 80°C  in  a dry oven for 4h to 
immobilise  the  DNA.  Unbound  surfaces  on  the  arrays  were  blocked  by 
incubating in 60 ml of in-house blocking solution at 50 °C for 45 min, followed by 
two  rinses in  dH20.  Then the arrays were heat-denatured at 95°C for 2  min,
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blocked again (with fresh solution) at 50°C for 30 min, and rinsed twice in dH20. 
Finally the arrays were dried by spinning at 200 g for 2 min.  Processed arrays 
were stored in a dry environment for use within 4h.
2.5.9  Validation of the HHV-6 arrays
Triplicate hybridisations of RNA prepared from mock-infected SupT1 against the 
universal  reference  (section  2.6.5)  were  performed  to  assess  the  specificity, 
spot depositions, and the reproducibility of the HHV-6 arrays.  Half a million of 
SupT1  cells  were  inoculated  with  1   ml  of  FCS  for  an  hour.  The  cells  were 
washed  with  PBS  twice  and  then  incubated  in  fresh,  complete  RPMI  1640 
medium for 59h.  The cells were lysed with TRIzol and the mRNA was prepared 
as  described  in  section  2.6.  Three  lots  of  mRNA  from  the  mocked-infected 
SupT1  (250 ng/reaction) were labeled with Cy5, and 3x 250 ng of the universal 
reference were  labeled  with  Cy3.  The  labeled-samples were  hybridised  onto 
three individual HHV-6 arrays, each consisted of one Cy5- and one Cy3-labeled 
cDNA.  The  array  hybridisation,  washing  and  scanning  were  carried  out  as 
described in sections 2.6.9 to 2.6.12.  All the arrays were assessed for:
(1) missing viral spots -  viral probes which emit no signals in both the Cy5- and 
Cy3- channel,
(2)  HHV-6  specificity  -   no  viral  probes  should  hybridise  with  mRNA  from 
mocked-infected  SupT1  i.e.  any  Cy5  signal  from  these  spots  indicates  non­
specific hybridisation,
(3) reproducibility -  the samples used in the three hybridisations were the same 
and  therefore the  reproducibility of array results was  estimated  by calculating 
the correlation between the expression ratios of the three arrays.
2.5.10  Optimising the cDNA labeling method
The  performance  of  three  different  labeling  kits  was  assessed:  (1)  direct  - 
Cyscribe  First-strand  cDNA  labeling  system  (GE  Healthcare),  (2)  indirect  - 
Superscript  indirect  labeling  system  (Invitrogen),  (3)  dendrimer  -  Genisphere 
Array900MPX (GRI, Essex, UK).  RNA used for all the labeling reactions (a kind 
gift from C Gale,  UCL) was amplified from the universal human reference RNA 
(Stratagene,  La Jolla,  CA).  For the direct- and  indirect-labeling, 750 ng of the
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amplified  RNA (aRNA) were  used  per reverse transcription  i.e.  1500 ng/array 
(750  ng  labeled  in  red  vs  750  ng  in  green).  The  higher  sensitivity  of  the 
Genisphere kit means that 1/8 of the amount of aRNA (93.8 ng) was used for 
the  labeling.  The  labeled  cDNA  samples  were  assessed  on  the  Human 
Genome Mapping Project (HGMP) 6k microarrays (MRC, Cambridge, UK).
The direct labeling of the aRNA was carried out as described  in section 2.6.6. 
For the indirect labeling, 750ng of aRNA were mixed with 2 pi of oligo(dT)2o  (2.5 
pg/pl), 1   pi of random hexamers, and adjusted to 18 pi with nuclease-free water. 
The mixture was heated at 70°C for 5 min and then transferred on ice for 1   min. 
This was followed by the addition of 6 pi of 5x First-strand buffer, 1.5 pi of 0.1  M 
dithiothreitol (DTT), 1.5 pi of dNTP mix, 1   pi of RNaseOUT (40 U/ul) and 2 pi of 
Superscript III reverse transcriptase.  The mixture was incubated at 46°C for 2h. 
After reverse transcription,  15  pi  of 1N  NaOH were added to the  mixture and 
heated  to  70°C  for  10  min  to  hydrolyse  the  RNA.  The  mixture  was  then 
neutralised  with  15ul  of  1N  HCI.  The cDNA was  purified  using the  Microcon 
YM-30  column  (Millipore)  to  remove  any  unincorporated  nucleotides  by  size 
filtration.  The cDNA reaction was mixed with 350 pi of nuclease-free water and 
transferred to the column.  The column was spun at  14,000 g for 8 min.  The 
column  was  washed  with  450  pi  of  nuclease-free  water  and  centrifuged  at 
14,000g  for  8  min.  The  wash  step  was  repeated  once  and  the  cDNA  was 
collected by placing the column,  in an inverted position, so that the membrane 
is facing the  bottom of a fresh collection tube and  spun  at  1,000 g for 3  min. 
The  cDNA was  pelleted  and  dried  using  a  speed  vac.  The  cDNA  pellet was 
resuspended in 5 pi of 2x coupling buffer (Invitrogen).  The cDNA sample was 
either labeled with Alexa 555 or Alexa 647 (both from  Invitrogen).  Each vial of 
dye was resuspended in 2 pi of DMSO.  The cDNA sample was then added to 
the  dissolved  dye  and  the  mixture  was  adjusted  to  10  pi  with  nuclease-free 
water.  The  tube was  left  in  the  dark for an  hour for the  dye  coupling.  Any 
unincorporated  dye  was  removed  using  the  QIAquick  purification  column 
(Qiagen).  The  labeling  reaction  was  mixed  with  250  pi  of  buffer  PB  and 
transferred to the column.  The column was placed in a 2 ml collection tube and 
spun  at  14,000  g  for  1   min.  The  eluate  was  discarded.  The  column  was
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washed with 750 pi of buffer PE and spun at 14,000 g for 1   min.  The collection 
tube was  emptied  and  the  column was  spun for another minute  at  14,000  g. 
The  column  was  transferred  to  a  fresh  microfuge  tube.  The  sample  was 
resuspended by adding 50 pi of nuclease-free water to the centre of the column 
membrane and left at room temperature for 2 min.  The sample was collected 
by centrifugation at 14,000 g for 1   min.  The labeled-cDNA was then dried and 
pelleted  in  a  speed  vac  (Eppendorf,  Hamburg,  Germany).  The  sample was 
resuspended in TE (appendix I) and hybridised on microarrays (section 2.6.7 to 
2.6.12).
For the dendrimer labeling,  93.8ng  of aRNA were  mixed  with 4  pi  of random 
primer,  1   pi of MPX dT primer, and adjusted to 11  pi with nuclease-free water. 
The sample was heated to 80°C for 10 min and transferred to ice for 2 min.  The 
following  components  were  then  added  to  the  mixture  to  set  up  the  reverse 
transcription:  (1)4 pi of 5x Superscript buffer,  (2) 2 pi of 0.1 M DTT,  (3) 1   pi of 
dNTP  mix,  (4)  1   pi  of  Superase-IN  RNase  inhibitor,  (5)  1   pi  of  Superscript 
reverse transcriptase (Invitrogen).  The reaction mix was incubated at 46°C for 
2h.  After reverse transcription,  15  pi of 1N  NaOH were  added to the  mixture 
and heated up to 70°C for 10 min to hydrolyse the RNA.  The mixture was then 
neutralised with  15  pi of 1N  HCI.  The cDNA was purified  using the QIAquick 
MinElute column (Qiagen).  The sample was mixed with 250 pi of buffer PB and 
transferred to the column.  The column was placed in a 2 ml collection tube and 
spun  at  14,000  g  for  1   min.  The  eluate  was  discarded.  The  column  was 
washed with 750 pi of buffer PE and spun at 14,000 g for 1   min.  The collection 
tube was emptied  and  the  column was spun for another minute  at  14,000  g. 
The  column  was  transferred  to  a  fresh  microfuge  tube.  The  sample  was 
resuspended by adding 10 pi of nuclease-free water to the centre of the column 
membrane and left at room temperature for 2 min.  The sample was collected 
by centrifugation at 14,000 g for 1   min.  The cDNA eluate was adjusted to 16.5 
pi with nuclease-free water, denatured at 80°C for 10 min, and then transferred 
on  ice  for  2  min.  The  terminal  deoxythymidine  triphosphate  (dTTP)  tailing 
reaction was set up by adding 2.5 pi of 10x tailing buffer, 4 pi of 10mM dTTP, 
and 2 pi terminal deoxynucleotidyl transferase to the cDNA.  The reaction mix
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was incubated at 37°C for 30 min.  The dT-tailed cDNA was heated to 95°C for 
10 min and immediately transferred on ice for 2 min.  The ligation of the capture 
sequence  was  set  up  by  adding  5  pi  of 6x  ligation  mix  (either Cy3-  or  Cy5- 
capture  sequence)  and  2  pi  of T4  DNA  ligase  to  the  dT-tailed  cDNA.  The 
mixture  was  incubated  at  room  temperature  for  30  min.  The  ligation  was 
stopped by adding 3.5 pi of 0.5M  EDTA.  The linked cDNA was purified using 
the Qiagen MinElute column as previously described.  The purified cDNA that is 
either linked with Cy3- or Cy5-sequence was eluted with 10 pi of nuclease-free 
water.  For the  hybridisation,  the Cy3- and  Cy5-linked  cDNA were combined, 
plus the addition of 2 pi of LNA dT blocker, 24 pi of 2x enhanced hybridisation 
buffer,  and  2  pi  of nuclease-free  water.  The  mixture was  then  incubated  at 
80°C  for  10  min.  The  mixture  was  vortexed  and  centrifuged  briefly  before 
hybridising  on  microarrays.  The  arrays  were  hybridised  at  65°C  overnight. 
Then the  arrays were transferred  into 50  ml  Falcon  tubes containing 2x SSC 
(Sigma)  +  0.2%  sodium  dodecyl  sulfate  (SDS)  for  2  min  for  removing  the 
coverslip.  The arrays were then transferred into fresh 2x SSC + 0.2% SDS and 
washed at 60°C for 15 min, followed by 15 min in 2x SSC at room temperature, 
and then 15 min in 0.2x SSC at room temperature.  The arrays were spun dried 
at 300g for 2  min.  The dendrimer hybridisation was prepared  by thawing the 
Cy3 and Cy5 capture reagents at room temperature for 20 min, vortexed for 3 s, 
and incubated at 55°C for 10 min.  The capture reagents were vortexed briefly 
and centrifuged to collect the contents at the bottom of the tube.  The dendrimer 
hybridisation mix was made up of 2.5 pi of Cy3- and Cy5-capture reagents,  16 
pi of nuclease-free water, and 21  pi of 2x hybridisation buffer.  The hybridisation 
mix was heated to 80°C for 10  min,  and was then transferred onto the arrays 
(the  one  that  has  previously  been  hybridised  with  cDNA).  The  arrays  were 
hybridised  at  65°C for 4h  in  the  dark to  allow the  binding  of the  dye-labeled 
capture  reagents  to  the  capture  sequences.  The  arrays  were  washed  as 
previously  described.  All  the  arrays  were  scanned  using  the  same  settings. 
The  signal  intensities and  Cy5-to-Cy3  ratios of the  different labeling  methods 
were compared.
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2.6  Microarray Analysis
2.6.1  RNA extraction
RNA  extraction  was  performed  using  TRIzol  reagent  (Invitrogen).  RNA was 
extracted  from  either  cultured  cells  or  PBMCs.  Cells  were  pelleted  by 
centrifugation  at  350  g  for  5  min.  Washing  cells  is  not  recommended  as  it 
increases  the  possibility  of  mRNA  degradation.  One  millilitre  of TRIzol  was 
used  per 5-10  x  106  cells.  Cells were  lysed  by  repetitive  pipetting.  The cell 
lysate was incubated at 70°C for 10 min to facilitate RNA dissociation from the 
cell  debris/nucleoprotein  complexes.  It  was  then  allowed  to  cool  to  room 
temperature.  Two hundred microlitres of chloroform (Sigma) were added per 1  
ml of TRIzol used.  The tube was shaken vigorously by hand for 15 s and left to 
stand  at  room  temperature  for  3  min.  The  sample  was  then  centrifuged  at
16,000  g for 15 min at 4°C.  Following centrifugation, the mixture was separated 
into  a  lower  red,  phenol-chloroform  phase,  an  interphase,  and  a  colourless 
upper aqueous  phase.  RNA  remains  exclusively  in  the  aqueous  phase.  Six 
hundred  microlitres  of the  aqueous  phase  were  transferred  into  a  fresh  tube, 
and the other two phases were saved for DNA & protein extraction (if required). 
Five hundred microlitres of chloroform were added to further purify the aqueous 
layer.  The tube was shaken  vigorously by hand for  15 s and  left to stand  at 
room temperature for 3 min.  The sample was then centrifuged at 16,000 g for 
15  min  at  4°C.  Following  centrifugation,  the  mixture  is  separated  into  two 
phases.  The  top  phase  was  transferred  into  a  fresh  tube.  RNA  was 
precipitated  by  adding  0.5  ml  of isopropanol  (BDH)  per  1   ml  of TRIzol  used. 
The sample was left at room temperature for 10 min and then spun at 13,000 g 
for 10 min at 4°C to pellet the RNA.  The supernatant was discarded.  The pellet 
was washed  with  1   ml  of 75%  ethanol.  The  sample  was  vortexed  and  then 
centrifuged at 7,500 g for 5 min at 4°C.  The supernatant was discarded.  The 
pellet was  left to air-dry for 5  min.  Fifty microlitres of RNase-free water were 
added and the sample was incubated at 55°C for 10 min to dissolve the  RNA 
pellet.  The sample was stored at -80°C until use.
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2.6.2  DNase treatment
The amount of DNase I (Ambion, Warrington, UK) required for each reaction is 
dependent  on  the  total  amount  of  RNA.  The  reaction  mix  was  prepared 
according to the following table.
[RNA] (ug/Ml) <100 100 150 200
RNA (pi) 50 100 100 100
10* buffer (pi) 10 20 30 40
DNase I (1U/pl) 5 10 15 20
RNase-free dH20 (pi) 35 70 155 240
Total volume (pi) 100 200 300 400
The  reaction  mix was  incubated  at 37°C for an  hour.  One tenth  of the total 
volume  of  10x  terminator  mix  (0.1  M  EDTA,  1   pg/pl  glycogen  -   Sigma  and 
Invitrogen,  respectively) was added and  mixed.  An equal volume of (25:24:1) 
phenol:  chloroform:  isoamylalcohol  (Sigma) was added  and  the tube vortexed 
for 10 s.  The mixture was centrifuged at 16,000 g for 10 min.  The top aqueous 
layer  was  transferred  to  a  new  tube  and  an  approximately  equal  volume  of 
phenol:  chloroform:  isoamylalcohol  was  added.  The  tube  was  vortexed  and 
centrifuged at 16,000 g for 10 min.  The top aqueous layer was transferred to a 
new tube and  an  approximately equal volume of chloroform was added.  The 
tube was vortexed and centrifuged at 16,000g for 10 min.  The aqueous phase 
was transferred to a new tube and  1/5th of the total volume of 8 M ammonium 
acetate and 2.5 times of the total volume of 95% ethanol (-20°C) were added. 
The  tube  was  incubated  at  -20°C  for  1-2h.  After  incubation  the  tube  was 
centrifuged  at  16,000  g  for  30  min  at 4°C.  The  supernatant was  discarded. 
Two hundred  microlitres of 80%  ethanol  (-20°C) were added to the  remaining 
pellet and the tube centrifuged at 16,000g for 10 min at 4°C.  The supernatant 
was removed and kept (stored at -80°C) and the remaining pellet was air dried 
at room temperature for 5 min.  The pellet was dissolved  in  100  pi of RNase- 
free water.
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2.6.3  Quality and quantity analysis of RNA
RNA  samples  were  analysed  using  the  RNA  6000  Nano  Assay  kit  and  the 
Agilent  Bioanalyser  2100  (Agilent,  Santa  Clara,  CA),  which  provides  an 
estimate of the total amount of RNA species in a sample, plus the ratio between 
the  two  ribosomal  peaks  (28S  vs  18S)  for  measuring  RNA  integrity.  Thirty 
minutes  before  running  the assay,  vortex nanomarkers and  gel-dye  mix were 
allowed to equilibrate to room temperature.  The gel-dye mix should be shielded 
as it is light-sensitive.  Microchannels (of the chip) were filled by pipetting 9 pi of 
gel-dye  mix  into  the  appropriate  well  and  then  forcing  the  mixture  into  the 
microchannels by applying pressure to the well via a 1   ml syringe.  The ladder 
well and sample wells were subsequently loaded with 5 pi of nanomarkers plus 
1   pi of either the molecular size ladder or sample,  respectively.  The chip was 
vortexed  for  1   min  and  loaded  onto  the  station.  The  Eukaryote  Total  RNA 
Nano- or mRNA Nano-assay was used for the analysis of total RNA or mRNA 
respectively.
2.6.4  Purification of poly(A)* RNA
The Oligotex mRNA midi kit (Qiagen) was used for mRNA extraction according 
to the manufacturer’s protocol.  Briefly, the reaction mix was prepared according 
to the table below:
Total RNA(pg) dH20(|jl) Buffer OBB(pl) Oligotex(pl)
<250 250 250 15
250-500 500 500 30
500-750 500 500 45
750-1000 500 500 55
The  mixture was incubated  at 70°C for 3  min,  followed  by incubation  at room 
temperature for 20 min.  The tubes were centrifuged at 16,000 g for 2 min and 
the supernatant removed.  The pellet was resuspended in 400 pi of buffer OW2 
and the suspension transferred onto a spin column.  The column was spun at
16.000  g  for  1   min  and  the  flow  through  discarded.  The  Oligotex  was 
resuspended in 400 pi buffer OW2 and the column spun for a further 1   min at
16.000 g.  The flow through was discarded and the spin column transferred to a
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new tube.  The  Oligotex  was  resuspended  in  200  pi  of buffer  OEB  and  the 
column  spun  at  16,000  g  for  1   min  (keep  the  flow  through,  which  contains 
mRNAs).  The  Oligotex  was  resuspended  in  a  further  200  pi  of buffer  OEB 
(70°C) and the column spun at 16,000 g for 1   min.  The sample was transferred 
into Microcon YM-30 column (Miilipore).  The column was spun at 13,000 g for 
7 min to concentrate the mRNA sample.  After concentration, the column was 
transferred into a fresh collection tube in an inverted position and spun at 1,000 
g  for  3  min  to  collect  the  mRNA.  The  sample  was  quantified  using  Agilent 
Bioanalyser 2100 (section 2.6.3) and stored at -80°C.
2.6.5  Preparing universal reference
The mRNA from nine different cell-lines was purified and mixed as follow:
Cell line Cell type Percentage (%)
U937 Monocytes 21.1
HeLa Epithelial cells 21.1
Ramos B-lymphocytes 12.6
SSCEM T-lymphocytes 12.6
Huh7 Hepatocytes 8.4
MRC5 Fibroblasts 4.2
HHV-7-SupT1 T-lymphocytes 10
HHV-6A(U1102)-SupT1 T-lymphocytes 5
HHV-6B(Z29)-SupT 1 T-lymphocytes 5
TRIzol lysates for the first six cell-lines were prepared by R Jenner, A Kwan, J 
Rasaiyaah and  C  Li  (Wohl Virion  Centre and  Centre for Virology,  UCL).  C  Li 
was also responsible for preparing the HHV-7 infected SupT1.
2.6.6  cDNA labeling and purification
The CyScribe first strand cDNA labeling kit (GE Healthcare) was used to label
the mRNA.  All reagents, except the reverse transcriptase, were placed on ice
to thaw prior to use.  The contents of all tubes were vortexed before use.  The
primer annealing mix was prepared in a 0.5 ml PCR tube as follows:
mRNA (250 ng)  9 pi max
RNase-free water  Adjust volume of mRNA to 9 pi
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Random nanomers  1   pi 
Anchored oligo-dT  1   |jl 
Total volume  11  pi
The mixture was incubated at 70°C for 5 min in a thermal cycler (MWG).  It was 
then cooled at room temperature for 10 min.  The tube was placed on ice before 
adding the components for the labeling reaction according to the table below:
*Cy3 for universal reference and Cy5 for samples (GE Healthcare)
The  mixture was vortexed  and  spun  at 16,000 g  briefly, followed  by a 90-min 
incubation at 42°C in a thermal cycler (MWG).
The mRNA was denatured by adding the following reagents:
0.5M EDTA (pH 8.0)  5 pi
0.1M NaOH  20 pi
The mixture was incubated at 70°C for 10  min  a thermal cycler.  The sample 
was then neutralised by adding:
0.1  M HCI  20 pi
Cot-1  DNA (Invitrogen)  3 pi
TE (pH 8.0)  450 pi
The mixture was transferred into a Microcon YM30 column (Millipore) and spun 
at 13,000 g for 7 min.  The column was transferred into a fresh collection tube, 
followed by the addition of 300 pi TE and spun at 13,000 g for 7 min.  The same 
step was repeated twice to wash away any unbound/excess dye.  The labeled 
cDNA was concentrated to a volume of no more than  12 pi.  The column was 
transferred into a new collection tube in an inverted position and centrifuged at 
1,000g  for  3  min  to  collect  the  sample.  The  volume  of  labeled  cDNA  was 
recorded and the sample stored in dark at -20°C.
2.6.7  Preparation of hybridisation mix
The hybridisation mixture was prepared as follows:
5* CyScript buffer 
0.1MDTT
dCTP nucleotide mix
dCTP CyDye-labeled nucleotide*
CyScript reverse transcriptase
4 pi 
2 pi 
1   pi 
1   pi 
1   pi
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20x saline sodium phosphate EDTA (SSPE; Sigma) 
0.5M EDTA
12 pi 
1.1  pi 
2 pi poly dA4o- 6o  (GE Healthcare; 5 units in 33.4pl) 
or poly dA4o  (Thermal Hybaid; 8mg/ml)
Yeast tRNA (Sigma; 100 units in 1138pl) 2 pi
(4mg/ml)
Cy3 labeled cDNA 
Cy5 labeled cDNA 
TE pH 8 
10% SDS
(add last and leave at room temperature) 
Total volume
adjust final volume to 44 pi 
1   pi
>12 pi 
>12 pi
45 pi
The mixture was vortexed and spun down briefly.  It was denatured at 98°C for 
2  min  and  incubated  at  37°C  for  20  min  in  a  thermal  cycler  (MWG).  One 
microlitre  of  100x  Denhardt’s  solution  (Sigma) was  added  to  the  mixture  and 
vortexed.  The mixture was centrifuged at 16,000 g for 15 min.  The mixture was 
stored in the dark until use.
2.6.8  Pre-hybridisation processing of the arrays and coverslips
Microarrays were processed as described in section 2.5.8.  Glass coverslips (22 
x 64 mm, No. 0; Scientific Laboratories,  UK) were washed in dH20 water for 2 
min, followed by 2 min in 95% ethanol, and dried by centrifugation at 300 g for 2 
min.  Both the arrays and coverslips were stored in a clean container until use.
2.6.9  Hybridisation
Forty microlitres of hybridisation  mix were transferred onto the coverslip along 
the central  axis.  The arrays were  hybridised to the coverslip  by inverting  the 
slide  so  that  the  DNA  side  was  facing  downwards.  The  slide  was  gently 
lowered  onto  the  coverslip  so  that  once  the  hybridisation  mix  contacted  the 
lowering slide,  it would  pick up the coverslip (by capillary action) and  result in 
the  sample  spreading  evenly across  the  arrays.  The  hybridised  arrays were 
inverted quickly and put into the hybridisation chamber (Ambion).  Two hundred 
microlitres  of 4*  SSPE  (65°C)  were  added  to  both  ends  of the  hybridisation
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chamber (roughly 100 pi at each end).  The hybridisation chamber was quickly 
sealed and incubated overnight in a 65°C waterbath (16-20h).
2.6.10  Array washing
The  hybridisation  chamber  was  removed  from  the  65°C  waterbath  and 
transferred to the top of a hot block.  The chamber was kept on the hot block 
whilst  disassembling  to  maintain  the  temperature  at  65°C.  The  hybridised 
arrays were transferred and  immersed  in 2x SSPE at 50°C (in a 50 ml  Falcon 
tube) until the coverslip became dissociated.  They were then transferred and 
immersed  in  another  tube  containing  2x  SSPE  at room  temperature.  The
incubation  lasted for 2 min.  The arrays were subsequently washed in 1x SSPE
for 2 min followed by another wash with 0.1x SSPE for 3 min.  The arrays were 
spun dry at 300 g for 2 min and stored in the dark (to prevent photo-bleaching) 
until scanning.
2.6.11  Array scanning
The GenePix 4000B array scanner (Molecular Devices, Toronto, Canada) was 
used  to  capture  fluorescent  signals  on  the  microarrays.  The  arrays  were 
inverted (DNA face down) and inserted into the holder.  The pixel size was set 
at 10 microns, lines to average at 1, and focus position at 0.  The arrays were 
first scanned in the PREVIEW mode which allows one to view the entire slide at 
a low resolution for defining the region for the subsequent detailed scan.  The 
PMT voltage of both channels was first set to 500 with the power at 100%.  It 
was then adjusted  individually for each channel  so that the signal  in  Cy3 and 
Cy5  was  roughly  1:1  according  to  the  histogram  (see  figure  3.12  for  an
example).  The raw image was stored as a tiff file.
2.6.12  Image analysis
The image was analysed using GenePix Pro 4.0 software (Molecular Devices). 
The software runs an algorithm to position, or grid, all the array elements.  The 
flawed elements, e.g. dust particles on the arrays, were automatically flagged. 
The  alignment tool  is  not error-free and thus the  user should  use the feature 
mode tool to check and rectify suspect features.  All fluorescent intensities were
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converted  into  numerical  values  and  the  data  were  exported  into  Microsoft 
Excel for further processing.
2.7  Temporal classification of HHV-6B ORFs
2.7.1  HHV-6B time course
SupT1  cells  were  re-fed  with  fresh  complete  medium  a  day  before  the 
experiment.  All cells were washed with PBS twice, the density adjusted to 1   x 
106  cells/ml,  and divided  into aliquots of 5 ml i.e.  5 x 106  cells/aliquot.  SupT1 
cells were spun at 325 g for 5 min and the supernatant discarded.  Individual 
cell pellet was resuspended in 1   ml of either 50% FCS (mock) or HHV-6B(Z29) 
inoculum.  After 1h of adsorption at 37°C, cells were first washed with  PBS to 
remove unbound virus, and then resuspended in fresh medium at a density of 5 
x  105  cells/ml.  The time  course comprised  six time  points:  6,  12,  24,  36,  48, 
60hpi.  Cells were cultured in 5% C02  at 37°C and harvested at the designated 
time.  For the  classification  of  IE  genes,  SupT1  cells  were  first  treated  with 
cycloheximide  (CHX,  200  pg/ml;  Sigma)  for  an  hour  prior  to  infection.  The 
infection  and  the  subsequent  incubation  were  carried  out  in  the  continual 
presence  of  CHX  and  the  infected  cells  were  harvested  at  6hpi.  For  the 
classification of E and L genes, the infected cells were cultured in the presence 
of  phosphonoacetate  acid  (PAA,  500  pg/ml  PAA;  Sigma)  and  harvested  at 
36hpi.  All cells were lysed in TRIzol (107  cells/ml), frozen immediately in liquid 
N2  and stored at -80°C until RNA extraction.
2.7.2  Array analysis
Time course samples were analysed as described in (Jenner et al., 2003) with 
modifications.  Briefly,  total  RNA  was  purified  with  TRIzol  (section  2.6.1), 
DNase-treated  (section 2.6.2), and  repurified  by phenol extraction and ethanol 
precipitation.  RNA  sample  was  further  purified  to  isolate  the  poly(A)+   RNA 
(section 2.6.4).  The quantity and quality of RNA were evaluated on an Agilent 
2100  bioanalyser  (section  2.6.3).  Poly(A)+   RNA  (250ng)  was  reverse 
transcribed  into  Cy5-dCTP  labeled  cDNA  (section  2.6.6).  Cy5-labeled  cDNA 
was  mixed  1:1  with  Cy3-labeled  cDNA  synthesised  from  a  custom-made 
universal reference (section 2.6.5) and hybridised to the HHV-6 arrays (section
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2.6.7  to 2.6.9).  Arrays were washed (section 2.6.10), scanned (section 2.6.11) 
and the images analysed (section 2.6.12).  The flagged elements were removed 
at this stage.  The log2 median of ratios (Cy5/Cy3) were filtered to remove all 
flagged  data  and  spots with  SNR<2  in  both  the  Cy3  and  Cy5  channel.  The 
median expression ratio from the triplicate spots of each array probe was used 
for  subsequent  analysis.  The  expression  ratios  generated  from  each  array 
hybridisation were assembled  and  filtered for genes  present in  all the arrays. 
The filtered  data were  median-centered  for both  genes  and  arrays  in  Cluster 
(Eisen et al., 1998) to normalise both the host and viral genes.  The normalised 
data of the viral genes were then extracted and re-adjusted by median centering 
in  Cluster to order and  compare the viral genes only.  Data were grouped  by 
average  linkage  hierarchical  clustering  by  using  the  uncentered  Pearson 
correlation  coefficient  as  the  similarity  metric.  The  ordering  of  the  nodes 
produced by clustering data from  11  (or 13 including 2 arrays for sample PAA) 
arrays  was  first  determined  in  Cluster  by  using  a  one-dimensional  self- 
organising  map  with  the  number of nodes  set to  n.  The  clustered  data  were 
visualized by using TREEVIEW (Eisen et al., 1998).
2.7.3  RT-PCR analysis of HHV-6 IE transcription
For  the  analysis  of  IE  transcription,  RT-PCR  was  preformed  using  poly  (A)+  
RNA isolated from SupT 1  cells that were:
1) briefly inoculated with virus stock at 4°C -  sample Ohpi,
2) infected with HHV-6B(Z29) for 6h at 37°C in the presence of CHX -  sample 
CHX,
3) infected with HHV-6B(Z29) for 6h at 37°C -  sample 6hpi.
First  strand  cDNA  synthesis  was  performed  using  the  Sensiscript  RT  kit 
(Qiagen) according to the manufacturer’s instructions.  Each reaction comprised 
50  ng  of poly(A)+   RNA,  1x  RT  buffer,  0.5  mM  each  dNTP,  1   pM  oligo-dT(i6) 
primer  (Roche,  Burgess  Hill,  UK),  10  units  of  RNase  inhibitor  (Applied 
Biosystems, Warrington,  UK) and  1   pi of Sensiscript reverse transcriptase in a 
total  volume of 20  pi.  For the  no  reverse transcription  (RT)  controls,  1   pi  of 
nuclease-free  water  was  added  instead  of  the  reverse  transcriptase.  The 
reactions were incubated at 37°C for 60 min, followed by a 3-minute incubation
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at 93°C to inactivate the reverse transcriptase.  PCR reactions were performed 
using HotStarTaq DNA polymerase kit (Qiagen).  Each reaction comprised  1   X 
PCR Buffer, 200 pM each dNTP, 0.4 pM forward and reverse primer, 2.5 U of 
HotStar Taq  DNA Polymerase,  and  1  /20th volume of cDNA or no  RT control. 
The  primers  used  for  RT-PCR  are  listed  in  appendix  II.  After  an  initial 
denaturation at 95°C for 15 min, conditions for PCR cycle were 94°C for 30 s, 
50°C from 30 s, and 72°C for 30 s.  The cycle was repeated 35 times, plus a 
final  extension  at  72°C  for  10  min  in  a  thermal  cycler  (MWG).  The  PCR 
products were analysed by gel electrophoresis (sections 2.2.3 and 2.2.4).
2.7.4  RT-PCR analysis of HHV-6 E/L transcription
For the  analysis  of  E/L  transcription,  RT-PCR  was  performed  using  poly(A)+  
RNA isolated from  SupT1  cells that were  infected  with  HHV-6B(Z29) for 36h, 
either  in  the  absence  or  presence  of  PAA  (sample  36hpi  and  sample  PAA, 
respectively).  The conditions for RT-PCR were as described  in section 2.7.3, 
except that the number of PCR cycle was reduced to 30.  The  PCR products 
were analysed by gel electrophoresis (sections 2.2.3 and 2.2.4).
2.7.5  RT-PCR profiling of HHV-6 gene expression
Gene  expression  was  profiled  by  RT-PCR  for  a  few  selected  HHV-6  ORFs. 
Poly(A)+   RNA of 6,  12,  24,  36, 48,  and  60hpi was analysed  and the  RT-PCR 
conditions  were  as  described  in  section  2.7.4.  The  PCR  products  were 
analysed by gel electrophoresis (sections 2.2.3 and 2.2.4).
2.7.6  Validation of intergenic transcripts by RT-PCR
RT-PCR  was  performed  using  poly(A)+   RNA  of  sample  24hpi  and  primers 
targeting the intergenic regions of HHV-6 genome (appendix II).  The RT-PCR 
conditions  were  as  described  in  section  2.7.4.  The  PCR  products  were 
analysed by gel electrophoresis (sections 2.2.3 and 2.2.4).
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2.8  Characterisation of the integrated HHV-6 DNA in V1
2.8.1  Overview
A healthy volunteer (V1), who is seropositive for HHV-6,  showing consistently 
high HHV-6 viral loads in eight blood samples collected over a 10-month period 
(Clark  et  al.,  1996).  B  cells  isolated  from  the  subject’s  PBMCs  were 
transformed  into  lymphoblastoid  cell  line  (V1-LCL)  and  fluorescent  in  situ 
hybridisation (FISH) analysis conducted on this cell-line confirmed the presence 
of integrated HHV-6 DNA at chrl 1p15.5 (Clark et al., 2006).
2.8.2  V1-LCL culture
V1-LCL was maintained  in  RPMI  1640 complete medium (section 2.2.1).  The 
culture was split 1:5 once a week.
2.8.3  Variant-typing PCR
V1-LCL  DNA  was  extracted  as  described  in  section  2.4.2  and  variant-typed 
(section 2.3.3).
2.8.4  Concatemeric PCR
V1-LCL DNA was analysed for the presence of the concatemeric region by PCR 
(see  appendix  II  for the  primers).  One  hundred  nanograms  of DNA of each 
DNA sample (HHV-6A(U1102), HHV-6B(Z29), and V1-LCL) were used for each 
reaction and the PCR conditions were as described in section 2.4.3.
2.8.5  Whole genome HHV-6  PCR
To  assess  the  organisation  of  the  integrated  genome,  V1-LCL  DNA  was 
screened by PCR for the presence of almost all HHV-6 ORFs (see appendix II 
for  list  of  primers).  One  hundred  nanograms  of  DNA  were  used  for  each 
reaction and the PCR conditions were as described in section 2.4.3.
2.8.6  Viral gene expression  in V1-LCL
RNA  extractions,  PCR  setup,  and  the  post-PCR  handling  were  performed  in 
different  laboratories  to  minimize  the  chance  of  PCR  contamination.  Four
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aliquots  of  5  x  106   V1-LCL  were  cultured  in  RPMI-complete  medium:  two 
aliquots were stimulated with  12-0- tetradecanoylphorbol 13-acetate (TPA, use 
at 20 ng/ml; Sigma) and two without treatment.  Cells were harvested either 4 or 
8 days after stimulation.  Total RNA was extracted from each sample using the 
TRIzol protocol (see section 2.6.1).  The RNA samples were DNase-treated and 
then  concentrated  by  ethanol  precipitation  (section  2.6.2).  The  quality  and 
quantity of each sample were assessed on the Agilent Bioanalyser (see section
2.6.3).  The presence of four HHV-6 transcripts (U39, U89/90, U94, and U100) 
in  V1-LCL  was  examined  and  the  primers  used  for  RT-PCR  are  listed  in 
appendix  III.  Two  micrograms  of  RNA  of  each  sample  were  reversed 
transcribed into cDNA using the Omniscript Reverse Transcriptase Kit (Qiagen). 
Each  reaction  comprised  1x  RT  buffer,  0.5mM  of  each  dNTP,  1pM  oligo-dT 
primer (Roche), 10 units of RNase inhibitor (Applied Biosystems), and 4 units of 
Omniscript  RT  in  a  total  volume  of  20  pi.  For  the  no  RT  controls,  1   pi  of 
nuclease-free  water  was  added  instead  of  the  reverse  transcriptase.  The 
reactions were  incubated  at 37°C for 60  min,  followed  by 3-min  incubation  at 
93°C  to  inactivate  the  reverse transcriptase.  PCR  reactions were  performed 
using HotStarTaq DNA polymerase kit (Qiagen).  Each reaction comprised  1   X 
PCR Buffer, 200 pM each dNTP, 0.4 pM forward and reverse primer, 2.5 U of 
HotStar Taq  DNA  Polymerase,  and  1/4th  volume  of cDNA or no  RT  control. 
After an  initial denaturation at 95°C for 15 min,  conditions for PCR cycle were 
94°C for 30 s, 50°C from 30 s, and 72°C for 30 s.  The cycle was repeated 35 
times, plus a final extension at 72°C for 10 min in a thermal cycler (MWG).  The 
PCR products were analysed by gel electrophoresis (sections 2.2.3 and 2.2.4).
2.8.7  IFA of V1-LCL
The expression of viral proteins was investigated by IFA.  V1-LCL cells treated 
with or without TPA for 4 and 8 days were fixed on slides (section 2.3.4) and 
assayed as described in section 2.3.5.
2.8.8  Western blotting of V1 -LCL
Western  blotting  was  carried  using  the  NuPAGE  Bis-Tris  4-12%  gel  system 
(Invitrogen).  SupT1,  HHV6B(Z29)-infected  SupT1  and  V1-LCL  cells  were
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resuspended  in 25 pi of 1x loading buffer (at a density of ~1x104  cells/pl) and 
lysed at 70°C for 10 min.  For electrophoresis under reduced condition, the cells 
were resuspended in 22.5 pi of 1x loading buffer plus 2.5 pi of reducing agent. 
The  samples  were  separated  using  the  NuPAGE  4-12%  pre-cast  gel.  Five 
microlitres  of  rainbow  marker  mix  (GE  Healthcare)  or  20  pi  of  lysate  were 
loaded per well.  Gel electrophoresis was run at 200 V for 45 min.  Proteins in 
the gel were transferred onto a PVDF membrane (GE Healthcare) using a semi­
dry  transfer  blotter  (BioRad,  Hercules,  CA).  The  ‘blotting  sandwich’  was 
assembled  in  the  following  sequence:  anode  plate,  2  pieces  of  filter  pads 
(BioRad) wetted with 1x transfer buffer, PVDF membrane, gel, another 2 pieces 
of wetted filter pad, cathode plate.  The transfer was carried out at lOOmAmps 
for an hour.  After the transfer, the PVDF membrane can either be, air-dried and 
stored  in  between  filter  paper  (Whatman,  Middlesex,  UK)  at  4°C,  or  used 
directly  in  the  immunostaining.  For the  latter,  the  membrane was washed  in 
TBST  buffer  (see  appendix  I)  for  15  min,  followed  by  an  1h  incubation  in 
blocking buffer (TBS + 5% non-fat milk (Tesco, Cheshunt, UK)).  All incubations 
steps  were  carried  out  on  a  shaking  platform  at  room  temperature  unless 
otherwise  stated.  Primary  antibody  (one  of the  following:  anti-GAPDH,  anti- 
p101,  and  anti-gp116)  was  diluted to working  concentration  using  2.5%  milk- 
TBST.  The  blot was  incubated  in  the  resulting  solution  for  1h.  It was  then 
washed three times with TBS, each wash lasted 5 minutes.  The blot was then 
incubated  with  an  alkaline  phosphatase-conjugated  anti-mouse  IgG  (BioRad) 
for 1h.  The wash was  repeated as previously described.  The staining of the 
blot was carried out by incubating the blot in the substrate solution (appendix I). 
The  colour development was stopped  by removing the substrate solution and 
rinsing the blot with dH20.
2.8.9  Viral gene expression in V1-PBMC
The  isolation  of  PBMCs  from  whole  blood  of V1  was  performed  by  Duncan 
Clark (Centre for Virology,  UCL).  Total  RNA of the  PBMCs was  purified  and 
reverse transcribed as described  in section 2.8.6.  Expression of the following 
HHV-6 transcripts was investigated: U11, U14, U27, U31,  U38,  U39,  U51, U69, 
U83, U90B, U91B, and U94_R (appendix III).  The RT-PCR conditions were as
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described  in  section  2.8.6.  Additionally,  the  PCR  conditions  for  the  nested 
amplification were modified as follow:
(1) the template used was 1   pi of the first round RT-PCR product,
(2) the PCR cycle was repeated 25 times.
The  PCR  products  were  analysed  by  gel  electrophoresis  (sections  2.2.3  and
2.2.4).
139Chapter 3
Development and Validation of HHV-6 Microarrays
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3.1  Introduction
The  high-throughput  nature  of microarrays  has transformed  the way in which 
gene expression is studied.  This is particularly true for transcription analysis of 
viruses,  as the  entire viral  genome  can  be  studied  in  one single  experiment. 
The characterisation of the global transcription  program of HSV-1  (Stingley et 
al.,  2000),  HCMV  (Chambers  et  al.,  1999)  and  KSHV  (Jenner  et  al.,  2001; 
Paulose-Murphy et al., 2001) by microarrays has proven to be a useful resource 
for the research of the respective herpesvirus, as indicated by their high citation 
number (scholar.google.com).  At the start of this  PhD  project,  the kinetics of 
HHV-6 genes had not been described in depth (Pellett and Black, 1996), and no 
microarrays were available for studying HHV-6 transcription.  This chapter aims 
to construct a set of DNA microarrays for HHV-6 research.  The HHV-6 arrays 
were subsequently used for the characterisation of the transcription program of 
HHV-6B (see chapter 4).
A typical microarray experiment can be divided into five main stages: (1) sample 
preparation,  (2)  array  construction,  (3)  sample  labeling  and  hybridisation,  (4) 
image  analysis,  and  (5)  data  mining  (to  discover  patterns  and  relationships 
within  the  data  set).  Previous  work  on  the  characterisation  of  KSHV  gene 
expression  at  UCL  has  established  protocols  for  all  stages  except  for  array 
construction  (Jenner,  2002;  Jenner et  al.,  2001).  For the  studies  on  KSHV, 
expertise  on  array  construction  was  provided  by  our  collaborators  at  the 
Institute of Cancer Research (ICR, Sutton site).  The KSHV array probes were 
generated in-house and subsequently sent to ICR for array spotting.  In addition 
to the  KSHV  probes,  about 6000  host array probes  (ICR resource) were also 
spotted  onto  the  same  arrays.  The  host-pathogen  arrays  allow  the 
simultaneous analysis of gene expression of both host and viral genes.
The  initial  arrangement for this  study was  similar to  that  used  for the  KSHV 
microarray work.  A set of HHV-6 array probes were generated and sent to ICR 
for array construction.  Unfortunately, the array printing at the ICR encountered 
a series of technical problems (see section 3.2.3), and the collaboration was not 
pursued from June 2003 onwards.  As a result,  I decided to construct the host-
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pathogen arrays In-house.  This chapter describes the processes involved in the 
development of cDNA microarrays for HHV-6.
3.1.1  Microarray construction
To understand the potential problems in the development of HHV-6 arrays, it is 
useful to begin with an overview of the major steps involved in the production of 
spotted  microarrays.  The  key  to  microarray  production  is  to  transfer  and 
immobilise DNA fragments of known identity in pre-defined  patterns onto solid 
supports.  This requires:
1.  preparation of the DNA fragments -  the array probes,
2.  precise transfer of the array probes onto the chosen platform,
3.  post-transfer treatment for the fixation of the array probes.
For cDNA microarrays, array probes are typically generated from PCR-amplified 
cDNA  clones.  The  majority  of cDNA  clones  used  for  microarray  production 
originate from the IMAGE (Integrated Molecular Analysis of Genomes and their 
Expression) consortium, which has the largest collection of cDNA clones (-6.4 
million  clones;  www.rzpd.de).  The  clones  are  prepared  at  different  times  in 
different laboratories,  resulting  in  the  generation  of many different libraries or 
clone  sets.  As  a  result,  the  cDNA  sequences  are  maintained  in  a  range  of 
bacterial vectors.  Since the majority of these vectors contain M13 priming sites, 
vector common  primers  can  be  used  to  generate  array  probes from  different 
libraries  by  PCR  (Hegde  et al.,  2000).  The  purification  of the  PCR  products 
prior  to  spotting  is  recommended  as  the  removal  of  proteins  and  free 
oligonucleotides  (which  may  block  the  pins  and  interfere  with  binding, 
respectively) improves the quality of the microarrays.  Purified array probes are 
typically resuspended in a small volume (5-10 pi) of spotting buffer.  The probe 
concentration  should  be  maintained  at  50ng/pl  or  above  to  prevent 
underestimation of the level of differential expression (Yue et al., 2001).  Array 
probes are commonly arranged in a 384-well plate format for printing.
The  main function of the spotting  buffer is to preserve and  stabilise the array 
probes during printing/storage.  This is necessary as a typical print run lasts for
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a few hours, and therefore the array materials are left at room temperature for a 
long period of time.  Since the array probes are resuspended in a small volume, 
they are prone to dehydration.  For this reason, spotting  buffers often contain 
additives to reduce evaporation.  It is important to select a spotting buffer that is 
compatible with the surface chemistry of the glass slides used.  For instance, 
the pH of a spotting buffer affects the coupling efficiency between array probes 
and  the  glass  surface  (Zammatteo  et  al.,  2000).  In  addition,  the  spot 
morphology of a spotting  buffer varies from one surface chemistry to another. 
In general,  most array surfaces are hydrophobic, therefore, the feature size is 
proportionally  related  to  the  degree  of  hydrophobicity  of  the  spotting  buffer. 
Strongly  hydrophobic  spotting  buffer  produces  larger  spot  sizes  and  should 
therefore be avoided for the production of high density microarrays.
Nylon  membranes  or  microscopic  glass  slides  are  typical  substrates  for  the 
printing  of spotted  microarrays  but the  latter  is  more  popular (Cheung  et  al., 
1999; Duggan et al., 1999; Southern et al., 1999) due to the following reasons:
1.  The ease of handling with glass slides.
2.  The non-porous nature of glass means only a small volume of samples is 
required per hybridisation.  In addition, the targets can access the array probes 
immediately without diffusing into pores, which enhances the hybridisation rate.
3.  Glass slides are more rigid and have a uniform surface compared to nylon 
membranes.  It  is  therefore  much  easier  to  find  a  focal  plane  for  signal 
detection, allowing more accurate measurement.
4.  Glass-based microarrays permit the hybridisation of more than one sample 
(each  labeled  with  different  fluorophors)  therefore  different  samples  can  be 
compared directly on the same assay.  Nylon arrays have only been compatible 
with  radiolabeled  cDNA,  therefore,  only  one  sample  can  be  assayed  per 
hybridisation.  Since different samples cannot be compared directly in the same 
array hybridisation, the data generated  using nylon arrays suffer from a higher 
degree  of variability.  However,  the  radiolabeled  method  offers  much  higher 
sensitivities,  which  requires  up  to  20-fold  less  sample  material  than  their 
fluorescence-based counterparts (Duggan et al., 1999).
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Nucleic  acids  do  not  bind  to  the  surface  silanol  groups  of  silicate  glass 
(Southern et al.,  1999).  Consequently, glass surface has to be modified, either 
covalently or non-covalently, with functional chemical groups (a process known 
as coating) to facilitate the DNA fixation (Stears et al., 2003).  The modification 
of the glass slides can be performed in-house but many researchers favour the 
use of commercial array slides due to their higher uniformity regarding the size, 
thickness and the evenness of the coating.  The type of surface chemistry used 
determines  the  binding  capacity  of  DNA  molecules  and  the  surface 
hydroprobicity, which in turn affects the spot morphology (Duggan et al., 1999). 
At  present,  there  are  five  commonly  used  surface  chemistries:  poly-lysine, 
amine,  epoxide,  aldehyde  and  activated  polymers.  The  characteristics  of 
individual surface chemistries are summarised in table 3.1.
Table 3.1  Microarray surface chemistries
Surface chemistry 
(binding method)
Modification
required
Coupling reaction Target type
Poly-lysine
(non-covalent)
None required Electrostatic, supplemented 
with heat or UV treatment for 
covalent attachment
Long oligonucleotides 
and cDNAs.
Aminosilane
(covalent)
None required Electrostatic, supplemented 
with heat or UV treatment for 
covalent attachment
Long oligonucleotides 
and cDNAs.
Epoxy silane 
(covalent)
None required Covalent via nucleophilic attack 
with primary aliphatic or 
aromatic amines
Long oligonucleotides, 
cDNAs, proteins.
Aldehyde
(covalent)
5’-aminolinker with 
6-carbon or 12- 
carbon spacer
Covalent Schiff base formation 
via nucleophilic attack and 
dehydration
Short oligonucleotides, 
long oligonucleotides, 
cDNAs.
Activated cross-linked
polymer
(covalent)
5’-aminolinker with 
6-carbon or 12- 
carbon spacer
Covalent bonding formed 
between the 5’-terminated 
amino and the reactive ester 
groups
Short oligonucleotides, 
long oligonucleotides, 
cDNAs and proteins.
Table adapted and modified from Stears et al., (2003).
The selection of glass surface chemistry is influenced by the type of array probe 
(oligonucleotides vs  PCR  products,  modified  vs  unmodified)  used  for printing. 
For  instance,  the  poly-lysine  coating  only  couples  effectively  with  long  DNA 
sequences  and  is  therefore  unsuitable  for  short  oligonucleotides  (<50-mer).
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The aldehyde and activated polymer coatings are only compatible with amino- 
modified  nucleic  acids  (Ramakrishnan  et  al.,  2002;  Zammatteo  et  al.,  2000). 
The  modification  is  typically  achieved  by  the  direct  attachment  of an  amino- 
linker to the 5’ end of the oligonucleotides (oligonucleotide arrays), or the use of 
5’  amino-modified  primer for the  generation  of PCR  products  (cDNA arrays). 
The sense strand  of cDNAs  is the one that hybridises with the  labeled target 
and therefore only the forward primer is amino-modified.  Since the attachment 
is  via  the  5’-termini,  a  large  part  of  the  DNA  molecule  is  available  for 
hybridisation.  The probes are therefore more accessible to the labeled targets. 
It  has  been  observed  that the  DNA  base  closer to  the  glass  surface  is  less 
accessible to the targets due to steric interference (Southern et al., 1999).  This 
is  particularly problematic for short oligonucleotide  array probes,  as the  steric 
interference significantly reduces the area available for target binding.  Hence, 
the addition of 6-carbon or 12-carbon spacers at the 5’ end is commonly used to 
alleviate this problem.  The binding of unmodified nucleic acids to aldehyde and 
activated  polymer is  negligible  (Ramakrishnan  et al.,  2002;  Zammatteo  et al., 
2000).  Hence,  there  is  minimal  non-specific  binding  of labeled  cDNA to  the 
glass  surface.  As  a  result,  the  aldehyde-  or activated  polymer-based  arrays 
tend  to  produce  better  signal-to-noise  ratios  compared  to  other  surface 
chemistries.  Despite these advantages, the use of these two chemistries is not 
popular for making  cDNA microarrays.  This  is  because the orientation of the 
cDNA insert is random when it is cloned, making it time-consuming and labour- 
intensive to work out the direction of the sense strand for each  of the clones 
before the amino-linker can be attached.
The other three surface chemistries (poly-lysine, aminosilane, epoxysilane) are 
all  compatible with  modified  or unmodified  long  DNA probes  (>50-mer).  The 
initial  binding  of the  DNA  molecules  to  both  the  poly-lysine  and  aminosilane 
relies  on  the  electrostatic  interactions  between  the  negatively-charged 
phosphate  backbone  and  the  positively-charged  surface.  The  attachment  is 
then further secured by covalent crosslinking by UV- or heat-treatment.  For the 
epoxysilane,  the  coupling  proceeds  via  the  covalent interactions  between  the 
primary amine groups on the A, G, and C bases of the DNA molecules and the 
surface epoxide groups.  For the unmodified array probes, the way in which the
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DNA molecules attach to the coating is undefined (as opposed to coupling via 
5’-termini for aldehyde/activated polymer coating, see figure 3.1).  The coupling 
occurs randomly along the stretch of DNA molecules and, as such, some DNA 
molecules might not be available for target binding due to steric interference (if 
the site of hybridisation is close to the surface of the glass).  The microarrays 
based  on  these  chemistries  therefore  perform  less well  in  terms  of signal-to- 
noise ratio.
Figure 3.1  A  schematic  representation  of  DNA  topologies  on  glass 
surface
Glass slides
The  attachment  of  DNA  molecules  to  glass  surface  in  random  fashion,  or
through 5’ amino-linker (filled square).
Note  that for a  two-colour  microarray experiment,  direct  comparison  is  made 
between  the  two  samples  in  the  same  array  hybridisation.  As  the  same 
constraint applies to both samples, the steric interference would have little effect 
on the expression ratios.
The use of poly-lysine-coated slides was initially popular due to its low cost and 
the ease of in-house production.  Indeed, it was the surface chemistry used for 
the very first spotted  cDNA microarrays  (Schena  et al.,  1995).  However,  the 
non-covalent attachment of the poly-lysine to the glass surface means that the 
coating is susceptible to damage during exposure to high temperatures or high 
salt concentrations (Zammatteo et al., 2000).  For this reason, the aminosilane 
and epoxysilane slides (both are covalently-coated onto the glass surface) are
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better-suited for making spotted  cDNA microarrays.  The former is particularly 
popular  as  demonstrated  by  a  greater  number  of  publications  employing 
aminosilane than epoxysilane.
Spotting  pins  for  microarraying  were  initially  made  with  hard  stainless  steel. 
However,  steel  pins  are  prone  to  mechanical  damage  (multiple spotting)  and 
oxidation  (multiple washing  cycles and  high-salt spotting  buffer).  Many users 
have switched to the use of tungsten pins which are more resistant to wear and 
oxidation,  but  also  more  expensive.  Two  more  recent  introductions  to  the 
market are ceramic and  silicon  pins  (George,  2006).  They are  both  cheaper 
than  the  tungsten  pins  but  apparently  possess  the  same  level  of  durability. 
Regardless of the pin  materials used, there are three main  pin designs:  solid, 
split, pin-&-ring (see figure 3.2).
Split  pins  are  the  most  popular  for  cDNA  array  fabrication.  The  pin-tip 
resembles a miniature fountain pen.  A 25-50^im wide slit, or reservoir, extends 
from the tip to the centre of the shaft.  The reservoir is filled by capillary action 
when the  pin-tip  is  in  contact with  the  probe solution.  The contact of loaded 
pins  onto  the  glass  slides  allows  the  deposition  of a  small  volume  of  probe 
solution to produce a spot.  These pins are not compatible with an absorbent 
substrate, such as nylon membrane, as the reservoir would be emptied through 
a  single  contact.  The  use  of  split  pins  allows  multiple  spotting  events  per 
sample-loading and therefore significantly reduces the time required for a print 
run.  One of the problems associated with split pins is sample carryover.  At the 
end of each print cycle, there is often residual DNA in the reservoir.  Dirty pins 
transfer  probe  DNA  from  one  well  to  another  leading  to  the  eventual 
contamination of the whole probe set.  It is essential that all pins are thoroughly 
cleaned before visiting the sample plate.
The pin-and-ring system, as the name suggests, consists of a small metal ring 
(as the reservoir) and a solid  pin.  When the ring comes into contact with the 
probe  solution,  a  thin  film  of  sample  formed  within  the  ring  structure.  The 
sample is deposited onto the substrate when the pin punches through the ring. 
Since the probe solution in the ring is not in contact with the substrate, this type
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of system is suitable for multiple spotting onto nylon membranes.  Carryover is 
also less of a problem as the diameter of the ring is relatively large, therefore, it 
is easier to wash away the probe solution.  Note that the pin-and-ring system is 
only available on Affymetrix cDNA microarrayer.
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Figure 3.2  Different types of microarraying pin
(a)  Split pin
(b) Pin-and-ring
A schematic diagram showing the pin-and-ring in operation
Figure (a) and (c) adapted from Microarray News, issue 1   which is available on 
the Genetix website: www.genetix.com.
Figure  (b)  adapted  from  http://www.uni-leipzig.de/~bader/groups/dna- 
microarray/dna-chiptechnology.htm.
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Solid  pins  are  like  the  pin-and-ring  system  without the  ring  i.e.  no  reservoir. 
Therefore, they can only spot once per sample loading.  As a result, the printing 
process is very time-consuming.
The most technologically demanding step for array fabrication is the precision- 
transfer of the  array  probes  (stored  in  384-well  plates)  onto  the  slides  in  an 
orderly fashion.  Such a task requires the use of a robotic arrayer, which can 
either  be  custom  built  in-house  (http://cmgm.stanford.edu/pbrown/mguide)  or 
acquired commercially.  The basic components of a typical arrayer include:
1)  a flat platform for mounting 384-well plates and glass slides,
2)  a robotic arm attached to a XYZ (axis) motion-controller,
3)  spotting pins for uploading/depositing array probes,
4)  pin holder for carrying the pins,
5)  wash/dry stations for cleaning the pins,
6)  operating software to control the printing process.
Additional  accessories  that  can  be  found  on  some  arrayers  include  an  air- 
filtration unit (dust reduction) and nebulizer (humidity control).
Several  mechanical  parameters  of the  arrayer  have  to  be  determined  before 
printing is possible:
1) the depth at which the pins are in contact with the array probes for sample 
loading,
2) the dwell time required for sample loading by capillary action (for split pins),
3) the depth at which the pins strike onto the glass slides,
4) the dwell time required for sample deposition onto the slides,
5) the depth at which the pins are immersed into the wash/dry stations
6) the time required for washing/drying the pins to prevent carryover.
Since the arrayer operates in  units of micrometer and  millisecond,  the margin 
for error is minimal.  The printing parameters have to be re-optimised if changes 
are  made to any of the printing components.  For instance,  a new set of pins 
may  be  of different  length  compared  to the  old  ones,  therefore the  depth  for 
sample loading and printing has to be adjusted accordingly.
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The  final  step  in  terms  of  array  construction  is  the  array  post-processing. 
Different  surface  chemistries  have  different  requirements  for  the  post­
processing  steps.  In  general,  the  post-processing  of  arrays  aims  to:  (1) 
facilitate the fixation of the  DNA molecules onto the array surface,  (2) remove 
excess  DNA  which  would  interfere  with  subsequent  hybridisation,  (3) 
block/inactivate  unbound  active  groups  on  the  array  surface  to  reduce  non­
specific binding.  Optimal  post-processing  is critical for the production of high- 
quality microarrays.
3.1.2  cDNA labeling
In addition to the creation of HHV-6 arrays, I have compared the performance of 
three different cDNA labeling methods: direct-,  indirect and dendrimer-labeling. 
Figure 3.3a shows a schematic diagram of all three labeling methods.  Both the 
direct-  and  indirect-labeling  involves  the  incorporation  of  dye-conjugated  or 
aminoallylated  nucleotides  (typically  deoxyuridine  triphosphate  (dUTP)  or 
dCTP) into the cDNA during reverse transcription.  The latter method  requires 
an  extra step to couple the fluorophors to the aminoallyated  nucleotides after 
reverse transcription.  The dye-conjugated  nucleotides are considerably larger 
than their aminoallyated counterparts (see figure 3.3b), as a result, the former is 
incorporated  less  efficiently  by  reverse  transcriptase  and  at  times  causes 
premature chain termination.  Hence,  it is expected that indirect-labeling would 
produce  cDNA with  longer sequence  and  of higher yield.  Cy5  dye-moiety  is 
also larger than that of Cy3, and therefore direct-labeling of cDNA often exhibits 
a signal bias towards Cy3.
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(a)  Different labeling strategies.
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Figure (a) adapted and modified from Yu et al„ (2002).
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Cy-labeled  nucleotides are larger than  aminoallylated  nucleotides.  Figure (b) adapted  and  modified from the  respective product 
inserts (aa-dCTP, Invitrogen; Cy3- and Cy5-dCTP, GE Healthcare).
(c) A schematic representation of a dendrimer molecule.
Figure (c) adapted from www.genisphere.com/about_3dna.html.Array Development
For  the  dendrimer  cDNA  labeling,  unmodified  nucleotides  are  used  in  the 
reverse transcription, which circumvent the problems associated with premature 
chain termination or signal bias.  Reverse transcription of RNA is primed using 
synthetic oligonucleotides, each containing a "capture sequence".  The labeled 
cDNA sample is then mixed with the dendrimer molecules.  Each dendrimer is 
tagged with a sequence that is complementary to the “capture sequence” and 
will  therefore  hybridise  with  the  labeled  cDNA.  The  “capture  sequence”  for 
individual  fluorescent  dye  is  unique.  For  instance,  Cy5-dendrimers  will  only 
hybridise with cDNA carrying the Cy5 capture sequence.  As each dendrimer is 
made  up  of highly-branched  synthetic  DNA  monomers  (see figure  3.3c),  and 
that  individual  monomer  is  linked  to  a  fluorescent  dye  (Nilsen  et  al.,  1997), 
every  cDNA  that  hybridises  with  a  dendrimer  is  bound  by  hundreds  of  dye 
molecules  (ranged  from  350-850  molecules  depending  on  the  type  of 
dendrimer).  This is in contrast to both the direct- and indirect-labeling methods, 
of which dye incorporation is dependent on the base composition of the mRNA 
sequence  (due  to  the  use  of  modified  dUTP  or  dCTP).  The  higher  signal 
intensity per cDNA molecule offered  by the dendrimer labeling method  means 
less starting RNA is required for each hybridisation.
Although  the  relative  merits  of  the  different  labeling  methods  are  well 
recognised  in  the  microarray  community,  there  is  no  consensus  as  to  which 
labeling  method  is  best for array analysis.  The  choice  of labeling  method  is 
influenced  by  various  factors  such  as  the  type  of  sample  (total  RNA  vs 
mRNA/aRNA) and/or the amount of sample available for analysis.  Therefore, 
the labeling efficiency of these three different approaches was evaluated to find 
the one best suited to this study i.e. fluorescent-labeling of purified mRNA.
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3.2  Results and Discussion
3.2.1  Preparation of the HHV-6 clone set
In total, 121 viral DNA sequences corresponding to 116 HHV-6 predicted ORFs 
and ten corresponding to the intergenic regions were cloned into pGEM-T Easy 
vector.  Some ORFs (LT1,  U88,  U92,  U93, and  RJ1) were not cloned as they 
could  not  be  amplified  by  PCR  due  to  repetitive  elements  within  the 
corresponding genomic regions.  The size of DNA fragments ranged from 95- 
353bp with  a  mean  value  of 281 bp  (see  section  2.4  and  figure  3.4),  and  the 
majority of genes were biased towards the 5’ end of the ORFs.  Purified plasmid 
DNA of all the HHV-6 clones were digested with EcoRI (two EcoRI sites flanking 
the  cloning  site)  and  the  size  of  individual  insert  was  confirmed  (data  not 
shown).  The  identity of each  clone was further verified  by  DNA sequencing. 
These  sequence-verified  plasmids  were  later  used  as  template  for  the  PCR 
amplification of the HHV-6 array probes.
3.2.2  Generation of the HHV-6 array probes
Common  vector  primers  flanking  the  cloning  site  were  used  for  the  PCR 
(Jenner, 2002).  The PCR reactions were set up in a 96-well plate format (see 
section 2.5).  Figure 3.4 shows two such 96-well plates of PCR products.  The 
two  96-well  plates  used  contained  DNA other than just  HHV-6  array  probes. 
Therefore  the  wells  labeled  “N/A”  should  be  ignored  as  the  resulting  PCR 
products are excluded from  HHV-6 gene expression analysis.  The majority of 
the  HHV-6  array  probes  were  successfully  amplified  at the  first  attempt;  the 
failed ones tended to be sequences of <200bp or with  high G/C content.  The 
addition of more plasmid  DNA or Qiagen Q solution  (optimised for genes with 
high G/C content) in these PCR reactions yielded a single product at the correct 
size in the second attempt (data not shown).  No PCR product was observed for 
all the water blank (WB) controls.  All PCR products were purified and sent to 
ICR for array fabrication.
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Array probes to individual  HHV-6 ORFs were PCR-amplified  using the HHV-6 cDNA clone set created as described in section 3.2.1.  The 
label indicates the name and size (bp) of each PCR product.
M - 100bp DNA ladder, the white arrow pointing at the 200bp band; WB - Water Blank, NA = Not Analysed.Array Development
3.2.3  ICR arrays
A total  of three  batches  of arrays were  produced  by  our collaborator at  ICR, 
however,  none  of  them  were  suitable  for  the  analysis  of  HHV-6  gene 
expression.  The  majority of the  spots  corresponding  to the viral genes were 
defective on the first and third batch of arrays (see figures 3.5a and 3.5c).  The 
“doughnut“ pattern seen on the first batch of arrays is often associated with pin 
blockage,  while  the  “comet  tails”  observed  on  the  third  batch  of  arrays  is 
associated  with  sub-optimal  post-processing.  As  depicted  in  figure  3.5b,  the 
second batch of arrays exhibited excellent spot morphology and signal-to-noise 
ratio.  However, the identity of individual spots cannot be recognised due to an 
error in tracking the order of sample printing.  It was impossible to interpret the 
data generated  using this  batch of arrays.  The  inaccessibility of good  quality 
microarrays from  ICR initiated  the need for in-house  production of the  HHV-6 
arrays.
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Figure 3.5  ICR arrays post-hybridisation
(a) An array image showing the morphology of array probes.
Viral
genes Host genes
An expanded view highlighting the 
appearance of “donuts”.
*   C
•  #
Mo
• *9
Host pathogen arrays (1st batch)
(b)  An image of the host-pathogen arrays (2nd batch), 
see section 3.2.3 for description.Array Development
Figure 3.5(cont’)
(c) An array image showing the morphology of the array probes.
Host-pathogen arrays (3rd batch)
An expanded view highlighting the appearance of “comet tails”.
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3.2.4  PCR of the host array probes
The design of the in-house HHV-6 arrays was similar to the approach used by 
the ICR.  Namely, the incorporation of both host and viral genes on the same 
microarrays.  The presence of host genes not only provides data on the effect of 
viral  infection  on  host  gene  expression,  but  more  importantly,  allows  data 
normalisation between different arrays (section 1.3.4).
Since the  ICR  host gene  set is  only accessible to their own  researchers,  the 
array probes for the host genes on our in-house arrays had to be alternatively 
sourced.  The  IMAGE  lymphochip  clone  set  was  acquired  from  the  MRC 
geneservice  (the  IMAGE  licenced  vendor  in  UK)  as  the  source  of  the  host 
genes.  The  clone  set  contains  cDNA  sequences  originating  from  lymphoid 
tissue.  This cDNA library was delivered as glycerol stocks in 96-well plates.  In 
contrast, the viral  probes were  PCR-amplified from  purified  plasmid  DNA.  To 
save  time  and  costs,  the  possibility  of  setting  up  PCR  using  cDNA  clones 
straight  from  the  glycerol  stock  was  investigated.  Eight  PCR  reactions 
containing common vector primers and 2 pi of the cDNA clones in glycerol were 
amplified in a final volume of 100 pi, along with a positive control (plasmid DNA 
with the same vector backbone).  Amplicons of the expected size were obtained 
for the positive control, while the eight cDNA-clone PCR failed to produce any 
PCR product (data not shown).  The presence of glycerol (at the concentration 
used) should not interfere with the PCR reaction.  PCR failure was probably due 
to insufficient input DNA although this was not investigated further.
I then investigated the possibility of using crude bacterial lysate as template for 
PCR.  It was  anticipated  that the  PCR  yield  would  be  dependent on  the  cell 
density of the bacterial culture, as the copies of template DNA is proportional to 
the number of cells.  Good yields can be expected for a typical overnight culture 
of E. coli in individual universal/flasks in a well-shaken 37°C incubator, however, 
the high number of cDNA clones required for array production demands a high- 
throughput culture  method.  Therefore,  the cDNA clones were cultured  in  96- 
deep-well  plates  in  a  37°C  plate  shaker.  Preliminary  analysis  showed  that 
many clones (up to 95%) showed  no observable growth when the culture was
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set up in this format.  I reasoned that the low growth rate was a result of high 
variations in the number of viable cells  between different glycerol  stocks,  and 
hypothesised that the use of starter culture would improve the growth success. 
The  initial  8h  incubation would  allow most clones to grow to a  higher density 
before  seeding  the  overnight  culture.  Indeed,  the  use  of  starter  culture 
significantly  enhanced  the  success  of  bacterial  growth  (average  >90%).  It 
should be noted that the culture in 96-deep-well plate was set up using 2x LB 
(as  recommended  by a  number of protocols).  It is  likely that the  culturing  of 
bacteria in 96-deep-well has a higher demand for nutrients, and consistent with 
this suggestion, it was observed that there was no overnight growth when 1x LB 
was used (data not shown).
PCR amplification of the host cDNA clones was carried out in collaboration with 
C. Li and J. Rasaiyaah (Wohl Virion Centre, UCL).  The average PCR success 
rate  was  ~75%  which  compared  favourably  to  5%  if the  starter  culture  was 
omitted  (data  not shown).  Products  of the  successful  PCR were  individually 
picked  and transferred  onto a  new 96-well  plate  using a  liquid-handling  robot, 
which  tracks  the  movement  of  all  the  samples  so  that  the  identity  of  each 
sample is known.
3.2.5  Spotting buffer
As both the viral and  host array probes were synthesised as unmodified  PCR 
products,  aminosilane  was  the  surface  chemistry  chosen  for  the  printing  of 
HHV-6 arrays.  The evaporation rate and spot morphology of four aminosilane- 
compatible  spotting  buffers  (3x  SSC,  DMSO,  Genetix,  and  Betaine)  were 
assessed (as described in section 2.5.4).  The use of 3x SSC was ruled out due 
to its high evaporation rate;  it was completely evaporated  (in  10  pi volume) at 
room temperature in under 20 minutes.  In contrast, the reduction in volume for 
the  other  three  buffers  was  under  10%  after  a  16h  incubation  at  room 
temperature.
Regarding the spot morphology, the average diameter of spots for 50% DMSO 
and Genetix buffer is 417.8 ± 17.78pm (range: 350-500pm), compared to 126.7
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± 5.53pm  (range:  100-150pm)  for  betaine spots.  The  array  probes  are  often 
deposited close to each other so that more spots can  be accommodated onto 
the  same  slide.  The  distance  from  the  centre  of  one  spot  to  another  was 
typically 350-400pm or 150-200pm for low- or high-density arrays, respectively. 
Large  spots  are  not  desirable  as  they  are  more  likely  to  merge  with  the 
neighbouring spots (see figure 3.6).
Figure 3.6  Spot size and morphology of two different spotting buffers
(a) 50% DMSO produced larger spots compared to that of the betaine buffer.
H
Betaine
(b)  An  image  illustrating  how  the  diameter  of  each  spot  can  be  determined 
using  the  GenePix  software.  Each  square  represents  a  pixel  (10  x  10pm). 
Hence, the diameter of the spot (betaine buffer) below is 130pm.
50% DMSOArray Development
The  betaine  buffer,  with  its  low  evaporation  rate  and  favourable  spot 
morphology,  was  used  to  resuspend  the  purified  array probes.  The  384-well 
plate containing the array probes were sealed using “sticky” foil lid and stored at 
-20°C  until  use.  It was  noted  that  precipitation  of the  array  probes  occurred 
after long term storage at low temperatures (Le Berre et al., 2003).  I found that 
improper  thawing  of  the  array  probes  has  led  to  inconsistent  array  printing 
(missing spots).  It is recommended that array probes should be agitated gently 
at 30°C  for an  hour,  spun  at  500g  for 5  minutes to  collect the  probes  to the 
bottom of the well, before removing the foil seal for arraying.
3.2.6  Optimisation of washing/drying conditions for printing with 
split pins
Since the printing was carried out using tungsten split pins, the washing/drying 
conditions  had to  be optimised  to  prevent  DNA carryover (see section  2.5.5). 
The spilt pins were used to print eight samples in the following sequence: blank, 
Cy3-labeled  nucleotides,  blank,  blank,  blank,  Cy5-labeled  nucleotides,  blank, 
blank.  In between the spotting of each sample, the pins were washed and dried 
for varying length of time.  The first blank acts as a  reference to establish the 
level  of  background  noise.  The  pins  were  then  loaded  with  Cy3-labeled 
nucleotides  during  the  second  visit.  Sub-optimal  washing/drying  conditions 
would lead to the carryover of Cy3 to the next spotting event(s).  The third and 
forth  blanks  can  be  used  to  determine  the  level  of  dye  carryover.  The 
arrangement  for  sample  5-8  is  similar  to  the  first  four  samples.  The  only 
difference  is  the  use  of  Cy5-  instead  of  Cy3-labeled  nucleotides.  The 
washing/drying conditions were adjusted until there is minimal carryover of the 
Cy  dyes  into  the  blanks  (see  figure  3.7.1  and  3.7.2).  Note  that  the  green 
fluorescence detected in the Cy5 spots originated from the autofluorescence of 
the betaine buffer used to prepare the Cy5-labeled nucleotides.
The  carryover test was repeated  but this time the actual  HHV-6 array probes 
were spotted onto the arrays.  The spotting of each viral probe was immediately 
followed  by two  buffer-only samples.  Any  DNA carryover would  result  in  the 
detection of fluorescence signal in the buffer-only spots.  The fact that no signal
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was observed  in  any of the buffer-only spots (see figure 3.7.3) confirmed that 
the washing/drying conditions were suitable for array printing.
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Figure 3.7  Optimisation of washing/drying conditions for printing with 
split pins
(a) Scanned image of the dye spotting test (see section 3.2.6 for description).
Blank 
Cy3 
Test 1  
Test 2 
Blank 
Cy5 
Test 3 
Test 4
All  “Test”  spots  exhibited  minimal  fluorescent  signal  suggesting  that  the 
washing/drying conditions used were efficient for cleaning the split pins.
Blank = buffer only, Cy3 and Cy5 = Cy3 and Cy5 dye suspended in 3x betaine 
buffer, respectively.
(b) A histogram showing the fluorescence intensity of the different spots.
Dye Carryover Test
50000.00
40000.00
30000.00
20000.00
10000.00
0.00
Blank Ref  Cy3  Testl  Test2  Blank Ref  Cy5  Test3  Test4
[■Cy5 ■Cy3]
This is the numerical representation of the image shown in figure 3.7a.  The low 
level of Cy3 signal detected in the Cy5 spots was generated as a result of the 
autofluorescence of the 3x betaine buffer used to resuspend the Cy5 dye.
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Figure 3.7 (cont’)
■
  HHV-6 U94 
Buffer only 
Buffer only 
HHV-6 U69 
Buffer only 
Buffer only 
HHV-6 U42 
Buffer only 
Buffer only
(c)  Scanned image of HHV-6 arrays printed using the optimised washing/drying 
conditions.
The arrays were printed and analysed as described in sections 2.5 and 2.6.
The identity of each spot is labeled.
The  white  circles  indicate  the  position  of  the  buffer-only  spots.  No  above­
background  signal  was  detected  for  these  buffer  only  spots  suggesting  that 
there was minimal DNA carryover between spotting events.
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3.2.7  Evaluation of aminosilane glass slides
Six  different  commercial  aminosilane  slides  were  tested  for  their  binding 
properties  and  background  fluorescence:  (1)  Corning  UltraGAPS,  (2)  Schott 
Nexterion  slide  A,  (3)  Amersham  7star,  (4)  Quantifoil,  (5)  Genetix  arrayXL 
cDNA,  and  (6) Genetix amine  (see section 2.5.6).  Pre-scanning of the slides 
before arraying revealed the uneven surface coating of Genetix cDNA slide, and 
therefore  it was excluded from further analysis.  As shown in figure 3.8,  over 
90% of the spots were absent on the Genetix amine slide.  It appeared that the 
coating was “peeled away” during post-processing and/or sample hybridisation, 
which  was  similar to  the  problems  associated  with  poly-lysine  coated  slides. 
The  array  probes  on  the  other  slides  (Corning,  Schott,  Amersham,  and 
Quantifoil) all produced detectable signals, however, the latter two suffered from 
high  background  noise.  Both  the  Corning  and  Schott slides  produced  spots 
with  the  high  signal-to-noise  ratio,  but taking  the  cost  into  consideration,  the 
latter was chosen for the in-house microarray production.
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Figure 3.8  Different makes of aminosilane slides post-hybridisation
Cost
Amersham
7Star
£12
Corning
UltraGAPS
£9
Schott Nexterion 
Slide A 
£8
Quantifoil
Aminosilane
£6
Genetix
Amine
The make and the cost of slide (as quoted in March 2003) were indicated. 
See section 3.2.7 for description.
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3.2.8  Post-processing optimisation
A closer inspection of spots on the Schott slides revealed a minor problem -  the 
presence of “comet tails” on  some  parts of the arrays  (see figure 3.9a).  The 
smearing of spots suggests that the manufacturer's protocol for post-processing 
was  sub-optimal.  It  has  been  suggested  that  excess  DNA  in  the  spots  re­
dissolves  in  the  succinic  anhydride  solution  (commonly  used  for  post­
processing),  and  subsequently spread to other parts of the slides  resulting  in 
the smearing of spots (Diehl et al., 2001).  For this reason, some manufacturers 
recommend  the  use  of  0.1%  bovine  serum  albumin  (BSA)  solution  as  the 
blocking  reagent.  Although  the  use  of  0.1%  BSA  helped  reducing  the 
occurrence of “comet tails”, it is less efficient in preventing non-specific binding 
of labeled  cDNA to the glass surface.  Hence,  arrays treated  using  BSA only 
tend to suffer from a higher background noise (data not shown).  BSA solution 
is also widely used in Western blotting as a blocking agent.  However, it is well 
recognised  that  BSA  does  not work  well  with  all  monoclonal  antibodies  and 
occasionally  leads  to  high  background  noise.  The  use  of  non-fat  milk  as  a 
replacement  to  reduce  background  signal  is  common  practice  in  Western 
blotting.  On this basis,  I  investigated whether the incorporation of non-fat milk 
into  the  blocking  buffer would  help  reducing  background  noise  of the  arrays 
(section 2.5.7).  Surprisingly, the treatment of the arrays with non-fat milk + BSA 
lowered the background fluorescence of the slide (see figure 3.9b).  However, 
the occurrence of “red rings” enclosing all the spots was noted.
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Figure 3.9  Optimisation of post-processing of microarrays
(a)  Succinic Anhydride
(b)  One step blocking 
0.05% BSA + 0.05% non-fat milk powder
(c) Two step blocking 
0.05% BSA + 0.05% non-fat milk powder
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These figures illustrate the effect of post-processing on spot morphology.Array Development
The  occurrence  of  these  “red  rings”  may  be  explained  by  the  difference 
between  the  working  principle  of  succinic  anhydride  and  BSA/non-fat  milk 
solution.  While the reactive amine groups on the glass surface were chemically 
inactivated by succinic anhydride solution (see figure 3.10), the latter probably 
works by physically binding to the reactive surface to prevent non-specific cDNA 
binding.  We  hypothesised  that the  BSA/non-fat  milk cannot access the  area 
immediately  surrounding  the  spots  due  to  the  steric  hindrance  of  the  DNA 
molecules.  However,  it is possible the steric factors were removed during the 
microarray denaturation (2 minutes at 98°C).  The area enclosing each spot is 
thus exposed to non-specific cDNA binding which may explain the occurrence 
of the  “red  rings”.  I  therefore  incorporated  a second  15-minute blocking  step 
after  array  denaturation.  As  depicted  in  figure  3.9c,  the  two  step  blocking 
procedure was successful in preventing the formation of the “red rings”.
Figure 3.10  Mechanism  of  the  inactivation  of  the  amine  group  by 
succinic anhydride
- nh2
o  o
II  M
c - ch2ch2~ c o
3.2.9  HHV-6 arrays
By using the optimised  protocols denoted  above,  a set of HHV-6  microarrays 
each containing 914 host genes and almost all putative HHV-6A and 6B ORFs 
were  constructed.  Triplicate  hybridisations  of  RNA  prepared  from  mock- 
infected  SupT1  against the universal  reference were performed to assess the 
specificity,  spot depositions,  and  the  reproducibility of the  HHV-6  arrays  (see 
section 2.5.9).  The Cy5-labeled mock-infected SupT1  sample consisted of host 
transcripts  only  and  therefore  should  not  have  hybridised  with  the  HHV-6- 
specific  probes.  Cy5  signals  were  consistently  detected  in  seventeen  viral 
probes (B3, B4, B5, B9, DR2, DR3, DR4, DR5, DR6, LJ1, U36, U61, U66, U68, 
U71,  U86, and  U98) suggesting either the potential for cross-hybridisation with 
host transcripts or impure  DNA probes.  The  Cy3-labeled  universal  reference
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consisted  of spike-in  HHV-6 transcripts and  should  hybridise with  all  the viral 
probes.  No  or  low  (below  background)  signals  were  detected  for  probes 
corresponding to eleven ORFs (B1, U1, U2, U18, U24, U58, U62, U90A, U91A, 
U94,  U95).  Errors  in  spot deposition  may account for these “missing”  spots. 
Alternatively,  the  corresponding  transcripts  may  be  of  absent  or  of  low 
abundance  in  the  universal  reference.  Spots  of compromised  quality  (either 
missing  or  cross-hybridising)  were  excluded  from  subsequent  microarray 
analysis of the HHV-6B time course (see chapter 4).  Pairwise comparisons of 
the  expression  ratio  of  the  filtered  spots  (spots  with  signal-to-noise  ratio 
(SNR)>2,  see section 2.5.9) for all three arrays (>2000 spots/array -  as each 
sample  were  spotted  in  triplicate)  were  made  and  the  average  Pearson 
correlation  coefficient  (R2)  was  found  to  be  0.921  (see figure  3.11).  Hence, 
results obtained using the HHV-6 arrays were highly reproducible.
172Figure 3.11  A diagram showing the reproducibility of data obtained using HHV-6 arrays
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3.2.10  Comparing cDNA labeling methods
In  addition  to  the  development  of  HHV-6  arrays,  the  performance  of  three 
different cDNA labeling methods (direct-, indirect- and dendrimer-labeling) was 
evaluated (see section 2.5.10).  As demonstrated in figure 3.12, direct labeling 
produced spots with the highest overall fluorescence.  The analysis of the array 
images also shows that the direct labeling produced significantly more spots at 
the higher end of the fluorescence intensity (see figure 3.13).
Since each array hybridisation was between Cy5- and Cy3-labeled of the same 
RNA sample, the ideal expression ratio for individual genes is 1.  As expected, 
the expression ratios of direct-labeled cDNA exhibited a signal bias toward Cy3 
(see figure  3.14),  while the overall trend  of the  expression  ratios for both the 
indirect- and dendrimer-labeling is closer to 1   (the R2  for both methods >0.98). 
However, the Cy3 bias associated with direct labeling is a systematic error i.e. 
all directly-labeled cDNA suffer from the same problem.  The Cy3 bias exhibited 
on  all  arrays  can  be  cancelled  out  by  data  normalisation.  Hence,  it  has  no 
adverse effect on the analysis of expression ratios.
Furthermore,  the  time  required  to  perform  the  protocol  is  shortest for  direct- 
labeling  (<6h),  followed  by  indirect-  (<9h)  and  dendrimer-labeling  (~16h). 
Taking all factors  into account,  the direct-labeling  method was  chosen for the 
subsequent array analysis of the HHV-6B time course.
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Figure 3.12  Scanned  images  of  HGMP  arrays  hybridised  with  cDNA 
prepared using different labeling methods
Direct Labeling
Indirect Labeling
Dendrimer Labeling
The fluorescent intensity of the spots arranged in descending order: 
Direct > Indirect »  Dendrimer.
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Figure 3.13  The distribution of pixels according to signal intensity
i
I
Number of pixel 
counts
High Low
Direct Labeling
Signal intensity
Indirect Labeling
Dendrimer Labeling
The  black  line  divides  the  pixels  into  low  (<32500)  and  high  fluorescent 
(>32500) intensity.  The histograms show that direct labeling of cDNA produced 
many more pixels at high-intensity compared to indirect and dendrimer labeling.
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Figure 3.14 A scatter plot depicting the signal intensity (Cy3 versus Cy5) of individual spots
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Direct labeling produced more spots exhibiting a Cy3-bias compare to the other two labeling methods. 
See section 3.2.10 for details.Array Development
3.3  Summary of Chapter 3
1.  A sequence validated cDNA clone set was created for HHV-6.
2.  A  protocol  for  printing  cDNA  microarrays  using  Genetix  QArray2   was 
developed.
3.  A  HHV-6  cDNA array,  containing  914  host genes,  was  constructed  for 
gene expression analysis.
4.  Gene  expression  ratios  measured  by  the  HHV-6  arrays  were  highly 
reproducible.
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Temporal  Classification  of  HHV-6B  Genes 
MicroarraysTemporal Expression of HHV-6B
4.1  Introduction
Herpesviruses adopt two distinct modes of gene expression during  latent and 
lytic  infection.  Latent infection  is characterised  by the expression  of a  limited 
number of genes from the episomal DNA, and the gene products are believed 
to be involved in the maintenance and propagation of the episomes (see section 
1.2.17).  Lytic replication  occurs during primary infection or reactivation of the 
latent genome,  leading  to  the  expression  of lytic genes for the  production  of 
infectious  progeny  (see  section  1.2.7.1).  It  is  well  recognised  that  the 
expression of viral genes follows a three wave temporal cascade: expression of 
IE genes occurs immediately after infection, which is followed by the expression 
of  E  genes  and  then  L  genes.  There  is  considerable  interest  in  the 
characterisation of transcription  kinetics of individual viral genes as it provides 
clues to function.  In addition, the knowledge on transcription kinetics facilitates 
the  development  of  immunological  and  molecular  biological  assays  for 
determining  the state of viral  infection  e.g.  latent- versus  lytic-infection,  or for 
evaluating the efficacy of antiviral drugs.
Microarray  analysis  allows  the  global  measurement  of viral  gene  expression, 
and subsequently, the re-organisation of genes into different groups based on 
the  similarity  of  their  expression  pattern.  As  discussed  in  section  1.3.5, 
microarrays  have  been  successfully  applied  to  characterise  the  viral 
transcriptome  of  most  human  herpesviruses.  Although  the  complete  DNA 
genomes  of  HHV-6A  and  -6B  have  been  published  in  1995  and  1999, 
respectively  (Dominguez  et  al.,  1999;  Gompels  et  al.,  1995;  Isegawa  et  al., 
1999),  there  have  been  a  limited  number of studies  examining  HHV-6  gene 
transcription except  those of Kondo and colleagues (2002b; 2003b) describing 
a  transitional  state  between  latent  and  lytic  infection.  Regarding  viral  gene 
expression  during  HHV-6  lytic  replication,  little  was  known  about  the 
transcription kinetics of the majority of HHV-6 genes at the start of this project 
(section  3.1).  The  aim  of this  chapter is to  apply the  HHV-6  arrays  made  in 
Chapter 3 for the global expression profiling and kinetic classification of HHV-6B 
genes during lytic replication.
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4.2  Results
4.2.1  RNA-free virus inocula
The virus inocula used in this study were prepared by lysing a large number of 
HHV-6B(Z29)-infected  SupT1  cells  (typically >108/ml).  RNA  released  into  the 
inocula  upon  cell  lysis  would  have  interfered  with  the  subsequent  microarray 
and  RT-PCR  analyses,  hence  its  removal  by  RNase  treatment was  essential. 
To confirm the absence of residual viral RNA, SupT1  cells were exposed to the 
virus  inocula  at  4°C,  and  immediately  harvested  for  RNA  extraction  (sample 
Ohpi).  RT-PCR was  performed  for (3-actin  and  four  HHV-6  genes  (U27,  U48, 
U90 and  U95) using  cDNA prepared from the Ohpi sample.  No amplicon was 
obtained  for the four viral  genes  tested,  as  shown  in  figure  4.1,  but the  PCR 
products for (3-actin were successfully amplified.  The results suggested that the 
Ohpi  sample contained  host but not viral  RNA,  thus confirming the absence of 
cell-free viral RNA in the virus inocula.
Figure 4.1  The  absence  of  cell-free  HHV-6  transcripts  in  the  virus 
inocula
P-actin(471) U90B(318) U95(300) U27(344) U48(487)
M  RNA  cDNA Ohpi  CHX  6hpi Ohpi  CHX  6hpi Ohpi  CHX  6hpi Ohpi  CHX  6hpi  M
The transcripts examined by RT-PCR and the size of the respective amplicons 
are labeled.  The presence of mRNA in the Ohpi sample was demonstrated  by 
the successful amplification of (3-actin.  The presence of amplicons for the RT- 
PCR of HHV-6 genes in the 6hpi,  but not the Ohpi sample,  indicated that virus 
replication is required for the detection of HHV-6 transcripts.
M  -  100bp  ladder,  RNA -  RNA extracted from the Ohpi  sample,  cDNA - cDNA 
reverse transcribed from  RNA of the Ohpi  sample,  Ohpi - cDNA prepared from 
HHV-6B-infected cells harvested at Ohpi,  CHX and 6hpi - cDNA prepared from 
SupT1  cells  infected  with  HHV-6B  for 6h  either with  or without cycloheximide 
treatment, respectively.
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4.2.2  Quality control of the RNA samples
Similarly, it was important to establish that all RNA samples were free from DNA 
contamination prior to RT-PCR analyses.  Five nanograms of mRNA from each 
time  course  sample  were  used  for  the  PCR  of  the  U91  and  U100  genes. 
Despite  using  a  40-cycle  PCR,  no  amplicon  was  obtained  for  any  of  the 
samples (data not shown).  These data confirmed the absence of residual viral 
DNA in all the RNA samples, which would be analysed by RT-PCR for HHV-6 
specific gene transcription.
4.2.3  Expression profiling of HHV-6B
The  HHV-6  arrays  (see  chapter  3)  were  applied  to  profile  HHV-6B  gene 
expression  in  SupT1  over  a  60h  time  course.  Other  studies  on  HHV-6 
transcription  kinetics  have  demonstrated  that  the  length  of  time  course  is 
sufficient for expression of genes in all kinetic classes (Mirandola et al.,  1998; 
Oster and  Hollsberg,  2002),  but insufficient for the release of progeny viruses 
from the  infected  cells  (Black et al.,  1989),  thereby avoiding  any confounding 
effect on  expression  analysis due to secondary infection.  Poly(A)+   RNA was 
extracted  from  each  time  course  sample,  fluorescently  labeled  with  Cy5,  and 
hybridised with the  Cy3-labeled  universal  reference to the  HHV-6 arrays  (see 
section 2.6 for details).
The  array  analysis  comprised  six  time  points:  6-,  12-,  24-,  36-,  48-,  60-hpi. 
Each time point,  except 48hpi, was represented by data obtained in two array 
hybridisations.  The 48hpi  sample was  also hybridised  in  duplicate,  however, 
the  lid  of one  of the  hybridisation  chambers  split during  overnight incubation. 
The affected slide was therefore excluded from the analysis.  Since there was a 
strong agreement between replicates for all the other time points (the average 
Pearson  correlation  coefficient  (R2)  is  0.812,  see  figure  4.2),  I  decided  to 
proceed with the analysis using data from only one array hybridisation for 48hpi.
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6hpi vs 6hpi  R2 = 0.869 6hpi vs 60hpi  R2 = 0.045
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These figures illustrate the correlation between the expression ratios derived from the two replicates of 6hpi (left) and 60hpi (right). 
The  middle plot shows that there is minimal correlation  between the expression  ratios of 6hpi vs 60hpi.  The R2  for all the time 
points: 0.869 (6hpi), 0.950 (12hpi), 0.815 (24hpi), 0.635 (36hpi), 0.921 (PAA), and 0.736 (60hpi), hence, the average R2  is 0.821.Temporal Expression of HHV-6B
To  profile the viral  gene  expression,  the data obtained from  all  hybridisations 
were  compiled  into  one  dataset  and  filtered  for  genes  present  in  all  eleven 
arrays.  As  described  in  section  3.2.9,  twenty  six  HHV-6  ORFs  and  two 
intergenic regions were excluded from the array analysis as their array probes 
were unreliable.  In addition, expression ratios for U6, U9, U33, U34, and B8 in 
some of the  arrays failed  to  pass the signal-to-noise filter and were therefore 
excluded from the array analysis.  Instead, expression pattern of some of these 
genes was profiled by RT-PCR and the results are presented in section 4.2.5.
The progressive changes in viral transcription over time were shown in the gene 
expression  map  (see  figure  4.3),  with  rows  representing  the  individual  viral 
genes  and  columns  representing  the  samples  collected  at the  corresponding 
time  points.  The gene  expression  ratios are colour-coded.  Black represents 
genes which were expressed at the baseline level (log2 median expression ratio 
= 0).  Expression ratios above zero are in red and below in green.  The colour 
intensity indicates the degree of deviation from zero i.e.  increasing expression 
ratios are shown in progressively richer shades of red.  The tree structures, or 
dendrograms,  illustrate the  relationship  between  each  node, with the distance 
between branch-points representing the degree of similarity.  The dendrogram 
at the top and on the left indicates the similarity of expression patterns between 
samples and genes, respectively.  Hence, samples or genes which have similar 
expression patterns are grouped closer together e.g. the replicates of 12hpi are 
immediately  next  to  each  other,  whereas  those  with  dissimilar  patterns  are 
grouped  further  apart  e.g.  6hpi  vs  60hpi  are  at  opposite  ends  of  the 
dendrogram.
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Each  column
represents  a  sample 
taken  at different times 
after  HHV-6B  infection 
e.g.  6h  post  infection 
(6hpi).  Each  row
represents  a  HHV-6 
ORF  and  the  names 
are  listed  on  the  right 
hand  side  of the  gene 
expression  map.  The 
dendrogram  on  the top 
IE/E  represents  the
relatedness  of  the
expression  patterns 
between samples, while 
the  one  on  the  left 
represents  the
relatedness  of  the
expression  patterns 
between genes.  Three 
main  clusters  of  virus 
genes  are  apparent: 
I E/E  (red),  E  (green) 
and  L  (blue)  genes. 
Gene  expression  is 
colour-coded  such  that 
E  increasing  log(2)
expression  ratios  are 
shown  in  red  and
decreasing  expression 
ratios green,  with  black 
being  the  row  median 
level of expression  (set 
to 0).
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Focusing on the dendrogram above the expression map shown in figure 4.3, the 
time  points were  divided  into  two  main  groups  and  arranged  in  the  expected 
order  i.e.  6hpi  to  60hpi.  Expression  profiles  for  time  points  in  the  left-hand 
cluster (6-,  12- and 24-hpi) were more similar to each other than to those in the 
right-hand cluster (36-, 48- and 60-hpi).  Profiles of the replicates for each time 
point  should  be  highly  similar,  and,  as  expected,  they were  all  placed  beside 
each other.
The array analysis profiled the expression patterns of 85 HHV-6 ORFs (HHV-6A 
biased:  12,  HHV-6B:  73)  and  eight  intergenic  regions.  Transcripts originating 
from  seven  intergenic  regions  (G17/18,  G41/42.1,  G41/42.2,  G86/90.2, 
G86/90.3,  G91/B8 and  G100/B9) were confirmed  by RT-PCR (see figure 4.4). 
G96/97 was  not tested  as  the  primers were  incompatible with  HHV-6B  cDNA 
(primers were designed using the HHV-6A sequence).
Figure 4.4  Confirmation  of transcription  from  the  intergenic  regions 
by RT-PCR
G17/18  G41/42.1  G41/42.2  G86/90.2  G86/90.3  G91/B8  G100/B9
(299)  (316)  (301)  (262)  (332)  (294)  (300)
M  Ohpi  24hpi  Ohpi  24hpi  Ohpi  24hpi  Ohpi  24hpi  Ohpi  24hpi  Ohpi  24hpi  Ohpi  24hpi  M
The  results demonstrated the presence of viral transcripts corresponding to all 
seven intergenic regions tested in the 24hpi sample.
The transcripts examined and the size of their amplicons (in bp) are labeled.
M - 100bp ladder, Ohpi and 24hpi - cDNA prepared from HHV-6B(Z29)-infected 
cells harvested at Ohpi or 24hpi, respectively.
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In this study,  all viral genes and  intergenic regions were broadly dividedly into 
three clusters:  I E/E,  E and  L (figure 4.3).  Genes in the top cluster (I E/E) were 
transcribed at high levels at early times during infection (6-12hpi).  This type of 
profile is reminiscent of typical IE- and E- genes.  Indeed, the cluster contained 
genes such as U41, U42, U73, U90, and U91, which have been reported as IE- 
or E- genes (Mirandola  et al.,  1998;  Rapp et al.,  2000; Schiewe et al.,  1994), 
thereby  providing  strong  support  for  the  I E/E  classification  in  this  study. 
Transcription of genes in the E cluster was largely undetected immediately after 
infection  (at  6hpi)  but  peaked  between  12-24hpi.  The  E  classification  was 
validated by the presence of two known E genes -  U51 and U69 (Menotti et al., 
1999;  Oster and  Hollsberg,  2002),  together with  genes that are thought to be 
involved  in  DNA  replication  such  as  U27,  U28,  and  U78  (Pellett  and 
Dominguez,  2001a;  Taniguchi  et al.,  2000).  The  bottom  cluster consisted  of 
genes expressed only at late times (>24hpi) during infection, and was therefore 
assigned  as the  L cluster.  Among this group of genes,  U11,  U22,  U23,  U47, 
and  U100  have  previously  been  described  as  L  genes  (French  et al.,  1999; 
Mirandola et al., 1998; Oster and Hollsberg, 2002).
The  array data  confirmed  that the transcription  program  of HHV-6B follows a 
temporal order, although transcription kinetics of some viral genes (particularly 
the IE- and E-genes) remains poorly defined.  Genes such as U8 and U41 were 
previously  reported  as  E  genes  (Oster and  Hollsberg,  2002)  but in  this study 
they were grouped in the same cluster as other known IE genes, e.g. U90.  To 
better define the  transition  between  lE-to-E  and  E-to-L  genes,  the  viral  gene 
expression in cells treated with cycloheximide (CHX; protein synthesis inhibitor) 
and phosphonoacetic acid (PAA; DNA synthesis inhibitor) was analysed for the 
classification of IE and  E/L genes,  respectively (see sections  1.2.7.1  and 2.7.1 
for experimental details on the kinetic classification of herpesviral genes).
4.2.4  Effect of PAA on HHV-6B gene expression
Transcription  of  L  genes  reaches  maximal  levels  post  DNA  synthesis.  To 
distinguish  between  E-  and  L-genes,  SupT1  cells were  infected with  HHV-6B 
and cultured for 36h in the presence of PAA (sample PAA), which inhibits HHV-
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6  viral  DNA  polymerase  in  vitro  (Shiraki  et  al.,  1989).  Any  gene  that  was 
significantly inhibited by PAA was assigned as an L gene.
Inclusion of data from the PAA arrays in the Cluster analysis led to changes in 
the topology of the dendrogram for the time points (see figure 4.5).  The time 
points  were  still  divided  into  two  clusters,  but  this  time  the  left-hand  cluster 
consisted of 6-,  12-hpi, and sample PAA, while the right-hand cluster consisted 
of 24-,  36-, 48-,  and  60-hpi.  The fact that the expression profiles of the  PAA 
samples were  more  similar to  those  at 6-  and  12-hpi  than  its  counterpart  at 
36hpi  suggests  that  the  PAA-treatment  was  effective  in  restricting  the 
expression to IE and E genes, which were more abundant at early time points.
188Figure 4.5 Lytic replication of HHV-6B with PAA treatment
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level  of  expression 
(set  to  0).  The
clustering  results 
show  that  PAA
treatment  was
effective  in  inhibiting 
the  expression  of  L- 
genes.
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-2 +1 +2A minor alteration  in  the  arrangement of genes was  also  noted.  The  kinetic 
classification  of  the  genes  remained  largely  unchanged  compared  with  the 
previous  Cluster analysis without  PAA array data,  except for ten  genes.  As 
expected,  most  genes  in  the  I E/E  cluster were  insensitive  to  PAA-treatment. 
This was not the case for the subset of genes comprising B6,  U21,  U83,  U99, 
and G100/B9.  These genes were previously assigned to the IE/E cluster, most 
likely due to the  detection  of relatively high  levels of their transcripts at 6hpi. 
However, the data clearly showed that their transcription was inhibited by PAA, 
resulting in a switch from the IE/E cluster to the L cluster.  Transcription of these 
genes  exhibited  a  biphasic  pattern  (peak  at  IE  and  at  L  time  points).  Their 
transcription kinetics were further characterised and the results are presented in 
section 4.2.7.
The other five genes affected by a change in classification were U14, U40, U81, 
U29,  and  U52.  Of these,  the  first  three  were  previously  assigned  to  the  L 
cluster.  Data  from  the  PAA arrays  demonstrated  that their transcription  was 
unaffected  by  PAA,  in  common  with  genes  in  the  E  cluster.  They  were 
therefore re-classified as E genes.  Conversely,  U29 and  U52 were previously 
clustered with the  E genes but as both were inhibited  in the presence of PAA 
i.e. they were re-assigned as L genes.
The classification of the E- and L-genes was validated by RT-PCR.  The results 
show that transcript levels of five E genes (U12, U27, U51, U69 and U73) were 
comparable  in  both  the  PAA-treated  and  untreated  sample  (see  figure  4.6). 
Similar  analysis  demonstrated  the  reduction  in  expression  of  9  out  of  10  L 
genes (DR1, U11, U32, U43, U48, U50, U56, U57 and U72; U38 being the only 
exception)  in  PAA-treated  compared  to  untreated  sample  (see  figure  4.6). 
Hence, the classification of 14 out of 15 genes examined was in agreement with 
the array analysis, suggesting that the microarray results were highly reliable.
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RNA  cDNA
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U27 (344)
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U73 (328)
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U11  307)
U32 (267)
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300bp 
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500bp
300bp
400bp 
200bp
400bp
200bp
400bp
200bp
400bp
200bp
U56 (323)
U57(3) (305) 
U72 (340)
The transcripts examined and the size of their amplicons (in bp) are labeled.
E and  L - ORFs that were assigned  as  E and  L genes by microarray analysis, 
respectively.  Except for the  U38 gene,  RT-PCR results are in agreement with 
the kinetic classification by microarrays.
RNA - purified mRNA, cDNA - reverse transcribed mRNA, M - 100bp ladder, 36 
-  HHV-6B-infected  cells  harvested  at  36hpi,  PAA  -  PAA-treated,  HHV-6B- 
infected cells harvested at 36hpi.
1914.2.5  Expression  profiling  and  PAA  analysis  of  the  ORFs 
excluded in the array analysis
RT-PCR was used to profile the expression patterns of twenty ORFs and two 
intergenic  regions  that  were  excluded  from  the  array  analysis  (see  sections
3.2.9  and  section  4.2.3).  Another  eleven  “excluded”  ORFs  were  not 
investigated  primarily  because  their  primers  are  HHV-6A  biased  and  thus 
unsuitable for HHV-6B RT-PCR.
As depicted in figure 4.7, all genes were divided into three groups (I -  III) based 
on  two  criteria:  the time  point at which  the  corresponding  transcript was first 
detected,  and that,  at which transcription  peaked.  Transcripts of the ORFs in 
group I (B1, U94, U95, B5, and B9) were detected at 6hpi and the level of their 
transcription  remained constant throughout the time course.  For group II  (U6, 
U18,  U33,  U34,  U36,  U62,  and  U71),  the  corresponding  transcripts  were 
detected  at  6hpi  but  peaked  at  12hpi  and  remained  constant  thereafter. 
Transcription of most ORFs in group  III  (B4,  B8,  U9,  U66,  U68 and G86/90.1) 
was detected  no earlier than  12hpi.  The exceptions were DR3,  DR6,  B3 and 
GB3/B4 which were found to be expressed at 6hpi.  Note that these four regions 
are duplicated in the viral genome.  The moderate levels of transcripts detected 
at 6hpi  may  result from  a  duplicated  number of templates  available for  PCR. 
The key factor linking the ORFs in group III is that their transcription peaked at 
or after 24hpi.
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Expression  patterns  as  characterised  by  RT-PCR  can  be  divided  into  three  groups: 
IE/E,  E and L.  The ORFs examined and the size of their amplicons (in bp) are labeled. 
Expression pattern of individual viral gene is shown in the middle panel.  The panel on 
the right showed the effect of PAA treatment on viral gene transcription.
RNA - purified mRNA, cDNA - reverse transcribed mRNA, M - 100bp ladder, WB - water 
blank, number above the gel  images denotes the time when a sample were harvested 
e.g. 6 - 6h post-infection (6hpi).  PAA - PAA-treated HHV-6B-infected cells harvested at 
36hpi.  * denotes ORFs that were also analysed by microarrays.
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Regarding the genes in group I, U94 and U95 have been described as lE-genes 
(Mirandola et al.,  1998; Takemoto et al., 2001), suggesting that other gene in 
this  group  (B1,  B5  and  B9)  may  be  transcribed  with  the  same  kinetics. 
Therefore,  these  genes  were  further  analysed  for  IE  transcription  and  the 
results are presented in section 4.2.6.
U73  and  U57  were  respectively  classified  as  E-  and  L-genes  in  the  array 
analysis  and  their expression  profiles were confirmed  by  RT-PCR (see figure 
4.7).  The expression pattern of U73 and U57 closely resembled those in group 
II  and  group  III,  respectively.  If the  kinetics  were  classified  on  the  basis  of 
expression patterns then the genes in group II would be E genes, whereas the 
ones in group III would  be L genes.  The  E/L transcription was later validated 
using  RT-PCR.  The results showed that expression of all group  II genes was 
insensitive  to  PAA-treatment.  In  contrast,  group  III  genes  (except  U9)  were 
expressed  at  a  reduced  level  in  the  presence  of  PAA.  Hence,  the  kinetic 
classification  of E/L transcription  based  on  gene  expression  patterns  alone  is 
highly reliable (18/19, 94.7%).  These results suggest that the use of metabolic 
inhibitors for kinetic analysis helps define ‘borderline’ cases such as U9, but it is 
not  essential  providing  a  reasonable  number  of  time  points  are  used  for 
expression profiling.
4.2.6  Analysis of HHV-6B IE transcription.
I  next attempted  to  characterise  IE  transcription  using  HHV-6  arrays,  but the 
analysis was complicated by low or no signals from the viral probes.  The fact 
that  strong  signals  were  observed  for  the  host  probes  suggests  that  the 
hybridisation technique was working (data not shown).  Thus, the weak signals 
observed for the viral  probes were likely to be explained  by low levels of viral 
transcripts present in the CHX-treated sample.  RT-PCR offers a  much higher 
sensitivity  for the  detection  of  low  abundance  transcripts,  and  was  therefore 
employed for the analysis of IE transcription.
Expression  of  IE  genes  is  independent  of  de  novo  protein  synthesis.  Any 
transcript that is present in the CHX-treated sample is classified as an IE gene. 
However,  the  sensitivity  of  RT-PCR  means  that  non-IE  genes  may  become
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detectable in the CHX-treated sample if a large amount of cDNA, and/or a high 
number of PCR cycles, is used.  The conditions for the RT-PCR were therefore 
optimised  to  avoid  spurious  classification.  Four genes  (U90,  U95,  U27,  and 
U48) of known kinetic classes were used to test the specificity of the RT-PCR. 
Transcripts for the two  known  IE genes,  U90 and  U95  (Schiewe et al.,  1994; 
Takemoto et al., 2001), were detected in the CHX-treated sample, whereas U27 
(E; Takemoto et al., 2001) and U48 (L; Isegawa et al., 1998) remained negative 
(please  refer back to figure 4.1).  In  addition,  transcripts  of four other non-IE 
genes  (E -  U51  and  U69;  L -  U11  and  U65) were  not detected  in the  CHX- 
treated sample (see figure 4.8a).  Hence, the conditions used for RT-PCR are 
suitable for the specific detection of IE transcripts (see section 2.7.3 for details 
of the RT-PCR conditions).
As  the  name  implies,  IE  genes  are  expressed  immediately  after  infection. 
Therefore,  IE  analysis was  restricted  to genes with  a  peak of transcription  at 
6hpi.  The  limited  amount of RNA available from  CHX-treated  sample  meant 
that not every gene could be analysed.  For the array-profiled ORFs/intergenic 
regions  to  be  examined,  priority  was  given  to  candidates  that were  grouped 
closely to known IE genes such as U90.  In terms of the RT-PCR-profiled genes 
(section 4.2.5), six were tested for IE transcription.  Four were selected (group I: 
B1,  B5,  B9 and  U94) based  on the high  levels of their transcripts detected  at 
6hpi.  The other two, DR3 and U18 were tested as the former overlaps with B1, 
and the  latter has  previously been described  as an  IE gene  (Mirandola et al.,
1998).  Figure 4.8b depicts the RT-PCR results of 35 ORFs and five intergenic 
regions examined.
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a) Optimisation of RT-PCR conditions for IE gene analysis.
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b) Effect of CHX on HHV-6B transcription.
U3(284)  U4(295)  U12(353)  U35(223)  U37(257)  U39(5)(296)
M  Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  M
4°°bp   ^   '  fV 
300bp  J
> w   S   ”■ IKE
U15(248)
M  Ohpi  CHX  6hpi
U17(291)
Ohpi  CHX  6hpi
G17/18(299)  U18(284)  U19(303)  U20(285)
Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  M
500bp
300bp  2'-  *   '  '  ‘  *-
10‘Jbp  J
U42(3)(314)
M  Ohpi  CHX  6hpi
U73(328)  U83(243)  U91(326)  U94(303)  U94  M(450)
Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  M
500bp  ^ S U fflS
i  5  -  1   a  I
10°bp
U41(336)
M  Ohpi  CHX  6hpi
U42(5)(310)  U60(290)  U74(330)  U21(287)  G100/B9(300)
Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  M
400bp
300bp
200bp  2
j £ j
U78(249)
M  Ohpi  CHX  6hpi
U79(297)
0hp^C H )^6hpi
U80(292)  U81(327)  U82(300)  U85(322)
Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  M
400bp  £   ^   , /,= ;■  = 7-
300bp  J
B1 (160)
M  Ohpi  CHX  6hpi
B2(183)  DR3B(150)  B3(182)  U25(312)  U8(300)
Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  M
400bp 
2oobP   2-.
1  oobp  J r.-  j--’ .   w   ;
B5(129)  B6_O(102)  B7(148)  G86/90.2(262)G86/90.3(332) G91/B8(284)
M  Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  Ohpi  CHX  6hpi  M
400bp  ;
a)  The  results  showed  that  the  RT-PCR  conditions  employed  did  not  support  the 
amplification of known  E and  L  HHV-6 genes,  thereby confirming the specificity of this 
assay for studying  HHV-6  IE  transcription,  b)  Transcription  of  HHV-6B  genes  in  the 
presence of CHX (see section 2.7.3 for details).
The transcripts examined and the size of their amplicons (in bp) are labeled.
M - 100bp ladder; Ohpi and 6hpi - cDNA prepared from HHV-6B infected cells harvested 
at  Ohpi  and  6hpi,  respectively;  CHX  -  cDNA  prepared  from  CHX-treated,  HHV-6B 
infected cells harvested at 6hpi.
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Overall,  transcripts  derived  from  13  of  the  41  genomic  regions  tested  were 
transcribed  in  the  CHX-treated  sample.  For  the  array-profiled  genes,  the 
detection of B7,  U79 and G91/B8 (which corresponds to 5’ untranslated region 
of  U90)  under  IE  conditions  is  in  agreement  with  previously  published  data 
(Oster  and  Hollsberg,  2002;  Schiewe  et  al.,  1994;  Taniguchi  et  al.,  2000). 
Several  previously  unclassified  transcripts  including  B2,  U85,  G86/90.2  and 
G86/90.3 were also detected under IE conditions.  In contrast, previous studies 
have  classified  B3,  U39,  U42,  U73,  and  U81  as  IE  genes  (Mirandola  et  al., 
1998; Oster and Hollsberg, 2002) but their IE expressions were not detected in 
this study.  Since transcription of B3 was inhibited by PAA,  it was re-classified 
as a L gene.  The other four genes (U39, U42, U73 and U81) were assigned as 
E genes, on the basis that their transcripts were insensitive to PAA treatment in 
this study.
For the  RT-PCR  profiled  genes,  only the  transcripts of B1,  B5,  and  B9 were 
detected in the CHX-treated sample.  However, the  IE classification of B1  was 
complicated by its significant overlap with the 5’ end of DR3.  Thus, a new set of 
primers was designed to amplify the 3’  end  region which  is  unique to  DR3 to 
determine  if  the  two  ORFs  were  regulated  independently.  RT-PCR  results 
showed  that  the  DR3  transcripts  were  not  detected  under  IE  conditions, 
suggesting  that  B1  and  DR3  have  different  transcription  kinetics.  The  IE 
classification  of  B2  offered  further  support  to  our  evaluation.  B2  is  located 
immediately after B1  in the HHV-6B genome and both ORFs are transcribed in 
the same orientation.  The expression of B1  and  B2,  but not DR3,  in the CHX 
sample suggested that the former two were co-regulated at IE times.  Hence, 
the  detection  of B1  under  IE  conditions was  independent of DR3,  suggesting 
that the former is a bona fide IE gene.  DR3 was classified as a L gene, based 
on its inhibition by both CHX- and PAA-treatment.
Interestingly, B9 expression was inhibited by PAA, but this was not observed for 
B1  or B5.  The transcription kinetics of B9 do not follow a typical IE profile i.e. 
gene expression  is  independent of de novo protein synthesis as well as  DNA 
replication.  B9 was detected at IE times but maximal expression relied on DNA 
replication.  Therefore, it was tentatively classified as a biphasic gene i.e. I E/L.
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The absence of U94 transcript in the CHX sample was unexpected, as it has 
been  reported  as  an  IE  gene  (Mirandola  et  al.,  1998;  Oster  and  Hollsberg, 
2002).  The  U94  RT-PCR  was  repeated  with  the  primer  set  described  in 
Mirandola  et  al.,  1998;  however,  the  results  remained  negative.  Thus,  the 
discrepancy cannot be explained by the difference in sensitivity of the primers.
U18 transcripts were not detected in the CHX sample, and its expression was 
unaffected by PAA, hence it was classified as an E gene in this study.
4.2.7  Genes with biphasic transcription
The array analysis demonstrated that a subset of genes (B6,  U21,  U83,  U99, 
and G100/B9) appeared to be expressed in two distinct phases during infection. 
Relatively  high  levels  of transcripts were  detected  at  IE times  (6hpi) and  late 
times (48-60hpi), but were at minimal levels between the two peaks (12-36hpi). 
In light of the presence of relatively high levels of transcripts at 6hpi, all genes in 
the  biphasic  cluster  were  analysed  for  IE  transcription  except  for  U99  (the 
primers are 6A-biased).  Three of the four genes tested (B6, U21, and G100/B9) 
were present in the CHX sample.  Although U83 transcripts were undetectable 
in this study, the IE expression of U83 has been described (French et al., 1999). 
In addition, the PAA-induced  downregulation of B6,  U21  and  U83 observed in 
this study was in agreement with previously published data (French et al., 1999; 
Oster and Hollsberg, 2002).
As  mentioned  previously,  B9  transcripts  were  detected  at  IE  times  and  its 
second  peak  in  expression  at  late  times was  dependent on  DNA  replication. 
The kinetics of B9 is similar to that of the biphasic genes and therefore it was 
tentatively assigned as a biphasic gene.  Transcription kinetics of HHV-6 genes 
according to the array and RT-PCR data in this study are depicted in figure 4.9. 
The expression data generated in this chapter are compared to that of HHV-6A 
(U1102) (Yao et al., 2006) and HHV-6B (PL-1) (Oster and Hollsberg, 2002) and 
summarised in table 4.1.
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A schematic diagram showing the distribution and the kinetic classification of HHV-6B ORFs.  Predicted ORFs are shown as block arrows.  Probes 
to intergenic regions are shown as solid blocks.  The white solid blocks within the arrows represent introns.  The gene nomenclature, except for the 
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Table 4.1  Summary of the transcription kinetics of HHV-6 genes
ORF/lntergenic region HHV-6B (Z29)1 HHV-6A (U1102)2 HHV-6B (PL1)3
DR1 L L
DR2 ND
DR3 L
B1 IE
B2 IE
DR4 ND
DR5 ND L
DR6 L
B3 L IE
GB3/B4 L
B4 L L
B5 IE E
DR7 L
DR8 E L
LJ1 ND L
U1 ND
U2 ND IE L
U3 E IE
U4 E I E/E
U5 E I E/E
U7EX E L E
U6 E L
U8 E L E
U9 E L E
U10 E IE/E
U11 L L
U12 E I E/E L
U13 E I E/E
U14 E I E/E L
U15 E I E/E
U16 E I E/E
U17 E I E/E
G17/18 E
U18 E I E/E
U19 E I E/E
U20 E I E/E
U21 B I E/E L
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Table 4.1 (cont’)
ORF/lntergenic region HHV-6B (Z29)1 HHV-6A (U1102)2 HHV-6B (PL1)3
U22 L L L
U23 L L L
U24 ND I E/E
U24a
U25
E
E I E/E
U26 E I E/E
U27 E I E/E L
U28 E I E/E
U29 L L L
U30 L L L
U31 L L
U32 L L
U33 E L
U34 E L
U35 E L L
U36 E L L
U37 E L L
U38 E-L L
U39 E L L
U40 E I E/E
U41 E I E/E E
G41/42.1
G41/42.2
U42
E
E
E I E/E
U43 L L
U44 L I E/E
U45 L I E/E
U46 L L
U47 L I E/E L
U48 L L
U49 L L
U50 L L
U51 I E/E E
U52 L L
U53 L I E/E
U54 L L L
U55 L L
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Table 4.1 (cont’)
ORF/lntergenic region HHV-6B (Z29)1 HHV-6A (U1102)2 HHV-6B (PL1)3
U56 L L
U57 L
U58 ND L L
U59 L L
U60 E L
U61 ND L
U62 E L
U63 E I E/E
U64 E L
U65 L L
U66 L L
U67 E L
U68 L L
U69 E I E/E E
U70 E I E/E
U71 E L
U72 L L
U73 E I E/E E
U74 E I E/E
U75 I E/E L
U76 L L
U77 I E/E L
B6 B IE
B7 IE IE
U78 E L
U79 IE IE
U80 E IE
U81 E I E/E IE
U82 E L
U83 B L
U84 E IE
U85 IE I E/E
U86 ND IE IE
G86/90.1 L
G86/90.2 IE
G86/90.3 IE
U87 I E/E I E/E
U89 I E/E
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Table 4.1 (cont’)
ORF/lntergenic region HHV-6B (Z29)1 HHV-6A (U1102)2 HHV-6B (PL1)3
U90 IE
U91 E I E/E
G91/B8 IE
B8 L L
U94 E L IE
U95 IE IE
U96 L L
G96/97 L
U97 L L
U98 ND
U99 B L
U100 L L L
G100/B9 B
B9 B
1   - according to the data of this chapter, 2 - (Yao et al., 2006), 3 - (Oster and 
Hollsberg, 2002).  IE - immediate early,  E- early,  L - late,  B - biphasic,  ND - 
not determined.
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4.3  Discussion
The HHV-6 arrays created in Chapter 3 were used for the profiling of the HHV- 
6B  lytic transcription  over a  60h  period  (<one  replication  cycle)  (Black et al., 
1989).  Of the 97 unique ORFs that have been annotated for the HHV-6B (Z29) 
genome  (Dominguez  et  al.,  1999),  the  expression  pattern  and  kinetics  of 93 
HHV-6B ORFs (except U2, U24, U58, and U86) and ten intergenic regions were 
characterised in this study.  The array analysis charted the expression pattern 
of  73  HHV-6B  ORFs  and  8  intergenic  regions,  with  the  remaining  data 
supplemented from  RT-PCR analyses.  Expression profiling reveals the timing 
at which transcription is initiated for individual HHV-6B transcripts, which forms 
the basis for kinetic classification.  The analysis of HHV-6B transcription in the 
presence  of  inhibitors  of  either  protein  synthesis  (CHX)  or  DNA  replication 
(PAA) further refined and validated the kinetic classification.  In this study, the 
criteria used for assigning  HHV-6B transcripts to different kinetic classes were 
as follows:
1)  IE  -   genes  that  are  transcribed  immediately  after  infection  (at  6h  post­
infection,  or 6hpi) with their transcripts detectable in infected-cells treated with 
CHX,
2) E -  genes that reach peak transcription before 24hpi, with their transcription 
inhibited by CHX- but not by PAA-treatment.
3)  L  -   genes  transcribed  at  late  times  during  infection  (>24hpi)  and  their 
transcription inhibited by PAA treatment.
The data presented in this chapter demonstrated that the expression patterns of 
HHV-6B genes can  be broadly divided into three main clusters,  reminiscent of 
the  classical  three-wave  expression  cascade:  1)  the  initial  expression  of  IE 
proteins for modifying cellular environment to facilitate the transcription of viral 
genome,  2)  expression  of  E  proteins  to  initiate  viral  DNA  replication,  3)  and 
expression of L proteins for viral assembly.
4.3.1  IE genes
Eight  HHV-6B  ORFs  (B1,  B2,  B5,  B7,  U79,  U85,  U90,  and  U95)  and  three 
intergenic  regions  (G86/90.2,  G86/90.3,  and  G91/B8)  were  classified  as  IE
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genes.  The  detection  of  transcripts  of  B7,  U79,  U90,  G91/B8  (which 
corresponds to the 5’ UTR of U90) and U95 under IE conditions is in agreement 
with  previously  published  data  (Oster  and  Hollsberg,  2002;  Schiewe  et  al., 
1994;  Taniguchi  et al.,  2000).  The function of most known  IE genes remains 
poorly characterised.  U79 encodes four splice variants and the gene products 
were implicated in the viral DNA replication complexes (Taniguchi et al., 2000). 
U85  may  be  involved  in  the  immunomodulation  of  the  infected  cells  as  its 
counterpart in  KSHV has  been  shown to suppress the activation of basophils 
and natural killer cells in vitro (Shiratori et al., 2005).  U90 encodes IE1  which 
has been shown to be a transactivator (Schiewe et al.,  1994).  B1, B2, B5 and 
B7 are unique to  HHV-6B among all human  herpesviruses (Dominguez et al.,
1999).  Their  functions  have  yet  to  be  defined,  however,  it  is  believed  that 
variant-specific genes evolve to help the virus to adapt to its specific biological 
environment  (Davison  et  al.,  2002).  The  IE  classifications  of  these  genes 
suggest that they may perform functions that are important for facilitating initial 
infection, e.g. transactivation or immunomodulation, which is consistent with the 
possible functions of other IE genes in the group.  As for the two IE intergenic 
transcripts: G86/90.2 and G86/90.3, they are located in a region of the HHV-6B 
genome with  CpG  suppression  (Dominguez et al.,  1999), which  is considered 
as  a  characteristic  feature  of  major  IE  (MIE)  region  of  betaherpesviruses. 
Indeed,  the  IE  transcription  of two  ORFs  (U86  and  U90)  located  in  the  MIE 
region has been demonstrated (Schiewe et al.,  1994).  Further work is required 
to characterise these two IE intergenic transcripts.
4.3.2  E genes
Forty  four  HHV-6B  ORFs  and  three  intergenic  regions  were  classified  as  E 
genes.  These  included  genes  that  encode  enzymes  that  are  involved  in 
nucleotide  metabolism  such  as  the  phosphotransferase  (U69),  alkaline 
exonuclease  (U70)  and  a  component of the  helicase-primase complex  (U74) 
(section  1.2.7).  Other viral  proteins  that  are  thought  to  be  involved  in  DNA 
replication  include  the  polymerase  processivity factor  (U27),  the  major  DNA- 
binding  protein  (U41),  the  origin  binding  protein  (U73),  and  uracil-DNA 
glycosylase (U81).  In  addition,  the  E kinetics described for U7,  U8,  U9,  U42, 
and  U51  is  in  agreement with  previously  reported  data  (Menotti  et al.,  1999;
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Oster and  Hollsberg,  2002;  Rapp  et al.,  2000;  Taniguchi  et al.,  2000).  Two 
extra mRNA species (G41/42.1  and G41/42.2) originated from near the or/Lyts 
region were detected.  Considering their locations in the viral genome, plus the 
fact that they were expressed with E-gene kinetics, suggest that they may play 
a role in initiating DNA replication.
4.3.3  L genes
Thirty  four  HHV-6B  ORFs  and  three  intergenic  regions  were  classified  as  L 
genes.  The function of 23 ORFs has been described (see table 1.3).  Except 
for U43 and  U45, which encode a component of the helicase-primase complex 
and  viral  dUTPase,  respectively,  the  other  21  ORFs  are  thought  to  encode 
proteins  that  are  required  for  virus  assembly.  These  include  six  viral 
glycoproteins  (U22,  U23,  U47,  U48,  U72,  and  U100),  five  tegument  proteins 
(U11,  U30,  U31,  U50,  and  U65),  four  capsid  proteins  (U29,  U32,  U56,  and 
U57),  three  virion-associated  proteins  (U46,  U49,  and  U54)  and  the  viral 
proteinase (U53) for capsid  processing. As for the  intergenic regions,  GB3/B4 
and  G96/97 were classified  as L genes.  The fact that they shared the same 
classification  with  the  ORFs  which  flank  them  (B3  and  B4,  U96  and  U97, 
respectively),  suggested  that  these  genes  were  co-regulated.  Interestingly, 
G86/90.1  is  located within  the  MIE  region  but  it exhibits transcription  kinetics 
characteristic of L gene.  It is tempting to speculate that this mRNA species may 
play a role in regulating the transcription of IE genes during later stages of lytic 
replication.
4.3.4  Biphasic genes
Four HHV-6B ORFs (B6, B9, U21  and U83) plus an intergenic region (G100/B9) 
were classified as biphasic genes.  Expression profile of this group of genes is 
characterised  by  the  detection  of  their  transcripts  under  IE  conditions,  but 
atypically  for  IE  genes,  their  maximal  expression  was  dependent  on  DNA 
replication.  Apart from U83, the transcripts of B6,  B9,  U21  and G100/B9 were 
detected in the CHX sample by RT-PCR.  The discrepancy between array and 
RT-PCR results for U83 may be explained by the poor efficiency of the primers 
used for this particular PCR.  However, the presence of U83 transcripts in CHX-
206Temporal Expression of HHV-6B
treated HHV6-infected cells has previously been reported (French et al.,  1999). 
The  array  analysis  reported  here  also  showed  that  transcription  from  these 
genomic regions was inhibited by PAA, and the reduction in B9 transcripts was 
validated by RT-PCR.  The PAA inhibition on transcription of B6, U21  and U83 
observed in this study was consistent with previously published data (French et 
al., 1999; Oster and Hollsberg, 2002; Zou et al., 1999).
One  possible  explanation  for  the  biphasic  nature  of these  transcripts  is  that 
these  regions  encode  transcript  variants  that  are  controlled  by  different 
promoters,  similar  to  the  report  on  the  biphasic  regulation  of the  HHV-6  IE 
region  (Schiewe  et  al.,  1994).  Alternatively,  the  expression  profile  for  the 
biphasic  genes  may  be  a  result  of  the  confounding  presence  of  virion- 
associated  RNAs.  The  packaging  of  viral  transcripts  in  virions  has  been 
observed in all three classes (a-, |3-, y-) of human herpesviruses (Bechtel et al., 
2005;  Bresnahan  and  Shenk,  2000;  Sciortino  et  al.,  2001).  These  virion- 
associated transcripts are characterised by their detection at early times during 
infection (Bechtel et al., 2005; Bresnahan and Shenk, 2000).  In addition, these 
genes are transcribed at maximal levels only at the time of viral assembly i.e. 
late times (Bechtel et al., 2005;  Bresnahan and Shenk, 2000).  These features 
are strikingly similar to those of the biphasic transcripts described in this study. 
Indeed,  the  confounding  effect of virion-associated  RNAs on  the transcription 
profiling  of  KSHV  by  microarrays  has  been  reported  (Bechtel  et  al.,  2005). 
Several  KSHV  lytic  genes  that  are  normally  expressed  at  late  times  during 
infection  were  detected  in  cells  shortly after infection.  The  early detection  of 
these  genes was  due  to  the  presence  of their corresponding  transcripts  that 
were delivered  into the cells with the virions, rather than a consequence of de 
novo  expression.  The  association  of the  biphasic  transcripts  defined  in  this 
study with the HHV-6B virion remains to be determined (see chapter 6 for future 
experiments).
The  functional  significance  of most virion  RNAs  is  not  immediately  apparent, 
however,  it is generally believed that viruses do not encode functions that are 
unnecessary.  It has  been  suggested  that virion  RNAs encode proteins which 
allow the modification of the cellular environment immediately after infection to
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facilitate viral  infection  (Bechtel et al., 2005).  This hypothesis is supported  by 
the  finding  of  virion  RNAs  encoding  anti-apoptotic  (K2  and  K7)  and 
immunomodulatory  proteins  (K2,  K4  and  K6)  in  KSHV.  As  for the  HHV-6B 
biphasic  genes,  U83  is  the  only  one  where  its  function  is  relatively  well 
characterised.  U83 is a spliced gene (French et al.,  1999) which encodes two 
isoforms of viral chemokines  (Dewin et al.,  2006).  It has been shown that,  in 
HHV-6A,  the  full-length  U83  proteins  chemoattracted  leukocytes  which  may 
facilitate  virus  dissemination  (Dewin  et  al.,  2006).  Interestingly,  the  shorter 
version of U83 proteins (originated from the spliced  gene) also bound to their 
target  receptors  on  leukocytes  but did  not  initiate  chemoattraction.  Hence,  it 
was hypothesised that the spliced version may compete and block the binding 
of cellular chemokines to the leukocytes,  leading to negative-modulation of the 
immune  response  (Dewin  et  al.,  2006).  U21  may  also  play  a  role  in
immunomodulation,  as its  homologue in  HHV-7 encodes a glycoprotein which 
has been shown to divert MHC class I  molecules to lysosomes (Hudson et al., 
2003;  Hudson et al., 2001).  The association of B6, B9, and G100/B9 with U83 
and  U21  suggested  that  their  products  may  be  involved  in  modulating  the 
immune response.
4.3.5  Unclassified genes
Transcription kinetics of three HHV-6B ORFs (U75, U77 and U38) could not be 
defined.  The array analysis grouped U75 and U77 close to other IE genes e.g. 
B7 and  U90.  However, they were not individually analysed for IE transcription 
by RT-PCR,  hence their I E/E classifications.  The array analysis demonstrated 
the  suppression  of  U38  transcription  by  PAA.  However,  this  was  not 
corroborated by the RT-PCR analysis, which showed that U38 transcripts were 
present in both untreated and PAA-treated samples.  The discrepancy between 
the array and RT-PCR results may be explained by the non-quantitative nature 
of conventional  PCR.  The amplification of U38 amplicons from both samples 
suggests  that they  contained  U38  transcripts  at  relatively  high  levels  initially. 
However, any fold difference between the two samples can only be accurately 
measured by real-time PCR.  In fact, it has been demonstrated, with the use of 
real-time quantitative PCR, that U38 transcription was inhibited in the presence 
of DNA synthesis inhibitors (Oster and Hollsberg, 2002).  It seems contradictory
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that  U38,  which  encodes  the  viral  DNA  polymerase,  achieved  its  maximal 
expression  after  DNA  replication.  It  is  possible  that  U38  is  expressed  at  a 
constant  level  before  DNA  replication  and  becomes  fully  activated  at  later 
stages in  infection.  However,  the advantage of this transcription  regulation  is 
not immediately apparent.
Alternatively, the transcriptional activities of HHV-6B U38 may be similar to that 
of the HCMV pol/gB region.  It has been shown that, in HCMV, the gene cluster 
consisting of viral DNA polymerase and glycoprotein B encodes a series of co­
terminal  transcripts  (Smuda  et  al.,  1997).  The  current design  of the  HHV-6 
arrays  does  not distinguish  between  co-terminal  transcripts.  Any co-terminal 
transcripts  arising  from  the  pol/gB  region  in  HHV-6  would  hybridise  with  the 
array probes corresponding to either U38 (pol) or U39 (gB), therefore affecting 
the  reliability  of  the  gene  expression  measurements  for  these  two  ORFs. 
Expression kinetics of individual ORFs within any co-terminal transcripts can be 
unambiguously classified by Northern blot analysis.
4.3.6  Comparative analysis of HHV-6A transcription patterns
After  this  study  was  completed,  a  microarray  analysis  of  HHV-6A  gene 
expression was published (Yao et al., 2006).  The microarrays employed in Yao 
and  colleagues  (2006)  contained  PCR-amplified,  full-length  HHV-6  ORFs  as 
array probes (Ghedin et al., 2004).  In contrast to the HHV-6 arrays presented in 
this thesis, the arrays produced by Ghedin and colleagues (2004) were HHV-6A 
biased  i.e. the majority of viral array probes were amplified from HHV-6A DNA 
(Ghedin et al.,  2004).  HHV-6A gene expression  in a human T cell-line JJhan 
was  monitored  over  a  7-day  (d)  time  course,  which  consisted  of seven  time 
points (5h, 8h, 12h, 24h, 3d, 5d and 7d).
In the study by Yao and colleagues (2006), each ORF was assigned to one of 
the following three classes: IE, IE/E and L (Yao et al., 2006).  However, there is 
insufficient  information  explaining  how  different  ORFs  were  assigned  to  a 
particular kinetic class.  Of the 8 IE genes described, only U84 was analysed for 
IE transcription (cells infected in the presence of CHX) by RT-PCR.  The same 
IE RT-PCR analysis examined two other ORFs (U12 and U67) outside of the IE
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cluster, and arguably,  amplicons were detected in the CHX-treated sample for 
both  U12  and  U67  (albeit a faint band).  It should  be noted that the template 
used for the IE RT-PCR assay had been amplified by in vitro transcription.  It is 
likely  that  the  amplification  step  has  inadvertently  affected  the  relative 
abundance  of the  viral  transcripts  and  therefore  the  RT-PCR  assay  may  be 
prone to error.  Nevertheless, the IE classification for 2 out of 6 ORFs analysed 
(U79 and U95) in both studies was in agreement.
About 30%  of the  ORFs were  assigned  in  a  combined  IE/E  grouping  but not 
separate IE and  E components in the study by Yao et al., (2006).  Hence, it is 
difficult to make a direct comparison between the results of the two studies for 
these genes.
There was a strong agreement on the classification of L genes between the two 
studies (25 out of 29 ORFs analysed in both studies).  It is well recognised that 
the  biological  properties  between  the  HHV-6  variants  are  distinct,  and  it  has 
been  hypothesised  that  the  difference  in  IE  gene  expression  may  be 
responsible  for  the  differences  (Oster  and  Hollsberg,  2002).  Products  of  L 
genes are generally involved in viral assembly and packaging; a process that is 
conserved across all herpesviruses, which explains the high degree of similarity 
between expression kinetics of the L genes for both HHV-6 variants.  Note that, 
however, viral gene expression in the presence of DNA synthesis inhibitor was 
not examined in the study by Yao and colleagues (2006).
The  difference  in  experimental  design  may  be  responsible  for  some  of  the 
discrepancies  between  the two  studies.  In  the  study  by Yao and  colleagues 
(2006), the transcriptional pattern of HHV-6A genes was profiled over a 7d time 
course.  By day 5 and 7 post-infection, it is likely that the cell culture would have 
consisted of a mixed population of HHV-6A-infected cells at different stages of 
the lytic cycle, which would interfere with the viral transcriptome analysis.
Furthermore,  for  a  typical  two-colour  microarray  experiment,  the  expression 
ratio of a gene is derived from the intensity of Cy5- divided by that of the Cy3- 
signal of the corresponding spot on the arrays.  For this reason, the universal
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reference that was employed in my study contained spike-in HHV-6 transcripts. 
This produced a controlled  Cy3 signal as a baseline for calculating expression 
ratios for the viral array probes.  Since the same universal reference was used 
in  each  array  hybridisation,  data  normalisation  between  different arrays could 
be achieved.  In the study by Yao and colleagues (2006), the expression data 
were generated  by hybridising  RNA samples obtained from virus-infected and 
uninfected cells.  It is unclear how the expression ratio was determined as there 
would be no or low Cy3 signal from the viral array probes.
4.3.7  Comparative analysis of HHV-6B transcription patterns
Transcription  kinetics of 35 ORFs of HHV-6B  (PL-1)  have  been studied  using 
real-time PCR by Oster and colleagues (2002).  The kinetics of two genes (U2 
and U58) were not determined in our study but for the remaining 33 genes, the 
results were  in  agreement for about two thirds of the genes.  The genes that 
were classified  differently in the two studies  included  B3,  B5,  U12,  U14,  U27, 
U35,  U36,  U37,  U39,  U81  and  U94.  The  difference  in  experiment  design, 
detection methods, virus strains, and cell types used between the studies may 
have accounted for the inconsistent classification in some cases.  Transcription 
kinetics of U12 and U94 are discussed further as there are more published data 
available on their transcription.
There are conflicting data on the expression kinetics of U12 in the literature.  It 
has been classified into all three kinetic classes; for example, IE gene in Yao et 
al., (2006), E gene in Donati et al., (2005), and L gene in Isegawa et al., (1998). 
The IE classification of U12 is questionable.  As mentioned in section 4.3.6, the 
IE RT-PCR assay described in Yao et al., (2006) may not be reliable due to the 
use of amplified RNA.  The absence of U12 transcripts under IE conditions has 
been described in three independent studies (De Bolle et al., 2005b; Isegawa et 
al., 1999; Oster and Hollsberg, 2002).  Although U12 was classified as a L gene 
in  Oster  et  al.,  (2002)  the  authors  acknowledged  that  the  inhibition  of  its 
expression  by  PAA was  unconvincing.  In  my  study,  U12  was  absent  in  the 
CHX-treated  sample.  Both  the  array  and  RT-PCR  analysis  showed  that  its 
expression was  insensitive  to  PAA treatment.  The  report  by  De  Bolle  et al., 
(2005) described similar findings.
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U94 has been described as an IE gene in the literature (Mirandola et al., 1998; 
Oster  and  Hollsberg,  2002)  but  its  IE  classification  is  not  supported  by  the 
results  in this chapter.  RT-PCR using two different sets of primers (including 
the same set of primers used in the study by Mirandola et al., (1998)) failed to 
detect  U94  expression  under  IE  conditions  and  similar  findings  have  been 
reported  by  Rapp  et  al.,  (2000)  The  low  abundance  of  U94  transcripts  in 
infected-cells  is  well  recognised  (Rapp  et  al.,  2000;  Rotola  et al.,  1998)  and 
therefore the difference in the sensitivities of RT-PCR methods may have led to 
the discrepancy.
4.3.8  Genes that are representative of different kinetic classes
The understanding of transcription kinetics of viral genes allows one to examine 
the  stages of lytic  replication  cycle.  Most antiviral  treatments for herpesvirus 
infection  act  by  inhibiting  viral  DNA  replication.  The  in  vitro  efficacy  of  an 
antiviral drug can be evaluated  using simple RT-PCR assays to determine the 
level of inhibition on L gene expression, as has been demonstrated in the report 
by  De  Bolle  and  colleagues  (2004a).  However,  the  kinetic  classification  of 
some HHV-6 genes varies between different studies e.g. U12, and therefore the 
use of these ‘variable’ genes should be avoided.  Below is a list of genes that 
has been consistently defined  in the same kinetic class (see table 4.1  and the 
cited reference below):
IE -  U90  (Isegawa  et al.,  1998;  Schiewe  et al.,  1994),  U95  (Takemoto  et al., 
2001);
E-U41  (Mirandola etal., 1998), U51, U69;
L- U11, U22, U23, U29, U30, U54, and U100 (Mirandola etal., 1998).
The fact that their kinetic classification  are consistent among  different studies 
suggests that their transcription  kinetics are conserved  regardless of the virus 
variants,  strains  or  cell-lines  used.  Hence,  these  genes  represent  the  ideal 
markers for determining the states of HHV-6 lytic replication.
In  summary,  the  HHV-6  arrays  have  been  applied  to  characterise  the 
expression  profile  of  HHV-6B  in  a  CD4+   human  T  cell-line  SupT1.  I  have 
defined  the  HHV-6B  genes  into  different  kinetic  classes,  based  on  their
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expression  profiles,  and  the  results  were  largely  in  agreement  with  the 
published  data.  The  array analysis  has  provided  information  on the possible 
function  of  some  uncharacterised  genes,  based  on  their  associations  with 
genes of known function.  Furthermore, ten mRNA species originating from the 
intergenic regions of the  HHV-6B genome were detected, transcription of nine 
of which  was  verified  by  RT-PCR.  The  data  described  in  this  study  would 
provide useful leads to facilitate further research into the functional genomics of 
HHV-6B.  Furthermore,  the  incorporation of host probes on the  HHV-6 arrays 
allows future studies on the effect of HHV-6 infection on host gene expression.
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4.4  Summary of Chapter 4
1.  Cluster analysis of the  HHV-6 array data grouped all the time  points in 
the expected  order i.e.  6 to 60hpi,  and the replicates were also placed 
right  next  to  each  other,  indicating  that  sample  identification  by 
expression profile is reliable.
2.  In support of the previous statement, the two replicates of sample PAA 
were also correctly differentiated from that of the 36hpi sample by Cluster 
analysis.
3.  Like  other  herpesviruses,  HHV-6B  lytic  replication  proceeds  through  a 
temporal cascade.
4.  Ninety three HHV-6B ORFs were kinetically classified.
5.  Genes  of  similar  putative  function  were  grouped  together,  suggesting 
that their expression is co-regulated.
6.  Transcripts  corresponding  to  ten  different  HHV-6B  integenic  regions 
were detected.
214Chapter 5
Characterisation of the Molecular Biology and Gene 
Expression of HHV-6 Integration
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5.1  Introduction
One  of the  characteristics  that  define  herpesviruses  is  their  ability to  remain 
latent  and  persist  lifelong  in  their  hosts  (see  section  1.2.17,  Roizman  and 
Pellett,  2001).  However,  some  herpesviruses  exhibit  an  atypical  form  of 
persistence  in  which  the  viral  genome,  despite  its  relatively  large  size, 
integrates into host chromosomes (chr).  To date, chromosomal integration has 
been demonstrated in three herpesviruses:  EBV,  Marek’s disease virus (MDV) 
and HHV-6.  The association of EBV DNA with cellular DNA was suggested as 
early  as  1972  (Nonoyama  and  Pagano,  1972).  Subsequently,  numerous 
studies  have  demonstrated  that  chromosomal  integration  can  occur  in  EBV- 
infected  cell  lines  (Kieff  and  Rickinson,  2001)  but  in  vivo  evidence  remains 
elusive.  Hence,  it is  believed  that integration  is  not a  regular feature of EBV 
infection  (Kieff and  Rickinson,  2001).  In  contrast,  the  fact that chromosomal 
integration in  vivo was observed for MDV (Delecluse et al.,  1993) and  HHV-6 
(Clark et al., 2006; Daibata et al.,  1999; Luppi et al.,  1993; Tanaka-Taya et al., 
2004)  indicated  that the  phenomenon  may be  more relevant to the biology of 
both of these viruses.
Before reviewing the current data on MDV and HHV-6 integration, it is useful to 
begin  with  a  brief  introduction  on  the  two  techniques  that  are  commonly 
employed for studying the phenomenon: fluorescent in situ hybridisation (FISH) 
and  Gardella  gel  analysis.  The  use  of  FISH  allows  one  to  locate  a  DNA 
sequence  of interest on  chromosomes  (Pinkel  et  al.,  1986).  It works  on  the 
same principle as  Northern blotting and  microarrays, namely the propensity of 
duplex formation between two complementary ssDNA sequences.  A sequence 
of interest (in  this  case,  viral  DNA)  is fluorescently  labeled  and  subsequently 
hybridised  with  metaphase  chromosomes  that are fixed  onto  a  glass slide  (a 
metaphase spread).  The binding of the fluorescent probes to the targets leads 
to the “painting” of the corresponding site(s) on chromosomes, thus allowing the 
mapping  of  the  sequence  of  interest  on  chromosomes  (see  figure  5.1).  It 
should  be noted that the use of FISH for studying herpesvirus integration may 
be  complicated  by  the  casual  association  of  viral  episomes  with  host 
chromosomes  in  latently-infected  cells,  resulting  in  the  random  “painting”  of
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chromosomes.  In  contrast,  for  a  genuine  case  of  virus  integration,  the 
integrated  DNA sequences should  produce symmetrical fluorescent signals at 
the  same  chromosomal  site(s)  in  the  majority  of  the  chromosomes  of  the 
metaphase spread.
Figure 5.1  FISH analysis of HHV-6 integration
FISH  image  of  a  metaphase  spread  prepared  from  a  bone  marrow  sample 
showing HHV-6 integration (green arrow) at chr17p13.3.  The red signals mark 
the telomeric regions of the long arm of chr17.
Adapted from Clark et al., (2006).
Regarding  Gardella  gel  analysis,  the  method  was  developed  for  separating 
episomal and linear herpesvirus DNA molecules from host chromosomes by gel 
electrophoresis  (Gardella  et  al.,  1984).  The  detection  of  different  forms  of 
herpesvirus  genome  provides  an  indication  of the  states  of infection,  on  the 
basis that episomal DNA is associated with latent infection, whereas linear DNA 
is  associated  with  virion  DNA  i.e.  lytic  infection  (Roizman  and  Knipe,  2001). 
Cells harbouring herpesvirus DNA molecules are gently lysed in the well of an 
agarose gel to  prevent the  shearing  of DNA due to the  mechanical  handling. 
The  released  DNA is then  resolved  by  electrophoresis,  followed  by Southern
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blotting  using  labeled  probes representing viral  DNA sequences to identify the 
different  forms  of  herpesvirus  genomes.  Figure  5.2  depicts  the  results  of  a 
typical  Gardella  gel  analysis.  The  extremely  high  molecular  weight  of  the 
chromosomal  DNA  means  it  is  trapped  in  the  wells  of the  gel,  whereas  the 
relatively small  size of herpesvirus  DNA can  enter the gel.  In addition,  linear 
viral  genomes  migrate  considerably  faster  than  their  episomal  counterparts, 
thus allowing the differentiation between lytic and latent replication.
Figure 5.2  Gardella gel analysis of herpesvirus-infected cells
Wells Wells
circular c irc u la r
Gardella gel  image  showing  the  detection  of linear and  episomal  DNA  in  cell 
lines  infected  with  MDV or EBV.  The  probes can  detect both  MDV and  EBV 
DNA.  MDV-transformed cell-lines:  NTC-2,  CU40,  CU25,  CU12,  RP19,  MSB1, 
the former four contain linear MDV DNA.  EBV-transformed cell-line: Raji. 
Adapted from Delecluse and Hammerschmidt, (1993).
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MDV is an avian, oncogenic alphaherpesvirus which causes lymphoproliferative 
diseases  in fowls  (reviewed  in  Osterrieder et al.,  2006).  The size of the viral 
genome is about 170kbp.  MDV integration was first discovered in six cell lines 
derived  from  Marek’s  disease  lymphoma  of chickens  and  turkeys  (Delecluse 
and Hammerschmidt, 1993), and was later demonstrated in primary T cells from 
chicken  lymphomas  (Delecluse  et  al.,  1993).  The  virus  preferentially  infects 
CD4+  T cells (Osterrieder et al., 2006) and  remains latent as episomes and/or 
integrated  genomes  (Delecluse  and  Hammerschmidt,  1993;  Delecluse  et  al., 
1993).  FISH analysis revealed that integrated MDV DNA was present in a wide 
distribution of host chromosomes but often mapped to the telomeric regions in 
all identifiable chromosomes (Delecluse and Hammerschmidt, 1993).
In  the  case  of  HHV-6  integration,  it  was  first  identified  in  three  patients  all 
suffering  from  different  diseases  (B  cell  lymphoma(BCL),  Hodgkin’s 
disease(HD) and multiple sclerosis(MS)) (Luppi et al.,  1993).  HHV-6 DNA was 
detected in uncultured PBMCs of all three subjects by Southern blot analysis -  
an indication of high viral  loads in their PBMCs, and which turned out to be a 
hallmark of individuals with  HHV-6  integration.  Total  DNA obtained from the 
PBMCs of all three subjects was digested with rare-cutting restriction enzymes, 
resolved  by pulse field gel electrophoresis (PFGE), and analysed by Southern 
blotting.  The analysis  revealed the  presence of HHV-6  DNA fragment that is 
larger than a unit-length viral genome.  Thus,  HHV-6 DNA in the PBMCs of all 
three subjects was likely to be integrated.  FISH analysis of phytohemagglutinin- 
stimulated  mononuclear cells from  all  three  patients was  later conducted  and 
confirmed the presence of integrated HHV-6 sequences at chr17p13 in all three 
cases (Torelli et al.,  1995).  Restriction fragment length  polymorphism (RFLP) 
analysis  revealed  that  the  integrated  viral  sequences  of  all  three  cases 
belonged  to  variant  B.  Further  characterisation  on  HHV-6  integration  of the 
BCL patient revealed that the site of integration is close to or within telomeric 
regions of the short arm of chr17 (chr17p13.3) (Morris et al., 1999).
Subsequently,  a  case  of  possible  vertical  transmission  of  integrated  HHV-6 
DNA was  reported  in  1998  (Daibata  et al.,  1998a).  HHV-6B  integration  was 
identified  in  an  83y  old  woman  with  acute  lymphoblastic  leukaemia  and  the
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integration  site  was  mapped  to  chr1q44.  Further  analysis  revealed  that 
integrated HHV-6 DNA was also present in the subject’s son and granddaughter 
at  the  same  chromosomal  site  (chr1q44),  and  that  all  integrated  sequences 
were of the same variant type  (HHV-6B).  Skin fibroblasts from the son were 
later analysed by FISH and confirmed the presence of HHV-6 DNA at chr1q44, 
suggesting the germ  line transmission of HHV-6 DNA (reply to  Hermouet and 
Minvielle,  2000).  The  same  group  later  reported  another  case  of  possible 
vertical  transmission  of  integrated  HHV-6  (Daibata  et  al.,  1999).  Integrated 
HHV-6B sequences were identified in three members of the same family.  The 
integration sites were mapped to chr22q13 for the mother (a 58y old Japanese 
woman with Burkitt's lymphoma) and chr1q44 for the father (a healthy, 68y old 
Japanese  man).  Interestingly,  the  integrated  HHV-6  sequences  identified  in 
their daughter (a healthy,  35-year-old Japanese woman) were mapped to both 
chr22q13  and  chr1q44,  representing  a  possible  case  of  chromosomal 
transmission of HHV-6 genomes.
Further evidence on vertical transmission of integrated  HHV-6 sequences was 
reported  in  2004  (Tanaka-Taya  et  al.,  2004).  In  a  PCR  survey  of  human 
herpesvirus infection in 7566 PBMC samples from 2332 individuals, high HHV-6 
loads  were  persistently  detected  in  PBMCs  obtained  from  five  individuals. 
HHV-6 DNA in four individuals was typed as variant B and the remaining case 
was variant A.  All five subjects were  not related.  Subsequently,  PBMC from 
family  members  of  these  five  individuals  were  examined  and  identified  five 
additional  subjects  with  high  HHV-6  loads.  For two  members  of one  of the 
families,  HHV-6 DNA was detected  in a wide range of tissues including throat 
swabs, buccal mucosa swabs and hair roots, suggesting that HHV-6 integration 
is present in the germ line.  FISH analysis was conducted on PBMCs collected 
from two consenting families  (four subjects), which confirmed the presence of 
HHV-6  DNA at chr22q13  in  all four cases.  Integrated  HHV-6  DNA in  all four 
subjects  was  typed  as  HHV-6B.  No  sample  was  available  from  the  other 
families for experimental verification of HHV-6 integration.
It has become clear that individuals with HHV-6 integration are characterised by 
the  presence  of persistently  high  HHV-6  loads  in  their  PBMCs.  Two  recent
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studies have demonstrated that the detection of high viral loads in sera is also a 
feature of HHV-6 integration  (Ward et al.,  2006; Ward et al., 2005b).  Prior to 
the  publication  of  these  reports,  the  detection  of  HHV-6  DNA  in  sera  was 
generally considered as a consequence of active infection, as HHV-6 DNA can 
often  be  detected  in  serum  collected  during the  acute  phase  of infection  but 
very  rarely  during  the  convalescent  phase  (Chiu  et  al.,  1998;  Ward  et  al., 
2005b).  However,  for  an  individual  with  germ  line  HHV-6  integration,  it  is 
conceivable that HHV-6 DNA is always present in serum.  Since HHV-6 DNA is 
present in every cell of the body, the passive release of DNA into serum from 
the  degraded  cells  is  possible  (Ward  et al.,  2006).  In  a  survey  investigating 
HHV-6  DNA  in  sera  obtained  from  children  with  neurological  disorders,  high 
levels  of  HHV-6  DNA  were  detected  consistently  in  all  the  serum  samples 
obtained from three children  (Ward  et al.,  2005b).  The initial diagnosis for all 
three  children  was  congenital  HHV-6  infection.  Tests  on  their  mother’s  sera 
revealed  that high  HHV-6  loads were present in  every serum sample.  These 
data suggest that all three families represent possible cases of inherited HHV-6 
integration, although this has not been experimentally verified.  The same study 
also identified a possible case of HHV-6 integration in a 23y old male with EBV 
encephalitis.  HHV-6 DNA was detected in all six sera collected over ~3-month 
period.  A follow up study on this patient,  alongside five other individuals with 
possible HHV-6 integration, showed that high HHV-6 loads were detected in all 
of their whole blood or serum samples (Ward et al.,  2006).  The mean  HHV-6 
loads  (logio  copies/mL)  in  whole  blood  and  serum  were  7.0  and  5.3, 
respectively.  FISH analyses confirmed the presence of integrated HHV-6 DNA 
in  all  cases.  In  addition,  HHV-6  DNA was  detected  in  hair follicles collected 
from all six individuals and the mean viral loads (logio copies/hair follicle) were 
4.2.  In contrast, no HHV-6 DNA was detected in hair follicles obtained from 44 
adult  volunteers.  The  fact  that  HHV-6  DNA  was  detected  in  somatic  cells 
suggested that viral integration was present in the germ line.
The mounting evidence on the presence of integrated  HHV-6 sequence in the 
germ  line  (Daibata  et al.,  1999;  Tanaka-Taya et al.,  2004;  Ward et al.,  2006) 
demonstrates  that  HHV-6  integration  as  a  means of the transmission  of viral 
sequences.  This  mode  of  vertical  transmission  is  novel  among  human
221HHV-6 Integration
herpesviruses.  For individuals with inherited HHV-6 integration, the presence of 
viral  DNA  in  every  cell  presents  an  unique  clinical  problem:  the  possibility of 
horizontal  transmission  of  integrated  viral  genomes  through  transplantation. 
Indeed,  such  a  scenario  was  recently  observed  in  a  case  of  stem-cell 
transplantation  (Clark  et  al.,  2006).  Pre-transplant  measurement  of  HHV-6 
loads revealed that the whole blood of the donor (a 37y old female) contained a 
high viral load, whereas that of the recipient (a 47y old male with acute myeloid 
leukaemia) was  negative for HHV-6.  However,  the  recipient became  positive 
for  HHV-6  PCR  7d  post-transplant,  and  high  HHV-6  loads  were  persistently 
detected  in multiple samples collected over a 76d period.  Interestingly, it was 
observed  that  the  rate  of  increase  in  HHV-6  loads  was  mirrored  by  the 
increases in white  blood  cell count.  Taken together,  it was hypothesised that 
the  donor’s  stem  cells  harbour chromosomal  HHV-6  integration,  and  that the 
reconstitution  of  the  recipient’s  haematopoietic  system  post-transplant  is 
responsible for the observed  rise in  HHV-6 loads in the whole blood samples. 
Subsequently,  HHV-6 integration in the donor was confirmed  by FISH and the 
integration site was mapped to chr17p13.3, while no HHV-6 DNA was detected 
in  the  recipient’s  bone  marrow  obtained  pre-transplant.  However,  integrated 
HHV-6  sequences were  detected  in  bone  marrow obtained from  the  recipient 
post-transplant, and the integration site was the same as that observed for the 
donor (chr17p13.3).  Further FISH analysis showed that the cells were of donor 
origin  (100%  XX  karyotype),  thus  confirming  the  horizontal  transmission  of 
chromosomally integrated HHV-6 through transplantation.
Of  all  the  cases  reported  thus  far,  HHV-6  integration  has  been  mapped  at 
chr1q44, chr17p13.3, chr22q13 (Clark et al., 2006; Daibata et al.,  1999;  Morris 
et  al.,  1999).  Nothing  is  known  about  the  molecular  mechanism  of 
chromosomal  integration of HHV-6,  or MDV for that matter.  But the fact that 
integrated  DNA  sequences  for  both  viruses  were  identified  in  different  host 
chromosomes  (Clark  et  al.,  2006;  Daibata  et  al.,  1999;  Delecluse  and 
Hammerschmidt,  1993;  Delecluse et al.,  1993;  Morris et al.,  1999) suggested 
that integration was chromosome-independent.  A common feature of MDV and 
HHV-6  integration  is that all  integrated viral sequences were mapped  close to 
the telomeric region of the chromosomes.  Intriguingly,  both viruses share the
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telomeric repeat sequences in their genomes (Kishi et al., 1988) which may play 
a role in mediating the integration event.
In terms of HHV-6 integration, the identification of integrated viral sequences of 
both  HHV-6A  and  HHV-6B  suggests  the  molecular  elements  required  for 
integrated  are shared  between the two variants.  One possible candidate that 
has  been  implicated  in  HHV-6  integration  is  HHV-6  U94  (or  HHV-6  REP) 
(Thomson et al.,  1991).  The protein shares a 24% peptide sequence identity 
with  the  REP68/78  protein  of the  human  adenovirus-associated  virus  type  2 
(AAV-2) (Thomson et al.,  1991).  AAV-2 is a small non-enveloped ssDNA virus 
(Muzyczka  and  Berns,  2001).  The  genome  is  4.7kb  and  comprises  Rep 
(replication) and  Cap (capsid) genes flanked  by two inverted  terminal  repeats 
(ITRs).  The  AAV-2  Rep  proteins  are  multifunctional  with  endonuclease, 
helicase and ATPase activity.  The Rep proteins are essential for AAV-2 gene 
expression, DNA replication and the site-specific integration of the virus into the 
host  cell  genome  at  chr19q13.3  (AAVS1  site)  to  establish  latent  infection 
(Linden et al.,  1996).  HHV-6 REP and AAV-2 REP both have a well conserved 
145aa  domain  (Thomson  et  al.,  1991)  containing  a  consensus  nucleoside 
triphosphate  binding  site  that  is  characteristic  of  DNA  and  RNA  helicases 
encoded  by a  number of unrelated  viruses  (Thomson  et al.,  1994).  The two 
proteins are also functionally related.  They both support the replication of AAV- 
2  genome  (Thomson  et al.,  1994),  regulate  the  activity of HIV-1  LTR in  vitro 
(Araujo et al., 1995; Thomson et al., 1994), repress the transforming activities of 
H-ras and BPV-1  on the transcriptional level (Araujo et al.,  1995; Araujo et al., 
1997), interact with hTBP (Mori et al., 2000) and bind to ssDNA in a sequence- 
independent manner (Dhepakson  et al.,  2002).  It was suggested that HHV-6 
REP  cannot support AAV-2  site-specific  integration  (at AAVS1) as  it failed  to 
interact  with  the  AAV  ITR  (Dhepakson  et  al.,  2002).  However,  it  has  been 
shown that the AAVS1  integration  requires only AAV-2  REP and  a  138bp cis 
element,  p5 integration efficiency element (p5IEE),  but not the ITR (Philpott et 
al.,  2002a).  The  possibility  of  HHV-6  REP  driven  site-specific  integration  of 
AAV-2 through p5IEE cannot be ruled out.
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A recently  identified  MDV gene:  a viral  homologue of telomerase  RNA (vTR) 
has  also  been  implicated  in  MDV  integration  (Osterrieder  et  al.,  2006). 
Telomerase RNA (TR), plus a protein component (TERT), forms the functional 
core complex of the telomerase.  MDV vTR shares 88% sequence identity with 
the  native  TR  (Fragnet  et  al.,  2003).  It  has  been  shown  that  the  vTR  can 
interact with the murine TERT (in murine cells lacking mTR) and function more 
efficiently than the native TRs (avian, murine and human) (Fragnet et al., 2003). 
It  is  well  recognised  that  telomerase  activity  is  essential  for  maintaining  the 
physical integrity of eukaryotic chromosomes.  It was speculated that the vTR- 
TERT  complex  may  interact with  the  TRS  in  the  MDV genome  and  facilitate 
integration (Osterrieder et al., 2006).
The biological significance of MDV and HHV-6 integrated remain to be defined. 
MDV  is  always  found  integrated  in  chromosomes  of  latently-infected  and 
lymphoma cells (Delecluse and Hammerschmidt, 1993; Delecluse et al.,  1993). 
However, it is unclear whether MDV integration is required for either latency or 
viral oncogenicity.
In the context of HHV-6 integration in the population, current literature estimates 
prevalence ranges from 0.21 to 3% depending on the studied populations (Clark 
et al.,  2006;  Leong et al.,  2007; Tanaka-Taya et al., 2004; Ward et al., 2006). 
The  relatively  low  prevalence  indicates  that  the  integration  mechanism  is 
inefficient,  hence it is  unlikely that the vertical transmission of viral genome  is 
the  main  aim  of  HHV-6  integration.  On  the  other  hand,  the  identification  of 
HHV-6  integration  in  subjects with varying  clinical  characteristics (Clark et al., 
2006; Daibata et al., 1999; Luppi et al., 1993; Tanaka-Taya et al., 2004; Ward et 
al.,  2006)  suggests  that  the  condition  is  not  associated  with  any  specific 
diseases,  although  further  studies  are  necessary  to  examine  any  clinical 
relevance.  The only recognised implication of HHV-6 integration thus far is its 
confounding  effect  on  the  clinical  diagnosis  of  HHV-6  infection.  Laboratory 
diagnosis of HHV-6 infection has often relied on the use of quantitative PCR to 
measure viral loads in clinical samples (Clark et al.,  1996; Gautheret-Dejean et 
al.,  2002;  Nitsche  et  al.,  2001)  such  as  whole  blood,  CSF,  and  plasma  etc. 
Several  studies  have  demonstrated  that  this  technique  allows  one  to
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differentiate between latent and active HHV-6 infection based on the difference 
in  viral  loads  (Chiu  et  al.,  1998;  Clark  et  al.,  1996;  Gautheret-Dejean  et  al., 
2002;  Sashihara et al., 2002).  However, it has been shown that subjects with 
inherited  HHV-6 integration have high HHV-6 loads in their whole blood, CSF, 
and serum samples (Clark et al., 2006; Tanaka-Taya et al., 2004; Ward et al., 
2006), which  may be  misinterpreted  as  HHV-6 active  infection.  This poses a 
problem  in  the  studies  of the  natural  history and  the  clinical  management of 
HHV-6  infection  (discussed  in  Clark  et  al.,  2006).  Hence,  it  is  important  to 
develop methods for distinguishing  between active infection and chromosomal 
integration of HHV-6.  The use of RT-PCR for detecting HHV-6 transcripts was 
suggested  as  one  possible  solution  (Ward,  2005).  Unlike  active  infection, 
integrated  HHV-6 sequences are thought to be transcriptionally dormant as no 
virus  has  been  isolated  from  any  of  the  subjects  with  HHV-6  integration 
(Daibata  et  al.,  1998a;  Tanaka-Taya  et  al.,  2004).  However,  there  is  little 
experimental data on gene expression of HHV-6 integration to support or reject 
such a notion.  One study reported the detection of two  HHV-6 transcripts (IE 
and U57) in the Katata cell line -  an EBV negative Burkitt’s lymphoma cell line 
harbouring  integrated  HHV-6  DNA  at  chr22q13  (Daibata  et  al.,  1998b). 
Transcription of both genes was detected only in the Katata cell line that was 
chemically-treated (chemicals for inducing herpesvirus reactivation, see section 
1.2.17.1),  and  induction  of  transcription  was  in  a  dose-dependent  manner. 
Gardella  gel  analysis  failed  to  detect  the  linear  or episomal  forms  of  HHV-6 
genome in the cell line,  suggesting that the viral transcripts were derived from 
the  integrated  HHV-6  DNA.  However,  gene  expression  of integrated  HHV-6 
DNA in vivo has yet to be investigated.
Previous  development  of  a  quantitative-competitive  PCR  assay  in  this 
department  for  measuring  HHV-6  viral  loads  identified  a  volunteer  (V1)  with 
consistently high viral loads in serial whole blood samples collected over a 10- 
month period (Clark et al.,  1996).  B cells isolated from the peripheral blood of 
V1  were  EBV-transformed  into  a  lymphoblastoid  cell  line  (LCL)  (Clark  et  al., 
2006).  FISH analysis on V1-LCL confirmed the presence of integrated  HHV-6 
sequences  and  the  integration  site  was  mapped  at  chr11p15.5  (Clark  et  al., 
2006).  This chapter aims to characterise the integrated HHV-6 sequence of V1
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in terms of its (1)  molecular biology,  (2) gene expression  in V1-LCL (in  vitro), 
and (3) gene expression in freshly isolated V1-PBMCs (ex vivo).
226HHV-6 Integration
5.2  Results
5.2.1  Variant typing of the integrated HHV-6 of V1
The  primer  sequences  for  HHV-6A  DR8  and  HHV-6B  B5  are  both  variant- 
specific i.e.  their corresponding  binding sites exist in one variant but not in the 
other (section 2.3.3).  The  integrated  HHV-6  DNA of V1  (referred to as the V1 
sequence from here on) was variant-typed by PCR using these primer sets.  For 
the  DR8  PCR,  amplicons  of  the  expected  size  were  obtained  using  HHV- 
6A(U1102)  DNA but  neither with  HHV-6B  (Z29)  nor V1-LCL  DNA (figure  5.3). 
In contrast,  amplicons for HHV-6B  B5 were successfully generated  using  DNA 
of Z29 and V1-LCL,  but not with that of U1102.  The results show that the V1 
sequence was HHV-6B.
Figure 5.3  The V1 sequence is of HHV-6B origin
HHV-6A DR8 (209)  HHV-6B B5 (129)
M  WB  U1102  Z29  V1  WB  U1102  Z29  V1  M
200bp
100bp
V1-LCL  DNA  was  analysed  by  PCR  using  variant-specific  primers  (section 
2.8.3).  DR8 is specific for HHV-6A while B5 for HHV-6B.  The expected size of 
the amplicons for the respective PCR reaction was indicated in brackets (in bp). 
The results indicate that the V1  sequence is of HHV-6 variant B.
M - 100bp DNA ladder, WB - water blank,  U1102 - DNA extracted from SupT1 
infected  with  HHV-6A(U1102),  Z29  -  DNA extracted  from  SupT1  infected with 
HHV-6B(Z29), V1 - DNA extracted from V1-LCL.
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5.2.2  The  absence/presence  of  concatemeric  region  in  the  V1 
sequence
The number of HHV-6 genomes in V1-LCL DNA was previously analysed using 
real-time  PCR  and  estimated  at  2-6  copies/per  cell  (Duncan  Clark,  UCL, 
personal  communication).  However,  the  FISH  analysis  of  V1-LCL
demonstrated the presence of only one integration site at chr11p15.5 (Clark et 
al.,  2006).  These  data  suggested  that  the  V1  sequence  may  exist  as  a 
concatemer.  This hypothesis was tested using a PCR assay that amplifies the 
concatemeric region of HHV-6 (see figure 5.4a and section 2.8.4).  As depicted 
in  figure  5.4b,  PCR  products  were  amplified  from  both  HHV-6A(U1102)  and 
HHV-6B(Z29) DNA but not for V1-LCL DNA.  The results suggested that the V1 
sequence  was  not  a  concatemer.  Alternatively,  sequence  changes  in  the 
concatemeric region of the V1  sequence due to mutations/recombinations may 
have disrupted the binding sites for the primers.
Figure 5.4  The absence of concatemeric region in the V1 sequence
H H V 6-
a.  HHV-6 replication is thought to proceed via a rolling circle mechanism which 
leads to the generation of head-to-tail concatemers.  A set of primers targeting 
the  junction  between  two  units  of  HHV-6  genomes  was  used  for  the 
concatemeric PCR (Dominguez et al., 1999).
200bp 
100bp
b.  The V1  sequence was analysed for the presence of the concatemeric region 
by PCR.  The expected size for the amplicons is about 156bp.
M - DNA ladder, WB - water blank, U1102 - DNA extracted from SupT1  infected 
with  HHV-6A(U1102),  Z29  -  DNA  extracted  from  SupT1  infected  with  HHV- 
6B(Z29), V1  - DNA extracted from V1-LCL.
Concatemeric PCR (156)
M  WB  U1102  Z29  V1
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5.2.3  The organisation of the V1 sequence
Previous  analysis  on  the  organisation  of  integrated  HHV-6  DNA  has 
demonstrated the presence of partially-deleted viral genome in some individuals 
with  possible  HHV-6  integration  (Torelli  et  al.,  1995).  To  investigate  the 
organisation  of the  V1  sequence,  V1-LCL  DNA was  analysed  by  PCR  using 
primers  to  almost  all  of the  HHV-6  predicted  ORFs  (see  section  2.8.5).  As 
depicted in figure 5.5, 89/108 ORFs tested were PCR positive.  Of the 19 failed 
PCRs,  the  primers  for  16  ORFs  were  designed  based  on  HHV-6A(U1102) 
sequence  (see  figure  5.5),  which  further  confirmed  the  6B-origin  of  the  V1 
sequence.  The remaining three PCR failures (B2, U58, U65) may be a result of 
sub-optimal PCR conditions, or there may be mutations in the V1 sequence that 
interfere with binding of the corresponding primers.  Importantly, the ORFs that 
were successfully amplified spanned from DR1 to B9, representing the start and 
the  end  of the  HHV-6B  genome.  The  results  suggest that the V1  sequence 
consisted of full-length HHV-6 genome.
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Figure 5.5  The organisation of HHV-6 genome of the V1  sequence
M  B1  B2  B3  B4  B5  B6  B7  B8  B9  U24a  DR4*  DR5*  DR7*  DR8‘  LJ1* U5*  U16*  U60*  M
160  183  182  298  129  232  148  161  302  156  241  320  288  209  106  301  316  290
M  U61*  U78*  U80*  U87*  U89*  U96*  U97*  U98*  U99*  DR1  DR3*  DR6*  U2  U3  U4  U6*  U7  U8  M
141  249  292  275  309  274  231  302  240  412  300  303  312  284  295  227  315  300
M  U10  U11  U12  U13  U14  U15 U17  U18  U19  U20  U21  U22  U23  U24*  U25  U26  U27  U28  M
300  307  350  227  321  248 377  284  303  285  287  305  296  230  312  239  344  303
300bp
200bp
100bp
M  U29  U30  U31  U32  U33  U34  U35  U36  U37  U38  U39  U40  U41  U42  U43  U44*  U45*  U46  M 
340  300  294  264  329  307  223  303  257  239  296  297  336  310  289  267  262  239
M  U47  U48*  U50  U51  U53  U54  U56  U57  U58  U59*  U62  U63  U64  U65  U66  U67  U68  M
300  295  338  302  280  351  321  293  268  333  177  290  287  312  300  278  240
mmmm
300bp 
200bp
100bp
M  U70  U72  U73  U74  U75  U76  U77*  U79  U81  U82  U83  U84*  U86*  U91B  U94  U95  U100  M
292  340  328  330  297  291  282  297  327  300  243  311  293  435  301  300  428
500bp  r  - = j 
300bp
100bp9
V1-LCL  DNA was  PCR analysed  for the  presence  of 108  HHV-6  ORFs.  The 
detection of the majority of the  HHV-6B ORFs suggests that the V1  sequence 
exists as an intact genome.
The  name of individual  ORFs and the size  (in  bp) of the  respective amplicons 
were labeled.  M - 100bp DNA ladder.
*  denotes  the  16  failed  PCRs  which  were  amplified  with  HHV-6A  biased 
primers:  DR3,  DR4,  DR5,  DR6, DR7, DR8,  LJ1,  U5, U24,  U48,  U84,  U86, U89, 
U96, U97, U98 and U99.
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5.2.4  HHV-6 gene expression in V1-LCL (in vitro)
It  is  unclear  whether  HHV-6  integration  represents  an  alternative  form  of 
persistence or latency.  The latter, by definition, retains the capacity to produce 
infectious virus upon reactivation.  To fulfill this requirement the integrated viral 
DNA has to be able to support gene expression.  The transcriptional status of 
the V1  sequence in  unstimulated and TPA-treated V1-LCL (see section 2.8.6) 
was therefore  investigated  by  RT-PCR.  As  shown  in  figure  5.6,  four  HHV-6 
transcripts (U39, U89/90,  U94 and  U100) were detected in the “V1-LCL cDNA” 
sample, regardless of the length of culture time and TPA-treatment.  The results 
suggested that the V1 sequence was transcriptionally active in vitro.
It should be noted that amplicons were also detected in the sample labeled as 
“Z29  RNA” which  represents the positive control without reverse transcription. 
Since  it  was  prepared  from  SupT1  cells  heavily  infected  with  HHV-6B,  the 
DNase-treatment employed  may not have been efficient enough to remove all 
viral DNA.  The primers for U89/90 and U100 were designed to span an intron 
of  both  spliced  genes.  The  size  difference  between  the  amplicons 
corresponding  to  cDNA  and  DNA  thus  allows  the  differentiation  between 
detection of contaminating viral  DNA and de novo transcripts.  In the PCR for 
both  U89/90  and  U100,  the  amplicons  detected  for  the  “Z29  RNA”  were  of 
higher  molecular  weight  than  that  of  the  “Z29  cDNA”  (positive  control  with 
reverse transcription), which  is consistent with the  interpretation that the “Z29 
RNA” sample contained residual viral DNA.  Importantly, apart from a faint band 
observed  for  the  U100  RT-PCR  (and  its  higher  molecular  weight  indicated 
contamination  of  viral  DNA),  no  amplicon  was  generated  from  “V1  RNA” 
(without prior reverse transcription)  in  other PCR reactions.  Overall,  the data 
indicated  that  all  amplicons  detected  in  the  “V1  cDNA”  sample  were  derived 
from genuine viral transcripts.
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Figure 5.6 HHV-6 gene expression in V1-LCL
Z29  4unstimulated  4 TPA  8unstimulated 8TPA
M WB c D N ^ R N ^ c D N ^ R N ^ c D N ^ R N ^ c D N ^ R N A c D N ^ R N A
U39
(236)
300bp
200bp
100bpa1
Z29  4unstimulated  4 TPA  8unstimulated  8 TPA
M WB DNA  cDNA  RNA  cDNA  RNA  cDNA  RNA  cDNA  RNA
U89/90*
300bp
b—-j■
(DNA-224, 
cDNA-1151
200bp
100bp
U100
(DNA-
428,
500bp
400bp
300bp 1
Z29  4unstimulated  4 TPA  8unstimulated
M WB WB*  cDNA  RNA  cDNA  RNA  cDNA  RNA  cDNA  RNA
U94
(388)
400bp
300bp
200bp
Expression of four HHV-6 genes (U39,  U89/90,  U94 and U100) in V1-LCL was 
assessed  by  RT-PCR.  Primers  for  U89/90  and  U100  target  intro-spanning 
region.  The  presence  of  HHV-6  transcripts  in  V1-LCL,  regardless  of  TPA- 
stimulation, suggests the V1  sequence is transcriptionally active.  The expected 
size of the respective amplicons was indicated in brackets (in bp).
M -  100bp  DNA ladder,  WB - water blank,  WB2  - water blank from first round 
PCR  (U94  only),  Z29  -  samples  prepared  from  SupT1  infected  with 
HHV6B(Z29),  4unstimulated  -  samples  prepared  from  4-day  culture  of 
unstimulated  V1-LCL,  4  TPA  -  samples  prepared  from  4-day  culture  of TPA- 
stimulated  V1-LCL,  8unstimulated  -  sample  prepared  from  8-day  culture  of 
unstimulated  V1-LCL,  8  TPA  -  sample  prepared  from  8-day  culture  of TPA- 
stimulated V1-LCL,  DNA - DNA extracted from corresponding samples, cDNA - 
cDNA of the corresponding samples, RNA - DNase-treated RNA extracted from 
corresponding samples.
* denotes primers as described in (Van den Bosch et al., 2001).
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5.2.5  HHV-6 protein expression in V1-LCL by IFA
In  light of the detection of HHV-6 transcripts in V1-LCL, the possibility of viral 
protein expression was investigated by IFA (see section 2.8.7) using three anti- 
HHV-6 mAbs.  V1-LCL, with or without TPA-treatment, were IFA negative for all 
three mAbs tested (p41, p101  and gp116), while the controls (HHV6A(U1102)-, 
and  HHV6B(Z29)-infected  SupT1)  were  IFA  positive  (data  not  shown).  The 
results  demonstrated  the  absence  of  productive  infection  in  V1-LCL. 
Alternatively, the antigens were expressed at a level below the detection limit of 
IFA.
5.2.6  V1-LCL Western blotting
Viral protein expression in V1-LCL was re-examined by Western blotting using 
two mAbs that can  recognise  HHV-6B viral proteins:  anti-p101  and anti-gp116 
(see section 2.8.8).  Both mAbs failed to react with any of the sample analysed, 
including the positive control, which is a lysate of HHV-6B(Z29)-infected SupT1 
cells (data not shown).  Sample separation by electrophoresis under reducing or 
non-reducing  conditions  did  not  improve the  detection  of viral  proteins  in  the 
positive control  (data  not shown).  The fact that all  samples  reacted with  the 
anti-GAPDH  mAb  suggests  that  the  procedure  for  Western  blotting  and 
immunostaining  was  performed  correctly  (see  figure  5.7).  The  failure  of the 
immuno-detection  of  the  positive  control,  especially  when  the  cells  used  to 
prepare the positive control have previously been shown to react with the same 
mAbs in  IFA (section 5.2.5), suggests that the denaturation of the sample may 
have destroyed the target epitopes for both mAbs.  As anti-p41/38 reacts with 
HHV-6A only, it was not used for the Western blot analysis of V1-LCL (HHV-6B 
origin).  The absence/presence of HHV-6 protein expression in V1-LCL remains 
inconclusive and should be re-investigated when reagents that are suitable for 
immuno-detection become available.
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Figure 5.7  Loading control of the Western blot analysis of V1-LCL
M  SupT1  Z29-SupT1  V1-LCL
45k----►
$ $   m * * - *   *****  - m , ^   T1ill
*
This  blot  shows  the  loading  control  for  the  Western  blot  analysis  of  HHV-6 
protein expression in V1-LCL.  The blot was stained with anti-GAPDH mAb (see 
section 2.8.8).
M - rainbow marker (GE  Healthcare),  SupT1  - uninfected SupT1, Z29-SupT1  - 
HHV-6B(Z29)-infected-SupT 1, V1-LCL - unstimulated V1-LCL.
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5.2.7  HHV-6 gene expression in V1-PBMC (ex vivo)
The detection of HHV-6 transcripts in V1-LCL suggested that the V1  sequence 
was transcriptionally active in vitro (section 5.2.4).  However, expression of viral 
genes from the V1  sequence may be influenced  by the presence of EBV viral 
proteins in the  LCL setting.  To clarify if viral gene expression was dependent 
on EBV transactivation, the transcriptional status of the V1  sequence in PBMCs 
was investigated.  Two samples of V1 -PBMCs were collected 20 months apart 
and  HHV-6  gene  expression  in  both  samples was  analysed  by  RT-PCR  (see 
section 2.8.9).
In  total,  12/12  HHV-6  transcripts  tested  were  detected  in  the  cDNA  sample 
prepared from the first batch of V1-PBMC: U11, U14, U27, U31, U38, U39, U51, 
U69,  U83,  U90,  U91,  and  U94  (figure 5.8a).  To determine  if the detection of 
viral  transcripts  in V1-PBMC was  reproducible,  RT-PCR was  repeated on the 
second  batch of V1-PBMC.  Due to the limited amount of RNA available from 
the  second  V1-PBMC  sample,  expression  of only  seven  HHV-6  genes  (U11, 
U14,  U27,  U83,  U90,  U91  and  U94) was determined,  and the  presence of all 
transcripts confirmed (figure 5.8b).
Again, the detection of PCR products in the “Z29 RNA” sample suggested that 
the DNase-treatment for the positive control was incomplete.  This interpretation 
was  supported  by  the  observation  that  the  “Z29  RNA”  sample  gave  rise  to 
amplicons corresponding to the unspliced gene of U83, U90 and U91, whereas 
both the “Z29 cDNA” and “V1-PBMC cDNA” yielded amplicons corresponding to 
the spliced counterparts.  In addition, no amplicon has ever been generated in 
the V1-PBMC sample without prior reverse transcription.  Taken together, the 
data demonstrated that HHV-6 transcripts were present in V1-PBMC.
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Figure 5.8  HHV-6 gene expression in V1-PBMC
a)
U11(307)/N11(98)
U14(321 )/N 14(250)
U27(344)/N27(207)
U31 (293)/N31 (154)
U38(303)/N38(254)
U39(236)/N39(183)
U51 (302)/N51 (154)
U69(310)/N69(232)
U83(DNA-243, cDNA-166)
/N83(DNA-142, cDNA-65)
U90B(DNA-514, cDNA-317)
/N90B(194)
U91B(DNA-435, cDNA-326)
/N91B(DNA-289, cDNA-180)
U94(450)/N94(388)
b)
U1  i (307)/N 11 (98)
U14(321 )/N 14(250)
U27(344)/N27(207)
U83(DNA-243, cDNA-166)
/N83(DNA-142, cDNA-65)
U90B(DNA-514, cDNA-317)
/N90B(194)
U91B(DNA-435, cDNA-326)
/N91B(DNA-289, cDNA-180)
U94(450)/N94(388)
1 0   M
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100bp
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a)  Transcripts  detected  in  the  first V1-PBMC  sample,  b)  Transcripts  detected  in  the 
second V1-PBMC sample.  The expected size of the respective amplicons was labeled 
in brackets (in bp).  All primers are specific to HHV-6, the corresponding amplicon was 
obtained  only with  cDNA prepared from  HHV-6B-infected  SupT1,  but not with  DNA or 
cDNA prepared from uninfected  SupT1  (data not shown).  All HHV-6 transcripts tested 
were detectable in V1-PBMCs.
Lane  1-5:  first  round  PCR,  lane  6-10:  nested-PCR.  M -  100bp  molecular  ladder,  1   - 
water blank, 2 and 7 - HHV-6B(Z29) cDNA, 3 and 8 - HHV-6B(Z29) RNA, 4 and 9 - V1- 
PBMC cDNA, 5 and 10 - V1-PBMC RNA.
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5.3  Discussion
Following  the  confirmation  of  HHV-6  integration  in  V1  (Clark  et  al.,  2006), 
further  analyses  were  conducted  to  characterise  the  molecular  biology  and 
gene expression of the integrated viral sequences in V1  (or the V1  sequence). 
A  significant  part  of  this  work  was  conducted  on  a  lymphoblastioid  cell  line 
established from the B cells of V1  (V1-LCL), the only exception being the HHV- 
6 gene expression analysis of the V1-PBMC.  PCR analyses revealed that the 
V1  sequence  was  HHV-6B  (section  5.2.1)  and  appeared  to  be  free  of 
concatemeric regions (section 5.2.2).  Of the 82 HHV-6B predicted genes tested 
by PCR, the presence of 79 was confirmed (96.3%), indicating the presence of 
an  intact  viral  genome  (section  5.2.3).  Taken  together with  other  published 
data,  36  subjects  with  possible  HHV-6  integration  were  described  (table  5.1) 
and  18 of them confirmed by FISH.  Of all the reported integrated HHV-6 DNA, 
seven  subjects were variant A  (19.4%)  and  29 were variant  B  (80.6%).  The 
higher  detection  rate  of  HHV-6B  integration  seems  to  mirror  the  higher 
prevalence of HHV-6B  infection  in the studied  population  (Tanaka-Taya et al., 
1996;  Ward  et  al.,  2005b;  Yoshikawa  et  al.,  2000).  HHV-6A  infection  is 
reportedly more  prevalent  in  Zambia  (Kasolo et al.,  1997),  and  it would  be of 
interest to  determine  if  HHV-6A  integration  occurs  in  higher  incidence  in  this 
population.
It is unclear at which stage the viral genome integrates into host chromosomes. 
However,  if the  integrated  HHV-6  DNA  existed  as  a  concatemer,  this  would 
suggest  that  the  integration  event  happened  after  lytic  replication.  The 
presence  of  concatemeric  regions  in  integrated  HHV-6  DNA  has  not  been 
analysed  prior  to  this  study.  The  V1  sequence  failed  to  support  the  PCR 
amplification  of the  concatemeric  regions  (section  5.2.2),  suggesting  that  it is 
not  in  concatemeric  form.  It  should  be  noted  that  the  failure  to  detect  the 
concatemeric regions  by  PCR  is  not a  proof of absence of the  corresponding 
region.  To  confirm  the  absence  of  the  concatemeric  regions,  restriction 
fragment analysis of the V1 sequence should be performed.
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A  key  aspect  of  viral  latency  is  the  capacity  to  support  the  production  of 
infectious  virions  upon  reactivation.  Any  deletion  of the  viral  genome  post­
integration  may  prevent  the  occurrence  of productive  infection.  In  total,  the 
genome  organisation  of integrated  HHV-6  DNA of  11  subjects was  examined 
and reported to be intact in all cases (table 1).  However, the methods used for 
assessing  the genome  organisation varied  between  different studies.  For the 
three cases reported by Torelli and colleagues (1995), the genome organisation 
was  assessed  by  RFLP  analysis,  which  demonstrated  the  integrated  HHV-6 
DNA hybridised with probes prepared from pZVH14, pZVB70 and pHD12.  The 
former two contain  DNA sequences corresponding to the 5’ end of the  HHV-6 
genome  and  the  latter to  the  3’  end.  For the  six  cases  reported  in  the  two 
studies by Daibata and colleagues (1998a; 1999), the genome organisation was 
studied by the PCR detection of seven HHV-6 predicted ORFs.  In contrast, the 
integrated  HHV-6  DNA  of  V1  and  that  of  the  donor  reported  by  Clark  and 
colleagues  (2006)  was  assessed  by  the  PCR  detection  of almost  all  HHV-6 
predicted ORFs (section 5.2.3).
Table 5.1 Summary of all the reported HHV-6 integration to date
Reference
Number of cases
Confirmation by FISH Genome organisation
HHV-6  A HHV-6B
(Luppi et al.,  1993) 3 3 3 intact
(Daibata et al.,  1998a) 3 3 3 intact
(Daibata et al.,  1999) 3 3 3 intact
(Tanaka-Taya et al., 
2004)
2 8 4(all HHV-6B) ND
(Ward et al., 2005b) 4 9* ND ND
(Clark et al., 2006) ** 1* 2*** 2 intact
(Ward et al., 2006) ^   * * 4* 3*** ND
ND - not determined.
*  of the  2/4  cases  described  in  (Ward  et al.,  2006),  one  has  been  previously 
described in (Ward et al., 2005b) and the other in (Clark et al., 2006).
** the same subject was described in both studies.
***excluding the subject that was also described in (Clark et al., 2006).
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The capacity of integrated HHV-6 DNA to support viral gene expression is also 
important for reactivation of the virus.  Four HHV-6 transcripts belonging to all 
three kinetic classes (IE-U89/90, E-U39 and U94, L-U100) were detected in V1- 
LCL,  regardless  of  the  TPA-treatment  (section  5.2.4;  see  chapter  4  for  the 
transcription  kinetics of HHV-6 genes).  Given that HHV-6 episome has never 
been detected in V1-LCL by Gardella gel and FISH analyses (Ting Li and Hoe 
Leong,  UCL,  personal  communication),  the  data  suggest  that  the  HHV-6 
transcripts were derived from the V1  sequence,  and thus  it is transcriptionally 
active.  This is in agreement with a previous report which described the possible 
viral  gene  expression  in  a  cell  line  (Katata)  harbouring  integrated  HHV-6 
sequences  (Daibata  et  al.,  1998b).  However,  in  the  study  by  Daibata  et al., 
(1998)  expression  of an  IE  and  a  late gene  (U57)  in  the  Katata  cell  line was 
dependent on  chemical  induction.  The  difference  in  the  reliance  of chemical 
stimulation for viral gene expression in V1-LCL and the Katata cell line may be 
explained  by  the  difference  in  integration  sites  (chr11p15.5  vs  chr22q13, 
respectively).  Gene expression is often regulated by cis-elements close to the 
gene  of interest  (Cremer and  Cremer,  2001).  The  chemical  induction  of the 
Katata cell line may have helped  remove factors that repress gene expression 
from the integrated HHV-6 sequence.  Alternatively, it should be noted that V1- 
LCL was  latently  infected  with  EBV,  whereas the  Katata  cell  line was free  of 
EBV  infection.  HHV-6  infection  has  been  shown  to  induce  replication  of the 
EBV genome,  primarily by the upregulation of EBV ZEBRA proteins (Flamand 
and  Menezes,  1996;  Flamand  et al.,  1993).  Although  it  has  not  been  shown 
experimentally,  it  is  possible  that  the  reverse  is  true  i.e.  EBV  viral  proteins 
transactivate the V1  sequence,  resulting  in  HHV-6 gene expression in V1-LCL 
without chemical stimulation.  The expression of late genes in both V1-LCL and 
Katata  cell  line  suggests  the  potential  for  integrated  HHV-6  sequences  to 
support lytic replication.  However, the failure in the detection of HHV-6 proteins 
by  IFA and Western  blot analysis suggests that lytic infection  in  both of these 
cell lines is abortive (Daibata et al., 1998b; sections 5.2.5 and 5.2.6).
The  finding  that  HHV-6  genes  were  expressed  in  V1-LCL  prompted  the 
investigation into gene expression of the V1  sequence in vivo.  Two batches of 
V1-PBMCs were collected  20  months apart,  and  on  both  occasions  individual
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V1  exhibited no sign of clinical symptoms.  RT-PCR analysis conducted on the 
first V1-PBMC  sample  detected  transcripts for all  12  HHV-6  genes  analysed: 
U11,  U14,  U27,  U31,  U38,  U39,  U51,  U69,  U83,  U90,  U91,  and  U94  (section 
5.2.7).  The detection of early and late HHV-6 genes in V1-PBMC suggests the 
occurrence  of  lytic  replication.  It  should  be  noted  that  individual  V1  is 
seropositive  for  HHV-6  (D  Clark,  UCL,  personal  communication)  i.e.  some 
PBMCs may contain both integrated and episomal HHV-6 DNA.  Hence, there 
are two possible interpretations of the data: 1) V1 was experiencing sub-clinical 
HHV-6 reactivation on the day of PBMC collection; 2) not only the V1  sequence 
was transcriptionally active in  vitro (section 5.2.4) but also in  vivo.  It must be 
acknowledged that there is currently no method to distinguish  between  HHV-6 
transcriptions  from  the  integrated  or  episomal  DNA.  Nevertheless,  the 
investigation of viral transcription by RT-PCR was repeated on the second V1- 
PBMC  sample  and  confirmed  the  presence  of all  seven  HHV-6  genes tested 
(U11, U14, U27, U83, U90, U91  and U94; see section 5.2.7).  The rationale for 
testing  the  second  PBMC  sample  is  that  late-gene  transcription  only  occurs 
during  lytic  replication  or  reactivation.  Although  the  frequency  of  HHV-6 
reactivation  in  immunocompetent adults  is  unclear,  it  has  been  demonstrated 
that the frequency inversely correlated with age in healthy children (Caserta et 
al., 2004).  The chance of individual V1  (>40 years of age) experiencing HHV-6 
reactivation  when  both  samples  were  collected  (20-months  apart)  is  thus 
remote.  The presence of HHV-6 transcripts in both V1-PBMC samples argues 
strongly  that  they  were  derived  from  the  V1  sequence  in  vivo.  This  finding 
argues that HHV-6 integration may be a confounding factor in the diagnosis of 
HHV-6 infection by RT-PCR.  The development of a new assay to identify active 
HHV-6  infection  in  patients  with  chromosomal  HHV-6  integration  should  be 
considered.
Interestingly, all HHV-6 transcripts in V1-PBMC were only detectable by nested- 
PCR,  indicating  that  they  were  transcribed  at  low  levels  and/or  in 
subpopulations  of cells.  The  implication  and  long-term  effect  of transcription 
from  integrated  HHV-6  DNA  is  unclear.  Based  on  the  observation  that 
integrated  HHV-6  DNA  at  different  chromosomal  sites  exhibited  differential
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propensity  of viral  gene  expression  in  vitro  (as  discussed  previously),  further 
work is required to determine if the same occurs in vivo.
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5.4  Summary of Chapter 5
1.  The V1  sequence is of HHV-6B origin.
2.  The V1  sequence appears to exist as an intact viral genome.
3.  The V1  sequence is transcriptionally active in the EBV-positive V1-LCL.
4.  The absence of viral  proteins in V1-LCL indicates that gene  expression
of the integrated sequence may be abortive.
5.  HHV-6 transcripts of all three kinetic classes (IE,  E,  L) were detected in 
two separate V1-PBMC samples,  which  suggest the V1  sequence may 
be transcriptionally active in vivo.
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6.1  Summary
In summary,  I have described the creation of the HHV-6 arrays (chapter 3) and 
their use  in  the  analysis  of HHV-6B  gene  expression  in  SupT1  cells.  I  have 
demonstrated that the HHV-6 arrays allow reproducible measurements of gene 
expression  (chapter 3) and the array analysis  provides expression  profile and 
kinetic classification of 93 out of 97 HHV-6B genes (chapter 4).  In addition, the 
results discussed in chapter 5 demonstrate the presence of HHV-6 transcripts in 
cells harbouring integrated HHV-6.  This is suggestive of viral gene expression 
from the integrated HHV-6 DNA.
6.2  Direction for future research
Like  most  investigations,  the  findings  discussed  in  this  thesis  raised  more 
questions  than  answers.  Regarding  HHV-6  lytic  replication,  the  transcription 
kinetics  were  defined  for the  majority  of  HHV-6B  genes  bar four  ORFs  (U2, 
U24,  U58,  U86).  In the study by Oster et al.,  (2002),  ORFs U2,  U58 and  U86 
have  been  assigned  as  L-,  L-  and  lE-genes,  respectively.  Nevertheless,  the 
expression  profiling for these four ORFs  by  RT-PCR should  be considered  to 
complete the characterisation of the temporal gene expression of HHV-6B.  The 
HHV-6  array  analysis  also  detected  ten  intergenic  transcripts  with  unknown 
functions.  The  physical  characterisation  of these transcripts  e.g.  mapping  by 
Northern  blotting  and  identification  of  the  transcriptional  start  site  by  rapid 
amplification of 5' complementary DNA ends, would  provide useful information 
for their functional  characterisation.  In addition,  the array analysis revealed  a 
group of five genes (B6,  B9,  U21,  U83,  G100/B9) with a biphasic transcription 
pattern, which  has been attributed as a feature of virion-associated transcripts 
(Bechtel  et  al.,  2005).  The  possible  association  of  these  transcripts  to  the 
virions  can  be  clarified  by  Northern  blot  or  RT-PCR  analyses  of  the  RNA 
composition of purified  HHV-6 virus particles.  In a  broader sense, the  HHV-6 
arrays  can  be further applied  to  investigate  host and  viral gene  expression  in 
HHV-6A-infected  SupT1,  which  allows  the  direct  comparison  between  the 
expression data of the two variants in the same cell-line.  The identification of 
host  and  viral  genes  that  are  differentially  expressed  in  SupT1  infected  with
244Summary
either HHV-6A or HHV-6B may provide clues to the molecular mechanism that 
explain the differential biological properties between the two variants.
Regarding HHV-6 integration, although the potential of viral gene expression in 
vivo from the V1  sequence was demonstrated, the work presented in this thesis 
fails to completely exclude the possibility of HHV-6 reactivation in V1.  The high 
prevalence of HHV-6 in the adult population means that most people with HHV- 
6 integration have previous exposure to HHV-6.  No test is currently available to 
clarify  the  origin  of  HHV-6  transcripts  in  cells  harbouring  both  episomal  and 
integrated  HHV-6  DNA.  Although  the  use  of  FISH,  Gardella  gel  and  PCR 
analyses allows one to demonstrate the non-detection of episomal HHV-6 DNA, 
the absence of a positive signal  is not necessarily a  proof of absence.  There 
are two possible approaches to demonstrate that HHV-6 transcripts are indeed 
originated  from  the  integrated  HHV-6  DNA:  one  can  investigate  HHV-6 
transcription  in  PBMCs  of  1)  individuals  with  HHV-6  integration  but  without 
HHV-6 infection,  or 2)  individuals with chromosomal  integration of one variant 
e.g.  HHV-6A,  but  infection  with  another  i.e.  HHV-6B.  However,  both 
approaches may not be executable in practice due to ethical reasons (screening 
for HHV-6 DNA in ‘healthy’ infants, as HHV-6 is usually acquired by two years 
of age)  and  the  lack  of reliable  assays  to  differentiate  between  HHV-6A and 
HHV-6B  infection.  There are two other more tangible experiments which  may 
help  improve  our  understanding  of  HHV-6  integration.  One  concerns  the 
molecular  mechanism  of  HHV-6  integration.  The  second  investigates  the 
potential to ‘rescue’ the integrated HHV-6 DNA.
The  molecular  mechanism  of  HHV-6  integration  remains  elusive.  ORF  U94, 
which  encodes a  homologue  of AAV-2  REP,  has  been shown to complement 
the replication of an AAV-2 replication-deficient mutant (Thomson et al.,  1994). 
As AAV-2 REP is also responsible for the site-specific integration of AAV-2, the 
implication  is  that  U94  play  a  role  in  HHV-6  integration  (see  section  5.1  for 
details).  To  clarify  if  U94  (HHV-6  REP)  is  functionally  involved  in  HHV-6 
integration,  I  have  initiated  a  pilot  experiment  in  collaboration  with  Dr  Nicola 
Philpott  (Department  of  Immunology  and  Molecular  Pathology,  UCL)  to 
investigate  whether  HHV-6  REP  can  support  the  site-specific  integration  of
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AAV-2.  The experiment employed the original assay used for the discovery of 
p5IEE as the element responsible for mediating the AAVS1  integration (Philpott 
et al.,  2002b).  However,  I  had  difficulty in detecting the expression of HHV-6 
REP  (cloned  into  pcDNA  3.1;  Invitrogen)  in  mammalian  cell-lines  (data  not 
shown).  The possible causes include the negative regulation of the HCMV IE 
promoter (used in pcDNA3.1) by HHV-6 REP (Caselli et al., 2006), or the quality 
of the antibodies  used for the detection of HHV-6  REP.  The experiment was 
discontinued due to time-constraints.
I  have  demonstrated  the  expression  of  HHV-6  genes  but  the  lack  of  viral 
proteins in V1-LCL (sections 5.2.4 to 5.2.6), which is a typical feature of abortive 
infection.  It should  be  noted  that V1-LCL  is originated  from  B  cells,  and  that 
there is no experimental data demonstrating the productive infection of B cells 
by  HHV-6  (HHV-6  preferentially replicates  in T cell  in  vitro).  The detection  of 
viral  transcripts  in  V1-LCL  suggests  that  the  V1  sequence  may  have  the 
potential  to  be  ‘reactivated’  i.e.  to  support  a  full  lytic  replication  cycle.  The 
absence of viral proteins in V1-LCL may be a result of B cell specific restriction 
of HHV-6 replication.  To draw from the knowledge of other integrated viruses, it 
has  been  well-documented  that  integrated  SV40  genomes  remain  dormant  in 
non-permissive  mouse  cells,  and  the  fusion  of  these  cells  with  permissive 
monkey  cells  yield  wild  type  SV40  particles  (Weinberg,  1980).  By  using  a 
similar approach, one could fuse the V1-LCL with different T cell-lines e.g. Molt- 
3  or  SupT1  (both  can  support  HHV-6B  replication  in  vitro)  and  look  for the 
presence of HHV-6 particles.
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Chemicals or reagents
Advanced Biotechnologies, Columbia, MD
Mouse anti-HHV-6 gp116 (100fig)
Agilent, Santa Clara, CA
RNA6000 nano regents
Aldrich, Poole, Uk
Succinic anhydride 
1  -methyl-2-pyrrolidone
Ambion, Warrington, UK
RNAse-free DNase I 
RNase Zap 
RNA 6000 ladder
Applied Biosystems, Warrington, UK
RNase inhibitor (2000units, 20U/p,l)
Beckman Coulter, High Wycombe, UK
Glycogen
Quick start sequencing mix
BDH, Lutterworth, UK
Acetone
Ethanol
Isopropanol
Methanol
Tris(hydroxymethyl)methylammonium chloride (Tris)
Bioline, London, UK
Hotstart Immolase kit 
HyperLadder IV (500 lanes)
Agarose
Boehringer Mannheim, Burgess Hill, UK
EcoRI (5000u)
Chemicon, Chandlers Ford, Uk
Mouse anti-HHV6 (induced early nuclear protein) p41/38 (lOOpg) 
Mouse anti-HHV6 (early protein) p101  (1 OOjug)
GE Healthcare, Amersham, UK
CyScribe 1st strand cDNA kitCy5 dye (25nmol)
Cy3 dye (25nmol)
Poly d(A)4o -6o
Genetix, New Milton, UK
Genetix spotting buffer
Hendley-Essex, Essex, UK
Multispot Microscope Slides (PTFE & Specialised Coating)
Invitrogen, Paisley, UK
Cot1  DNA (500mg)
Foetal calf serum (FCS)
Penicillin-streptomycin solution
RPMI 1640 medium with L-Glutamine (500ml)
TRIzol
Yeast tRNA (50mg)
Mallinckrodt Baker, Phillipsburg, NJ
Deionised formamide
Millipore, Consett, UK
PCR384 purification kit 
YM-30 Microcon
National Diagnostics, Atlanta, GA
10x TBE (Tris-Borate-EDTA)
Oxoid, Basingstoke, UK
Agar bacteriological 
Phosphate buffered saline (PBS)
Promega, Southampton, UK
JM109 competent cells >107cfu/|ag 
Nuclease free water
pGEM-T Easy Vector System I (20 reactions)
Set of deoxyadenosine triphosphate (dATP), dCTP, dGTP, dTTP (40pmol) 
T4 ligase
Wizard Genomic DNA Purification Kit (500 isolations)
X-Gal (5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside, 10Omg)
Qiagen, Crawley, UK
HotStarTaq DNA polymerase (1000 units)
Minelute PCR purification kit (50 reactions)
Oligotex mRNA midikit
Omniscript reverse transcriptase (50 reactions)
QIAquick 96 PCR purification kit
QIAquick spin PCR purification kit (250 reactions)
QIAprep spin Miniprep kit (250 preps)
Sensiscript reverse transcriptase (50 reactions)
292Small spin columns (24) for mRNA purification
Roche, Burgess Hill, UK
Oligo d(T)i6 (50pM, 5nmoles)
Sigma, Poole, UK
0.5M EDTA disodium salt
100x Denhardts solution20x SSPE buffer
20x SSC (saline sodium citrate)
20x SSPE (saline sodium phosphate EDTA)
5M betaine solution 
7.5M ammonium acetate 
Ampicillin 
BCIP/NBT tablet 
Boric acid
Bovine serum albumin (BSA) Fraction V 
Calcium chloride (CaCI2)
Chloroform
Cycloheximide (CHX) solution (100mg/ml)
Dimethyl Sulfoxide (DMSO)
DMSO Hybri-Max (cell culture grade)
Ethidium bromide tablets (10mg)
Fluorescein isothiocyanate (FITC) -conjugated rabbit anti-mouse IgG
Glucose
Glycerol
Herring sperm DNA (1ml)
Isopropanol
L-Glu penicillin-streptomycin 
Lennox L Broth (LB)
Manganese chloride (MnCl2.4H20)
Magnesium chloride (MgCI2)
MOPS (3-(N-morpholino)propanesulfonic acid)
Phorbol 12-Myristate 13-Actetate (TPA)
Phosphonoacetic acid (PAA)
Potassium chloride (KCI)
Potassium hydroxide (KOH)
Phenol:chloroform:isoamyl alcohol (25:24:1)
Ribonuclease A type1-AS 
Sodium chloride (NaCI)
Sodium hydroxide (NaOH)
Tween 20 
Yeast tRNA
UKC, Canterbury, UK
Citifluor mounting fluid
Vector Laboratories, Peterborough, UK
DAB substrate kit for peroxidase
293Buffers and solutions
1M CaCI2
14.7g CaCI2  
100ml dH20
1M sodium borate
Dissolve 61.8 g of boric acid in 800 ml of dH20 
Adjust the pH to 8.0 with NaOH
1M Glucose
18g glucose
Adjust to 100ml with dH20 
Filter sterilised
1MKCI
14.91g KCI
Adjust to 200ml with dH20
2M MgCI2
38g MgCI2
Adjust to 100ml with dH20
2x Betaine buffer (6x SSC + 3M betaine)
3ml of 20x SSC 
6ml of 5M betaine 
1ml of dH20 
Mix well
5M KOH
56g KOH
Adjust to 200ml with dH20
5M NaOH
20g NaOH
Adjust to 200ml with dH20
In-house blocking solution
15ml of 20x SSC 
0.3g of BSA
0.3g non-fat milk powder (Tesco)
Adjust to 60ml with dH20
Filter the solution through a 0.2pM filter (Millipore)
Succinic anhydride solution
335 ml of 1-methyl-2-pyrrolidinone 
5.5g of succinic anhydride
Immediately after succinic anhydride dissolves, add 15 ml of 1M sodium borate 
(pH 8).
294LB-agar
8g LB
6g Agar Bacteriological 
Adjust to 400ml with dH20 
Autoclave before use
LB-broth
8g LB
400ml dH20 
Autoclave before use
Milk-TBST
5% milk
Mix with appropriate volume of TBST (see below)
Milk-TBS
5% milk for block, 2.5% milk for co-incubating with antibodies  - 
Mix with appropriate volume of TBS (see below)
PBS
Dissolve one PBS tablet in 100ml dH20 
Autoclave before use
SOB
8g LB 
1ml 1M KCI 
80 pi NaOH
Adjust to 400ml with dH20 
Autoclave
Add 5ml 2M MgCI2  (filtered sterilised before use)
soc
400ml of SOB
8ml sterile 1M glucose
TB buffer
1.05g MOPS)
125ml 1M KCI 
7.5ml 1M CaCI2  
450ml dH20 
pH to 6.7 with 5M KOH 
Adjust to 495ml with dH20 
5.45g MnCI2.4H20 
Filter sterilised 
Store at 4°C
TRIS buffered saline (TBS)
4.84g Tris 
17.6g NaCI 
Dissolve in 1L dH20
295pH to 7.5
Top up to 2L with CIH 2O 
Store at 4°C
TBS + Tween (TBST):
250 |J Tween 20 
Mix with 500ml TBS 
Store at 4°C
Western substrate solution
One BCIP/NBT tablet (Sigma) per 10ml dH20 
Mix well and ready for use
Western transfer buffer
25ml of 20x transfer buffer (Invitrogen)
50ml of methanol 
425ml of dH20
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Primers used for the HHV-6 array studies (sections 2.4, 2.5 and 2.7).
ORF Forward primer Reverse Primer Size(bp)
DR1 CACACCCTGCATCGTCTTC GTGATGAGGCCCAGAGGTAG 299
B1 C  GAGAACAC  GC  GAGACATC GATCTGGCCCTCAGGTGAC 160
B2 AAAAACACACCACCGCAAG GAGAGAGTCGGCGCGTAT 183
DR  6 ATGACAACGCGACACACG ACGGATCTGGGTCTCACG 293
B3 CTATCCGCCTGCGTGTATG GGTGTCTCACGGACAGGAAG 182
GB3/B4 GAAAGGCGGAGACACATAGC TTGTGGTAGATGGGGTAGGG 292
B4 CCGGAGGAAAGAGAGAACG TGTGTGTATGCTTTCGCTCAC 298
B5 CAAAGACAACCACGAAAACG CGTAGGGACTGCGAGGAC 129
DR7 TTTGGGTTAAACGCCTCTTC GCAGCCCTCGTCTTGTAAAC 288
DR  8 TCCAATCAACGGGGTGTATC GACAACGGATTACGGAGGTG 209
U3 TCTCGAAAACACAGCACGTC CTGGGATACGTGAAGAAAAGG 284
U4 CTGACGTTTCGTCCTCAAAAG CGGGTCACGTATACCATTCC 295
U5 CACATCGTAGGGTTCACCAAG GGAATCTACTCGGCAACTGG 301
U7EX CACGGCAATGGTCTTTCC TTCGCCTTGTCATCATGTGT 315
U6 GCAGTCCGAAGAGGGATGT GGCTTGTGAAAGACCGTAGC 227
U8 ACAAGCCATGACGGTACACA GGAACTGCTGGCTGAGATTC 300
U9 ACGCTTTCCTCCGCATGTA AAATCGAAATCCGAGGAGTG 266
U10 CAAGACGGTTTCAGCGAGAT GGGAGTGTGATGCTAGTCCAG 300
Ull GAGTATCGATCGGAACATTGC TGTGTCGTGAGAGAGGGAGA 307
U12 TTTTGTGCTCATGTGGTGTG TCAC  CGC  TAGAAACAG  T  TC  G 353
U13 GACGGACGATCCCATATTGT CTGGATCGATAGGGTAGACGA 227
U14 GTTCTCTCACGCGCCAAC ACGAGCATCGACAAACAGC 321
U15 TCGTTTACTTTCCGGATGTTC CAAGAATGCCGTGAATTGTG 248
U16 CCCGTCATACGGCATACTCT ACGGAACGATTTGCAGTTCT 297
U17 GGATCATAACGACGCAATCC AAGTCGGTGCTTGGTGATTT 291
G17/18 AAGCCACAAACCCTCACAAC AAGTCTGCCTGTGGAAAGGA 299
U18 CAAAGCTCTGAGCATCACTCC TGGGAGTCTGCTTTACATCG 284
U19 AAGCACTTGACCAGTTGACG CGCATGTTGCAGTTTAAGGA 303
U20 ACGTAGCTGCCAGACAACTG TCAGACCGTTATTGGCATTG 285
U21 TGTCATTTTTCCATGACCACA GGAACGATGAAGCGGTTAGA 287
U22 GCTCGGAAAGGAAACATTACA TGTCGGTGATACCGTCTTTG 305
U2  3 CAGTTTCCCAAAGAGCCTGA CGAAACGTGGGGTAAAAATG 296
U24a TGAAATACACGGCGAGGAC AGCAAAACTCTATTCCCCATTC 230
U25 AAGCCACGTGATAAAGACTTCTG TGTCTTCAAGCAAAGACATCG 312
U2  6 TCGGAAAATATCAAGCAGATCA GCTAAGGGTGCCGTTATTCC 239
U27 CCTCAGGATTCGAGATGATGT AGAGATGGAGCGCGGTAGT 344
U2  8 AAAGGGAAAACGCCAGTTCT CATGCCCGAATGTGATTATG 303
U2  9 GGCAGGGTAATTCCACGATA AAAACATTCACGGGCTTACG 340
U30 ATTCAGTTTCCAGGCGACAC ATTTTCGGTTCCGAGGAAGT 300
U31 CCACACAAACAGAGCGACAC TTGGTTCGGAGAGGTTTTTG 293
U32 TCAATCACTCCCTGTTTTTGTG ACGACCATACGTAGTGATGATTTG 267
297U33 GGGAAATGACAAAACGTGCT TTGTTTTGCTCGCCTATCTG 329
U34 TCGTGAACACTGCAAAAGTTG ACTGAGCGGAATCTATTGTCG 307
U35 GACCTCTCTATGCACGCAATC GATGGATTCCTCACCTGAAAAG 223
U36 GATGGGACTCAGAAGCGTTG GCGCGTAGTTGCATTTGTAG 303
U37 TCTACACACCGTCTTCAACCTG GCATGACGTTGTTGACTTGG 257
U38 TCGCATTAGTCACAGCCTTG TTTTTCAAAATCGGGCAGAC 303
U39  (5) TAAACCACACCCACATCACG TTCCTGGCTGTCTTTTTGATG 296
U39 (3) CCTCCTCTTTTTCCGAAACC GTGTTACGGCAGGAGCACTT 291
U40 AAATCTGCAACCCTTCTTGG TTCTTTGTGCGTCAGCTTTG 297
U41 GACAGTTTGCTCCCCATCC ATTTGTCATGTTGCGTGTGG 336
G41/42  .1 TTCCACGCAGATGACATGA TTTTGAAATTCCGCTGAAAAG 316
G41/42.2 GCAAGTTCTTCGAGGTTTGC AAGGTTCAAACAATGCAATCG 301
C
M
D (5) GCAAGACAAGGTGAGTTGGTC AAGAAAAACGCGCTCAAAAC 310
U42 (3) TTTCACAGGTGTCAGCTTCA AAGTCGCGACCTACCTCAGA 314
U43 GTGTTTTCCGTGAAGCATTG GCCTCAACGACAAAGAAACC 289
U44 TGGGGTATTGGGGTGTTATG AACGCTCCATAACCGTATGC 267
U45 GAGTGTGATTTTGTTGGTGTCC CTCTTATCAACGCCCAATCC 262
U4  6 GTTGTAAGAAAGGCGCAAGG CACCGTCTCTGAAGCAAAAGT 239
•   U47 TGGTGGATCTGCGGTATATG AATTGGAGCGACGAACAAAG 300
U48 TTGTTTGACCGAAGGTACAGG TCCCTGTTACGGTTGGAGAC 295
U4  9 TCTTTGACAGGTTTGCCTGA GCCTGATGAATGCAGTTGTG 323
U50 GAATGATGGGGAGGTAAACG GATACACCGTCGCTTGCTC 338
U51 TTTTCGTCCATCCAGTTGTG AGAGCCTTGGAATTCTCGTTC 302
U52 GTGACTGACATTTCCGCTGT CCACAAAACTGCTTAGAAACGA 305
U53 CCAGAGACACGGTTCAAAAAG GAAAGCGATAGACCAGGAAAAC 280
U54 TTTTAATGCGCGTGAGAGG TATTAAAACCCGGCGAACTG 351
U55 TGGTATCGATGCTGAACACG ACCCATTTATCTGCCGTCAC 250
U56 GCTGTCGGAACGACTAAAGG ATACCGATCCCAGCTCACC 323
U57 (5) CTGGGAGAGTATGCTGGTGAG TCGTCCTGACCATGAATGAG 293
U57 (3) TTTCGCTGATCTGCGTATTG CACGGCACACAGAGAACAAC 305
U59 GCGCGATTAGGTTAGATTCG CGTGCTTCCACTTCAATTCC 333
U60 TATTGCTGCTATGCCTGTGC CTTGCTACCGACTCCACAAAC 290
U61 TCCGGAATTGGTCGAAGATA CAGAGTATACGCGGACAGAGC 141
U62 GGCGTTAAACGGGATAAAAGA TTAAATATCTCCACCGCGAGA 177
U63 ACGGTTAATGTCGTGGTGGT TCTTCTCGTTTCCGACGACT 290
U64 CGAACTTTTTACCGGTTTGG GCTCTAAAGGTCCCTGCTGA 287
U65 TTGGCGATTTGGGTTATCTT GGGTTATGCTTCCCAATTCC 312
U66 TCAAAGGATTTGTCGGAAGC TACCTGCGACATAACCCACA 300
U67 ATGTGGGTTATGTCGCAGGT AAATTATCCAGAGCGGCATC 278
U68 TTGGAGGTGAGACATCGAGA CGCTGCCGTATCAATTATTTC 240
U69 TTGCGATTGTTCTGCGATAG GTGAGGGACGTAGACCACTGA 286
U70 ACGGGAAAAGATCAAGCAAG CCGAGTTTCACGCTCTACG 292
U71 AATCGGAAGAGGAAGGGATG TTTTTCAGCTTCCGTATCACA 95
U72 TGTCCCCCATCCAGGTAATA TTACGGATCTGGCTGGTCTC 340
U73 GCAGCCGATAAAACTGGTTC GGTTTTTGTCATCGTTTTGGA 328
U74 GTGTGCGTGTCATCTTAGCC AACCCGTCATCTCCAAGAAC 330
U75 GGAGATAGGACGGGGAAAAG ATGGTTCCACTTGGAAGACG 297
U7  6 CCGCACTATGTCGTGGATTA CACGATGAATGGAAACGTCA 291
298U77 GCAAATGACGAGAGGTCGAT CGAACCCACACACACGATAC 282
B6 TGAGCTGACATCTGCAAAAAC TCATCTTATTCTTACCCCGATACC 232
B7 GATTTGTAGTTCGCGGTTTAGC ACCTTTACGTATTGCGTCAGC 148
U7  8 TTGATGTTTTCGATGGTATTCG ATTGCTTCTGGCTGTGGTTC 249
U7  9 GCTGACTCTGGAACGTGTGA ATCGCCCAGATTTCGTAGC 297
U80 GCTTAGGGCCAAACTTGTTG GATTGTCCTGGTCCGTTGTC 292
U81 TGGAATCGAGCACTCTTTCAC TGGATGTTAGATCACGTTCAGG 327
U82 TTATCGCTGATGCAGGTTGT AAAT  T  G  CAC  GAGAT  C  C  GAAG 300
U83 ATATGTAGTTCCCCCGATGC AAGACTTGTCGGCGATGC 243
U84 TATTCCGATCTTGCCTTTGG CAATCTATCTCCGCAAACCAC 311
U85 GACTTATATCGAATCATGAG GTCACGGTCCACGTAACGTC 322
G86/90.1 AT  C  C  CGT  GCAGAGAAT  GAT  G ATGCATTATTCCGCTTCTGC 384
G86/90.2 CATTCATTATTGGCGTGCAG CATATCCATCCCCACGGTAG 262
G86/90.3 TGGTTTGGATACTTTCATCGTG TTCCAGCTTTCTTGAAGATGTG 332
U87 CTGGGCCTATACGGATGATG CAGACCCACAGACAATGCAC 275
U8  9 ATCCCCGTCTCAGAAGTTTG TGTCCAATCCTGACATCTCC 309
U90B GTTTCATGGCAGCCTTCACT ACCCTCTGGAAACAACATGG 318
U91B TCTCGAAGCTGTGACTGTGG ACACATTCATTTCAGTTTTCGGTA 326
G91/B8 CAAGGTGGAGGTTTCTTTGG CGCTGCAGTCTGGTAAGTCA 294
B8 AACAGGAACTGTTGTTGCTTTG TGCCCATACGGATGAGAACT 161
U94 CCCTGATTTCCGTTGTGTGT GAGTGGGAGGCAGAAATCC 303
U95 TGGCAACAAATTCTCAGTATGG GGAAAT  GGGT  T  GAAAGGT  CA 300
U96 GAGCCAATACCAACGTGAGG GTTGGCACGCAAAAACG 274
G96/97 CGACAAAACTTCTGGCCTTC CCGCTTTTTAGCACGTTACC 293
U97 TCAGGTCCTCACGACAGTAGG ACCGGAACTTCAAAACAACG 231
U99 TCACTTTGTAGTTTTGGCGTAGC TTCCTCTCTCGGCTGACAAC 240
U100 GCCGCTAGAGAGAATCTGTGA GAACGCTACCCGAAATCATC 296
G100/B9 ATCCTACGAGGACGGGAGAG CCTCCCCCGTTTTATATCGT 300
B9 CGGGCCACTTCTTTTCATAC CGACTTCCCGATGCAGAG 302
Universal PCR
pGEMT-
universal
GTCACGGTACACGTAACGTC GACTTATATCGAATCATGAG N/A
Concatemeric PCR
HHV-6cc TAACCCATCCCCCAACGCGC TTAGGGTTAATACCCCCCTTT 156
Sequencing primers
T7 TGTAATACGACTCACTATAGGGC N/A
Sp6 ATTTAGGTGACACTATAGAATAC N/A
Array PCR
T7/T3 TTGTAAAACGACGGCCAGTG GGGAATTTGGCCCTCGAGG N/A
RT-PCR
DR3(6B) CCAGATCTCCGTTCATCTCC GAGATGCCGATGAGGGAAC 150B6_0ster
U94
Mirandola 
U4  8
P-actin
GGGAAACCTCAAAAATGCAC
CATCGCATACGTCTCCCAG
CTTAGGACACCATCCAAGC
TCTCTAACGTGTCCGTGCC
102
450
TGGTCTATATCGATTCCGAC  TGGAGATGCTATCCGTATAC  487
CTAGAAGCATTTGCGGTGGACGATGGAGGG GCCCTGGACTTCGAGCAAGAGATGGCCAC 471
300Appendix III
Primers used for the investigation of viral gene expression of the V1 sequence 
by RT-PCR (sections 2.8.6 and 2.8.9).
ORF Forward Reverse
U11 G  AGTAT  CGAT  CGG  AACATT  GC T  GT  GT  CGT  G  AGAGAGGGAG  A
N11 ATAATCCGGCTTCCGTTTAG GAGAGGG  AGAAGAT  GT  AG  AC
U14 GTT  CT  CT  CACGCGCCAAC ACG  AGCAT  CGAC  AAAC  AGC
N14 TACTCATCCGAGACTCCTAC T  CGAGTT  GT  CGCAT  GGCTT  C
U27 CCT  CAGG  ATT  CG  AGAT  GAT  GT AGAGATGGAGCGCGGTAGT
N27 GTCAGCI  I  I  IGCACGAGATG T  CAT  CAT  CGT  GAT  CACCGT  G
U31 CCACACAAACAGAGCGACAC TT  GGTT  CGG  AG  AGGTTTTT  G
N31 TTTAT  CTACCGCCGAT  GT  CC TATT  GTT  GGGCGG  AAGTT  GG
U38 T  CGC  ATT  AGT  C  AC  AG C CTTG TTTTT  C  AAAAT  CGGGCAGAC
N38 CCGCATGTATAGGAATCTTG AAATCGGGCAGACGTGAGAC
U39 GACACCACTCCACCCACAATATCC TTCGCCGGACGAATTGAGTAGAGC
N39 TCCTGCCGT  AAC  ACTTAT  AACC GCAAACGTTTTCGATTTAGAGA
U51 I  I  I  ICGTCCATCCAGTTGTG AGAGCCTT  GG  AATT  CT  CGTT  C
N51 GGATT  GCT  G  AGT  GG  AC  ATT  G CGTT  C  AAC  AACGGT  GTGCTG
U69 T  GACAGATAAACGCGG  AT  GT GCAAGACCT  CCT  CT  GATT  GG
N69 CT  AACG  AGGCCT  GTCGATT  G ATT  G GCT  GACGTCT  GGTAAG
U83 ATATGTAGTTCCCCCGATGC AAGACTT  GT  CGGCG  AT  GC
N83 TT  GCACAGATT  GGT  CCGCTG CTGCCATATCACACATCGAG
U 89/90 GTT  CCT  GTTT  CAT  GGC  A TCCAGTAATGTGGAAGAAGG
U90B GTTT  CAT  GGC  AGCCTT  CACT ACCCT  CT  GGAAACAACAT  GG
N90B CGT  CAGAT  GCT  CCTT  CTT  CC ACTACCATCCCGATCCAGTG
U91B T  CT  CG  AAGCT  GT  G  ACT  GTGG ACACATT  C  ATTT  CAGTTTT  CGGTA
N91B CT  CTT  GCCAACT  GC  ACT  G  AA TGGTCCAGGAACATGTAATGA
U94 CAT  CGCAT  ACGT  CT  CCCAG TCTCTAACGTGTCCGTGCC
N94 CCCATT  GGAACT  GT  GGT  CT TT  C  AGGGCT  ATGCACT  C  ACC
U100 GCCGCTAGAGAGAAT  CT  GT  GA GAACGCTACCCGAAATCATC
301